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ABSTRACT	
	
A	 non-invasive,	 inflammatory	 bowel	 disease	 (IBD)-specific	 biomarker	 would	 be	
clinically	 useful	 due	 to	 the	 often	 inaccurate	 and	 unpleasant	 current	 diagnostic	
methods.	 The	 duration	 and	 extent	 of	 IBD	 increases	 the	 risk	 for	 colorectal	 cancer	
(CRC)	therefore	non-invasive	screening	for	CRC	in	patients	with	long-term	IBD	may	
lead	to	early	detection	of	abnormal	changes	and	improve	the	chance	of	survival.	To	
date,	human	metabolomic	studies	have	shown	potential	for	the	identification	of	a	
faecal	 marker	 of	 IBD,	 but	 are	 limited	 by	 variation	 from	 diet,	 environment	 and	
medication.	The	aim	of	this	work	was	to	report	the	first	study	using	HS-SPME-GC-
MS	to	detect	the	VOC	faecal	metabolome	in	commonly	used	mouse	models	of	IBD	
and	 CRC.	 Using	 an	 optimized	 method,	 the	 identification	 of	 the	 healthy	 murine	
faecal	VOC	profile	resulted	in	little	variation	between	individual	mice	with	a	noted	
significant	effect	of	gender	and	age.	Comparison	of	healthy	mouse	to	human	found	
39	and	62	VOCs	 respectively	with	33%	overlap	between	 the	 two	species,	 thereby	
demonstrating	the	more	complex	gut	environment	of	humans.	These	studies	led	to	
the	identification	of	a	VOC	profile,	characterized	by	an	increase	in	aldehydes	and	a	
decrease	 in	 alcohols,	 as	 a	marker	 of	 acute	 diarrhoea,	 compared	 to	 a	 significantly	
different	 profile	 for	 chronic	 colitis,	 characterised	 by	 the	 presence	 of	 methyl	
ketones.	In	addition,	VOC	profiling	is	capable	of	detecting	murine-specific	metabolic	
signatures	associated	with	premalignant	lesions	of	the	colon,	providing	rationale	for	
the	 investigation	of	new	non-invasive	methods	 for	 early	 tumour	detection.	 These	
results	were	supported	by	findings	questioning	the	specificity	of	faecal	calproctectin	
as	a	marker	of	IBD	due	to	the	increased	levels	of	calprotectin	found	in	both	colitis	
and	cancer	groups,	compared	to	healthy	controls.		In	conclusion,	we	have	provided	
evidence	 that	 the	 identification	 of	 disease-associated	 VOC	 concentration	 ranges	
combined	 with	 specific	 marker	 compounds	 would	 potentially	 increase	 the	
likelihood	 of	 finding	 an	 IBD-specific	 faecal	 VOC	 marker	 profile.	 This	 work	 has	
presented	rationale	for	future	studies	to	investigate	further	the	true	origin	of	these	
marker	VOCs	by	performing	both	in	vitro	and	further	in	vivo	work.	The	investigation	
of	the	faecal	metabolome	of	a	number	of	different	murine	models	in	combination,	
VI	
	
rather	 than	 the	 use	 of	 a	 single	 mechanistic	 model	 may	 be	 provide	 a	 better	
reflection	of	human	disease.		
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1.1 GASTROINTESTINAL	DISEASES	
	
Gastrointestinal	 (GI)	 diseases	 are	 disorders	 of	 the	 alimentary	 canal,	 occurring	
anywhere	 from	 the	 buccal	 cavity	 to	 the	 anus,	 affecting	 people	 of	 all	 ages,	 from	
premature	babies	 to	 the	 elderly.	 Some	GI	 diseases	 are	 acute	 and	 life-threatening	
(e.g.	liver	failure	or	cancer),	whereas	others	are	more	chronic	and	less	dangerous	to	
life,	 but	 are	 still	 severely	 debilitating	 (e.g.	 inflammatory	 bowel	 disease	 (IBD)).	
Recently,	 there	 has	 been	 an	 increase	 in	 the	 incidence	 of	 most	 GI	 diseases	 (e.g.	
hepatitis	 B	 and	 C	 infections,	 pancreatitis,	 alcoholic	 liver	 disease,	 Barrett’s	
oesophagus,	 diverticular	 disease	 and	 colorectal	 cancer	 (CRC)),	 which	 bring	major	
implications	for	future	healthcare	needs	[1].	Consequently,	the	burden	of	GI	disease	
is	heavy	for	patients,	the	NHS,	and	the	economy.	It	is	reported	that	diseases	related	
to	 the	 GI	 tract	 are	 the	 third	 most	 common	 cause	 of	 death,	 the	 second	 most	
common	cause	of	cancer-related	death	in	both	male	and	females,	and	the	second	
most	 common	 cause	of	 hospital	 admission,	 after	 circulatory	 disorders,	 in	 the	UK.	
About	one	in	six	admissions	to	hospital	is	for	a	primary	diagnosis	of	GI	disease	and	
one	 in	six	of	 the	main	surgical	procedures	 in	general	hospitals	being	performed	 is	
on	the	digestive	tract	[2].		
	
The	human	lower	GI	tract	 is	composed	of	the	small	and	large	intestines	with	each	
having	a	specific	role	to	play	in	the	digestion,	secretion	and	adsorption	of	nutrients	
from	food.	The	GI	tract	also	has	an	extremely	important	role	to	play	in	the	immune	
system;	 it	 is	 the	 first	 line	of	defence	against	any	harmful	bacteria	and	 toxins	 that	
may	enter	the	gut	[3].		IBD	is	an	example	of	a	disease	involving	a	breakdown	in	the	
epithelial	 defences.	 Furthermore,	 patients	 suffering	 from	 long-term	 IBD	are	 at	 an	
increased	risk	of	developing	CRC,	 further	contributing	to	the	burden	of	GI	disease	
for	patients,	their	families	and	the	economy.		
	
1.2	INFLAMMATORY	BOWEL	DISEASE		
	
Human	 IBD	has	 two	major	phenotypes,	Crohn’s	disease	 (CD)	and	ulcerative	colitis	
(UC)	 and	 is	 characterised	 by	 chronic	 inflammation	 of	 the	 GI	 tract.	 UC,	 otherwise	
3	
	
known	as	idiopathic	proctocolitis,	causes	inflammation	and	diffuse	ulceration	in	the	
colon,	whereas	CD	differs	in	the	location,	which	may	occur	anywhere	along	the	GI	
tract,	 and	 the	 nature	 of	 inflammatory	 changes,	which	 are	 usually	 transmural	 [4].	
Clinically,	 patients	 diagnosed	 with	 UC	 or	 CD	 present	 with	 symptoms	 such	 as	
abdominal	 pain,	 diarrhoea,	 rectal	 bleeding	 and	 weight	 loss.	 Both	 diseases	 affect	
people	of	all	ages	but	predominantly	arise	 in	 the	younger	population,	and	due	 to	
their	remitting	and	relapsing	nature,	have	a	significant	impact	on	their	educational,	
social,	 professional	 and	 family	 life	 [5].	 Complications	 of	 continual	 disease	 activity	
may	 include	 intestinal	 fibrosis,	 strictures	 and	 fistula	 formation	 and	 cancer,	
especially	of	 the	colon;	 in	some	patients,	 IBD	can	have	extra-intestinal	symptoms,	
affecting	 the	 joints,	eyes	and/or	 skin	 [6].	There	 is	a	need	 to	 focus	on	methods	 to	
control	 the	 underlying	 pathology	 in	 order	 to	 improve	 the	 quality	 of	 life	 and	
treatment	 for	 patients.	 In	 addition,	 the	 diagnosis	may	 be	 delayed,	 sometimes	 by	
years,	 as	 the	 symptoms	may	be	 confused	with	 the	more	 common	 irritable	bowel	
syndrome	(IBS),	so	attention	also	needs	to	be	given	to	a	better	means	of	diagnosing	
IBD.	
	
1.2.1	Epidemiology	of	IBD	
	
Reportedly,	 IBD	 affects	 an	 estimated	 1.5	 million	 Americans,	 2.2	 million	 people	
within	 Europe	 and	 several	 hundred	 thousand	 more	 worldwide.	 Considerable	
variation	 in	 the	epidemiology	of	 IBD	has	been	observed	around	 the	world	with	 a	
wide	 range	 of	 estimates	 both	 within,	 and	 between,	 geographic	 regions.	 IBD	 is	
believed	 to	 be	 associated	 with	 the	 industrialization	 of	 nations,	 with	 its	 highest	
incidence	rates	and	prevalence	in	North	America	and	Europe	[7].		
	
1.2.1.1	Incidence	and	prevalence		
	
The	incidence	of	 IBD	(both	CD	and	UC)	has	 increased	dramatically	 in	economically	
prosperous	 countries	 since	 the	 1950s,	 in	 particular	 in	 the	 established	 high-
prevalence	populations	of	 IBD	 in	North	America	and	Western	Europe	 (Figure	1.1)	
[8].	Specifically,	the	annual	incidence	of	UC	varied	from	0	-	19.2	per	100,000	people	
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in	 North	 America	 and	 0.6	 -–	 24.3	 per	 100,000	 in	 Europe,	 corresponding	 to	 a	
prevalence	of	37.5	-	248.6	per	100,000	and	4.9	-	505	per	100,000,	respectively	[9].	
The	incidence	of	CD	was	similar	to	that	of	UC,	varying	from	0	–	20.2	per	100,000	in	
North	 America	 and	 0.3	 –	 12.7	 per	 100,000	 in	 Europe.	 Furthermore,	 populations	
previously	considered	‘low	risk’,	such	as	Japan,	Hong	Kong,	South	Korea	and	India,	
have	also	witnessed	an	increase	in	incidence	of	both	UC	and	CD	between	1950	and	
2008.	 It	 is	 clear	 that	Westernisation	 is	contributing	 to	 the	onset	of	 the	disease	as	
immigrants	 into	 these	countries	acquire	 the	same	endemic	 risk	of	developing	 IBD	
within	a	decade	or	two	[10].	
	
The	 incidence	of	 IBD	 in	 the	UK,	of	 both	UC	and	CD,	 continues	 to	 rise	 and	 is	 now	
estimated	to	affect	1	in	200	people	with	a	total	estimated	cost	to	the	NHS	of	£720	
million,	based	on	the	prevalence	and	an	average	cost	of	£3,000	per	year	per	patient	
[11].	Recent	European	data	has	reported	the	prevalence	to	be	between	0.5	-	1%	of	
the	total	population.	In	the	UK,	it	is	estimated	that	at	least	115,000	people	have	CD	
and	around	146,000	have	a	diagnosis	of	UC	[12].		
	
1.2.1.2	Sex,	age	and	racial	incidence		
	
Incidence	in	Western	populations	is	similar	in	men	and	women,	but	is	influenced	by	
race	and	ethnicity.	 It	has	been	reported	that	the	female	to	male	ratio	varies	from	
0.51	to	1.58	for	UC	and	0.34	to	1.65	for	CD,	suggesting	an	IBD	diagnosis	is	not	sex	
specific	 [13].	 In	most	studies,	 the	peak	 incidence	of	 IBD	 is	 in	the	second	to	fourth	
decade	of	life.	78%	of	CD	cases	are	diagnosed	between	the	age	of	20	and	29,	for	UC	
it	is	51.1%,	and	has	remained	unchanged	over	several	decades	[9].	As	a	result,	IBD	
appears	 to	 affect	 individuals	 in	 the	 most	 productive	 years	 of	 life,	 potentially	
resulting	in	long-term	problems	and	costs	for	patient,	healthcare	and	society.		
	
As	previously	mentioned,	the	highest	occurrence	of	both	UC	and	CD	is	found	within	
North	America	and	Europe.	Within	Europe,	the	highest	incidence	rates	are	found	in	
Scandinavia	 and	 the	 UK,	 whilst	 they	 remain	 low	 in	 southern	 eastern	 European	
countries	 [14].	Total	 incidence	rates	 in	northern	Europe	were	6.3	 for	CD	and	11.4	
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for	 UC	 per	 100,000	 person	 years,	 compared	 to	 3.6	 and	 8.0	 per	 100,000	 person	
years,	 respectively,	 in	 southern	 Europe.	 These	 rates	 suggest	 a	 north-west/south-
east	gradient	in	IBD	incidence	in	Europe	[14].	This	is	also	apparent	in	the	UK,	with	a	
North-South	gradient	demonstrated	by	a	higher	incidence	in	Scotland,	compared	to	
England	[11].			
	
The	risk	of	 IBD	 is	 increased	3-fold	 in	 the	 Jewish	population	compared	to	 the	non-
Jewish	 Caucasians	 populations	 and	 is	 higher,	 particularly	 among	 Ashkenazi,	
American	and	European	Jewish	populations,	compared	with	those	residing	in	Israel	
[9].		However,	the	incidence	of	IBD	in	Hispanic	and	Asian	people	has	been	shown	to	
be	 increasing,	 and	 studies	 have	 shown	 that	 individuals	 emigrating	 from	 low	
prevalent	 regions	 (e.g.	 Asia)	 to	 higher	 prevalent	 countries	 (e.g.	 England)	 are	 at	
increased	 risk	 for	 developing	 IBD,	 particularly	 among	 first-generation	 children	 [9,	
15].		
	 	
6	
	
	
	
Figure	 1.1	 The	 combined	 incidence	 and	 prevalence	 rates	 of	 IBD	 worldwide,	 as	
reported	by	Molodecky	et	al.	in	2012	[9].	Data	found	as	a	result	from	a	systematic	
literature	 search	 for	CD	and	UC,	 respectively,	 before	1960	 (A	&	D),	 from	1960	 to	
1979	(B	&	E))	and	after	1980	(C	&	F).	Incidence	and	prevalence	values	were	ranked	
into	quintiles	representing	low	(dark	and	light	blue)	to	intermediate	(green)	to	high	
(yellow	and	 red)	 occurrence	of	 disease.	 Copyright	 has	 been	 granted	 and	 figure	 is	
used	with	permission.		
D 
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1.2.2	Aetiology	and	pathogenesis	of	IBD	
	
The	 aetiology	 of	 IBD	 has	 been	 extensively	 studied	 in	 the	 past	 few	 decades;	
however,	 the	 disease	 pathogenesis	 is	 not	 fully	 understood.	 It	 has	 been	 widely	
hypothesised	 that	 the	 pathogenesis	 of	 IBD	 results	 from	 an	 interaction	 of	
environmental	factors	(e.g.	smoking,	oral	contraceptives,	high-fat	diet)	affecting	the	
intestinal	microbiota	compared	with	an	inappropriate	immune	response,	often	but	
not	 only,	 in	 a	 genetically	 predisposed	 person	 (Figure	 1.2).	 Risk	 alleles	 include	
changes	 in	 the	NOD2,	 IL-23R	 and	ATG16	 genes	 [16],	 and	more	 recently,	 genome-
wide	association	studies	and	subsequent	meta-analyses	have	been	able	to	identify	
separate	 phenotypes	 between	 CD	 and	 UC.	 One	 hundred	 and	 sixty	 three	 IBD	 loci	
have	 been	 identified	 in	 total	 with	 100	 loci	 contributing	 to	 both	 CD	 and	 UC	 (e.g.	
IL23R	and	CD48),	but	also	some	showing	specificity	for	either	CD	(30	e.g.	ATG16L1,	
NOD2,	and	IL6ST)	[17]	or	UC	(23	e.g.	TNFRSF14,	CARD9,	and	ORMDL3)	[18].	The	gut	
immunological	balance	is	perturbed	with	a	shift	towards	the	pro-inflammatory	side,	
resulting	in	over-production	of	pro-inflammatory	cytokines	(e.g.	TNF-α,	IL-6),	which	
results	 in	 significant	 tissue	 damage.	Nuclear	 transcription	 factor	 kappa	 B	 (NFκB2)	
has	been	identified	as	one	of	the	key	regulators	in	the	immunological	setting	[19].	
	
1.2.2.1	Environmental	factors	implicated	in	IBD	
	
Environmental	 influences	 have	 become	 well-established	 risk	 factors	 for	 IBD;	
although	appendectomy	for	appendicitis	can	protect	against	UC	[20].	Recently	oral	
contraceptives	 and	 diet	 have	 been	 proposed	 to	 increase	 an	 individual’s	 risk	 of	
developing	 the	 disease	 [21,	 22].	 Potential	 environmental	 factors	 increasing	 an	
individual’s	 chance	 of	 developing	 IBD	 span	 the	 spectrum	 of	 life,	 from	 mode	 of	
childbirth	and	early-life	exposures	(including	breastfeeding	and	antibiotic	exposure)	
to	exposures	later	on	in	adulthood	(including	smoking,	major	life	stresses,	diet	and	
lifestyle)	 [8].	 Data	 support	 a	 risk	 association	 between	 smoking	 and	 CD	 whereas	
smoking	cessation,	but	not	current	smoking,	is	associated	with	an	increased	risk	of	
UC	[23].	A	significantly	lower	intake	of	dietary	fibre	(fruits	and	vegetables),	a	higher	
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intake	of	 saturated	 fats,	 depression	and	 impaired	 sleep,	 and	 low	vitamin	D	 levels	
have	all	been	associated	with	the	onset	of	IBD	[8].		
	
1.2.2.2	Role	of	intestinal	microbiota	in	pathogenesis	of	IBD	
	
During	 health,	 the	 GI	 tract	 is	 colonized	 by	 a	 broad	 range	 of	 highly	 diverse	
microorganisms,	 which	 is	 collectively	 termed	 the	 gut	 microbiota.	 The	 gut	
microbiota	 is	 responsible	 for	 the	metabolism	of	 exfoliated	epithelial	 cells,	 dietary	
carbohydrates	 and	 amino	 acids,	 and	 mucus,	 resulting	 in	 the	 production	 of	
metabolites	 that	 affect	 the	 function	 of	 the	 gut,	 including	 intestinal	 epithelial	 cell	
state.	 Biproducts	 of	 digestion	 also	 influence	 host	 energy	 balance,	 immune	
regulation	and	homeostasis	[24].	These	bidirectional	communications	between	the	
microbiota	 and	 the	host	 composed	of	bacterial	 and	human	genes,	 determine	 the	
metabolic	profile	of	the	host.		
	
The	composition	and	luminal	numbers	of	dominant	microbial	species	in	the	human	
GI	 tract	 vary	between	 the	gastric,	 proximal	 and	distal	 small	 intestinal	 and	 colonic	
microenvironments.	 Bacterial	 counts	 are	 very	 low	 in	 the	 stomach	 at	 0-102/g	
compared	 to	1011/g	 to	1012/g	 in	 the	distal	 luminal	 contents	 in	 the	colon	 [24].	The	
gut	 microbiota	 is	 primarily	 composed	 of	 four	 major	 phyla:	 Firmicutes	 (49-76%),	
Bacteroidetes	 (16-23%),	 followed	 by	 the	 less	 prevalent	 phyla,	 Proteobacteria	 and	
Actinobacteria	[25].	Recent	evidence	indicates	that	the	intestinal	microbiota	play	a	
role	 in	 initiating,	 maintaining	 and	 determining	 the	 phenotype	 of	 IBD	 [26].	 It	 has	
been	 well-documented	 that	 there	 are	 four	 broad	 mechanisms	 explaining	 the	
complex	relationship	between	the	commensal	microbiota	and	IBD:	(i)	dysbiosis	(i.e.	
altered	 balance)	 of	 the	 intestinal	 microbiota;	 (ii)	 induction	 of	 intestinal	
inflammation	by	presence	of	pathogens	and	functional	alterations	 in	the	bacteria;	
(iii)	 host	 genetic	 defects	 in	 containing	 commensal	 microbiota;	 and	 (iv)	 defective	
host	immunoregulation	[24].		
	
Intestinal	dysbiosis	can	be	defined	as	an	abnormal	 ratio	of	beneficial	and	harmful	
bacteria	species;	evidence	has	suggested	that	 it	 is	the	central	characteristic	of	the	
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gut	microbiota	in	IBD	[27].	However,	it	remains	unclear	whether	this	dysbiosis	is	a	
cause	 or	 consequence	 of	 the	 onset	 of	 IBD	 [28].	 A	 common	 feature	 of	 the	 gut	
microbiome	 in	 IBD	 is	 that	overall	 species	diversity	 is	 generally	 reduced	 in	CD	and	
UC.	Specifically,	there	is	a	reduced	abundance	of	several	types	of	bacteria	species,	
in	particular,	members	of	 the	Firmicutes	and	Bacteroidetes	phyla	 [29,	 30]	 and	an	
increase	 in	 the	 abundance	 of	 others,	 including	 the	 Actinobacteria	 and	
Proteobacteria	 phyla	 [24].	 A	 study	 on	 the	 faecal	 microbiota	 of	 patients	 with	 UC	
compared	 to	 healthy	 controls	 looked	 at	 clustering	 of	 the	 faecal	 microbial	
communities	and	found	the	control	group	samples	to	cluster	separate	to	7	clusters	
consisting	 of	 the	 UC	 patients	 was	 reported.	 Unclassified	 bacteria,	 Eubacterium,	
Fusobacterium,	 Ruminococcus,	 Gammaproteobacteria,	 Bacteroides,	 and	
Lactobacillus	 were	 responsible	 for	 these	 differences.	 This	 indicates	 that	 these	
bacteria	 could	 be	 used	 to	 distinguish	 between	 patients	 with	 UC	 and	 healthy	
controls	and	thus	could	be	potential	IBD	biomarkers	[31].		
	
Adherent-invasive	Escherichia	coli	(AIEC)	are	a	potential	causative	agent	in	CD	[32-
34].	Martinez-Medina	et	al.	 reported	 that	a	Western	diet	 (e.g.	 saturated	 fats,	 red	
meats,	 lack	 of	 fresh	 fruits)	 given	 to	 mice	 expressing	 human	 carcinoembryonic	
antigen-related	 cell	 adhesion	 molecules	 (CEACAMs)	 resulted	 in	 changes	 to	 the	
composition	of	the	intestinal	microbiota.	This	 led	to	alterations	in	the	host	barrier	
function	 and	 immunity,	 thereby	 creating	 a	microenvironment	 that	 facilitated	 the	
colonisation	 of	 AIEC	 to	 the	 intestinal	 tract	 and	 consequently	 exacerbated	 the	
inflammatory	response	[32].	Other	enteric	bacterial	pathogens	that	may	exacerbate	
intestinal	 inflammation	 include	 toxin	 A-producing	 Clostridium	 difficile	 [35]	 and	
enterotoxigenic	Bacteroides	fragilis	[36].	
	
Studies	to	date	investigating	the	role	of	the	gut	microbiota	in	IBD	have	focused	on	
the	presence	of	specific	bacteria	species	rather	than	the	non-bacterial	components	
of	 the	microbiota.	Viruses	 are	 the	most	 abundant	biological	 entity	within	 the	 gut	
and	their	function	in	health	and	GI	disease	is	not	well	defined.	However,	it	has	been	
demonstrated	 that	 virus	 populations	 are	 more	 diverse	 and	 are	 present	 at	
significantly	 higher	 levels	 in	 patients	 with	 CD	 than	 in	 controls,	 thereby	 showing	
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potential	as	a	viral	biomarker	for	CD	[37].	Furthermore,	recent	investigations	have	
also	begun	 to	 investigate	 the	 role	of	 a	 commensal	 fungal	 community	on	mucosal	
surfaces,	the	‘mycobiome’.	An	overall	 increase	in	“opportunistic	pathogenic”	fungi	
(Candida,	 Trichosporon)	 and	 a	 decrease	 in	 nonpathogenic	 fungi	 (Saccharomyces)	
has	been	found	in	the	presence	of	gut	inflammation,	as	expected	when	considering	
the	that	inflammation	drives	changes	in	the	gut	bacterial	population	[38].		
	
With	 the	 increasing	 knowledge	 of	 the	 role	 of	 the	 intestinal	 microbiota	 and	 the	
growing	 evidence	 of	 the	 gut	 mycobiome	 in	 the	 pathogenesis	 of	 IBD,	 the	
development	 of	 novel	 non-invasive	 diagnostic	 tools	 may	 be	 investigated.	 If	 the	
dysbiotic	 microbiota	 play	 a	 role	 in	 disease	 pathogenesis,	 interventions	 that	
‘normalise	 it’	 might	 be	 a	 strategy	 to	 treat	 certain	 disease	 processes	 e.g.	 faecal	
transplantation	in	the	treatment	of	C.	difficile	infection	[39].	However,	evidence	to	
date	 suggests	 that	 the	use	of	 faecal	 transplantation	 as	 a	novel	 treatment	 for	 IBD	
remains	variable	and	further	randomized	controlled	trials	are	needed	to	prove	the	
efficacy	of	this	[40].		
	
1.2.2.3	Inappropriate	immune	response	in	a	genetically	predisposed	person		
	
A	 role	 for	 genetics	 in	 the	 pathogenesis	 of	 IBD	 was	 initially	 derived	 from	 familial	
aggregation	 studies	 and	 twin	 studies,	 which	 suggested	 an	 important	 hereditary	
component.	There	are	between	2-14%	of	CD	patients	that	report	a	family	history	of	
the	disease	with	a	similar	proportion	for	UC	patients	(8-14%)	[41].	 If	both	parents	
suffer	from	IBD,	the	risk	of	the	offspring	developing	the	disorder	before	the	age	of	
30	years	is	estimated	to	be	as	high	as	one-in-three	[42].	The	familial	nature	of	IBD	
has	been	linked	with	CD-associated	genes	such	as	the	NOD2	mutation,	described	in	
2001	 [43-45],	 and	 the	 163	 other	 risk	 alleles	 reported,	 in	 predominantly	 white	
populations	 [17].	 Combined	 with	 our	 improved	 understanding	 of	 the	 functional	
consequences	 of	 these	 disease-associated	 genes,	 it	 has	 become	widely	 accepted	
that	 the	 genetic	 risk	 factors	 do	 not	 act	 in	 isolation	 but	 in	 synergy	with	 both	 the	
external	and	internal	(gut	microbiota)	environments.	The	recognised	risk	genes	can	
be	broadly	divided	into	those	that	influence	the	maintenance	of	the	integrity	of	the	
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epithelial	 barrier	 (e.g.	 GNA12),	 response	 to	 oxidative	 stress	 (e.g.	 PRDX5),	 innate	
immune	response	and	microbial	defence	(e.g.	NOD2),	 restitution	and	 injury	repair	
(e.g.	STAT3),	adaptive	immune	responses	(e.g.	IL10)	and	autophagy	(e.g.	ATG16)	[8].	
These	genetic	variants	 in	 IBD	are	discussed	 in	more	detail	 in	a	number	of	 specific	
reviews	[46-48].			
	
The	hygiene	hypothesis	proposes	 that	during	early	 childhood	 the	 immune	system	
must	be	exposed	to	stimuli	such	as	 infectious	agents	and	symbiotic	bacteria.	Such	
exposure	 will	 allow	 adequate	 development	 of	 regulatory	 T	 cells	 and	 natural	
progression	of	the	 immune	system	to	avoid	becoming	susceptible	to	autoimmune	
diseases	 late	on	 in	 life	 [49].	Host	genetic	defects	 involved	 in	 innate	 immunity	can	
also	contribute	to	dysbiosis	of	the	gut	microbiota	in	patients	with	IBD;	a	number	of	
which	 can	 be	 expected	 to	 have	 an	 impact	 on	 the	 composition	 of	 the	 intestinal	
microbiota	(e.g.	NOD2,	ATG16,	NCF4,	IRGM)	[24].			
	
1.2.2.4	NFκB’s	role	in	intestinal	inflammation	
	
The	 family	 of	NFκB	 proteins	 control	 the	 transcription	 of	 DNA	 and	 consist	 of	 five	
different	members,	p65	RelA,	c-Rel,	RelB,	p50/p105	(NFκB1)	and	p52/p100	(NFκB2)	
which	are	all	characterised	by	a	structurally	conserved	N-terminal	300	amino	acid	
region	 containing	 specific	 domains,	 responsible	 for	 dimerisation,	 nuclear	
localisation	and	DNA-binding	[50].	In	order	to	activate	this	family	of	proteins,	there	
are	two	different	intracellular	pathways,	the	classical	and	the	alternative	activation	
pathways,	resulting	in	the	release	of	NFκB	and	the	translocation	to	the	nucleus	to	
modulate	pro-death	or	pro-survival	responses	to	cellular	stresses,	such	as	infection	
and	 inflammation	 [19].	 The	 classical	 pathway	 is	 activated	 by	 the	 presence	 of	
microbial	products	and	pro-inflammatory	cytokines,	specifically	TNFα,	 followed	by	
activation	of	RelA-	or	c-Rel	complexes.	The	alternative	pathway	is	triggered	by	TNF-
family	 cytokines	 (e.g.	CD40	or	 lymphotoxin	β	 receptor,	but	not	TNFα,	 resulting	 in	
activation	of	RelB	and	NFκB2	[51],	however,	the	role	of	the	alternative	pathway	in	
inflammation	 is	 still	 unclear.	 The	 expression	 and	 activation	 of	 NFκB	 is	 strongly	
induced	in	the	inflamed	gut	of	IBD	patients	[52],	with	sites	of	inflammation	found	to	
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be	 associated	 with	 the	 activation	 of	 the	 classical	 pathway	 [53].	 There	 is	
accumulating	evidence	to	suggest	 that	activation	of	 the	alternative	NFκB	pathway	
also	plays	an	important	role	in	the	pathogenesis	of	IBD,	and	IBD-associated	cancer.	
For	 instance,	Burkitt	et	al.	 showed	that	mice	 lacking	 the	c-Rel	 subunit	were	more	
susceptible	 to	 colitis-associated	 cancer	 compared	 to	wild-type	mice.	Mice	 lacking	
NFκB2	were	resistant	to	both	colitis	and	colitis-associated	cancer,	developing	fewer	
polyps	per	colon	compared	to	wild-type	mice	[54].		
	
To	 summarise,	 the	 anti-apoptotic	 functions	 of	 NFκB	 can	 protect	 against	
inflammation,	 in	 the	 case	 of	 epithelial	 cell	 survival	 and	mucosal	 barrier	 integrity,	
and	 also	 maintain	 the	 inflammatory	 response	 through	 persistent	 leukocyte	
activation	[51].	NFκB2	is	necessary	for	the	development	of	colitis,	whilst	c-Rel-	and	
NFκB1-mediated	signalling	regulates	epithelial	cell	turnover	following	DNA	damage.	
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Figure	 1.2	 Pathogenesis	 of	 IBD.	 A	 complex	 interplay	 between	 the	 host	 immune	 system	 and	 the	 symbiotic	microbiota	 is	 necessary	 for	 gut	
homeostasis.	 Anti-inflammatory	 activities	 from	 the	 presence	 of	 beneficial	 bacteria	 species	 suppress	 the	 colitis-inducing	 pathobionts	 either	
directly	or	through	 induction	of	regulatory	 immune	response	(left-hand	side).	 In	 IBD,	the	combination	of	genetic	and	environmental	 factors	
result	in	dysbiosis	which	in	turn	leads	to	a	loss	of	the	barrier	function	and	an	increase	in	pathobionts	and,	consequently,	chronic	inflammation	
(right-hand	side).	It	is	unknown	whether	unclassified	bacteria	have	a	role	in	the	pathogenesis	of	IBD	(Modified	from	[55]).	
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1.2.3	Risk	of	CRC	in	IBD	
	
Patients	 with	 IBD	 are	 at	 increased	 risk	 for	 developing	 CRC	 because	 of	 the	 long	
duration	 and	 extent	 of	 colitis	 and	 may	 further	 increase	 when	 combined	 with	 a	
familial	history	of	CRC	[56].	 IBD	is	considered	the	third	highest	risk	factor	for	CRC,	
behind	 familial	 adenomatous	 polyposis	 (FAP)	 and	 hereditary	 non-polyposis	
colorectal	 cancer	 syndrome	 (HNPCC)	 [57].	 Chronic	 inflammation	 is	 believed	 to	
promote	carcinogenesis,	thereby	making	it	a	key	risk	factor	for	CRC	in	patients	with	
IBD.	Depending	on	the	study	and	geographical	location,	the	risk	of	CRC	in	patients	
with	 UC	 varies	 between	 0.9	 and	 8.8	 fold	with	 a	 probability	 of	 2%	 10	 years	 after	
diagnosis,	8%	after	20	years	and	18%	after	30	years	 [58].	Choi	et	al.	performed	a	
forty-year	colonoscopic	surveillance	programme	for	CRC	 in	UC	patients	and	found	
the	 incidence	 rate	 to	be	4.7	per	1000	patient-years,	 concluding	 that	 colonoscopic	
surveillance	may	have	a	significant	role	in	reducing	the	risk	of	CRC	in	patients	with	
long-standing	UC	[59].	With	CD,	there	is	no	statistically	significant	increase	in	cancer	
risk	 identified	 when	 including	 all	 patients	 irrespective	 of	 disease	 extent	 and	
duration,	 but	when	 considering	 those	 patients	with	 longstanding	 colonic	 CD,	 the	
risk	of	developing	CRC	is	similar	to	that	seen	in	UC	patients	[60].		
 
1.2.4	Current	diagnostic	methods	of	IBD	
	
The	 current	 investigations	 offered	 to	 an	 individual	 suspected	 of	 having	UC	 or	 CD	
involve	blood	tests,	stool	tests,	endoscopies,	imaging	(e.g.	CT,	MRI,	ultrasound	and	
bariums),	 and	 possibly,	 examination	 under	 anaesthetic	 (EUA)	 (Crohn's	 and	 Colitis	
UK,	2013	[61]).	Several	blood	tests	can	be	used	to	support	a	diagnosis	of	IBD,	or	to	
monitor	the	effects	of	IBD	or	 its	treatment.	A	full	blood	count	(FBC)	measures	the	
levels	 of	 red,	 white	 and	 platelet	 blood	 cells	 in	 order	 to	 monitor	 signs	 of	
inflammation	 and	 detect	 anaemia.	 Inflammatory	 marker	 tests	 (e.g.	 C-reactive	
protein	 (CRP)	 and	 erythrocyte	 sedimentation	 rate	 (ESR))	 are	 also	 used	 to	 detect	
inflammation;	liver	function	tests	are	mainly	used	to	measure	serum	albumin,	low	
levels	of	which	may	occur	 in	 inflammatory	conditions.	Other	blood	tests	that	may	
be	 helpful	 in	 IBD	 include	 ferritin,	 transferrin,	 vitamin	 B12	 and	 folic	 acid	 levels.		
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Faecal	 calprotectin	 and	 faecal	 lactoferrin	 assays	 are	 used	 to	 look	 for	 signs	 of	
intestinal	 inflammation	and	endoscopies	are	used	by	clinicians	to	directly	examine	
the	intestinal	mucosa	[61].			
	
Despite	 the	wide	 range	 of	 tests	 available,	 the	 diagnosis	 and	 care	 of	 IBD	 remains	
difficult	 for	 clinicians	 and	 is	 commonly	 based	 on	 the	 presenting	 symptoms	 and	 a	
range	 of	 investigations	 mentioned	 previously.	 Most	 of	 these	 diagnostic	 methods	
are	 invasive,	 expensive	 and	are	 considered	unpleasant	by	 the	patient.	 The	 serum	
markers	 such	 as	 CRP	 and	 ESR	 lack	 specificity	 and	 are	 increased	 in	 other	
inflammatory	 diseases	 [62].	 Recently,	 non-invasive	methods	 of	 assessing	 diseases	
have	become	the	‘holy	grail’	for	research	into	diagnostics.	Examples	include	faecal	
calprotectin	 and	 lactoferrin	 are	 neutrophil	 proteins	 that	 pass	 into	 the	 lumen	 and	
enter	the	faeces	when	the	intestine	is	inflamed	and	can	be	measured	directly	in	the	
faeces	of	patients	with	active	IBD	[63].	However,	although	these	faecal	markers	are	
informative	when	diagnosing	IBD,	they	have	a	slow	turnaround	and	are	also	raised	
in	the	presence	of	faecal	blood	(e.g.	haemorrhoids,	polyps	or	gut	infections	such	as	
Clostridium	difficile);	 so	may	be	unable	 to	distinguish	between	 infectious	diseases	
and	IBD	[64].		
	
A	 recent	 review	 describes	 the	 investigation	 of	 faecal	 volatile	 organic	 compounds	
(VOCs)	as	a	novel,	cheaper	method	of	diagnosing	IBD	[65].	This	is	also	discussed	in	
more	detail	in	section	1.8.6.		
	
1.3	COLORECTAL	CANCER	(CRC)	
	
CRC	is	a	major	worldwide	health	problem	because	of	its	high	prevalence	and	
mortality	rate,	which	may	be	attributed	to	late	diagnosis.		Regions	with	the	highest	
incidence	rates	include	Australia,	New	Zealand,	Canada,	U.S.A	and	Europe;	China,	
India	and	Africa	have	the	lowest	incidence	rates.	Risk	factors	believed	to	increase	
an	individual’s	chance	of	developing	CRC	include	a	family	history	of	bowel	cancer,	
long-term	IBD,	a	high	fat	diet	with	low	consumption	of	fibre,	smoking	and	a	lack	of	
exercise	[66].		
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1.3.1	Epidemiology	of	CRC	in	the	UK	
	
National	statistics,	reported	by	Cancer	Research	UK,	have	reported	that	CRC	is	the	
fourth	most	common	cancer	in	the	UK	(2011),	accounting	for	13%	of	all	new	cases	
of	 cancer.	 It	 is	 the	 third	most	 common	 cancer	 in	 both	males	 (14%	 of	 cancers	 in	
men)	and	females	(11%)	separately.	Data	collected	in	2011	found	that	there	were	
41,581	new	cases	of	CRC	in	the	UK	with	male:	female	ratio	of	13:10	(23,171	(56%)	in	
men	 and	18,410	 (44%)	 in	women)	 [67].	 The	 age-standardised	 incidence	 rates	 are	
significantly	 lower	 in	England	compared	 to	Wales,	 Scotland	and	Northern	 Ireland,	
primarily	 due	 to	 a	 north-south	 divide	 across	 the	 UK	 [67].	 When	 looking	 at	 CRC	
incidence	by	age,	an	average	of	43%	of	cases	were	diagnosed	in	people	aged	75	and	
over,	 and	 95%	 in	 those	 aged	 >50,	 indicating	 that	 the	 incidence	 of	 CRC	 is	 very	
strongly	 related	 to	age	 [67]	 (Figure	1.3).	 Furthermore,	 approximately	50%	of	CRC	
patients	will	eventually	develop	metastatic	cancer,	with	an	overall	survival	 rate	of	
five	years	for	50-60%	of	patients	[68].		
	
Figure	1.3	CRC	incidence	statistics,	by	age.	Average	number	of	new	CRC	cases	per	
year	 and	 age-specific	 incidence	 rates	 per	 100,000	 of	 the	 population	 in	 the	 UK,	
Cancer	 Research	 UK,	 May	 2015	 [67].	 Permission	 granted	 for	 use	 of	 figure	 from	
CRUK	website.		
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1.3.2	Risk	factors	for	CRC	
	
Several	risk	factors	have	been	reported	to	be	associated	with	the	incidence	of	CRC.	
These	 risk	 factors	 include	 uncontrollable	 factors,	 such	 as	 age	 and	 an	 inherited	
genetic	 risk,	 as	 well	 as	 a	 substantial	 number	 of	 environmental	 and	 lifestyle	 risk	
factors	including	diet,	obesity,	smoking,	and	heavy	alcohol	consumption.		
	
1.3.2.1	Age	
	
The	probability	 of	 developing	CRC	 increases	 after	 the	 age	of	 40	 and	 rises	 sharply	
after	the	age	of	50,	with	more	than	90%	of	CRC	cases	occurring	in	people	age	50	or	
older	[66].	However,	the	incidence	of	CRC	appears	to	be	increasing	among	younger	
people	with	more	people	aged	20-49	being	diagnosed	[69],	but	the	explanation	for	
this	 is	unclear	 [69].	Meanwhile,	 the	United	European	Gastroenterology	 (UEG)	has	
called	for	primary	care	physicians	to	be	more	alert	to	the	symptoms	of	CRC	in	young	
people	[69].		
	
1.3.2.2	Personal	or	family	history	of	CRC	or	polyps	
	
Neoplastic	 polyps	 of	 the	 bowel	 are	 often	 benign	 and	 are	 referred	 to	 as	 pre-
cancerous	lesions	or	adenomas.	Compared	with	individuals	with	no	personal	history	
of	 adenomas,	 those	 individuals	 with	 a	 history	 of	 precursor	 lesions	 are	 at	 an	
increased	risk	of	developing	CRC	[70].	It	is	estimated	that	it	takes	5	to	10	years	for	
the	 development	 of	 malignancy	 from	 benign	 adenomas	 [70],	 therefore	 the	
detection	and	removal	of	these	precursor	lesions	is	vital	in	order	to	reduce	the	risk	
of	CRC.		
	
1.3.2.3	Inherited	genetic	risk	
	
Sporadic	 CRC	 is	 a	 term	 used	 to	 define	 cancers	 that	 appear	 in	 the	 absence	 of	 a	
known	 syndrome	or	 family	 history.	 The	 vast	majority	 of	 CRC	 (60-80%)	 are	 of	 the	
sporadic	 type	 [68].	 However,	 approximately	 5-10%	 of	 CRC	 are	 a	 consequence	 of	
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recognised	 hereditary	 conditions	 [66].	 Most	 commonly,	 these	 include	 FAP	 and	
HNPCC,	 also	 known	as	 Lynch	 syndrome.	HNPCC	accounts	 for	 about	 2-6%	of	 CRCs	
[71]	and	is	associated	with	mutations	such	as	the	MLH1	and	MSH2	genes,	which	are	
involved	in	the	DNA	repair	pathway	[72].	FAP	accounts	for	less	than	1%	of	all	CRCs	
[66]	and	is	related	to	mutations	in	the	tumour	suppressor	gene	APC	[73].	Although	
relatively	low	in	incidence,	almost	all	individuals	with	FAP	will	have	developed	CRC	
by	age	40	if	the	colon	is	not	removed	[74].		
	
1.3.2.4	Personal	history	of	IBD	
	
As	 mentioned	 in	 section	 1.2.3,	 the	 duration	 and	 extent	 of	 IBD	 increase	 an	
individual’s	risk	of	developing	CRC.	Therefore,	regardless	of	age	and	other	factors,	
those	 individuals	 with	 IBD	 are	 encouraged	 to	 be	 screened	 for	 CRC	 on	 a	 more	
frequent	basis	than	those	without	IBD.		
	
1.3.2.5	Lifestyle	risk	factors		
	
A	 large	 proportion	 of	 CRC	 cases	 may	 be	 preventable	 by	 recognition	 of	 certain	
lifestyle	 risk	 factors.	 These	 contributing	 factors	 include	 lack	 of	 regular	 physical	
activity,	 low	 fruit	 and	 vegetable	 intake,	 a	 low-fibre	 and	 high-fat	 diet,	 obesity,	
alcohol	consumption	and	smoking	[75].	It	has	been	reported	that	obesity	and	a	lack	
of	 physical	 activity	 account	 for	 about	 a	 quarter	 to	 a	 third	 of	 CRCs.	 This	 may	 be	
explained	 by	 increasing	 the	 body’s	 metabolic	 efficiency	 and	 reducing	 blood	
pressure	 and	 insulin	 resistance	 [66].	 Smoking	 is	 not	 only	 associated	 with	 lung	
cancer,	but	is	also	extremely	harmful	to	the	colon,	as	tobacco	is	associated	with	the	
formation	 and	 growth	 rate	 of	 adenomas	 [76].	 Heavy	 alcohol	 consumption	 acts	
synergistically	with	 smoking	and,	 combined	with	a	diet	 low	 in	essential	 nutrients,	
make	tissues	susceptible	to	carcinogenesis.	Diet	strongly	influences	the	risk	of	CRC	
and	is	discussed	in	detail	in	section	1.3.4.2.4.		
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1.3.3	IBD-associated	CRC		
	
Individuals	suffering	from	long-term	IBD	are	at	an	increased	risk	of	developing	CRC	
during	 later	 life,	with	UC	and	CD	patients	having	a	10-	 and	4-	 fold	 increased	 risk,	
respectively	[77].	UC-associated	CRC	was	first	reported	by	Crohn	and	Rosenburg	in	
1925	 [78],	 and	 CD	 in	 1945	 [79].	 There	 is	 no	 known	 genetic	 basis	 for	 the	
predisposition	to	CRC	in	patients	with	IBD.	The	mortality	rate	is	higher	in	this	type	
of	CRC	than	that	for	sporadic	CRC	[80].	This	risk	can	be	related	to	the	duration	and	
extent	 of	 the	 disease	 with	 growing	 evidence	 to	 support	 the	 hypothesis	 that	
inflammatory	 cells	 present	 from	 IBD	 can	 be	 actively	 tumour	 promoting	 [81].	 A	
significant	correlation	has	been	reported	between	the	colonoscopic	and	histologic	
inflammation	 scores	 and	 the	 risk	 of	 colorectal	 neoplasia	 [82].	 However,	 the	
pathogenesis	 of	 IBD-related	 CRC	 remains	 poorly	 understood	 but	 influencing	 risk	
factors	 include	 genetic	 instability,	 epigenetic	 alteration,	 impaired	 immune	
responses	 by	 mucosal	 inflammatory	 mediators,	 the	 presence	 of	 oxidative	 stress,	
diet	and	the	intestinal	microbiota	[83].				
	
1.3.4	Pathogenesis	of	CRC	
	
The	 primary	 focus	 of	 this	 thesis	 is	 inflammation-associated	 CRC	 but	 to	 begin	 to	
understand	 its	pathogenesis,	 it	 is	 first	helpful	to	appreciate	the	molecular	basis	of	
sporadic	CRC.		
	
1.3.4.1	Pathogenesis	of	sporadic	CRC	
	
Sporadic	 CRC	 arises	 from	 genomic	 instability,	 resulting	 in	 a	 loss	 of	 chromosomal	
material,	termed	aneuploidy,	which	contributes	to	the	loss	of	function,	or	mutation,	
of	 key	 tumour	 suppressor	 genes	 such	 as	 APC	 (an	 early	 event)	 and	 p53	 (a	 later	
event)	 (Figure	 1.4).	 This	 accumulation	 of	mutations	 drives	 the	 transformation	 of	
normal	 colonic	 epithelium	 to	 adenomas	 to	 cancer	 [84].	 During	 the	 adenoma-
carcinoma	 sequence,	 further	 changes	 occur	 in	 the	 genetic	 regulation,	 such	 as	
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induction	 of	 K-ras	 oncogene.	 Individuals	 with	 FAP	 often	 progress	 to	 CRC	 via	 this	
pathway	[84].		
	
1.3.4.2	Pathogenesis	of	IBD-associated	CRC	
	
CRC	 in	the	setting	of	 IBD	 is	believed	arise	 from	the	progression	of	no	dysplasia	to	
indefinite	dysplasia	to	low-grade	to	high-grade	dysplasia	to	carcinoma	(Figure	1.4).	
Inflammation-associated	 CRC	 differs	 from	 sporadic	 CRC	 in	 the	 way	 that	 it	 is	 not	
unusual	for	dysplasia	or	cancer	to	be	multifocal,	rather	than	sporadic,	arising	in	one	
or	 two	 focal	 areas	 of	 the	 colon	 [84].	 IBD	 clearly	 predisposes	 individuals	 to	 CRC	
development;	 the	 role	of,	and	 interactions	of,	 inflammation,	diet,	oxidative	 stress	
and	 the	 intestinal	 microbiota	 in	 the	 pathogenesis	 of	 IBD-associated	 CRC	 are	
discussed	below.		
	
	
	
Figure	 1.4	 The	 differences	 in	 the	 molecular	 pathogenesis	 of	 sporadic	 CRC	 and	
inflammation-associated	 CRC.	 Sporadic	 CRC	 is	 driven	 by	 genomic	 instability	
resulting	in	a	sporadic	adenoma-carcinoma	sequence.	Inflammation-associated	CRC	
occurs	by	a	progression	from	no	dysplasia	to	indefinite	to	low-grade	to	high-grade	
dysplasia	 to	 carcinoma.	 Mutations/loss	 of	 function	 in	 genes:	 APC,	 adenomatous	
polyposis	coli;	p53,	tumour	suppressor	protein	p53.	Adapted	from	[84].		
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1.3.4.2.1	Inflammation-dysplasia-carcinoma	sequence	
	
Inflammation	 is	 an	 important	 risk	 factor	 for	 the	 development	 of	 CRC	 in	 patients	
with	 IBD	 and	 the	 epidemiological	 data	 support	 this	 assumption	 [60].	 It	 has	 been	
postulated	 that	 inflammation	 results	 in	 malignant	 transformation	 by	 enhancing	
epithelial	cell	turnover	in	the	colonic	mucosa.	This	is	supported	by	the	observation	
of	high	rates	of	mitosis	and	apoptosis	in	association	with	active	UC	[85].	In	addition,	
it	is	believed	that	mutagenic	assault	and	sustained	DNA	damage	appear	to	drive	the	
whole	process.	A	number	of	inflammation-associated	genes	(e.g.	cyclooxygenase-2	
(COX-2),	nitric	oxide	synthase-2	(NOS2)	and	the	Fragilis	interferon-inducible	gene	1-
8U)	have	also	been	found	to	be	over-expressed	in	areas	of	inflamed	mucosa	[85].	A	
recent	 study	 found	Toll-like	 receptor	4	 (TLR4)	 signalling	 is	 over-expressed	 in	both	
human	 and	 murine	 inflammation-driven	 CRC	 and	 that	 TLR4-deficient	 mice	 were	
protected	from	CRC	[86].	The	authors	hypothesised	that	TLR4	signalling	promotes	
CRC	as	a	result	of	inflammation	by	enhancement	of	COX-2	expression	and	increased	
estimated	Glomerular	Filtration	Rate	(eGFR).		
	
The	detection	of	these	early	inflammatory	related	changes	would	result	in	a	better	
prognosis	 for	 patients	 at	 risk	 of	 developing	 CRC.	 Aberrant	 crypt	 foci	 (ACF)	 were	
originally	 described	 in	 rodents	 treated	 with	 colon-specific	 carcinogens	 [87],	 but	
have	also	been	 identified	 in	humans	at	high	risk	of	CRC	as	cancer	biomarkers	[88,	
89].	However,	whether	ACF	are	signs	of	pre-malignancy	or	not	has	been	questioned	
[90].	 For	 example,	 the	 spontaneous	 development	 of	 ACF	 in	 rats	was	 investigated	
but	results	suggested	that	spontaneous	ACF	rarely	progress	to	colon	tumours	[91].	
In	addition,	promoters	of	CRC	such	as	cholic	acid,	have	been	reported	to	decrease	
the	expression	of	ACF	in	rats,	rather	than	increase	it	[92].	More	recently,	dysplastic	
foci	depleted	of	mucins	(MDF)	 in	the	colon	of	rodents	[93]	and	humans	[94]	have	
been	described.	Similar	to	colonic	tumours,	MDF	show	activation	of	wnt	signalling	
driven	by	mutations	 in	 the	β-catenin	 gene	and	APC,	 both	 key	 to	CRC	progression	
[94,	95].		
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1.3.4.2.2	Oxidative	stress	and	CRC	
	
Essentially,	oxidative	stress	is	an	imbalance	between	the	production	of	free	radicals	
and	the	ability	of	the	body	to	counteract	their	harmful	effects	[96].	Cellular	damage	
caused	by	oxidative	stress	is	an	important	feature	of	UC;	phagocytic	leukocytes	are	
increased	and	result	 in	enhanced	production	of	pro-oxidant	molecules	 [84].	 It	has	
been	hypothesised	that	inflammation	may	be	the	link	between	oxidative	stress	and	
the	 development	 of	 CRC;	 wherein	 the	 increase	 in	 activated	 leukocytes	 results	 in	
overproduction	of	reactive	oxygen	species	(ROS)	[96].	Inflammatory	phagocytic	cells	
(e.g.	 neutrophils)	 have	 an	 enzyme,	 nicotinamide	 adenine	 dinucleotide	 phosphate	
(NADPH)	 oxidase	 (NOX),	 present	 on	 their	 surface	where	 it	 produces	 ROS	 that	 kill	
bacteria.	 The	 intestinal	 NOX1	 isoform	 appears	 over-expressed	 in	 CRC	 tissue,	
compared	to	normal	colonic	mucosa	[96,	97].	Furthermore,	improved	formation	of	
8-nitroguanine,	 representative	 of	 nitrative	 damage	 to	 nucleobases,	 has	 been	
detected	in	IBD	[60].	Consequently,	oxidative	stress	can	pave	the	way	for	malignant	
tumours	 to	 develop	 in	 inflamed	 tissue,	 and	 ROS	 and	 nitric	 oxide	 (NO)	 may	
contribute	to	this.		
	
1.3.4.2.3	Inflammation,	intestinal	microbiota	and	CRC	
	
The	human	gut	is	home	to	a	complex	community	of	bacteria	that	play	a	vital	part	in	
the	overall	homeostasis	of	 the	host.	Currently,	 the	mechanisms	by	which	bacteria	
contribute	 to	CRC	are	not	 fully	understood,	but	evidence	suggests	a	 link	between	
the	gut	microbiota	and	inflammation	in	the	development	of	CRC.	It	is	thought	that	
the	 intake	 of	 dietary	 products	 interacts	 with	 the	 different	 species	 of	 bacteria	
present	within	the	gut	 to	promote	the	chronic	 inflammation	described	above	and	
drive	 the	 progression	 of	 CRC	 through	 direct	 influence	 of	 host	 cell	 physiology,	
cellular	 homeostasis,	 energy	 regulation,	 and/or	 metabolism	 of	 xenobiotics	 [98]	
(Figure	1.5).		
	
	
	
23	
	
1.3.4.2.4	Diet,	intestinal	microbiota	and	CRC	
	
Diets	that	are	high	in	fat,	in	particular	animal	fat,	are	a	key	risk	factor	for	CRC.	This	
can	be	linked	to	the	concept	that	the	typical	Western	diet	 is	high	in	fat,	favouring	
the	development	of	a	gut	microbiota	capable	of	degrading	bile	salts	to	potentially	
carcinogenic	compounds,	N-nitroso	compounds	[99].	 Increased	meat	consumption	
is	also	a	major	factor	to	be	considered	in	the	development	of	CRC.	Cooking	meat	at	
high	 temperatures	 results	 in	 the	 production	 of	 compounds	 with	 carcinogenic	
properties,	namely	heterocyclic	amines	and	polycyclic	aromatic	hydrocarbons	[100].	
In	addition,	heme	iron	from	meat	has	been	implicated	in	the	increased	risk	of	CRC	
[101].	Individuals	who	have	a	diet	low	in	fruit	and	vegetables	may	be	at	a	higher	risk	
of	 developing	 CRC.	 These	 intake	 differences	 in	 dietary	 fibre	 may	 therefore	 be	
responsible	for	the	geographic	differences	in	the	CRC	incidence	rates.	For	example,	
dietary	fibre	has	been	proposed	to	account	for	the	differences	in	the	rates	of	CRC	
between	 Africa	 and	Westernised	 countries	 [102].	 The	 increased	 intake	 of	 dietary	
fibre	 in	 Africa	may	 dilute	 faecal	 content,	 increase	 faecal	 bulk	 and	 reduce	 transit	
time.	Figure	1.6	presents	 the	 interactions	of	various	components	of	 the	diet	with	
the	intestinal	microbiota	during	the	development	of	CRC.	
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Figure	 1.5	 Role	 of	 the	 intestinal	 microbiota	 in	 the	 progression	 of	 chronic	
inflammation	 to	 adenoma	 and	 CRC.	 Bacterial	 dysbiosis	 causes	 a	 breakdown	 in	
epithelial	barrier	function,	resulting	in	bacterial	translocation.	In	turn,	this	triggers	a	
pro-inflammatory	 response	 leading	 to	 suppression	 of	 apoptosis,	 cell	 hyper-
proliferation	 and	 the	 production	 of	 ROS.	 Chronic	 inflammation	 eventually	
progresses	to	adenoma	and	CRC.	Adapted	from	[98].		
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Figure	1.6	The	 interaction	of	various	 components	of	 the	diet	with	 the	 intestinal	
microbiota	in	CRC.	Carbohydrates,	protein	and	fat	are	the	principal	components	of	
diet	 intake	 and	 undergo	 colonic	 bacterial	 digestion.	 By-products	 produced	 are	
shown	here	to	be	involved	in	CRC	via	various	mechanisms.	Adapted	from	[98].		
	
1.3.5	CRC	screening	techniques	 	
	
In	general,	the	purpose	of	CRC	screening	is	to	reduce	morbidity	and	mortality	from	
CRC.	Other	than	cervical	cancer,	CRC	is	the	only	cancer	for	which	population-based	
screening	 has	 shown	 to	 improve	 disease	 prognosis.	 The	 detection	 of	 CRC	 at	 an	
earlier	stage	from	a	premalignant	polyp	is	associated	with	better	survival,	therefore	
making	 CRC	 one	 of	 the	 most	 preventable	 cancers	 [103].	 This	 has	 been	
demonstrated	by	the	development	of	the	first	staging	system	for	CRC,	Dukes’	stages	
of	 colon	 cancer,	where	Dukes	 and	 colleagues	 showed	 that	better	patient	 survival	
was	accompanied	by	a	disease	diagnosis	at	an	earlier	stage	[104].		
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People	 in	 England	 are	 currently	 offered	 bowel	 screening	 at	 2-year	 intervals	
between	 the	 ages	 of	 60-69	 to	 avoid	 late	 detection	 and	 poor	 prognosis.	 This	
screening	involves	a	faecal	occult	blood	test	(FOBT),	which	is	cost-effective	but	may	
fail	to	detect	early	stage	lesions.	In	March	2015,	a	new	NHS	bowel	scope	screening	
programme	was	 introduced,	 offered	 to	men	 and	women	 aged	 55	 and	 involves	 a	
flexible	 sigmoidoscopy	 [105].	 A	 sigmoidoscopy	 and	 a	 colonoscopy	 are	 more	
sensitive	 procedures,	 but	 extremely	 invasive	 and	 expensive	 [106].	 As	 a	 result,	
scientists	 and	 clinicians	 are	working	 together	 to	 find	 an	 alternative	 non-invasive,	
cheaper	method	of	CRC	screening	such	as	disease-specific	biomarkers.		
	
1.4	MURINE	MODELS	OF	GI	DISEASE		
	
Over	 the	 past	 century,	 the	 mouse	 has	 developed	 into	 the	 primary	 mammal	 for	
scientific	research.	Scientists	from	a	wide	range	of	biomedical	fields	have	gravitated	
to	the	mouse	because	of	its	close	genetic	and	physiological	similarities	to	humans,	
as	well	as	the	ease	with	which	its	genome	can	be	manipulated	and	analysed	[107].	
Mouse	models	of	disease	can	be	referred	to	as	a	‘pure’	group	of	subjects;	scientists	
can	 control	 for	many	 resulting	 interfering	 factors.	 This	 is	 unlike	 results	 produced	
from	 human	 patients	 who	 may	 be	 influenced	 by	 smoking,	 antibiotics,	 diet	 and	
social	environments.		
	
1.4.1	Murine	models	of	colitis		
	
Murine	models	 of	 experimentally	 induced	 IBD	 are	 useful	 tools	 to	 investigate	 the	
pathogenesis	 of	 the	 disease	 and	 to	 develop	 novel	 therapeutics	 and	 diagnostic	
methods	 to	 improve	 the	 quality	 of	 life	 for	 patients	 suffering	 from	 IBD.	 Mouse	
models	of	colitis	either	focus	on	the	more	general	abnormalities	and	mechansims	of	
gut	 inflammation,	 and	 those	 that	 have	 a	more	 particular	 focus.	 There	 have	 been	
several	mouse	models	of	IBD	developed,	including	chemically-induced	(e.g.		dextran	
sulphate	sodium	(DSS)-induced	experimental	colitis	model	[108]),	bacterial-induced	
(e.g.	 Salmonella	 administration	 [109]),	 spontaneous	 (e.g.	 SAMP1/4it	 [110]),	
genetically-engineered	 (e.g.	 interleukin-10-/-	 knockout	 model	 (IL-10)	 [111]),	
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transgenic	 (e.g.	TNFΔARE/WT	model	 [112])	 and	 adoptive	 transfer	 (e.g.	 CD45RB	 high-
transfer	 [109])	Table	1.1.	Although	these	models	do	not	represent	the	complexity	
of	 human	 disease,	 they	 are	 an	 indispensable	 tool	 to	 decipher	 the	 underlying	
mechanisms	 of	 IBD	pathogenesis	 as	well	 as	 to	 evaluate	 potential	 diagnostics	 and	
therapeutics.		
	
Experimental	genetically	modified	transgenic	and	spontaneous	models	of	colitis	are	
useful	 in	 determining	 disease	 causation	 and	 identifying	 potential	 therapeutic	
targets.	 The	 ITF-dnRII	 transgenic	mouse	was	 first	 described	 in	 2001	 [110,	 113]	 to	
explore	 the	 effects	 of	 transforming	 growth	 factor	 (TGFβ1)	 on	 bowel	 immunity,	
extracellular	matrix	protein	expression,	and	carcinogenesis	 finding	that	the	 loss	of	
TGFβ1	signalling	 in	the	 intestine	does	contribute	to	tissue	 injury	 in	 IBD.	The	Muc2	
colitis	 [114]	 and	 the	 MDR1a	 colitis	 [115]	 models	 are	 common	 examples	 of	
spontaneous	colitis	models	with	inflammation	reportedly	associated	with	increases	
in	 intestinal	 lymphocytes,	 TNFα	 and	 IL-1β	 for	 Muc2	 colitis,	 and	 driven	 by	 Th1	
cytokines	for	the	MDR1a	colitis.	The	 IL-10-/-	model	 is	one	of	the	earliest	models	of	
intestinal	 inflammation	 [116,	 117]	 and	 continues	 to	 have	 great	 value	 given	 the	
important	 anti-inflammatory	 function	 of	 this	 cytokine.	 Genetic	 polymorphisms	 at	
the	 IL-10	 locus	 have	been	 reported	 to	 increase	 the	 risk	 of	 both	UC	 [118]	 and	CD	
[119],	and	perhaps	a	familial	form	of	early	onset	CD	[120].	
	
Chemically-induced	colitis	models	are	 the	most	commonly	 [121]	used	and	 include	
acetic	 acid-induced	 colitis	 [122],	 indomethacin-induced	 enterocolitis	 [123],	 2,4,6-
trinitrobenzene	 sulphonic	 acid	 (TNBS)-induced	 colitis	 [124],	 peptidoglycan-
polysaccharide	(PG-PS)	model	 [125],	 lambda-carrageenan-induced	rat	model	 [126]	
and	 oxazolone-induced	 colitis	 [127].	 Acetic	 acid-induced	 colitis	 causes	 epithelial	
damage	 accompanied	 by	 mucosal	 and	 submucosal	 inflammation	 in	 the	 colon.	
Indomethacin-induced	enterocolitis	can	either	be	based	on	subcutaneous	injection	
or	the	addition	of	dissolved	indomethacin	to	the	diet,	resulting	 in	 inflammation	in	
the	small	 intestine	and	colon	of	rodents.	TNBS-	and	oxazolone-induced	colitis	and	
DSS-induced	colitis	can	either	be	administered	once	for	acute	colitis	or	by	repeated	
administration	 for	 chronic	 colitis.	 Although	 similar	 to	 DSS-induced	 colitis	 with	
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clinical	 and	 histological	 features,	 these	models	 do	 not	 show	 high	 reproducibility,	
unlike	 the	DSS	model	which	 is	used	 in	 this	 thesis,	 and	 is	discussed	 in	more	detail	
below.	 It	 is	 important	 to	 note	 that	 no	 single	 model	 of	 colitis	 will	 capture	 the	
complexity	 of	 human	 IBD	 but	 each	 model	 has	 the	 potential	 to	 provide	 valuable	
insights	into	major	aspects	of	colitis,	and	together	they	have	led	to	a	generally	well-
accepted	hypothesis	for	human	IBD	pathogenesis.		
	
Table	1.1	Animal	models	of	IBD	according	to	the	two	major	human	IBD	phenotypes,	
UC	or	CD	(Adapted	from	[109]).		
Animal	models	of	IBD		 Human	IBD	phenotype	
	 UC	 CD	
Chemically	induced		 DSS	 TNBS/DNBS	
	 TNBS/DNBS	 Indomethacin	
	 Oxazolone	 PG-PS	
	 Acetic	acid	 	
	 Carregeenan		 	
	 Iodoacetamide		 	
Immunologic	 2,4-Dinitrochlorobenzene	(DNCB)	 	
Bacterial	induced		 Salmonella	administration	 	
	 Adherent	invasive	E.coli		 	
	 Helicobacter	hepaticus	[128]		 	
Spontaneous	 	 C3H/HejBir	mice	
	 	 SAMP1/4it	mice	
Genetically	engineered	 TGFβ-/-	 IL-10-/-	
	 IL-2-/-	 NOD2-/-	
	 MDR1A-/-	 A20-/-	
	 GaI2-/-	 IL-23-/-	
	 TCRα-/- NEMO-/-	
	 XBP1-/-	 	
	 NEMO-/-	 	
Transgenic		 IL-17	Tg		 STAT4	
	 HLA-B27	 HLA-B27	
	 	 DNN	Cadherin	Tg		
Mutation	knock	in	 	 TNF
DARE		
Adoptive	transfer	 CD45RB	high-transfer	 CD45RB	high-transfer	
	
1.4.1.1	Dextran	sulphate	sodium	(DSS)-induced	colitis	
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Oral	administration	of	DSS	has	been	used	to	induce	colitis	in	experimental	animals	
since	1990	[129]	and	to	date	there	have	been	around	1000	papers	published	using	
this	 model	 [130].	 DSS	 is	 a	 water-soluble,	 negatively	 charged,	 sulphated	
polysaccharide	with	a	highly	variable	molecular	weight,	ranging	from	5	to	1400	kDa	
[131].	DSS	 is	administered	orally	 in	sterile	drinking	water	at	a	dose	between	1-5%	
for	 5	 days,	 followed	 by	 7	 days	 normal	 drinking	 water	 to	 induce	 colitis.	 This	
experimental	model	 shares	 clinical	 (diarrhoea,	bloody	 stools	and	weight	 loss)	and	
histological	 (crypt	 erosion,	 goblet	 cell	 depletion,	 ulceration)	 features	with	 human	
UC	 [108].	 It	 is	 one	 of	 the	 most	 commonly	 used	 methods	 to	 investigate	 the	
pathogenesis	of	 IBD;	producing	a	high	degree	of	uniformity	and	 reproducibility	of	
most	 lesions	 in	 the	 distal	 colon	 [132].	 The	 typical	 features	 appear	 by	 day	 5,	 are	
maximally	expressed	by	day	8,	and	show	signs	of	recovery	by	day	11.		Depending	on	
the	 concentration,	 the	 duration	 and	 the	 frequency	 of	 DSS	 administration,	 the	
animals	may	develop	acute	or	chronic	colitis.	The	exact	mechanism	by	which	DSS	
induces	intestinal	inflammation	is	unknown,	but	it	likely	to	be	the	result	of	the	large	
DSS	molecules	interfering	with	the	intestinal	barrier	function	by	causing	erosion	of	
the	epithelial	monolayer	and	stimulation	of	 local	 inflammation	leading	to	 immune	
cell	infiltration,	an	increase	in	pro-inflammatory	cytokines,	such	as	IL-6	and	TNF-α,	
and	consequently,	a	dysbiosis	of	the	microbiota	(Figure	1.7).	
	
1.4.1.1.1	Important	factors	that	influence	DSS-induced	colitis	
	
The	reproducible	induction	of	DSS-colitis	depends	on	a	number	of	key	factors,	such	
as	molecular	weight	(MW),	concentration,	duration	of	exposure,	mouse	strain,	age,	
gender,	body	weight	and	all	environmental	factors	[133].	These	factors	can	be	split	
in	to	three	different	groups,	those	related	to:	
1. The	 nature	 of	 DSS	 itself	 and	 its	 mode	 of	 administration	 e.g.	 MW,	
concentration,	duration,	manufacturer	and	batch	of	administered	DSS.		
2. The	animal	species,	animal	strain,	and	gender.		
3. Environmental	 factors	 such	 as	 housing	 conditions	 and	 the	 intestinal	
microbiota.	
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The	MW	of	DSS	is	highly	variable;	ranging	from	5	kDa	to	1400	kDa	and	depending	
on	the	administration	of	DSS	at	different	MWs,	the	severity	and	 location	of	colitis	
differs.	 Evidence	 for	 this	 is	 provided	 by	 Kitajima	 et	 al.	who	 observed	 the	 most	
severe	colitis	in	the	middle	and	distal	third	of	the	colon	in	BALB/c	mice	treated	with	
DSS	of	 40	 kDa	while	mice	 treated	with	DSS	of	 5	 kDa	developed	a	milder	 form	of	
colitis	mainly	 in	 the	 caecum	and	upper	 colon.	 There	were	no	 lesions	 identified	 in	
the	 colons	 of	 mice	 treated	 with	 500	 kDa,	 which	 may	 be	 due	 to	 its	 high	 MW	
preventing	 the	 passage	 of	 the	 DSS	 molecules	 through	 the	 mucosal	 membrane	
[134].	Acute	(early)	colitis	 is	usually	 induced	by	continuous	administration	of	2-5%	
DSS	 for	 short	 periods	 whereas	 chronic	 (advanced)	 colitis	 may	 be	 induced	 by	
continuous	treatment	of	a	lower	concentration,	or	by	cyclic	administration,	of	DSS.		
	
The	 responsiveness	 of	 DSS	 differs	 among	 strains	 shown	 by	 a	 quantitative	
histological	analysis	in	nine	mouse	strains,	which	demonstrated	major	differences	in	
the	severity	of	DSS-induced	colitis	with	C3H/HeJ	being	very	susceptible	and	DBA/2J	
mice	 being	 less	 susceptible	 [135].	 These	 differences	 were	 either	 attributable	 to	
genetic	differences	in	the	ability	of	the	mucosa	to	withstand	inflammatory	damage,	
differences	 in	the	ability	to	 limit	the	 inflammatory	response,	or	both	[108].	This	 is	
also	 demonstrated	 in	 BALB/c	 and	 C57BL/6	 mice,	 after	 the	 withdrawal	 of	 DSS,	
C57BL/6	 mice	 progressed	 to	 chronic	 colitis	 whereas	 BALB/c	 recovered	 [136].	
Differences	 related	 to	 gender	 have	 also	 been	 investigated	 with	 a	 greater	 male	
susceptibility	 to	 DSS-induced	 colonic	 colitis,	 not	 caecal	 lesions,	 being	 reported	
[135].	 DSS-induced	 breakdown	 of	 epithelial	 barrier	 function	 allows	 the	 entry	 of	
luminal	 microorganisms	 into	 the	 mucosa	 causing	 an	 inflammatory	 response,	 as	
shown	 by	 the	 reduced	 susceptibility	 of	 germ-free	 (GF)	 animals	 [137]	 and	 the	
improvement	 in	 histological	 parameters	 in	 mice	 treated	 with	 antibiotics	 [138].	
Furthermore,	DSS	is	resistant	to	degradation	by	intestinal	microflora	or	the	effects	
of	different	pH	conditions	and	anaerobic	incubation	[108,	139].		
	
31	
	
	
Figure	 1.7	 Schematic	 representation	 of	 DSS-induced	 colitis.	 The	 mechanism	 by	
which	 DSS	 is	 thought	 to	 induce	 colitis	 in	 mice	 is	 unclear,	 however	 is	 thought	 to	
result	 from	 a	 breakdown	 in	 barrier	 function,	 stimulation	 of	 inflammation	 and	
dysbiosis.	Modified	from	[133].	
 
1.4.2	Animal	models	of	CRC	
	
Existing	data	from	current	animal	models	of	IBD	and	CRC	indicate	that	inflammation	
predisposes	 to	CRC	 [140,	141].	 These	 include	genetic,	 chemical	 and	bacterial	CRC	
studies	employing	animal	models	and	are	discussed	in	detail	in	an	excellent	review	
[142].	The	sporadic	and	 IBD-associated	CRC	murine	models	used	 in	 this	 thesis	are	
discussed	 below;	 refer	 to	 methods	 chapter	 sections	 2.2.4	 and	 2.2.5	 for	 specific	
protocols	used.			
	
32	
	
1.4.2.1	Sporadic	CRC		
	
The	 carcinogens	 1,2-dimethylhydrazine	 (DMH)	 and	 its	 metabolite,	 azoxymethane	
(AOM),	 are	 the	 two	 most	 commonly	 used	 chemicals	 to	 controllably	 induce	 and	
promote	CRC	in	rodents.	Both	DMH	and	AOM	are	DNA	alkylating	compounds	that	
induce	CRC	by	intraperitoneal	(I.P.)	injections	over	several	weeks	to	induce	tumours	
in	the	distal	colon	[142].	This	model	of	CRC	 is	similar	to	HNPCC	as	the	majority	of	
the	 tumours	 either	 display	 aberrant	 protein	 expression	 for	 APC	 or	 involve	
mutations	 in	 the	β-catenin	 gene	 which	 both	 cause	 an	 increase	 in	WNT	 signaling	
independently,	 driving	 tumourigenesis	 [143],	 therefore	 resembling	 human	 CRC.	
AOM	has	some	advantages	over	DMH	including	higher	potency,	reproducibility	and	
greater	stability	 in	the	dosing	solution	[144].	 It	 involves	a	stepwise	activation	post	
injection,	including	a	hydroxylation	step	mediated	by	cytochrome	P450	in	the	liver,	
excretion	and	further	metabolism	by	the	microbiota	[144]	(Figure	1.8).		
	
	
	
Figure	 1.8	 Activation	 of	 AOM.	 The	 AOM	 murine	 model	 of	 CRC	 is	 successful	 in	
investigating	 numerous	 factors	 involved	 in	 the	 role	 of	 tumour	 initiation	 and	
progression.	Adapted	from	[144].	
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1.4.2.2	IBD-associated	CRC		
	
An	 alternative	 option	 using	AOM	 includes	 the	 pro-inflammatory	 reagent	DSS	 and	
induces	 a	 colitis-associated	 tumour	 development.	 This	 combination	 also	
dramatically	 shortens	 the	 latency	 time	 for	 the	 development	 of	 CRC	 compared	 to	
AOM	alone	 [95]	 (10	weeks	 vs	 30	weeks,	 respectively).	 This	model	 is	 useful	when	
studying	the	tumour	progression	driven	by	chronic	inflammation,	as	seen	in	UC	or	
CD	patients	[144].	The	induction	of	colitis	by	oral	administration	of	DSS	is	described	
in	section	2.2.1;	a	two-stage	CRC	model	combines	AOM	and	DSS	and	is	based	on	a	
single	injection	of	AOM	and	three	cycles	of	DSS	[144].	AOM/DSS	treatment	in	mice	
is	a	powerful	model	for	the	initiation	of	ACF	(early	precursor	lesions)	[145].		
	
1.5	BACTERIAL	COMMUNITY	OF	THE	MURINE	GI	TRACT	
	
In	gut	microbiota	 research,	mouse	models	are	being	 increasingly	used.	Therefore,	
the	comprehensive	characterisation	of	 the	normal	murine	GI	microbiota	 is	 critical	
to	 understand	 and	 predict	 alterations	 in	 bacterial	 communities	 in	 relation	 to	
disease.	 Gu	 et	 al.	 used	 16S	 rRNA	 gene	 sequence	 based	 analysis	 to	 examine	 the	
microbiota	along	the	entire	GI	tract	of	healthy	C57BL/6	specific	pathogen	free	(SPF)	
mice	[146].	They	found	that	jejunal	and	ileal	samples	had	the	lowest	diversity	whilst	
samples	from	the	caecum,	colon,	and	faeces	had	the	highest	diversity	of	bacterial	
communities.	 Twenty	 one	 different	 bacterial	 phyla	 were	 identified	 with	 the	
majority	of	sequences	obtained	belonging	to	Bacteroidetes	(61.94%)	and	Firmicutes	
(30.55%)	 with	 the	 rest	 distributed	 among	 Proteobacteria	 (5.39%),	 Cyanobacteria	
(0.63%),	Tenericutes	(0.165%),	Actinobacteria	(0.13%),	Deferribacteres	(0.10%)	and	
unclassified	bacteria	 (0.95%).	Higher	 inter-mouse	variations	were	detected	among	
the	gastric	and	small	 intestinal	samples	than	among	the	large	intestinal	and	faecal	
samples.	 In	addition,	 clustering	of	bacterial	 communities	 suggested	 that	 the	 large	
intestine	and	faeces	were	distinct	from	those	in	the	stomach	and	small	intestine.	
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1.5.1	Gut	microbiota	in	murine	models	of	IBD	
	
One	 of	 the	 earliest	 studies	 reporting	 the	 induction	 of	 colitis	 by	 administration	 of	
DSS	 in	 1990	 also	 provided	 evidence	 for	 the	 role	 of	 microbiota	 in	 experimental	
colitis.	 Okayasu	 et	 al.	 found	 a	 significant	 increase	 in	members	 of	Bacteroidaceae	
and	Clostridiaceae	spp.	Families,	in	particular	species	such	as	Bacteroides	distasonis	
and	Clostridium	 ramonsum,	 in	 the	 intestines	of	mice	exposed	 to	DSS	 [129].	More	
recently,	C57BL/6	female	mice	were	administered	4%	DSS	and	resulted	in	elevated	
16S	 rRNA	 gene	 copy	 numbers	 of	 the	 mucin-degrading	 Gram-negative	 bacterium	
Akkermansia	muciniphila	and	of	Enterobacteriaceae	[147,	148].	The	gut	microbiota	
is	enriched	in	colonic	polyps	in	ApcΔ468/Il-10-/-	mice	compared	to	healthy	tissues,	in	
particular,	two	genera,	Bacteroides	and	Porphyromonas	[149].	The	microorganisms	
reported	 to	 be	 associated	 with	murine	models	 of	 IBD	 have	 been	 summarized	 in	
Table	1.2.			
	
A	breakthrough	in	the	understanding	of	the	role	of	microbiota	in	mouse	models	of	
IBD	 came	 with	 observations	 that	 treatment	 with	 antibiotics	 or	 GF	 breeding	 is	
associated	with	significantly	 less	severe	bowel	 inflammation	and	cancer	[148].	For	
instance,	Dove	et	 al.	 showed	 that	ApcMin/+	 housed	 in	 a	GF	environment	displayed	
more	 than	 a	 50%	 reduction	 in	 tumour	 growth,	 compared	 to	 the	 same	 animals	
housed	in	SPF	[150].	Also,	IL-10	deficient	mice	were	resistant	to	spontaneous	colitis	
when	kept	in	GF	environment	[151].		
	
Different	bacterial	species	may	coordinate	the	 initiation	of	 inflammation,	whereas	
others	 may	 have	 a	 role	 in	 its	 continual	 progression	 [152].	 The	 administration	 of	
probiotics,	 including	 Lactobacillus,	 Bifidobacterium	 and	 Streptococcus	 salivarious,	
has	 beneficial	 effects	 on	 both	 humans,	 and	murine	models	 of	 IBD	 [153],	 but	 not	
with	colitis-associated	CRC	mouse	models	[154].		
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Table	1.2	Bacterial	species	reported	to	be	altered	in	IBD	murine	models.	Modified	
from	[148].		
Type	of	model	 Microorganisms	 Final	effect	
DSS-induced	colitis	 Bacteroides	distasonis,	
Clostridium	ramonsum,	
Akkermansia	
muciniphila,	
Enterobacteriaceae	
Increased	numbers	correlate	with	
acute	and	chronic	UC	[129,	147]	
IL-10	deficient	
spontaneous	colitis	
Enterobacteriaceae,	
adherent-invasive	E.	
coli	
Increased	numbers	correlate	with	
inflammation	(Enterobacteriaceae)	
and	cancer	(E.	coli)	[155,	156]	
Colitis	in	pcCΔ468/Il-10-/-	
hereditary	CRC	model	
Bacteroides,	
Porphyromonas	genera	
Increased	numbers	correlate	with	
inflammation	and	colon	polyposis	
[149]	
TNBS-induced	colitis	 Enterobacteriaceae,	
Bacteroides	
Increased	numbers	correlate	with	
inflammation	[157]	
 
1.6	THE	SCENT	OF	DISEASE	
	
Although	 the	 analysis	 of	 disease-specific	 odours	 is	 a	 relatively	 young	 field	 of	
research,	 the	 detection	 of	 abnormal	 human	 smells	 as	 an	 indicator	 of	 certain	
diseases	dates	back	to	around	400	BC.	The	Ancient	Greek	physician	and	the	father	
of	 medicine,	 Hippocrates,	 instructed	 his	 students	 to	 smell	 the	 breath	 of	 their	
patients	 and	pour	human	 saliva	on	hot	 coals	 as	 an	effective	means	of	 identifying	
their	 ailments	 [158,	 159].	 Later	 during	 the	 11th	 century,	 the	 Arab	 physician	 and	
philosopher,	Avicenna,	noted	differences	in	the	smell	of	urine	from	patients	with	an	
illness,	compared	to	those	without	[160].	Traditional	Chinese	medicines	were	able	
to	diagnose	diabetes	in	patients	whose	urine	emitted	a	smell	of	a	rotten	apple	[161,	
162].	In	1857,	Wilhelm	Petters	discovered	acetone	in	the	urine	of	diabetic	patients	
[163]	and	Johannes	Muller	made	the	first	quantitative	measurements	of	acetone	in	
the	breath	of	diabetic	patients	in	1898	[164].	Robert	Koch	investigated	the	presence	
of	 foul	 odours	 from	 infected	 wounds	 and	 odours	 produced	 from	 pathogenic	
bacteria	grown	in	culture	for	proof	of	his	germ	theory,	based	on	experiments	with	
anthrax	 in	 the	 19th	 century	 [165].	 In	 1923,	 Omelianski	 et	 al.	 supported	 these	
findings	by	reporting	on	odours	 from	naturally-liberated	microbes	associated	with	
the	accumulation	of	staling	metabolic	products	such	as	organic	acids	and	alcohols	in	
cultures	of	Mycobacterium	tuberculosis	and	Pseudomonas	aeruginosa	[166].		
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The	 characterisation	 of	 abnormal	 odours	 associated	 with	 diseases	 has	 been	
investigated	further	since	the	development	of	gas	chromatography	(GC)	and	mass	
spectrometry	 (MS)	 instruments.	 Davies	 and	 Hayward	 identified	 acetylcholine	
emitted	 from	 patients’	 urine	 and	 proposed	 that	 it	 may	 be	 a	 precursor	 of	
trimethylamine,	 a	 possible	 early	 microbial	 chemical	 marker	 of	 urinary	 tract	
infections	caused	by	Proteus	and	Klebsiella	species	[167].	The	first	half	of	the	1980s	
saw	the	clinical	application	of	the	urea	breath	test	applied	in	gastroenterology	for	
the	 diagnosis	 of	 gastritis	 associated	 with	 Helicobacter	 pylori	 [168].	 Even	 though	
many	of	these	practices	are	centuries	old,	they	provide	evidence	that	early	medical	
practitioners	were	 clearly	 able	 to	 recognise	 that	 the	presence	of	 human	diseases	
could	 change	 the	 odour	 of	 bodily	 excretions,	 including	 breath,	 blood,	 urine	 and	
faeces.		
	
1.7	METABOLOMICS	
	
Systems	 biology	 studies	 the	 complex	 interactions	 and	 behaviours	 of	 a	 cell	 or	
organism.	 It	has	developed	into	an	 inter-disciplinary	science,	combining	genomics,	
transcriptomics,	 proteomics	 and	 metabolomics	 [169].	 The	 latter	 represents	 the	
outcome	of	systems	biology,	such	that	the	varying	concentrations	of	metabolites	in	
a	 cell	 are	 relative	 to	 the	 changes	 occurring	 in	 the	 genome,	 transcriptome	 and	
proteome.	Metabolomics	can	be	defined	as	the	investigation	of	a	group	of	endpoint	
metabolites	of	a	physiological	or	pathophysiological	process,	aiming	 to	define	 the	
chemical	 fingerprint	 unique	 to	 a	 specific	 organism	 [170].	 Therefore,	 it	 has	 the	
potential	 to	provide	 answers	 to	 some	unanswered	questions	 in	order	 to	 improve	
the	diagnosis,	treatment	and	prevention	of	diseases.	More	recently,	the	detection	
of	 abnormal	 smells	 as	 indicators	 of	 specific	 diseases	 from	 bodily	 fluids	 such	 as	
faeces	or	breath	has	been	termed	the	Faecal,	or	Breath,	Metabolome.	A	number	of	
studies	 have	 emphasized	 the	 role	 of	 VOCs	 in	 identifying	 disease-specific	
metabolome	patterns.		
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1.8	VOLATILE	ORGANIC	COMPOUNDS	(VOCS)	
	
VOCs	 are,	 by	 definition,	 a	 large	 and	 diverse	 group	 of	 carbon-based	 chemicals,	
related	 by	 their	 volatility	 at	 room	 temperature	 and	 which	 include	 hydrocarbons,	
alcohols,	aldehydes,	ketones,	esters	and	organic	acids.	Most	vapours	emitted	from	
biological	 samples	 (e.g.	 breath,	 sweat,	 blood,	 urine	 and	 faeces)	 contain	 odorous	
VOCs	 and	 those	 that	 vary	 between	 conditions	 may	 be	 used	 as	 an	 indication	 of	
cellular	 metabolism	 leading	 to,	 or	 indicative,	 of	 a	 diseased	 state.	 VOCs	 can	 be	
thought	of	as	intermediates	of	metabolic	pathways	such	that	observed	changes	in	
the	 presence	 or	 levels	 of	 certain	 VOCs	 will	 indicate	 the	 change	 in	 a	 person’s	
phenotype.	 The	 method	 of	 detection	 of	 VOCs	 is	 a	 key	 step	 and	 of	 paramount	
importance,	 therefore	 considerable	 effort	 has	 been	 invested	 in	 developing	 and	
improving	the	sampling	and	pre-concentration	techniques.		
	
1.8.1	The	origin	of	VOCs	
	
The	current	understanding	of	the	human	VOC	spectrum	is	at	an	early	stage	[171].	
However,	a	recent	review	reported	1,840	VOCs	appearing	in	exhaled	breath	(872),	
skin	 emanations	 (532),	 urine	 (279),	 saliva	 (359),	 human	 breast	 milk	 (256),	 blood	
(154)	 and	 faeces	 (381)	 [172].	 Interestingly,	 only	 0.7%	 were	 ubiquitous	 to	 all	 the	
bodily	fluids	and	breath	examined:	acetylaldehyde,	2-propanone,	benzaldehyde,	1-
butanol,	 2-butanone,	 hexanal,	 heptanal,	 octanal,	 pentanol,	 benzene,	 styrene	 and	
toluene.	The	major	sources	of	VOCs	include	breath,	blood,	urine	and	faeces	and	can	
vary	 with	 age,	 diet,	 sex,	 disease	 and	 physiological	 status	 and	 possible	 genetic	
background.	
	
1.8.1.1	Breath	
	
Of	 the	1,840	compounds	 identified	emitted	 from	bodily	 fluids	of	healthy	humans,	
the	majority	were	 identified	 in	breath	 (872)	 [172].	Of	 these	exhaled	breath	VOCs,	
isoprene	 and	 acetone	were	 the	most	 prominent	 [172]	 and	 29	 dienes,	 27	 alkenes	
and	 3	 alkynes	 are	 related,	 but	 not	 specific,	 to	 smoking	 [173].	 Isoprene	 is	 formed	
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along	the	mevalonic	pathway	of	cholesterol	synthesis	and	it	is	thought	to	relate	to	
oxidative	damage	within	the	fluid	lining	of	the	lung	[174,	175].	Acetone	is	one	of	the	
most	 abundant	 VOCs	 in	 breath	 and	 its	 concentration	 increases	 in	 patients	 with	
diabetes	 mellitus	 [176].	 Other	 VOCs	 may	 be	 related	 to	 food	 consumption	 or	
medication,	and	their	interactions	or	degradation	with	the	gut	microbiota,	such	as	
hydrogen	 or	 methane	 [172].	 Exhaled	 breath	 aliphatic	 hydrocarbons	 have	 been	
regarded	 as	 stable	markers	 of	 lipid	 peroxidation	 and,	 therefore,	may	 be	 used	 to	
monitor	levels	of	oxidative	damage	in	the	body	[174].		
	
To	 name	 a	 few	 examples,	 breath	markers	 have	 been	 found	 in	 patients	with	 lung	
cancer	 [177],	 cystic	 fibrosis	 [178],	 lung	 transplantation	 [179],	 and	 kidney	 failure	
[180].	 Despite	 the	 number	 of	 promising	 results	 showing	 diagnostic	 potential	 of	
detection	of	VOCs	from	breath,	it	has	not	yet	been	introduced	into	clinical	practice.	
This	is	because	of	the	limitations	with	sampling,	pre-concentration	and	analysis.		
	
1.8.1.2	Urine	
	
A	recent	review	of	VOCs	from	urine	from	apparently	healthy	volunteers	found	nine	
to	 be	 ubiquitous	 to	 all	 samples	 tested:	 propanone,	 2-butanone,	 2-pentanone,	 2-
heptanone,	 3-hexanone,	 4-heptanone,	 2,5-dimethylfuran,	 2-ethyl-5-methylfuran,	
and	toluene	[181].	Authors	suggested	that	the	source	of	some	or	all	of	these	VOCs	
is	 likely	 to	 be	 the	 gut,	 as	 some	 are	 also	 found	 in	 faeces.	 In	 addition,	 the	 large	
number	of	ketones	identified	in	urine	probably	arise	as	products	of	metabolism	by	
the	gut	microbiota	as	ketones	were	decreased	significantly	 in	the	urine	of	GF	rats	
[182].	Alterations	in	the	urine	VOC	metabolome	have	been	used	to	detect	diseases	
including	urinary	tract	infections	[183],	liver	disease	[184]	and	bladder,	prostate	and	
other	cancers	[171].	
	
1.8.1.3	Faeces	
	
Patients	often	report	an	abnormal	odour	emitted	from	their	faeces	during	disease	
relapse,	yet	there	has	been	little	research	performed	to	investigate	the	composition	
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of	 faecal	 gases.	 The	 human	 gut	microbiota	 is	 comprised	 of	 numerous	 species	 of	
bacteria,	which	during	health,	are	 thought	 to	 contribute	 to	 the	mucosal	 integrity,	
the	 maintenance	 of	 host	 health	 and,	 thus,	 the	 protection	 against	 invading	
organisms	 [185].	 This	 resident	 microbiota	 is	 responsible	 for	 the	 fermentation	 of	
undigested	 foods	 in	 the	 colon,	 producing	 putrefactive	 compounds	 such	 as	
ammonia,	aliphatic	amines,	branched	chain	fatty	acids,	 indole,	phenol	and	volatile	
sulphur	 containing	 compounds,	 hence,	 affecting	 both	 the	 colonic	 and	 metabolic	
health	 [185,	 186].	 Faecal	 VOCs	 have	 been	 implicated	 in	 differentiating	 between	
certain	 infectious	and	non-infectious	bowel	conditions	such	as	Clostridium	difficile	
[187],	 Salmonella	 [171],	 Cholera	 [64],	 Campylobacter	 [188]	 and	 irritable	 bowel	
syndrome	(IBS)	[189]	and	IBD	[190].			
	
1.8.1.4	Other		
	
Blood,	 skin	secretions,	 saliva	and	milk	are	examples	of	other	biological	 sources	of	
VOCs.	Although	the	analysis	of	blood-derived	VOCs	is	an	active	area	of	research	and	
can	 directly	 reflect	 the	 internal	 environment	 of	 the	 body,	 obtaining	 samples	
requires	trained	phlebotomists	and	may	be	less	tolerated	by	patients	compared	to	
urine	 or	 breath.	 Skin	 secretions	 produced	 a	 large	 number	 of	 VOCs;	 however,	 an	
individual’s	odour	 is	very	particular	and	can	vary	significantly	depending	on	which	
part	 of	 the	 skin	 is	 tested.	 Currently,	 there	 are	 limited	 number	 of	 studies	 on	 the	
analysis	of	VOCs	in	saliva	and	milk	[172].	
	
1.8.2	Chemical	composition	of	VOCs	
	
The	chemical	analysis	of	VOCs	for	the	biological	sources	described	above	results	in	a	
list	 of	 compound	 classes	 as	 follows:	 hydrocarbons,	 acids,	 esters,	 alcohols,	
aldehydes,	 ketones,	 furans	 and	 ethers,	 sulphur	 containing,	 nitrogen	 containing,	
halogen	containing,	chloro	biphenyls	and	others	[172].	Figure	1.9	presents	the	total	
classes	of	compounds	based	on	the	number	of	different	VOCs	identified,	not	upon	
their	relative	concentration,	found	in	each	bodily	fluid.		
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Figure	1.9	Classes	of	VOCs	 in	human	biological	material.	 The	 relative	number	of	
different	compound	classes	that	have	been	detected	in	faeces,	urine,	breath,	skin,	
milk,	 blood	 and	 saliva,	 as	 reported	 by	 Costello	 et	 al.	 The	 total	 number	 of	 VOCs	
identified	 in	 each	 compound	 class	 represented	 as	 a	 percentage	 of	 the	 total	 VOC	
profile	 for	each	biological	matrix.	Copyright	has	been	granted	 from	publisher	and	
authors	and	figure	is	used	with	permission	[172].		
	
1.8.3	Oxidative	stress	and	VOCs	
	
All	organisms	need	oxygen	to	live,	but	high	concentrations	can	be	toxic,	therefore,	
organisms	 have	 developed	 protective	 mechanisms	 in	 order	 to	 maintain	 oxygen	
homeostasis.	Energy	is	obtained	via	processes	involving	the	four-electron	reduction	
of	oxygen	to	water;	also	generating	dangerous	by-products	(i.e.	free	radicals,	ROS).		
The	implication	of	ROS	in	the	pathogenesis	of	diseases	involves	the	reaction	of	ROS	
with	 cellular	 components	 such	 as	 lipids,	 proteins	 and	 nucleic	 acids	 causing	 tissue	
damage	[171].	Lipid	peroxidation	is	a	chain	reaction	with	initiation,	propagation	and	
termination	 steps.	 Peroxidation	 of	 lipids	 and	 other	 biomolecules	 by	 ROS	 produce	
measurable	VOCs	(e.g.	ethane,	1-pentane)	(Figure	1.10).	The	non-invasive	detection	
and	 monitoring	 of	 oxidative	 stress	 is	 not	 only	 desirable	 in	 autoimmune,	
neurological,	 inflammatory	 diseases	 and	 cancer,	 but	 also	 during	 surgery	 and	 in	
41	
	
intensive	 care	 units.	 Oxidative	 stress	 due	 to	 smoking	 could	 cause	 increased	 lipid	
peroxidation	resulting	in	diene	formation,	therefore	offering	an	explanation	for	the	
presence	 of	 butadiene,	 a	 notable	 carcinogenic	 compound	 related	 to	 tobacco	
smoking	[191].		
	
	
Figure	 1.10	 Lipid	 peroxidation.	 Possible	 reactions	 and	 products	 of	 free	 radical-
mediated	 lipid	 peroxidation	 [174].	 Copyright	 has	 been	 granted	 and	 figure	 is	 used	
with	permission.	
	
1.8.4	Microbial	VOCs	
	
Microbial	 VOCs	 are	 a	 group	 of	 compounds	 produced	 from	 the	 metabolism	 of	
bacteria	and	fungi,	formed	during	either	primary	(e.g.	DNA	synthesis)	or	secondary	
metabolism	 (e.g.	 intermediates	 of	 primary	 metabolism).	 They	 often	 have	 strong	
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odours	and	are	 responsible	 for	 the	smells	 including	“old	cheese”,	 “dirty	 socks”	or	
“locker	 room”	 [192];	 all	 smells	 associated	 with	mould	 and	 bacterial	 growth.	 The	
investigation	of	bacterial	and	cell	cultures	in	vitro	may	open	up	new	possibilities	for	
the	 clarification	 of	 the	 biochemical	 background	 of	 such	 VOCs.	 The	 resultant	 VOC	
profile	of	biological	 samples	 is	 said	 to	 reflect	 the	microbial	metabolic	activity	and	
may	potentially	be	a	specific	biomarker	of	colonic	disease	[193].		
	
1.8.5	Diet	and	VOCs		
	
Interactions	 between	 the	 gut	 microbiota	 and	 their	 host	 include	 the	 microbial	
breakdown	 of	 nutrients,	 in	 particular	 carbohydrates,	 in	 order	 to	 salvage	 energy.	
Short-chain	 fatty	 acids	 (SCFAs)	 (e.g.	 acetate,	 propionate,	 butyrate)	 are	 commonly	
detected	in	the	faeces	of	humans	and	are	most	likely	to	arise	from	the	metabolism	
of	 undigested	 carbohydrate	 by	 colonic	 bacteria	 [188]	 (Figure	 1.11).	 Hydrogen	
sulphide	 and	 methanethiol	 are	 generated	 from	 sulphur-containing	 substances	 in	
the	diet	 and	 can	be	 very	 damaging	 to	 the	 colonic	 epithelium	 [194].	Garner	et	 al.	
also	 reported	 that	 the	 commonly	 detected	 VOCs,	 toluene	 and	 xylene,	might	 also	
have	 dietary	 origin;	 possibly	 from	 potatoes	 [188].	 Pro-inflammatory	 molecules	
including	lipopolysaccharide	and	peptidoglycan	are	produced	by	the	gut	microbiota	
and	may	influence	host	metabolism.	For	example,	choline	obtained	from	the	diet	is	
metabolised	 to	 generate	 bioactive	 VOCs,	 which	 can	 eventually	 lead	 to	
cardiovascular	disease	[195].	Detection	of	the	compounds	may	be	indicative	of	the	
disease	state	of	an	individual.		
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Figure	1.11	Host	and	microbial	contributions	to	carbohydrate	degradation	in	the	
intestine.	 Absorption	 of	 simple	 sugars	 from	 the	 breakdown	 of	 ingested	
carbohydrates	via	active	transport	occurs	in	the	small	intestine.	Undigested	matter	
passes	through	to	the	colon	where	they	undergo	degradation	by	resident	bacterial	
communities.	 By-products	 of	 the	 gut	 fermentation,	 including	 SCFAs	 are	 absorbed	
and	utilised	by	the	host.	Adapted	from	[196].		
	
1.8.6	VOCs	in	human	GI	disease	
	
Pathological	processes,	 including	different	bacterial	 infections,	 inherited	disorders	
of	metabolism	and	various	cancers,	can	 influence	odour	 fingerprints	by	producing	
new	VOCs	or	by	changing	the	ratio	of	VOCs	that	are	produced	normally.	The	human	
GI	tract	harbours	over	100	trillion	bacteria,	causing	the	gut	microbiome	to	be	100	
times	more	abundant	than	the	host	genome	[197].	 Identification	of	the	metabolic	
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profiles	 associated	 with	 IBD	 and	 CRC	 onset	 and	 progression	 will	 improve	 the	
diagnosis	and	 treatment	of	 these	diseases.	This	may	also	enable	 the	dissection	of	
the	metabolic	profiles	involved	with	the	metabolism	of	such	bacteria,	fungi,	genes	
and	 proteins	 within	 the	 gut,	 during	 health	 and	 in	 the	 presence	 of	 disease.	 An	
advantage	of	 acquiring	 a	better	understanding	of	 the	unique	metabolic	 profile	of	
CRC	would	be	to	improve	the	possibility	of	a	clear	distinction	between	cancer	cells	
and	normal	cells.		
	
Progress	 in	 analytical	 methods	 such	 as	 gas	 chromatography-mass	 spectrometry	
(GC-MS),	or	devices	that	electronically	mimic	the	human	olfactory	system,	termed	
the	 ‘electronic	 nose’;	 have	 been	 developed	 to	 provide	 an	 opportunity	 to	 identify	
VOCs	 related	 to	diseases	 in	 research	 laboratories	 [198].	Dogs	can	also	be	used	as	
detectors	 of	 certain	 cancers	 as	 they	 have	 an	 extraordinary	 sense	 of	 smell	 with	
odour	 detection	 thresholds	 as	 low	 as	 parts	 per	 trillion.	 In	 cases	 of	 melanoma,	
bladder,	ovarian	and	colorectal	cancer,	dogs	can	be	trained	to	distinguish	patients	
based	on	VOCs	from	patients’	urine,	tumours	or	breath	samples,	more	successfully	
than	 would	 be	 expected	 by	 chance	 alone	 [199,	 200].	 The	 development	 of	 the	
electronic	 sensors	 and	 analytical	 methods	 will	 continue	 to	 improve	 the	 accuracy	
and	sensitivity	of	marker	VOCs	from	complex	biological	samples,	allowing	disease-
specific	‘volatile	biomarkers’	to	be	used	more	regularly	in	clinical	practice.	There	are	
currently	a	limited	number	of	studies	investigating	the	murine	metabolome	of	IBD-
induced	models	[112,	125,	201,	202].	
 
1.9	GAS	CHROMATOGRAPHY-MASS	SPECTROMETRY	
	
Numerous	 volatile	 and	 non-volatile,	 polar	 and	 non-polar	 metabolites	 can	 be	
measured	with	GC-MS	systems	[203].	GC-MS	is	used	in	this	work	for	the	separation	
and	 identification	 of	 thermally	 stable	 and	 volatile	 compounds	 emitted	 from	
samples	 into	 the	 headspace	 (HS)	 of	 sample	 glass	 vials.	 This	 platform	 is	 a	
combination	of	two	different	analytical	techniques	comprising	a	gas	chromatograph	
coupled	to	a	mass	spectrometer.		
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Metabolites	are	introduced	into	the	instrument	via	injection	through	a	septum	into	
the	GC	injection	port	where	they	travel	 in	a	flowing	carrier	gas	(helium)	to	the	GC	
column.	 The	 GC	 column	 determines	 when	 the	 compound	 is	 eluted,	 its	 retention	
time	 (RT),	 depending	 on	 the	 columns	 length,	 diameter	 and	 phase	 thickness.	 The	
VOCs	continue	to	travel	along	the	column	and	undergo	separation	by	their	relative	
affinity	for	the	stationary	phase	of	the	column	based	of	their	chemical	properties.	
The	MS	 is	 then	able	 to	 capture,	 ionize,	 accelerate,	deflect	 and	detect	 the	 ionized	
molecule	 separately.	 Each	 molecule	 is	 broken	 into	 fragments,	 which	 are	 then	
detected	 using	 their	 mass-to-charge	 ratio.	 GC-MS	 has	 been	 described	 as	 a	 “gold	
standard”	for	forensic	science	due	to	its	high	degree	of	specificity	and	sensitivity.		
	
1.10	SOLID	PHASE	MICROEXTRACTION	
	
Solid	 phase	 microextraction	 (SPME)	 was	 developed	 in	 the	 1990s	 by	 Professor	 J	
Pawliszyn	to	provide	a	quick	and	solvent-less	technique	for	the	isolation	of	analytes	
in	a	sample	matrix	[204].	SPME	operates	with	a	stationary-phase-coated	fused-silica	
fibre,	 contained	 within	 a	 syringe	 device	 that	 provides	 both	 protection	 and	 easy	
transport	 of	 the	 fibre	 phase	 [205].	 	 For	 analysis,	 the	 syringe	 is	 placed	 into	 the	
analyte	 solution	 or	 into	 the	 headspace	 above	 the	 sample	 and	 the	 coated	 fibre	 is	
exposed	for	a	fixed	amount	of	time	to	allow	for	absorption	of	compounds.	Once	the	
equilibrium	is	reached,	the	fibre	is	retracted	into	the	needle	and	removed	from	the	
sample	vial	and	inserted	in	the	GC	injector	for	desorption	of	VOCs	into	the	column	
(Figure	1.13).		
	
1.10.1	Principles	of	SPME	
	
As	 previously	 mentioned,	 the	 extraction	 of	 VOCs	 by	 SPME	 is	 based	 on	 an	
equilibrium	forming	between	the	fibre	and	the	sample.	Extraction	of	VOCs	from	the	
sample	headspace	onto	the	fibre	coating	begins	as	soon	as	the	fibre	is	inserted	into	
the	sampling	vial.	This	process	is	completed	when	the	VOC	concentration	adsorbed	
has	 reached	 its	 distribution	 equilibrium	 between	 the	 fibre	 coating	 and	 sample	
headspace	(Figure	1.12).	This	equilibrium	forms	between	three	phases:	
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1. Fibre	coating	to	sample	phase	
2. Headspace	to	sample	phase	
3. Fibre	coating	to	headspace	
	
The	distribution	about	the	three	phases	after	equilibrium	can	be	represented	by:	
	 CoVo	=	Ch∞Vh	+	Cs∞Vs	+	Cf∞Vf	
	 Where:	
	 	 Co	=	initial	concentration	of	the	compound	in	the	sample	
	 	 Ch∞,	Cs∞	and	Cf∞	=	equilibrium	concentrations	of	the	compound	 in	the	
	 	 	 headspace	(h),	sample	(s)	and	fibre	coating	(f),	respectively.		
	 	 Vh,	Vs	and	Vf	=	volumes	of	headspace	(h),	sample	(s)	and	fibre	coating	
	 	 	 (f),	respectively.		
	
The	time	required	to	reach	equilibrium	in	SPME	is	driven	by	diffusion	kinetics	of	the	
analytes	 in	 the	 phases	 that	 are	 present	 in	 the	 sample	 vial.	 An	 extraction	 is	
considered	 complete	when	 the	analyte	 concentration	has	 reached	 its	 distribution	
equilibrium	between	the	SPME	coating	and	the	sample	biological	matrix.		
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Figure	1.12	Adsorption	mechanism	for	SPME.	Distribution	equilibrium	between	the	
fibre	coating	and	the	sample	matrix.		
	
1.10.2	HS-SPME-GC-MS	platform		
	
The	platform	used	for	the	extraction	and	detection	of	VOCs	is	accurate	and	reliable.	
There	are	three	types	of	VOC	extraction	methods	that	can	be	utilised	with	a	SPME	
fibre:	 direct	 extraction,	 HS	 and	 membrane-protected	 SPME.	 Direct	 extraction	
involves	 the	 SPME	 fibre	 being	 directly	 immersed	 into	 the	 sample	 matrix.	
Membrane-protected	 SPME	 extraction	 is	 similar	 to	 direct	 extraction	 but	 is	
protected	by	a	selective	membrane	(e.g.	porous	polypropylene).	HS	sampling	with	
SPME	 is	 the	preferred	method	 to	extract	VOCs	and	was	developed	 in	1993	 [206].	
This	 is	 the	 method	 used	 throughout	 this	 work	 and	 involves	 a	 SPME	 fibre	 being	
exposed	to	the	HS	above	the	sample	matrix	(Figure	1.13).	It	is	reliant	on	kinetics	of	
mass	 transport,	 such	 that	 the	 analytes	 in	 the	 sample	 matrix	 undergo	 a	 series	 a	
transport	processes	into	the	gas	phase,	and	then	to	the	fibre	coating.	Advantages	of	
HS	sampling	include	protection	of	the	fibre	from	damage	by	high	molecular	weight	
and	non-volatile	metabolites	in	the	matrix.		
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Figure	1.13	Schematic	diagram	of	the	headspace	SPME	apparatus.	A	SPME	needle	is	inserted	into	a	glass	vial	via	piercing	the	septum	and	the	
SPME	fibre	is	exposed	to	the	headspace	of	the	sample	for	a	fixed	amount	of	time	then	retracted	and	device	is	removed.	Desorption	of	VOCs	
involves	injection	of	SPME	needle	into	GC	injector,	exposure	of	fibre,	retraction	and	removal.	Adapted	from	Steven	Smith’s	thesis,	University	of	
the	West	of	England	[207].	
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1.11	SYNOPSIS		
	
The	 burden	 of	 GI	 disease	 has	 dramatically	 increased	 during	 the	 20th	 century,	
significantly	 affecting	 millions	 of	 persons	 worldwide,	 inducing	 a	 considerable	
economical	impact	compromising	healthcare	and	an	individual’s	quality	of	life.	This	
thesis	 will	 focus	 on	 IBD	 and	 IBD-related	 CRC.	 The	 pathogenesis	 of	 IBD	 is	 poorly	
understood,	 but	 is	 believed	 to	 be	 a	 combination	 of	 genetics,	 a	 disruption	 to	 the	
immune	 system	 and	 an	 imbalance	 of	 the	 gut	 microbiota.	 The	 duration	 and	
anatomic	 extent	 of	 IBD	 increases	 the	 risk	 for	 CRC;	 the	mortality	 is	 higher	 in	 CRC	
patients	in	the	setting	of	IBD,	compared	to	those	with	sporadic	CRC.	Currently,	the	
diagnosis	 of	 IBD	 is	 difficult,	 invasive	 and	 not	 always	 accurate	 which	may	 have	 a	
profound	effect	on	patient	care.	Therefore,	a	non-invasive,	 IBD-specific	biomarker	
would	 be	 clinically	 useful.	 The	 early	 detection	 of	 CRC	 significantly	 improves	 the	
prognosis	and	 increases	 the	chances	of	 survival	beyond	 five	years	 from	diagnosis.	
Recently,	the	investigation	of	the	metabolome	in	IBD	patients	compared	to	healthy	
controls	has	begun	to	receive	considerable	attention	and	correlations	between	the	
faecal	 VOC	 metabolome	 and	 IBD	 are	 emerging.	 	 However,	 human	 studies	 are	
limited	by	the	variation	in	diet	and	the	unpredictability	of	the	disease.	As	a	result,	
animal	models	have	been	widely	used	as	model	organisms	 in	biomedical	research	
to	gain	insight	into	the	workings	of	human	disease.	Here,	we	report	the	first	study	
using	HS-SPME-GC-MS	to	detect	the	VOC	faecal	metabolome	in	the	commonly	used	
mouse	models	of	IBD	and	CRC,	DSS-induced	colitis	and	AOM-induced	CRC.		
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1.12	HYPOTHESIS	
	
The	 murine	 faecal	 VOC	 metabolome	 will	 significantly	 differ	 according	 to	 the	
alteration	of	gut	metabolism	by	the	 induction	of	GI	diseases.	The	 identification	of	
these	 changes	 by	 the	 detection	 of	 the	 faecal	 VOC	 profile	 will	 enable	 the	
investigation	 into	 the	 pathogenesis	 of	 such	 diseases	 and	 provide	 evidence	 for	
further	investigation	of	human	GI	disease.		
	
1.13	AIMS	
	
The	aims	are	to:	
1) develop	standard	operating	procedure	(SOP)	for	the	detection	of	VOCs	in	the	HS	
of	faeces	from	healthy	WT	C57BL/6	mice	using	a	SPME-GC-MS	platform;		
2) characterise	 the	 normal	murine	 faecal	metabolome,	 considering	 the	 effect	 of	
gender,	age,	presence	of	microbiota,	diet	and	housing	conditions;		
3) investigate	the	metabolic	differences	in	the	development	of:-	
i) Acute	colitis	
ii) Chronic	colitis	
iii) Inflammation-associated	CRC	
iv) Sporadic	CRC	
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Chapter	2	
	
Materials	and	Methods
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2.1	ANIMALS	
	
2.1.1	Wild-type	C57BL/6	mice	
	
Inbred,	 wild-type	 (WT)	 C57BL/6	 mice	 were	 purchased	 from	 Charles	 River	
Laboratories	 (Margate,	 UK),	 and	 were	 acclimatised	 under	 standard	 animal	 unit	
conditions	specific	pathogen	free	(SPF)	for	a	minimum	of	1	week	prior	to	being	used	
in	experimental	procedures.	For	the	optimisation	of	sample	volume,	a	cage	of	four	
9-week	old	males	were	used,	and	for	SPME	method	development,	four	5-week	old	
male	mice,	 housed	 individually,	 were	 used.	 For	 the	 establishment	 of	 the	 healthy	
murine	metabolome,	both	male	and	female	mice	aged	5	weeks	old	were	used	and	
for	 all	 disease	 induction	 experiments,	 adult	 9	 or	 10	 week	 old	 female	mice	 were	
used.	For	all	experiments	used	in	chapters	3-8	all	animals	were	housed	individually	
under	conventional	conditions	with	food	and	water	ad	libtum	throughout.	Animals	
were	 kept	 on	 a	 12:12	 hour	 light-dark	 cycle.	Mice	 were	 fed	 a	 standard	 pelleted	 diet	
suitable	for	short	term	maintenance	supplied	by	Special	Diets	Services	(SDS),	Essex,	UK.	
	
	2.1.2	NFκB2-null	mice	
	
An	NFκB2-null	 strain	 of	mice	was	 generated	 on	 the	 C57BL/6	 genetic	 background	
and	 kindly	 donated	 to	 our	 laboratory	 by	 Dr	 Jorge	 Caamano	 of	 the	 University	 of	
Birmingham.	The	homozygote	NFκB2-/-	 colony	was	maintained	under	conventional	
conditions.	 Confirmation	 of	 this	 genotype	 was	 previously	 performed	 by	 Dr	 Mike	
Burkitt	of	 the	Department	of	Gastroenterology,	Univeristy	of	Liverpool	by	PCR.	Dr	
Jonathan	Williams	of	 the	Department	of	Gastroenterology,	University	of	Liverpool	
conducted	all	 experiments	 involving	NFκB2-null	mice	used	 in	 this	 thesis,	with	 the	
assistance	of	the	author,	and	faecal	samples	were	donated	for	analysis	by	GC-MS.	
	
2.1.3	Germ-free	mice	
	
The	GF	colonies,	C3H/HeN	and	Junbo	mice	and	their	non-GF	SPF	strain	equivalent	
were	 bred	MRC	 Harwell,	 Oxford.	 The	 Junbo	 colony	 is	 maintained	 on	 a	 C3H/HeN	
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background	 and	 are	 otherwise	 healthy	 animals,	 but	 with	 a	 hearing	 defect	 [208].	
Faecal	 samples	were	kindly	provided	by	Ms	 Julie	Roberts	of	MRC	Harwell,	Oxford	
from	healthy	GF	and	non-GF	mice	from	a	mixture	of	male	and	female	mice	of	6-7	
weeks	old	and	were	fed	a	standard	diet	of	chow.	
 
2.2	ANIMAL	PROCEDURES		
	
Experiments	were	conducted	with	UK	Home	Office	approval	under	a	project	licence	
as	specified	by	the	Animals	(Scientific	Procedures)	Act	1986.	All	experiments	were	
performed	by	 the	author,	 as	 a	UK	Home	Office	personal	 licensee,	 and	 conducted	
within	 an	 SPF	 animal	 unit	 with	 barrier	 precautions	 in	 place	 to	 maintain	 the	
microbiological	 status	 of	 the	 animals	 housed	 within	 it,	 at	 the	 University	 of	
Liverpool.	All	experiments	were	conducted	during	the	daytime	starting	between	9-
11am.		
	
2.2.1	Induction	of	colitis	using	dextran	sulphate	sodium	(DSS)	
	
2.2.1.1	Optimal	dosing	of	DSS	
	
The	 optimal	 dose	 of	 DSS	 to	 induce	 colitis	 in	 the	 C57BL/6	 strain	was	 investigated	
using	doses	between	2	and	5%	(M.W	=	36,000-50,000;	Catalogue	number:	160110;	
Lot	number:	5237K;	MP	Biomedicals,	LLC,	UK).	These	pilot	studies	were	designed	to	
determine	 the	 DSS	 dosing	 regimen	 to	 induce	 an	 acute	 colitis	 with	 a	 maximum	
weight	 loss	 of	 20-25%	 before	 euthanasia	 administration,	 in	 accordance	 with	 the	
project	 license	 and	 Institutional	 Animal	 Care	 and	 Use	 Committee	 (IACUC)	
recommendations.	In	order	to	determine	the	optimal	dose	of	DSS	concentrations	of	
2,	3,	4,	4.5	and	5%	DSS	were	used.	Ideally,	a	maximum	weight	loss	of	20-25%	would	
signify	an	acute	form	of	intestinal	damage.	
	
C57BL/6	female	mice	were	given	DSS	in	their	drinking	water	at	concentrations	of	2,	
3,	4	and	5%	for	5	days,	followed	by	4	days	of	normal	water	to	induce	acute	colitis.	
Concentrations	of	2	and	3%	DSS	did	not	cause	weight	loss	or	show	any	clinical	signs	
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of	colitis	 (n=2	per	dose).	The	concentration	of	DSS	was	consequently	 increased	to	
4%,	resulting	in	a	very	mild	colitis	with	an	average	weight	loss	of	9.5	±	1.3%	at	day	6	
with	slightly	 loose	stools	and	no	visible	signs	of	 rectal	bleeding	 (mean	±	SD,	n=2).	
Subsequently,	 4.5	and	5%	DSS	were	 too	 severe	with	a	 significant	weight	 loss	and	
mice	were	unable	 to	recover.	Therefore,	 the	experiment	was	 terminated	early,	at	
day	 7	 (Figure	 2.1A).	 Histological	 analysis	 of	 H&E-stained	 distal	 colonic	 sections	
confirmed	these	clinical	findings	(Figure	2.1B).		
	
	
Figure	2.1	Optimal	dosing	of	DSS-induced	intestinal	inflammation	in	mice.	(A)	The	
change	in	the	body	weight	of	mice	was	measured	daily	with	a	maximum	weight	loss	
of	20%	reached	according	to	ethical	guidelines	of	protocol.		Values	are	represented	
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as	mean	±	SD.	(B)	H&E	stained	colonic	sections	from	mice	culled	at	day	9	(top)	and	
day	7	(bottom)	after	DSS	treatment.		
	
	
2.2.1.2	Preliminary	investigations	of	the	metabolism	of	DSS	
	
Preliminary	 investigations	were	performed	 to	determine	 the	effect	of	DSS	on	 the	
murine	 intestines.	Analysis	by	HS-SPME-GC-MS	was	performed	of	 isolated	colonic	
epithelial	 cells	 incubated	 with	 and	 without	 DSS,	 and	 also	 the	 analysis	 of	 colonic	
tissue	 from	mice	 treated	with	 and	without	 DSS.	 Results	 included	 chromatograms	
with	no	peaks,	indicating	the	lack	of	VOCs	emitted	from	these	matrices	and	leading	
to	 the	 conclusion	 that	 future	 studies	 involving	 detection	 of	 VOCs	 from	 faecal	
samples	are	likely	to	originate	from	the	presence	of	the	intestinal	microbiota.		
	
Furthermore,	 it	 has	 been	 reported	 that	 DSS	 remains	 as	 an	 intact	 sulphated	
macromolecule	 through	 the	 murine	 intestine	 and	 is	 not	 broken	 down	 [ref	 107].	
Analysis	 of	 DSS	 powder	 and	 DSS	 drinking	 water	 by	 HS-SPME-GC-MS	 produced	
chromatograms	with	no	peaks	therefore	also	indicating	that	future	studies	involving	
the	detection	 fo	VOCs	 from	 faecal	 samples	are	unlikely	 to	originate	 from	the	DSS	
molecules.		
	
2.2.1.3	Acute	DSS-induced	colitis		
	
C57BL/6	female	mice	were	administered	4.25%	DSS	(wt/vol)	in	their	drinking	water	
for	 5	 days	 followed	 by	 6	 days	 of	 normal	 water,	 in	 order	 to	 induce	 acute	 colitis	
(Figure	 2.2).	 	 Clinical	 parameters	 of	 body	 weight	 loss,	 stool	 consistency	 and	 the	
presence	 of	 rectal	 bleeding	 were	 assessed	 daily.	 Mice	 were	 sacrificed	 at	
experimental	days	0	(n=11),	5	(n=11),	8	(n=11)	and	11	(n=8);	colonic,	caecal,	small	
intestine	contents	and	mid-large	bowel	and	distal	small	bowel	tissues	sections	were	
taken	from	each	mouse	and	stored	at	-20°C	prior	to	analysis	by	GC-MS.	The	entire	
small	 and	 large	 intestine	 tissues	 were	 taken	 for	 histological	 analysis.	 Samples	
collected	 from	mice	euthanized	at	day	0	were	 treated	as	untreated	control	 to	be	
compared	with	days	5,	8	and	11.		
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Figure	2.2	Timeline	of	DSS-induced	acute	colitis.	C57BL/6	mice	were	administered	
4.25%	DSS	in	their	drinking	water	for	5	days.	The	typical	disease	features	appear	by	
day	5,	are	maximally	expressed	by	8	and	present	with	signs	of	recovery	by	day	11	
(n=11	sacrificed	at	day	0,	5,	8	and	11).			
	
2.2.1.4	Further	DSS	dose	optimisation	
	
The	 induction	 of	 acute	 colitis	 using	 4.25%	 DSS	 was	 repeated	 3	 times,	 each	
experiment	 increasing	 the	 number	 of	 mice	 used.	 The	 third	 and	 final	 experiment	
resulted	in	a	variable	acute	colitis	across	the	animals,	with	a	couple	of	mice	having	
very	severe	colitis	at	day	8.	Although	the	majority	of	mice	were	able	to	recover	by	
day	11,	 it	was	 concluded	 that	 this	 dose	was	 too	high	 for	 future	 experiments	 and	
further	optimising	was	required.	Concentrations	of	4,	3.75,	3.25	and	3%	DSS	were	
administered	to	groups	of	3	mice	each	following	the	same	timeline	shown	in	Figure	
2.2.	 A	 maximum	 weight	 loss	 of	 15-20%	 was	 considered	 necessary.	 The	 lowest	
concentration	of	3%	resulted	in	a	weight	loss	of	16±2%	(mean±SD)	(Figure	2.3).	The	
animal	unit	used	to	perform	these	experiments	 in	was	newly	opened	as	this	work	
began.	We	have	speculated	that	over	the	space	of	12	months,	since	the	opening	of	
the	unit,	the	increase	in	sensitivity	to	DSS	was	due	to	stabilisation	of	the	barrier	to	
microbes	and	environment	within	the	unit.		
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Figure	 2.3	Optimal	 dosing	of	DSS.	Due	 to	 the	onset	 of	 a	moderate/severe	 colitis	
during	 the	 latest	4.25%	acute	colitis	experiment,	 lower	doses	of	4,	3.75,	3.25	and	
3%	were	used	to	determine	an	acute	form	of	colitis	with	a	maximum	weight	loss	of	
15-20%.	Values	are	represented	as	mean	±	SD	(n=3/concentration	of	DSS).	
	
2.2.1.5	Induction	of	acute	colitis	by	DSS	in	NFκB2-/-	mice	
	
An	additional	experiment	took	place	using	male	NFκB2-null	mice	and	was	led	by	Dr	
Jonathan	 Williams,	 assisted	 by	 the	 author	 of	 this	 thesis.	 The	 induction	 of	 acute	
colitis	 was	 performed	 with	 mice	 receiving	 2%	 DSS.	 Four	 groups	 of	 mice	 were	
included:	NFκB2-/-	DSS	treated	(n=6),	NFκB2-/-	untreated	control	(n=4),	C57BL/6	DSS	
treated	(n=6),	and	C57BL/6	untreated	controls	(n=4).		
	
2.2.1.6	Chronic	DSS-induced	colitis		
	
In	order	to	induce	a	chronic	form	of	colitis,	cyclic	DSS	administration	was	used,	the	
concentration	required	should	be	considerably	lower	than	that	for	the	acute	colitis.	
Mice	 were	 administered	 0.75%	 DSS	 (wt/vol)	 in	 their	 drinking	 water	 for	 5	 days,	
followed	by	7	days	of	normal	water.	This	cycle	was	repeated	three	times	to	induce	
chronic	colitis	[108];	the	DSS	concentration	 increased	slightly	to	1%	for	cycles	two	
and	 three	 and	 to	 1.25%	 for	 cycle	 four	 (Figure	 2.4).	 The	 control	 group	 of	 mice	
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remained	on	normal	drinking	water	throughout	the	course	of	the	experiment	(n=6	
control;	n=6	treated).	Clinical	parameters	of	body	weight	loss,	stool	consistency	and	
the	 presence	 of	 rectal	 bleeding	 were	 assessed	 daily,	 as	 with	 the	 acute	 colitis	
experiment.	 Faecal	 samples	 were	 collected	 on	 experimental	 days	 5,	 8	 and	 11	 of	
each	cycle	from	each	individual	cage.	Colonic,	caecal,	small	 intestine	contents	and	
mid-large	bowel	and	distal	small	bowel	tissue	sections	were	taken	from	each	mouse	
and	stored	at	-20°C	prior	to	analysis	by	GC-MS.	The	entire	small	and	large	intestine	
tissues	were	taken	for	histological	analysis.		
	
	
Figure	2.4	 Timeline	of	DSS-induced	 chronic	 colitis.	 Chronic	 colitis	was	 induced	 in	
C57BL/6	mice	by	4	cycles	of	0.75-1.25%	DSS	for	5	days	followed	by	7	days	of	normal	
water	(n=6	control;	n=6	treated).		
	
2.2.2	Induction	of	osmotic	diarrhoea	using	MgSO4	
	
Diarrhoea	was	 induced	 by	 oral	 administration	 of	 anhydrous	magnesium	 sulphate	
(MgSO4)	 at	 the	 dose	 of	 2g/kg	 to	 each	mouse	with	 a	 control	 group	 receiving	 one	
dose	 of	 distilled	 water	 (n=3	 control;	 n=5	 treated)	 [209].	 Animals	 were	 fasted	
overnight	 before	 the	 experiment.	 Following	 the	 administration	 of	 the	MgSO4,	 the	
animals	 were	 placed	 on	 filter	 paper,	 which	 was	 changed	 every	 hour.	 Both	 the	
amount	and	consistency	of	the	faeces	were	assessed	each	hour	for	6	hours.	Faecal	
samples	 were	 collected	 every	 hour	 and	 at	 termination	 of	 the	 experiment.	 These	
faecal	 samples	 were	 used	 as	 controls	 against	 the	 DSS	 colitis	 samples	 to	 identify	
compounds	 differentiated	 from	 colitis	 that	 are	 produced	 as	 a	 result	 of	 an	
inflammatory	response.		
	
2.2.3	Induction	of	colorectal	cancer	using	azoxymethane	(AOM)	
	
The	 induction	 of	 colonic	 tumours	 in	 C57BL/6	 female	mice	 using	 AOM	 had	 never	
been	performed	before	 in	 the	 SPF	animal	unit	 at	 the	University	 at	 Liverpool.	 The	
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experiment	was	therefore	based	on	the	Nature	protocol	of	cancer	induction	using	
AOM	[144].	The	C57BL/6	mice	have	a	lower	susceptibility	to	this	cancer	model	[210]	
compared	 to	 other	 strains	 so	 the	 concentration	 of	 AOM	 was	 increased	 from	
10mg/kg	to	12.5mg/kg.	To	begin,	a	stock	solution	of	AOM	was	prepared	in	distilled	
water	 at	 12.5mg/ml,	 aliquoted	 in	 glass	 tubes	 and	 stored	 at	 -20°C.	 Immediately	
before	use,	 stock	 solution	aliquots,	 as	 required,	were	 thawed	and	 further	diluted	
1:10	in	sterile	isotonic	saline	to	obtain	a	working	solution	of	final	concentration	of	
1.25mg/ml.	On	day	1	of	the	experiment,	mice	were	weighed	and	injected	i.p.	with	
AOM	working	solution	(12.5mg/kg	body	weight,	i.e.	125µl	working	solution	per	10g	
mouse	body	weight)	for	the	treated	group	or	sterile	isotonic	saline	for	the	control	
group.	For	spontaneous	tumour	progression,	this	process	was	repeated	at	the	start	
of	weeks	2,	3,	4,	5	and	6	to	give	a	total	of	6	 injections/mouse	(Figure	2.5).	Faecal	
samples	were	collected	once	a	week	 from	each	mouse	 through	 the	course	of	 the	
experiment.	At	week	30,	animals	were	killed	via	cervical	dislocation	for	tumour	load	
analysis.	 The	 entire	 small	 and	 large	 intestine	 tissues	 were	 taken	 for	 histological	
analysis.	Initially,	the	experiment	was	performed	using	a	control	and	AOM-treated	
group	(n=4/group)	in	order	to	see	the	outcome	of	using	12.5mg/kg	of	AOM.	It	was	
successful	 (for	 results,	 refer	 to	section	7.5.1)	and	was	repeated	using	n=6	mice	 in	
each	group.				
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Figure	2.5	AOM-induced	CRC	development.	Scheme	for	the	experimental	course	of	
AOM-induced	CRC	with	spontaneous	 tumour	progression	by	6	weekly	 injection	of	
12.5mg/kg	AOM;	w	=	week.		
	
	
2.2.4	Induction	of	inflammation-associated	colorectal	cancer	using	AOM/DSS	
	
Based	 on	 the	 findings	 observed	 in	 both	 the	 chronic	 DSS-induced	 colitis	 and	 the	
AOM-induced	CRC	experiments	 (sections	2.2.1.6	and	2.2.3,	 respectively),	C57BL/6	
female	 mice	 were	 dosed	 with	 one	 injection	 of	 12.5mg/kg	 AOM	 and	 received	 4	
cycles	of	1.5%	DSS	for	the	induction	of	inflammation-associated	CRC.	The	AOM	was	
prepared	 as	 described	 in	 section	 2.2.3	 and	 the	 treated	 group	 received	 one	 i.p.	
injection	at	12.5mg/kg	body	weight	(n=6)	on	day	1	with	the	control	group	receiving	
one	 injection	 of	 sterile	 isotonic	 saline	 (n=6).	 Five	 days	 following	 AOM	 injection,	
1.5%	DSS	was	administered	in	the	drinking	water	for	5	days	followed	by	16	days	of	
ordinary	 water;	 the	 control	 group	 remained	 on	 ordinary	 water	 throughout	 the	
experiment.	This	DSS	cycle	was	repeated	twice	and	animals	were	sacrificed	12	days	
after	the	final	cycle,	as	described	by	Greten	et	al.	2004	[211]	(Figure	2.6).		
	
w1 w4 w7 w30 
Tumour	evaluation AOM	
injections 
	 61	
	
Figure	 2.6	 Timeline	of	AOM/DSS-induced	 inflammation-associated	CRC.	 C57BL/6	
mice	received	one	injection	of	12.5mg/kg	AOM	followed	by	3	cycles	of	1.5%	DSS.		
	
2.3	TISSUE	DISSECTION	AND	PREPARATION	
	
All	animals	were	sacrificed	via	schedule	1	and	standard	dissection	techniques	were	
used	 to	 excise	 the	 small	 intestine	 and	 the	 colon.	 Faecal	 matter	 was	 carefully	
removed	from	the	small	 intestine,	caecum	and	colon	with	curved	tweezers	onto	a	
glass	 slide.	 The	 faecal	 content	was	 immediately	 transferred	 to	 labelled	 glass	 vials	
and	frozen	at	-20°C	within	one	hour	of	collection.	A	0.5	cm	tissue	section	from	the	
distal	 small	 intestine	 and	 mid-colon	 were	 also	 stored	 the	 same	 as	 the	 faecal	
contents.	The	remaining	excised	 intestines	were	rinsed	with	PBS	and	 immersed	 in	
4%	formalin	solution	overnight	to	preserves	tissues	from	degradation.	Tissues	were	
then	stored	in	70%	ethanol	prior	to	gut	bundling.		
 
2.3.1	Gut	bundling,	processing,	embedding	and	cutting	of	tissues	
	
The	fixed	colon	tissue	was	divided	into	proximal	and	distal	colon,	before	bundling,	
whereas	the	entire	small	 intestine	tissue	was	bundled	in	one	piece.	Both	were	cut	
into	 roughly	 1	 cm	 sections	 and	 placed,	 with	 care,	 into	 loops	 of	 about	 3	 cm	
micropore	surgical	tape,	creating	bundles	by	squeezing	the	tape	around	the	tissue.	
Each	 bundle	was	 then	 cut	 into	 roughly	 0.6	 cm	 lengths	with	 any	 excess	 tape	 and	
tissue	cut	off	using	a	Swann-Morton	size	22	scalpel	blade	 (VWR	 international	Ltd,	
Lutterworth,	UK).	All	bundles	were	placed	in	histology	cassettes	and	stored	in	70%	
ethanol	 prior	 to	 tissue	 processing	 overnight,	 before	 being	 embedded	 in	 paraffin	
wax	 the	 morning	 after.	 During	 the	 embedding	 step,	 bundles	 were	 orientated	
vertically	in	order	to	obtain	transverse	sections	during	tissue	cutting.	Once	the	wax	
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had	 set,	 the	 hardened	 blocks	 are	 ready	 to	 be	 sectioned.	 Vertical	 sectioning	
perpendicular	 to	 the	 surface	 of	 the	 tissue	 is	 the	 usual	 method.	 A	 steel	 knife	 is	
mounted	in	a	microtome	and	used	to	cut	10	µm	thick	tissue	sections	which	are	then	
carefully	transferred	to	a	60°C	water	bath	and	mounted	on	a	glass	microscope	slide.		
	
2.3.2	The	‘Swiss	roll’	technique	for	the	analysis	of	colon	tumours	
	
This	technique	was	used	for	the	preparation	of	colonic	tissue	from	animal	models	of	
CRC	[212].	After	excision	of	the	small	and	large	intestine,	the	large	bowel	was	cut	at	
the	 caecum	 to	 separate	 from	 small	 intestine;	 both	were	 flushed	 and	 rinsed	with	
PBS.	 Tissues	 were	 then	 fixed	 in	 4%	 formalin	 for	 maximum	 of	 1	 hour	 before	
performing	the	 ‘swiss	 roll’	 technique.	The	entire	 length	of	 the	colon	was	carefully	
slit	open	with	scissors	from	the	distal	end	and	any	remaining	faeces	were	removed.	
Mucosal	side	exposed,	the	colon	was	carefully	rolled	around	a	wooden	cotton	bud	
and	secured	with	a	needle	 (Figure	2.7)	before	undergoing	 fixation	 in	4%	 formalin	
solution	for	24	hours.		
	
	
Figure	2.7	CRC	tissue	preparation.	Photograph	of	a	swiss	roll	preparation	of	large	
intestine	treated	with	AOM±DSS.		
	
2.3.3	Haematoxylin	and	eosin	(H&E)	staining	
	
The	 transverse	 tissue	 sections	 of	 4	 µm	 thick	 attached	 to	 glass	microscope	 slides	
were	dried	at	37°C	for	24	hours	or	60°C	for	1	hour.	Slides	were	then	immediately	
de-paraffinized	 in	 xylene	 for	 10	minutes	 and	 subsequently	 rehydrated	 by	 passing	
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through	 a	 series	 of	 decreasing	 ethanol	 concentrations	 to	 distilled	 water	 (100%,	
90%,	70%,	H2O).	The	nuclei	of	the	tissues	undergo	regressive	staining	by	immersing	
in	haematoxylin	 (Sigma-Aldrich	Co,	Dorset,	UK)	 for	3	minutes	and	then	washed	 in	
running	tap	water	until	 the	water	turned	clear	(5-10	minutes).	The	tissue	sections	
were	 then	 placed	 in	 eosin	 (Sigma-Aldrich	 Co,	 Dorset,	 UK)	 for	 4	 minutes	 to	
regressively	stain	the	cytoplasm.	Any	excess	eosin	was	removed	by	washing	under	
running	water	for	roughly	1	minute.	Sections	were	then	dehydrated	by	dipping	the	
slides	 briefly	 in	 70%,	 90%	 then	 100%	 ethanol	 (<30	 seconds	 each).	 Finally,	 after	
clearing	 in	 xylene	 for	 about	 10	minutes,	 the	 slides	 were	 carefully	 mounted	 with	
Distrene,	Plasticisel,	Xylene	(DPX)	and	a	cover	slip	and	left	to	dry	for	24	hours.	The	
transverse	sections	of	tissues	were	then	examined	under	a	light	microscope.		
	
2.3.4	Masson’s	Trichrome	stain	
	
Masson’s	 Trichrome	 (MT)	 is	 used	 to	 distinguish	 collagen	 from	 muscle	 tissue,	 an	
indicator	 of	 fibrosis.	 Distal	 colon	 tissue	 sections	 of	 4	 µm	 thick	 attached	 to	 glass	
microscope	slides	were	dried	at	37°C	for	24	hours	or	60°C	for	1	hour.	Slides	were	
then	 immediately	 de-paraffinized	 in	 xylene	 for	 10	 minutes	 and	 subsequently	
rehydrated	 by	 passing	 through	 a	 series	 of	 decreasing	 ethanol	 concentrations	 to	
distilled	water	(100%,	90%,	70%,	H2O).	All	tissues	were	formalin	fixed	and	prior	to	
staining,	were	 re-fixed	 in	 Bouin’s	 solution	 for	 1	 hour	 at	 56°C	 to	 improve	 staining	
quality.	Slides	were	then	rinsed	under	running	tap	water	for	10	mins	to	remove	the	
yellow	colour	before	undergoing	staining	with	Weigert’s	iron	haematoxylin	working	
solution	 for	 10	mins	 (Weigert’s	 haematoxylin	A	 and	B	 at	 a	 1:1	 ratio).	 Slides	were	
then	 rinsed	 for	 a	 second	 time	 in	 running	 warm	 water	 for	 10	 minutes,	 quickly	
washed	in	distilled	water	and	stained	in	Biebrich	scarlet-acid	fuchsin	solution	for	10-
15	 minutes.	 After	 another	 rinse	 in	 distilled	 water,	 slides	 were	 differentiated	 in	
phosphomolybdic-phosphotungstic	acid	solution	for	10-15	minutes	or	until	collagen	
was	no	longer	red.	Sections	were	transferred	directly	(without	rinse)	to	aniline	blue	
solution	and	stained	for	5-10	minutes	before	being	rinsed	briefly	 in	distilled	water	
and	 differentiated	 in	 1%	 acetic	 acid	 solution	 for	 2-5	 minutes.	 Slides	 were	 then	
washed	in	distilled	water	for	a	final	time	and	dehydrated	very	quickly	through	95%	
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and	100%	ethanol,	cleared	in	xylene	and	mounted	with	resinous	mounting	medium,	
DPX.	 Results	 should	 show	 collagen	 stained	blue,	 nuclei	 stained	black	 and	muscle,	
cytoplasm,	keratin	stained	red.		
	
2.3.5	High	iron	diamine	(HID)	and	Alcian	blue	(AB)	stain	
	
MDF	are	foci	of	crypts	depleted	of	mucins	 in	a	background	of	normal	crypts	using	
the	HID-AB	 technique	 [213],	which	allows	differentiation	between	sialomucin	and	
sulfomucin	 production.	 Firstly,	 the	 HID	 solution	 was	 prepared	 in	 a	 Coplin	 jar	 by	
dissolving	 the	 two	 diamine	 salts,	 N,N-dimethyl-meta-phenylenediamine-
dihydrochloride	 (120mg)	 and	 N,N-dimethyl-para-phenylenediamine-
dihydrochloride	 (20mg),	 in	 50ml	 distilled	water	 and	 adding	 freshly	 prepared	 60%	
ferric	chloride	solution	(1.4ml).	Distal	colon	tissue	sections	of	4	µm	thick	attached	
to	glass	microscope	slides	were	dried	at	37°C	for	24	hours	or	60°C	for	1	hour.	Slides	
were	then	immediately	de-paraffinized	in	xylene	for	10	minutes	and	subsequently	
rehydrated	 by	 passing	 through	 a	 series	 of	 decreasing	 ethanol	 concentrations	 to	
distilled	water	(100%,	90%,	70%,	H2O).	Sections	were	then	taken	to	distilled	water	
for	 5	minutes	 and	 treated	 in	 HID	 solution	 for	 18-24	 hours	 at	 room	 temperature.	
Next,	slides	were	washed	well	in	running	tap	water	for	5-10	minutes	and	stained	in	
1%	AB	in	3%	acetic	acid	(pH	2.5)	for	5	minutes.	Finally,	sections	were	rinsed	in	tap	
water	 and	 dehydrated,	 cleared	 and	 mounted,	 as	 described	 previously.	 Expected	
results	are	to	see	sulphated	mucins	stained	brown/black	and	carboxylated	mucins	
stained	blue.		
	
2.4	PHYSIOLOGICAL	AND	HISTOLOGICAL	SCORING	METHODS	
	
There	 were	 various	 methods	 applied	 to	 quantify	 and	 confirm	 the	 physiological	
responses	 following	 different	 treatments.	 All	 scoring	 procedures	were	 performed	
by	the	author	who	was	blinded	to	the	treatment	of	the	samples	being	scored.	The	
author	 received	 training	 for	 these	 different	 scoring	 methods	 from	 a	 certified	
veterinary	pathologist,	Dr	Jonathan	Williams.				
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2.4.1	Disease	activity	index	scoring	in	DSS-induced	acute/chronic	colitis	
	
Daily	 clinical	 assessment	 of	 body	 weight,	 stool	 consistency,	 presence	 of	 rectal	
bleeding,	 and	 general	 appearance	 and	 well-being	 of	 the	 DSS-treated	 mice	 was	
performed.	Each	animal	was	given	a	disease	activity	index	(DAI)	score,	according	to	
Table	 2.1,	 providing	 a	 comprehensive	 functional	 measure	 similar	 to	 the	 clinical	
symptoms	observed	 in	human	 IBD.	The	DAI	was	 scored	using	a	validated	method	
described	previously	[201,	214].	
	
Table	2.1	Disease	activity	index	(DAI)	scoring.		
Score	 Weight	loss	(%)	 Stool	consistency	 Occult/gross	
0	 None	 normal	 normal	
1	 1-5	 -	 -	
2	 5-10	 loose	stools	 Hemoccult	+	
3	 10-15	 -	 -	
4	 >15	 diarrhoea	 gross	bleeding	
DAI	 =	 (combined	 score	 of	weight	 loss,	 stool	 consistency	 and	bleeding)/3.	
Normal	stool	=	well-formed	pellets;	loose	stools	=	pasty	stools	that	do	not	
stick	to	the	anus;	and	diarrhoea	=	liquid	stools	that	stick	to	the	anus	[201,	
214].	
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2.4.2	Histological	scoring	of	colitis	severity		
	
Following	fixation	in	4%	formalin	and	embedding	in	paraffin,	sections	were	stained	
with	 H&E	 as	 described	 previously.	 In	 order	 to	 quantify	 inflammatory	 changes	
following	DSS	administration,	a	histological	scoring	system	was	applied	as	described	
[215].	The	histological	colitis	severity	score	(range	from	0	to	6)	was	determined	as	
shown	in	Table	2.2.		
	
Table	2.2	Histological	scoring	of	colitis	severity.		
Score	 Cell	infiltration	 Tissue	damage	
0	 None	 None	
1	
Focally	 increased	 numbers	 of	
inflammatory	 cells	 in	 the	 lamina	
propria	
Discrete	epithelial	lesions	
2	 Confluence	 of	 inflammatory	 cells	extending	into	the	submucoa	 Mucosal	erosions	
3	 Transmural	 extension	 of	 the	infiltrate	
Extensive	 mucosal	 damage	 and/or	
extension	 through	 deeper	
structures	of	the	bowel	wall	
The	combined	histological	colitis	severity	score,	ranging	from	0	to	6,	is	the	sum	of	the	two	
equally	weighted	sub-scores	(cell	infiltration	and	tissue	damage).	
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2.4.3	Histological	fibrosis	scoring	method	
	
Following	fixation	in	4%	formalin	and	embedding	in	paraffin,	sections	were	stained	
with	MT	stain	as	described	previously.	 In	order	to	quantify	 the	amount	of	 fibrosis	
present	 following	DSS	administration,	a	histological	scoring	system	was	applied	as	
described	by	Ding	et	al.	2012	[216].	
	
Table	2.3	Histological	fibrosis	scoring	method.	
Category	 Score	 Description	
Collagen	(fibrosis)	 0	 No	increase	
	 1	 Increased	in	the	submucosa	
	 2	 Increased	in	the	mucosa	
	 3		 Increased	 in	 the	muscularis	mucosa;	 thickening/dis-organisation	of	the	muscularis	mucosa	
	 4	 Increased	in	the	muscularis	propria	
	 5	 Gross	disorganisation	of	the	muscularis	propria	
Percent	involvement	 1	 1-25%	of	section	
	 2	 26-50%	of	section	
	 3	 51-75%	of	section	
	 4	 76-100%	of	section	
The	 fibrosis	 score	 for	 each	 animal	 is	 the	 sum	 of	 the	 collagen	 score	 and	 the	 percent	
involvement.		
	
2.4.4	Faecal	output	scoring	in	MgSO4-induced	diarrhoea	
	
On	the	basis	of	consistency	of	stool,	a	numerical	score	was	assigned	as	follow:	1	=	
normal	 stool,	 2	 =	 semi-solid,	 3	 =	watery	 stool.	 The	 faecal	 output	 index	 (FOI)	was	
defined	as	the	sum	of	the	consistency	scores	of	all	 the	motions	passed	within	the	
observation	period	of	3	hours.	A	mouse	passing	a	stool	of	score	2	at	least	once	was	
counted	as	suffering	from	diarrhoea	[217].	
	
2.4.5	Measurement	of	colon	tumour	number	and	size	
	
At	the	end	of	the	AOM±DSS	experiments,	described	previously	in	sections	2.2.3	and	
2.2.4,	mice	were	sacrificed	and	the	whole	colon	was	carefully	dissected	and	flushed	
with	 PBS.	 The	 colon	was	 cut	 open	 longitudinally	 and	 gently	 washed	with	 PBS	 to	
remove	 any	 remaining	 faecal	 content.	 The	 opened	 colon	was	 carefully	 inspected	
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macroscopically	for	the	presence	and	location	of	polyps.	The	size	and	the	number	
of	polyps,	 if	 any,	were	 then	carefully	measured.	The	 swiss	 roll	 technique	 (section	
2.3.2)	was	then	used	to	prepare	tissues	for	histological	analysis.		
	
2.4.6	Identification	of	Mucin-depleted	foci	(MDF)	
	
Mucin	 production	 was	 analysed	 by	 staining	 distal	 colonic	 sections	 with	 HID-AB.	
MDF	were	identified	as	focal	lesions	by	the	following	criteria:		
i. Absence	or	very	small	production	of	mucins	
ii. Distortion	of	the	opening	of	the	lumen	compared	with	normal	surrounding	
crypts	
iii. Elevation	of	the	lesion	above	the	surface	of	the	colon	
iv. Multiplicity	 (i.e.	 the	 number	 of	 crypts	 forming	 each	 focus)	 higher	 than	 3	
crypts	
To	be	defined	as	an	MDF	a	focus	has	to	fulfil	the	first	criterion	and	at	least	two	of	
the	other	criteria	[218].	
	
2.5	CALPROTECTIN	MOUSE	ELISA	
	
All	murine	faecal	samples	were	stored	at	 -20°C	post-GC-MS	run	until	used	for	the	
quantitative	 determination	 of	 calprotectin	 via	 the	 “sandwich”	 S100A8/S100A9	
(calprotectin)	ELISA	technique	using	a	96-well	plate	(Biohit	Healthcare,	Cheshire,	UK	
(suppliers),	 Immunodiagnostik,	 Germany	 (manufacturers)).	 All	 ELISA	 reagents	 and	
samples	were	 brought	 to	 room	 temperature	 prior	 to	 the	 start	 of	 the	 assay.	 Each	
sample	 was	 extracted	 1:50	 in	 extraction	 buffer	 (100mg	 stool	 +	 5ml	 extraction	
buffer),	and	centrifuged	for	5	minutes	at	13000g.		
	
To	begin,	 each	well	 used	was	washed	5	 times	with	 250µl	 of	 diluted	wash	buffer,	
firmly	tapping	the	 inverted	plate	on	absorbent	paper	after	the	final	washing	step.	
This	was	 followed	by	adding	100µl	of	calprotectin	standards	 (of	concentrations	0,	
0.25,	0.98,	3.9,	15.6	ng/ml),	samples	and	controls	in	duplicate	to	wells	coated	with	
high	 affinity	 monoclonal	 anti-S100A8/S100A9	 antibodies.	 The	 plate	 was	 covered	
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tightly	 with	 foil	 and	 left	 to	 incubate	 for	 1	 hour	 at	 37°C	 to	 allow	 for	 any	
S100A8/S100A9	 present	 in	 the	 samples	 to	 bind	 to	 the	 immobilized	 antibodies.	
Contents	of	each	well	were	then	aspirated	and	the	plate	was	washed	5	times	with	
250µl	 of	 diluted	 washing	 buffer,	 firmly	 tapping	 the	 inverted	 plate	 on	 absorbent	
paper	 after	 the	 final	washing	 step.	 In	 a	 next	 incubation	 step,	 a	monoclonal	 anti-	
S100A8/S100A9	 antibody	 is	 added	 at	 100µl/well,	 covered	with	 foil	 and	 left	 for	 1	
hour	at	37°C.	The	contents	were	then	aspirated	and	the	washing	step	was	repeated	
a	 third	 time.	 Then	 a	 peroxidase	 labelled	 anti-mouse	 conjugate	 is	 added	 at	
100µl/well,	covered	with	foil	and	left	for	1	hour	at	37°C.	This	allows	the	following	
complex	 to	 form:	 capture	 antibodies	 –	 S100A8/S100A9	 –	 detection	 antibody	 –	
peroxidase	 conjugate.	 After	 aspirating	 the	 contents,	 washing	 with	 250µl/well	 of	
washing	 buffer	 and	 tapping	 the	 plate	 on	 absorbent	 paper,	 100µl/	 well	 of	
tetramethylbenzidine	(TMB)	was	added	as	a	substrate	for	peroxidise.	The	plate	was	
incubated	 for	 5-15	minutes	 at	 room	 temperature	 in	 the	 dark	 and	 observed	 for	 a	
colour	 change	 (blue	 to	 yellow).	 Finally,	 an	 acidic	 stop	 solution	 was	 added	 to	
terminate	the	reaction.	The	intensity	of	colour	change	is	sensitive	so	care	was	taken	
to	 ensure	 the	 reaction	 was	 stopped	 upon	 good	 differentiation.	 Absorption	 was	
determined	immediately	with	an	ELISA	reader	at	450	nm	and	a	dose	response	curve	
of	the	absorbance	(optical	density,	OD	at	450	nm)	vs.	concentration	was	generated	
using	 the	 value	 obtained	 from	 the	 standards	 (Figure	 2.9).	 S100A8/S100A9	
(calprotectin)	present	in	faecal	samples	was	determined	directly	from	this	curve.		
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Figure	2.8	Calprotectin	ELISA.	Standard	curve	for	the	measurement	of	calprotectin	
concentration	(ng/ml)	by	ELISA.		
	
	
2.6	VOLATILE	ORGANIC	COMPOUND	(VOC)	ANALYSIS		
	
2.6.1	 Solid	 phase	microextraction	 (SPME)	 coupled	 to	 gas	 chromatography-mass	
spectrometry	(GC-MS)		
	
A	 PerkinElmer	Clarus	 500	GC-MS	quadrupole	benchtop	 system	 (Beaconsfield,	UK)	
was	 used	 in	 combination	 with	 a	 Combi	 PAL	 auto-sampler	 (CTC	 Analytics,	
Switzerland)	for	the	analysis	of	all	samples.	The	GC	column	used	was	a	Zebron	ZB-
624	with	inner	diameter	0.25mm,	length	60m,	film	thickness	1.4µm	(Phenomenex,	
Macclesfield,	 UK).	 The	 carrier	 gas	 used	 was	 helium	 of	 99.996%	 purity	 (BOC,	
Sheffield,	 UK).	 The	 SPME	 fibres	 used	 were	 carboxen-polydimethylsiloxane	 (CAR-
PDMS)	85µm	and	divinylbenzene	(DVB)-CAR-PDMS	50/30µm	(1cm)	(Sigma-Aldrich,	
Dorset,	UK).	Both	 fibres	were	pre-conditioned	before	use,	 in	accordance	with	 the	
manufacturer’s	 manual.	 Vials	 with	 magnetic	 caps	 of	 2	 ml	 (Crawford	 Scientific,	
Lanarkshire,	UK)	and	10	ml	(Sigma-Aldrich,	Dorset,	UK)	volume	were	used.	The	fibre	
desorption	conditions	were	5	minutes	at	220°C.	The	 initial	temperature	of	the	GC	
oven	was	set	at	40°C	and	held	for	1	minute	before	increasing	to	220°C	at	a	rate	of	
5°C/min	and	held	for	4	min	with	a	total	run	time	of	41	min.	A	solvent	delay	was	set	
for	the	first	6	min	and	the	MS	was	operated	in	electron	impact	ionization	EI+	mode,	
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scanning	from	ion	mass	fragments	10	to	300	m/z	with	an	inter-scan	delay	of	0.1	sec	
and	a	resolution	of	1000	at	FWHM	(Full	Width	at	Half	Maximum).	The	helium	gas	
flow	 rate	was	 set	 at	 1	ml/min.	 The	 sensitivity	 of	 the	 instrument	was	 determined	
with	2-pentanone	only	and	will	vary	for	other	compounds.	The	limit	of	detection,	as	
being	3	times	the	signal/noise	ratio,	of	the	method	for	2-pentanone	with	DVB-CAR-
PDMS	is	16	ppm	and	with	CAR-PDMS	is	40	ppm.	
	
2.6.2	Method	development	for	HS-SPME-GC-MS	analysis	of	murine	faecal	samples		
	
Substantial	 quantification	 of	 VOCs	 using	 HS-SPME	 in	 complex	 mixtures	 with	
unknown	 composition	 is	 difficult.	 The	 reason	 is	 that	 the	 recovery	 rate	 of	 any	
individual	 compound	 using	 the	 SPME	 fibre	 is	 unknown	 and	 also	 that	 in	 complex	
VOC	mixtures	the	compounds	will	compete	against	each	other.	The	‘weaker’	VOCs	
will	 be	 discriminated	 by	 ‘stronger’	 VOCs	 and	 this	 discrimination	 depends	 on	 the	
VOC	composition	within	the	complex	mixture	present	in	the	headspace	of	samples	
such	as	faecal	samples.	As	a	result,	‘semi-quantification’	with	SPME	is	the	best	that	
can	 be	 achieved.	 Furthermore,	 an	 internal	 standard	 will	 not	 help	 because	 the	
recovery	 rate	 of	 the	 standard	 compound	 is	 also	 unknown.	 Therefore,	 in	 order	 to	
achieve	 ‘semi-quantitative’	results,	standardisation	of	the	VOC	extraction	protocol	
is	required	and	is	typical	of	a	non-targeted	approach	[219].			
	
2.6.2.1	Sample	volume	
	
Samples	 (mean	±	SEM)	of	3	 (40.0	±	14.1	mg),	5	 (76.7	±	25.0	mg),	10	 (133.3	±	7.0	
mg)	and	20	(233.0	±	25.0	mg)	pellets	of	mice	faeces	were	collected	in	10	ml	glass	
vials	from	one	cage	of	four	inbred	wild-type	male	C57BL/6	9-week	old	mice,	once	a	
week	 for	 3	 weeks	 and	 stored	 at	 -20°C.	 Each	 sample	 size,	 in	 triplicate,	 was	 pre-
incubated	at	60°C	for	30	minutes	before	VOC	extraction	using	a	CAR-PDMS	SPME	
fibre	 at	 60°C	 for	 20	 minutes	 prior	 to	 desorption	 into	 the	 GC	 oven.	 Only	 VOCs	
identified	 in	 every	 sample	 were	 then	 used	 for	 comparing	 the	 VOC	 abundances	
according	to	the	sample	size	used.	All	data	were	processed	according	to	the	‘Data	
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processing’	 section	 of	 this	 chapter	 with	 a	 one-way	 ANOVA	 with	 Tukey’s	 HSD	
followed	 by	 Bonferroni,	 applied	 to	 test	 for	 differences	 between	 the	 different	
sample	sizes.		
	
The	number	of	VOCs	identified	and	their	abundances	were	evaluated	according	to	
different	sample	sizes.	Samples	of	3	pellets	showed	a	significantly	lower	number	of	
VOCs	 than	 20	 pellets	 (p<0.05),	 with	 no	 significant	 differences	 in	 the	 number	 of	
VOCs	 between	 10	 and	 20	 pellets	 (p=0.87).	 Six	 compounds	 (pentanal,	 pentane,	
propanal,	 hexanal,	 2,3-butanedione	 and	 benzaldehyde)	were	 consistently	 present	
in	every	sample	with	the	compounds	pentane	and	pentanal	detected	at	significantly	
lower	abundances	in	3	and	5	pellets	compared	to	10	and	20	pellets.		
	
An	increase	in	sample	size	led	to	an	increase	in	both	the	number	of	VOCs	detected	
and	their	abundances,	therefore	reaching	a	limit	of	VOCs	identified;	a	result	of	fibre	
overload.	Samples	of	>20	pellets	were	not	included	as	no	significant	difference	was	
found	 between	 samples	 of	 10	 and	 20	 pellets	 and	 it	 was	 found	 experimentally	
difficult	to	collect	>20	pellets	from	individual	mice.	Therefore,	it	was	predicted	that	
any	 number	 of	 faecal	 pellets	 higher	 than	 20	 pellets	 would	 also	 produce	 a	 non-
significant	result.	Samples	of	10	pellets	were	used	for	all	future	experiments	(Figure	
2.9A&B).		
	
2.6.2.2	Vial	size	
	
For	 each	 vial	 volume	 of	 2	 and	 10	 ml,	 samples	 of	 10	 pellets	 (n=4),	 were	 pre-
incubated	at	60°C	for	30	minutes	before	VOC	extraction	using	a	CAR-PDMS	SPME	
fibre	 at	 60°C	 for	 20	minutes	 prior	 to	 desorption	 into	 the	GC	 oven.	 All	 data	were	
processed	according	to	‘Data	processing’	section	of	this	chapter	with	a	Student’s	t-
test	applied	to	test	for	differences	between	different	vial	sizes.		
	
The	number	of	VOCs	identified	and	their	abundances	were	evaluated	according	to	
different	vial	volumes	used	for	SPME-GC-MS	analysis.	Vials	of	2	ml	showed	a	slightly	
higher	number	of	VOCs	 identified	 than	10	ml;	however,	 there	were	no	significant	
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differences	 in	VOC	abundances	between	vial	size	(p>0.05).	This	difference	may	be	
explained	 by	 the	 fact	 that	 if	 the	 volume	 of	 headspace	 surrounding	 the	 sample	
decreases,	the	concentration	of	compounds	increases,	leading	to	better	coverage	of	
the	VOC	profile	in	the	samples.	Therefore,	2	ml	vials	were	used	for	all	later	samples	
(Figure	2.9C).		
		
2.6.2.3	VOC	extraction	time	and	temperature	
	
Extraction	 time:	samples	of	10	pellets	were	pre-incubated	at	60°C	 for	30	minutes	
before	VOC	extraction	using	a	CAR-PDMS	SPME	fibre	at	60°C	for	10	(n=3),	20	(n=3)	
or	30	minutes	(n=3)	prior	to	desorption	into	the	GC	oven.		
	
Extraction	 temperature:	 samples	 of	 10	 pellets	were	 pre-incubated	 at	 60°C	 for	 30	
minutes	before	VOC	extraction	using	a	CAR-PDMS	SPME	fibre	at	50	(n=3),	60	(n=3)	
or	70°C	 (n=3)	 for	20	minutes	prior	 to	desorption	 into	 the	GC	oven.	All	data	were	
processed	 according	 to	 ‘Data	 processing’	 section	 of	 this	 chapter	 with	 a	 one-way	
ANOVA	 with	 Tukey’s	 HSD	 followed	 by	 Bonferroni	 correction,	 applied	 to	 test	 for	
differences	between	the	different	extraction	times	and	temperatures	tested.	
	
Although	there	was	no	significant	difference	in	the	number	of	VOCs	reported	by	the	
exposure	times	tested,	20	minutes	produced	the	highest	number	of	VOCs	(p=0.5).	
The	exposure	temperatures	of	60,	and	70°C	showed	a	significantly	higher	number	
of	VOCs	than	50°C	(p=0.03).	Although	there	was	no	significant	differences	between	
60	 and	 70°C	 (p=0.33),	 the	 exposure	 temperature	 of	 60°C	 produced	 the	 highest	
number	 of	 VOCs.	 Therefore,	 the	 extraction	 time	 and	 temperature	 of	 20	minutes	
and	60°C	was	used	for	all	later	experiments.		
	
Typically,	 the	 SPME	 extraction	 process	 is	 considered	 complete	 when	 the	 analyte	
concentration	has	reached	distribution	equilibrium	between	the	sample	matrix	and	
the	fibre	coating.	Prior	to	the	distribution	equilibrium	being	reached,	the	extraction	
process	is	considered	in	pre-equilibrium	state.	These	results	show	that	an	increase	
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in	 extraction	 time	 and	 temperature	 result	 in	 higher	 numbers	 of	 VOCs	 identified.	
However,	 extraction	 times	 higher	 than	 20	 minutes	 and	 extraction	 temperatures	
higher	 than	 60°C	 showed	 no	 improvement.	 This	 indicates	 that	 in	 the	 pre-
equilibrium	state,	a	small	change	in	extraction	time	and	temperature	may	result	in	
a	 large	 change	 in	 the	 amount	 of	 analyte	 being	 absorbed.	 However,	 once	 the	
distribution	gets	close	to	the	equilibrium,	there	are	either	no	changes	or	only	small	
changes	 in	 the	 amount	 of	 analyte	 absorbed.	 Therefore,	 the	 extraction	 time	 and	
temperature	are	not	critical	once	equilibrium	is	nearly	reached	(Figure	2.9D&E).		
	
2.6.2.4	SPME	fibre	coating	
	
Samples	 of	 10	 pellets	 were	 pre-incubated	 at	 60°C	 for	 30	 minutes	 before	 VOC	
extraction	using	a	CAR-PDMS	(n=5)	or	a	DVB-CAR-PDMS	(n=5)	SPME	fibre	at	60°C	
for	 20	 minutes	 prior	 to	 desorption	 into	 the	 GC	 oven.	 All	 data	 were	 processed	
according	to	‘Data	processing’	section	of	this	chapter	with	a	Student’s	t-test	applied	
to	test	for	differences	between	different	SPME	fibres.		
	
Use	 of	 the	 DVB-CAR-PDMS	 fibre	 led	 to	 the	 identification	 of	 a	 significantly	 higher	
number	 of	 VOCs	 compared	 to	 the	 CAR-PDMS	 fibre	 (p=0.04).	 Seven	 compounds	
were	exclusively	associated	with	 the	DVB-CAR-PDMS,	while	 two	compounds	were	
associated	 with	 the	 CAR-PDMS.	 Therefore,	 when	 possible,	 the	 use	 of	 different	
SPME	 fibres	 is	 ideal	 to	 extract	 a	 greater	 diversity	 of	 compounds,	 which	 is	 in	
agreement	with	previous	work	 from	Dixon	and	collaborators	 [220].	However,	due	
to	 the	 significantly	 higher	 number	 of	 identified	 VOCs	 between	 fibres	 for	 murine	
samples,	a	DVB-CAR-PDMS	fibre	was	primarily	used	for	the	analysis	of	later	samples	
(Figure	2.9F).	Every	200	runs,	the	SPME	fibre	was	replaced	and	care	was	taken	to	
avoid	 damaging	 fibre,	 as	 advised	 by	 Perkin	 Elmer	 GC-MS	 technicians	 (maximum	
runs	of	100-200	depending	on	lab	conditions).		
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2.6.2.5	Optimised	method	
	
Based	on	results	presented	in	section	2.6.2,	an	optimised	SPME-GC-MS	method	for	
analysing	murine	samples	includes	samples	of	10	to	20	pellets,	stored	in	2	ml	glass	
vials,	 incubated	 for	 30	min	 at	 60°C	 and	 extracted	 by	 DVB-CAR-PDMS	 for	 20	min	
[221].		
	
Furthermore,	all	samples	were	frozen	at	-80°C	within	1	hour	of	collection	and	were	
run	 at	 random	 to	 avoid	 the	 effect	 of	 a	 sequential	 pattern	 influencing	 the	 VOC	
profiles.	Samples	were	run	through	the	GC-MS	in	blocks	of	1-4	weeks	depending	on	
the	 quantity	 of	 samples	 in	 the	 sample	 set.	 This	 was	 put	 in	 place	 to	 avoid	
contamination	 from	 other	 sample	 matrices.	 Further	 optimisation	 also	 led	 to	
introducing	 a	 ‘blank’	 run	 every	 6	 samples	 to	 avoid	 carryover	 of	 sampling.	
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Figure	2.9	Optimised	SPME-GC-MS	method	for	murine	faecal	VOC	analysis.	 (A-B)	
The	number	and	abundance	of	VOCs	identified	in	murine	faecal	samples	of	3,	5,	10	
and	20	pellets,	with	VOC	abundances	normalized	to	their	abundances	in	samples	of	
20	pellets	(n=3/group).	(C-F)	The	number	of	VOCs	identified	in	samples	of	10	pellets	
according	 to	vial	 size	 (C)	 (n=4/vial	 size),	extraction	 time	 (n=3/time)	 (D),	extraction	
temperature	 (n=3/temperature)	 (E)	 and	 SPME	 fibre	 coating	 (n=3/coating)	 (F).	
ANOVA	with	Tukey’s	HSD	followed	by	Bonferroni;	*p<0.05,	**p<0.01,	***p<0.001.		
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2.7	DATA	PROCESSING	AND	ANALYSIS			
	
2.7.1	Turbomass	
	
The	GC-MS	instrument	used	for	all	experiments	in	this	study	is	used	in	conjunction	
with	the	PerkinElmer	Turbomass	GC-MS	software.	All	raw	data	is	generated	by	this	
software	on	a	PC	to	view	all	chromatograms	before	being	transferred	to	personal	
PCs	for	further	data	analysis.	Turbomass	 is	responsible	for	maintaining	the	GC-MS	
and	can	be	used	for	data	acquisition,	analysis,	and	representation	of	GC-MS	data.		
	
2.7.2	AMDIS,	NIST,	R		
	
All	GC-MS	data	were	processed	using	the	Automated	Mass	Spectral	Deconvolution	
System	using	default	settings	(AMDIS	–	version	2.71,	2012)	in	conjunction	with	the	
NIST	mass	spectral	library	(version	2.0,	2011)	and	the	R	package	Metab	[222].	VOCs	
were	 identified	 using	 an	 in-house	 library	 built	with	 AMDIS	 in	 combination	 to	 the	
NIST	library.		
	
2.7.3	Data	pre-processing	
	
An	 in-house	 library	was	 built	 using	 faecal	 samples	 collected	 as	 part	 of	 a	 baseline	
murine	 study	 (Chapter	 3).	 For	 each	 dataset,	 hereafter,	 at	 least	 50%	 of	
chromatograms	were	 randomly	 chosen	 for	 long	hand	AMDIS	analysis,	 adding	any	
unidentified	compounds	to	the	library.		
	
To	begin	with,	raw	data	in	the	form	of	a	chromatogram,	generated	from	the	GC-MS	
was	converted	 to	 the	Net.CDF	data	 format	using	 the	data	bridge	 tool	 (Turbomass	
software).	Chromatograms	were	then	analysed	against	the	murine-specific	in-house	
library	prior	to	batch	report	generation	of	complete	datasets	using	AMDIS	and	the	
in-house	compound	library.	Using	Metab	[222],	an	excel	report	is	created	using	the	
AMDIS	batch	report,	Net.CDF	data	and	the	in-house	library.	This	consists	of	a	list	of	
all	 compounds	 present	 in	 all	 samples	 with	 the	 corresponding	 corrected	 peak	
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abundances	using	a	Time	Window	of	0.5	minutes.	Metab	selects	the	most	probable	
metabolite	 associated	 to	 each	 retention	 time,	 by	 correcting	 the	 base	 peak	 value	
calculated	 by	 AMDIS.	 	 It	 considers	 the	 number	 of	 question	 marks	 reported	 by	
AMDIS	and	the	difference	between	expected	and	observed	retention	times,	using	
the	ion	mass	fragments	in	the	library	and	the	raw	data	to	report	the	corrected	peak	
abundances	 in	 a	 single	 spreadsheet	 [222].	Appendix	 1	 includes	 a	 comparison	 of	
Metab	 vs.	 manual,	 long-hand	 analysis	 to	 demonstrate	 the	 robustness	 of	 this	
method.	
	
2.8	STATISTICAL	ANALYSIS	
	
All	 univariate	 statistics	 were	 performed	 using	 SPSS	 and/or	 R.	 All	 multivariate	
statistics	were	performed	using	R	version	3.0.2.	Due	to	the	large	amount	of	missing	
data	having	a	significant	effect	of	results,	NA	values	were	replaced	with	1	prior	to	
any	 quantitative	 statistical	 analysis	 being	 performed	 [223].	 All	 raw	 data	were	 log	
transformed	prior	to	any	statistical	analysis	in	order	to	normalise	the	metabolomics	
data	 [224].	 Many	 compounds	 of	 low	 frequency	 are	 likely	 to	 reflect	 individual	
characteristics	 and,	 therefore,	 were	 not	 readily	 selected	 for	 further	 statistical	
analysis.	 Compounds	 present	 in	 less	 than	 30%	 of	 at	 least	 one	 condition	 were	
removed	 prior	 to	 further	 analysis	 when	 determining	 differences	 between	 health	
and	 disease.	 A	 Student’s	 t-test	 (two	 groups)	 or	 a	 one-way	 analysis	 of	 variance	
(ANOVA)	 (more	 than	 two	 groups)	 followed	 by	 Tukey’s	 HSD	 post-hoc	 test	 were	
applied	 to	 test	quantitative	differences	between	data	 classes.	 In	order	 to	 test	 for	
qualitative	 differences,	 the	 presence	 or	 absence	 of	 each	 compound	 	 was	 “1”	 to	
denote	 the	 presence	 of	 the	 compound	 and	 “0”	 to	 denote	 its	 absence	 in	 that	
sample.	The	presence/absence	data	were	then	tested	for	differences	between	data	
classes	 by	 applying	 a	 Chi-squared	 test.	 Final	 p-values	 were	 adjusted	 for	multiple	
comparisons	 using	 Bonferroni	 correction.	 P-values	 <	 0.05	 were	 considered	 as	
significant.	 A	 principle	 component	 analysis	 (PCA)	 was	 used	 to	 show	 similarities	
within	data	classes.	The	purpose	of	a	PCA	is	to	represent	as	much	of	the	variation	as	
possible	within	the	first	 two	components	with	each	point	representing	a	different	
sample	with	 the	 different	 shapes	 signifying	 the	 different	 time	 points.	 A	 heatmap	
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and	 dendrogram	 were	 produced	 using	 hierarchical	 cluster	 analysis	 with	 the	
complete	 linkage	 method	 to	 find	 similar	 clusters,	 which	 is	 a	 visualising	 tool	 for	
classifying	different	phenotypes.	A	heatmap	is	a	graphical	method	of	displaying	the	
concentration	of	each	compound	by	using	colour	to	represent	the	numerical	values.	
The	 clustering	 algorithm	 (complete-linkage,	 default)	 grouped	 related	 rows	 and/or	
columns	 together	by	 similarity,	 represented	by	a	dendrogram.	The	PCA,	heatmap	
and	 dendrogram	 were	 produced	 in	 R.	 Time	 series	 analysis	 (two-way	 repeated	
measures	ANOVA)	was	performed	using	the	online	metabolomics	software,	MetAtt	
[225].		
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Chapter	3	
	
Healthy	Murine	Faecal	VOC	
Metabolome	
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3.1	INTRODUCTION	
	
The	variability	of	the	metabolome	in	healthy	human	cohorts	is	large.	Its	biochemical	
origin	 is	not	completely	understood	because	of	 limiting	 factors,	 such	as	diet,	age,	
sex	and	medication.	Murine	models	of	disease	are	used	 in	biomedical	research	to	
address	 almost	 every	 aspect	 of	 human	 health	 and	 disease,	 including	 disease	
pathogenesis,	diagnosis	and	treatment.	The	composition	of	the	gut	microbiota	has	
received	considerable	attention	as	a	significant	factor	influencing	the	health	of	the	
host	and	contributing	to	the	development	of	experimental	inflammatory	disease	in	
animal	models.	Identifying	and	reducing	gut	microbiota	variation	within	laboratory	
animals	 will	 control	 disease	 parameters	 and	 provide	 more	 consistent	 and	
equivalent	models.		
	
Metabolomics	is	the	characterisation	of	metabolites	generated	by	an	organism	in	a	
specified	 physiological	 and	 environmental	 context.	 Identification	 of	 the	
metabolome	 could	 enable	 a	 better	 understanding	 of	 the	 metabolism	 of	 our	 gut	
microbial	 communities	 and,	 consequently,	 the	 role	 it	 has	 to	 play	 in	 health	 and	
disease	 [226].	 The	 sensitivity	 of	 metabolomics	 and	 other	 “–omics”	 technologies	
relies	on	the	ability	to	identify	the	subtle	differences	occurring	as	a	direct	result	of	
pathological	 stimuli	 from	 numerous	 variables,	 therefore	 representing	 the	 many	
fluctuating	 physiological	 and/or	 biochemical	 processes.	 It	 is	 essential,	 therefore,	
that	 “normal”	 is	 defined	 with	 regard	 to	 an	 organism’s	 integrated	 physiological	
profile,	 considering	 the	effects	of	both	environmental	and	genetic	 factors	 such	as	
gender,	 age,	 strain,	 and	 diet	 to	 effectively	 differentiate	 such	 variation	 from	 that	
caused	by	disease.		
	
Rogers	et	al.	 revealed	 that	 the	 faecal	microbiota	of	healthy	mice	 is	dominated	by	
the	phyla	Bacteroidetes	and	Firmicutes.	Marked	variation	in	the	relative	abundance	
of	 phyla	 between	 different	 housing	 rooms	 and	 between	 individual	 genetically-
identical	animals	was	also	observed.	They	went	on	to	hypothesise	that	there	would	
be	 differences	 when	 comparing	 the	 metabolome	 of	 faeces	 from	 healthy	 mice	
whose	 faecal	 microbiota	 were	 distinct.	 1H	 nuclear	 magnetic	 resonance	 (NMR)	
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spectroscopy	 was	 performed	 on	 faecal	 extracts	 from	 the	 same	 samples	 used	
previously	 for	 microbiota	 sequencing,	 resulting	 in	 clear	 metabolomic	 differences	
between	 the	 murine	 faecal	 samples	 based	 on	 the	 composition	 of	 the	 bacteria	
present	[227].		
	
Gender-dependent	 metabolic	 variation	 was	 investigated	 using	 1H	 NMR	 of	 urine	
from	 Han	Wistar	 rats.	 Discriminating	molecules,	 such	 as	 trimethylamine-N-oxide,	
N,N’-dimethylglycine	 and	 m-hydroxyphenylpropionic	 acid	 were	 all	 excreted	 in	
higher	concentrations	in	samples	from	female	mice		[228].	More	recently,	the	urine	
metabolomic	profiles	of	male	and	female	IL-10	KO	mice	were	examined.	The	results	
demonstrated	 that	 both	 IL-10	 deficient	 and	 WT	 mice	 exhibited	 gender-related	
changes	 over	 time.	 Specific	 patterns	 imperative	 in	 the	 development	 of	 intestinal	
inflammation	 could	 be	 identified	which	were	 significant	 for	 the	 gender-	 and	 age-
specific	 differences	 in	 IBD	 development	 [202].	 Unlike	 urine	 which	 has	 been	
relatively	 well-characterised,	 the	 effect	 of	 gender	 and	 temporal	 variation	 on	 the	
murine	faecal	metabolite	profile	has	not	been	assessed	thoroughly.		
	
HS	 gases	 from	 both	 the	 urine	 and	 faecal	 pellets	 of	wild	 and	 laboratory	mice	 are	
known	to	be	rich	in	VOCs	[229].	It	has	previously	been	reported	that	the	analysis	of	
VOCs	produced	from	fresh	and	aged	pellets	by	GC-MS	resulted	in	the	identification	
of	many	 compounds,	with	 ketones,	 alcohols	 and	 carboxylic	 acids	 being	 the	most	
common.	Goodrich	et	al.	assessed	the	effects	of	VOCs	on	the	behaviour	of	mice.		It	
was	 found	 that	 the	 introduction	 of	 volatiles	 from	 faecal	 pellets	 from	 one	mouse	
into	the	territory	of	another	altered	the	site	at	which	the	resident	mouse	deposited	
its	 faeces.	 	 In	 addition,	 transferring	 the	 faecal	 pellets	 of	 one	 mouse	 into	 the	
environment	of	 another	 improved	 the	 success	of	 a	 social	 encounter	between	 the	
two	mice	[230].		
	
Here,	 we	 use	 our	 optimised	 HS-SPME-GC-MS	 method	 (Chapter	 2)	 to	 establish	 a	
baseline	 faecal	VOC	profile	 for	healthy	WT	male	and	 female	C57BL/6	mice,	which	
will	aid	the	analysis	of	later	studies	included	in	this	thesis.		
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3.2	HYPOTHESIS	
	
The	hypotheses	were:	
• The	 healthy	 murine	 faecal	 VOC	 metabolome	 will	 be	 similar	 between	
individual	mice	of	the	same	age	and	gender.		
• There	will	be	significant	differences	between	the	VOC	profiles	emitted	from	
the	faecal	pellet	between	mice	of	different	gender	and	age.		
• The	 composition	 of	 VOCs	 emitted	 from	 faeces	 will	 differ	 according	 to	
location	of	the	lower	GI	tract.	
 
3.3	AIMS	
	
1. Detect	and	 identify	VOCs	present	 in	 the	headspace	of	 faeces	 from	healthy	
WT	C57BL/6	mice	using	a	SPME-GC-MS	platform.	
2. Establish	 similarities	 or	 differences	 in	 the	 abundance	 and	 presence	 of	
specific	VOCs	according	to	the	age	and/or	gender	of	mice,	or	the	location	of	
faeces	in	the	lower	GI	tract.	
3. Investigate	the	composition	of	VOC	emitted	from	faeces	of	GF	mice.	
	
3.4	METHODS	
	
3.4.1	Experimental	design	
	
3.4.1.1	Baseline	murine	study	
	
A	 detailed	 description	 of	 the	 methods	 can	 be	 found	 in	 Chapter	 2.	 Briefly,	 a	
longitudinal	experiment	was	performed	to	determine	similarities	or	differences	 in	
abundance	of	 specific	VOCs	emitted	 from	 the	 faeces	of	mice,	 taking	 into	account	
the	 effects	 of	 gender	 and	 age.	 Six	 male	 and	 6	 female	 WT	 C57BL/6	 mice	 were	
purchased	 and	 housed	 individually	 for	 a	 total	 of	 8	 weeks	 (5-12	 w)	 with	 faecal	
samples	(10	pellets)	collected	from	each	cage	once	per	week	for	the	course	of	the	
entire	experiment.	Bedding	was	replaced	with	autoclaved	blotting	paper	24	hours	
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preceding	 the	 faecal	 pellet	 collection	 and	 replaced	 immediately	 following	
collection.	All	samples	were	stored	at	-20°C	until	needed.	Mice	were	sacrificed	and	
the	 faecal	 content	 collected.	 	 Aliquots	 of	 food	 and	 bedding	 (n=3)	 were	 also	
collected	 and	 analysed	 via	 the	 same	method	 used	 for	 the	 analysis	 of	 VOCs	 from	
faecal	samples.		
	
3.4.1.2	Germ-free	study	
	
Briefly,	faecal	samples	from	the	GF	colonies,	C3H/HeN	and	Junbo	mice	(n=6	in	total;	
n=3/strain)	 and	 non-GF	 SPF	 (n=6)	 strain,	were	 provided	 by	MRC	Harwell,	Oxford.	
The	VOC	profile	of	the	faecal	pellet	from	GF	mice	was	compared	with	their	non-GF	
SPF	equivalent	and	with	the	VOC	profile	from	the	WT	C57BL/6	SPF	(age-matched)	at	
the	University	of	Liverpool.		
	
3.4.2	HS-SPME-GC-MS	sample	preparation	and	analysis	
	
Where	 possible,	 10	 pellets	 or	 130mg	 (maximum	 volume)	 of	 stool	 were	 collected	
and	stored	 in	2ml	glass	vials	at	 -20°C.	Prior	 to	VOC	extraction,	 samples	were	pre-
incubated	for	30	mins	at	60°C	before	headspace	extraction	using	the	SPME	with	a	
CAR/PDMS/DVB	 fibre	 for	 20	mins	prior	 to	desorption	 into	 the	GC	oven	 [221].	 For	
GC-MS	conditions,	please	refer	to	section	2.6.1.		
	
3.4.3	Data	processing	and	statistical	analysis		
	
Chromatograms	were	processed	using	the	AMDIS	in	conjunction	with	the	NIST	mass	
spectral	 library	 (version	2.0,	 2011).	VOCs	were	 identified	and	added	 to	 a	murine-
specific	 VOC	 library.	 A	 batch	 report	 was	 generated	 in	 AMDIS	 and	 a	 spreadsheet	
created	 using	 the	 R	 package,	 Metab	 [222],	 consisting	 of	 a	 list	 of	 all	 compounds	
present	 in	 all	 samples	 with	 the	 corresponding	 peak	 abundances	 using	 a	 time	
window	of	0.5	minutes.	Compounds	identified	in	at	least	30%	of	samples,	in	at	least	
one	condition,	were	used	for	statistical	analysis;	this	was	applied	to	all	datasets.	
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All	 statistics	 were	 performed	 using	 SPSS,	 R	 version	 3.0.2	 and/or	Microsoft	 Excel.	
Missing	 data	 have	 a	 significant	 effect	 on	 results	 and	 so	NA	 values	were	 replaced	
with	 1	 prior	 to	 any	 statistical	 analysis	 [223].	 A	 Student’s	 t-test	 or	 an	 ANOVA	
followed	by	Tukey’s	HSD	test	were	applied	to	test	differences	between	data	classes.	
A	PCA	was	used	to	illustrate	variation	both	within	and	between	data	classes.	Final	
p-values	 were	 adjusted	 for	 multiple	 comparisons	 using	 Bonferroni	 correction.	 P-
values	<	0.05	were	considered	to	be	significant.	
	
3.5	RESULTS	
	
3.5.1	Biological	variation	in	VOCs	from	C57BL/6	mice	
	
Inspection	 of	 overlaid	 gas	 chromatograms	 from	 faecal	 pellets	 from	 both	 female	
(n=6)	 and	male	 (n=6)	 C57BL/6	WT	mice	 at	 each	week	 showed	 the	 reproducibility	
and	limited	biological	variation	between	individual	mice	(Figures	3.2-3.9).	This	was	
not	unexpected;	C57BL/6	mice	are	nearly	identical	to	each	other,	in	genotype,	as	a	
result	of	long	term	in-breeding.	Closer	inspection	of	Figures	3.2-3.9	revealed	a	shift	
in	RT	of	peaks	at	12.5	and	19.5	minutes.	The	peak	at	12.5	mins	was	 identified	as	
acetic	acid	and	was	ubiquitous	to	all	samples	of	both	genders	at	every	time	point	
tested.	At	weeks	3,	5,	6	and	7,	acetic	acid	is	identified	at	a	RT	of	0.3	minutes	later	
(12.8	mins)	in	a	number	of	female	mice	and	at	weeks	1,	5,	6	and	7	in	a	number	of	
male	mice.	The	peak	at	19.5	mins	was	 identified	as	butanoic	acid,	also	present	 in	
every	 sample	 tested.	At	weeks	 3	 and	5,	 for	 female	mice,	 and	weeks	 1	 and	6,	 for	
male	mice,	there	appeared	to	be	a	RT	shift	of	0.2	minutes	(19.7	mins)	in	a	number	
of	mice.	 In	order	to	confirm	that	this,	 the	mass	spectrum	was	compared	between	
samples	at	each	RT	shift	occurrence	(Figure	3.1).		Figure	3.1A	shows	an	example	of	
this	RT	 shift	 for	acetic	 acid;	upon	examination	of	 the	mass	 spectrum	pattern,	 the	
identity	of	acetic	acid	in	all	6	female	mice	tested	at	week	3	was	confirmed.	Similarly,	
Figure	 3.1B	 presents	 the	 RT	 shift	 in	male	mice	 at	week	 6	 for	 butanoic	 acid,	 also	
confirming	 the	 identification	as	 found	using	 the	NIST	 library.	This	was	 the	case	 in	
both	genders	at	each	time	point	mentioned	above.	As	this	RT	shift	is	<0.5	mins	and	
uncommon,	it	was	concluded	to	be	a	result	of	the	samples	being	run	over	a	period	
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of	 time	and	the	GC-MS	conditions	may	have	varied	slightly.	Processing	of	the	raw	
data	 for	 all	 8	 time	 points	 yielded	 two	 VOC	master	 lists	 of	 90	 and	 103	 VOCs	 for	
female	 and	 male	 mice,	 respectively	 (Table	 3.2).	 There	 were	 83	 VOCs	 shared	
between	female	and	male	mice,	with	7	VOCs	found	exclusively	in	female	mice	and	
20	in	male	mice.		
	
To	 show	 the	 uniformity	 and	 reproducibility	 of	 the	 WT	 mouse	 strain,	 it	 was	
important	to	be	able	to	show	a	 low	level	of	 intra-mouse	variability	with	regard	to	
their	 VOC	 faecal	 profile.	 Using	 each	master	 list,	 Table	 3.1	 shows	 the	 number	 of	
VOCs	 specific	 to	 each	 time	 point	 and	 the	 percentage	 of	which	were	 identified	 in	
50%	of	samples.	Across	the	8	weeks	sampled,	between	56.7	to	77.3%	of	VOCs	were	
identified	 in	 at	 least	 50%	 of	 samples	 from	 female	mice,	 with	 week	 5	 having	 the	
lowest	 and	 week	 6	 having	 the	 highest	 number,	 showing	 	 the	 reproducibility	 of	
identified	 compounds	 between	 samples	 of	 individual	 female	mice.	 Overall,	 there	
was	a	slightly	lower	percentage	of	VOCs	identified	in	at	least	50%	of	samples	from	
male	mice	across	all	8	weeks	sampled,	from	54.1%	at	week	3	to	70.2%	at	week	6.	In	
both	 genders,	week	 6	 (age	 10	weeks	 old)	 data	 showed	 the	 largest	 percentage	of	
total	VOCs	identified	in	at	least	50%	of	samples.		
	
To	 further	 investigate	 the	 biological	 variation	 between	 faecal	 samples	 from	
individual	C57BL/6	female	and	male	mice,	the	SD	of	the	abundance	of	all	VOCs	was	
examined.	Of	 the	VOCs	present	 in	50%	of	 samples	at	each	week,	more	 than	50%	
were	within	±3SD	of	the	mean	abundance	for	females	and	slightly	lower	for	males	
(>40%),	showing	that	a	large	number	of	VOCs	varied	very	little	between	individual	
mice	of	both	genders,	at	each	time	point	(Table	3.1).		
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Figure	 3.1	Comparison	 of	MS	 pattern	 of	 acetic	 acid	 and	 butanoic	 acid	 between	
individual	mice	at	specific	time	points.	There	was	a	shift	in	RT	of	compounds	acetic	
acid	 (A.)	 and	 butanoic	 acid	 (B.)	 at	 12.5	 and	 19.5	 minutes,	 respectively.	 The	 MS	
pattern	 confirms	 there	 was	 a	 shift	 but	 that	 the	 peaks	 identified	 were	 the	 same	
compound	for	both	cases.		
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Figure	3.2	Overlay	of	gas	chromatograms	 from	female	 (n=6)	 (A.)	and	male	 (n=6)	
(B.)	C57BL/6	murine	faecal	samples	collected	at	experimental	week	1	when	mice	
were	 5	weeks	 old.	 Samples	were	 collected	 from	 all	 animals	 once	 a	week	 and	 all	
samples	were	run	through	the	GC-MS,	method	previously	described.	Peak	intensity	
versus	RT	from	10	to	30	minutes	(RT	=	retention	time).	
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Figure	 3.3	 Overlay	 of	 gas	 chromatograms	 female	 (n=6)	 (A.)	 and	male	 (n=6)	 (B.)	
C57BL/6	murine	faecal	samples	collected	at	experimental	week	2	when	mice	were	
6	weeks	old.	Samples	were	collected	from	all	animals	once	a	week	and	all	samples	
were	 run	 through	 the	GC-MS,	method	previously	described.	Peak	 intensity	versus	
RT	from	10	to	30	minutes	(RT	=	retention	time).		
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Figure	3.4	Overlay	of	gas	chromatograms	 from	female	 (n=6)	 (A.)	and	male	 (n=6)	
(B.)	C57BL/6	murine	faecal	samples	collected	at	experimental	week	3	when	mice	
were	 7	weeks	 old.	 Samples	were	 collected	 from	 all	 animals	 once	 a	week	 and	 all	
samples	 were	 run	 through	 the	 GC-MS,	 method	 previously	 described.	 .	 Peak	
intensity	versus	RT	from	10	to	30	minutes	(RT	=	retention	time).	
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Figure	3.5	Overlay	of	gas	chromatograms	 from	female	 (n=6)	 (A.)	and	male	 (n=6)	
(B.)	C57BL/6	murine	faecal	samples	collected	at	experimental	week	4	when	mice	
were	 8	weeks	 old.	 Samples	were	 collected	 from	 all	 animals	 once	 a	week	 and	 all	
samples	were	run	through	the	GC-MS,	method	previously	described.	Peak	intensity	
versus	RT	from	10	to	30	minutes	(RT	=	retention	time).	
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Figure	3.6	Overlay	of	gas	chromatograms	 from	female	 (n=6)	 (A.)	and	male	 (n=6)	
(B.)	C57BL/6	murine	faecal	samples	collected	at	experimental	week	5	when	mice	
were	 9	weeks	 old.	 Samples	were	 collected	 from	 all	 animals	 once	 a	week	 and	 all	
samples	were	run	through	the	GC-MS,	method	previously	described.	Peak	intensity	
versus	RT	from	10	to	30	minutes	(RT	=	retention	time).	
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Figure	3.7	Overlay	of	gas	chromatograms	 from	female	 (n=6)	 (A.)	and	male	 (n=6)	
(B.)	C57BL/6	murine	faecal	samples	collected	at	experimental	week	6	when	mice	
were	10	weeks	old.	Samples	were	collected	 from	all	animals	once	a	week	and	all	
samples	were	run	through	the	GC-MS,	method	previously	described.	Peak	intensity	
versus	RT	from	10	to	30	minutes	(RT	=	retention	time).		
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Figure	3.8	Overlay	of	gas	chromatograms	 from	female	 (n=6)	 (A.)	and	male	 (n=6)	
(B.)	C57BL/6	murine	faecal	samples	collected	at	experimental	week	7	when	mice	
were	11	weeks	old.	Samples	were	collected	 from	all	animals	once	a	week	and	all	
samples	were	run	through	the	GC-MS,	method	previously	described.	Peak	intensity	
versus	RT	from	10	to	30	minutes	(RT	=	retention	time).	
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Figure	3.9	Overlay	of	gas	chromatograms	 from	female	 (n=6)	 (A.)	and	male	 (n=6)	
(B.)	C57BL/6	murine	faecal	samples	collected	at	experimental	week	8	when	mice	
were	12	weeks	old.	Samples	were	collected	 from	all	animals	once	a	week	and	all	
samples	were	run	through	the	GC-MS,	method	previously	described.	Peak	intensity	
versus	RT	from	10	to	30	minutes	(RT	=	retention	time).	
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Table	3.1	Percentage	of	VOCs	 identified	 in	50%	of	samples	at	each	time	point	 for	
both	female	and	male	C57BL/6	mice	and	a	percentage	of	which	fall	within	±3	SD	of	
the	mean	abundance	(n=6/gender).		
 
	 Females		
Weeks	
Total	number	
of	VOCs	
identified	
Number	of	VOCs	
present	in	50%	of	
samples	(%	of	total	
VOCs)	
%	of	these	VOCs	
within	±3SD	of	the	
mean	abundance	
1	 68	 48	(70.6%)	 66.7	
2	 62	 39	(62.9%)	 69.2	
3	 80	 53	(66.3%)	 77.4	
4	 59	 37	(62.7%)	 56.8	
5	 60	 34	(56.7%)	 58.8	
6	 75	 58	(77.3%)	 58.6	
7	 47	 29	(61.7%)	 65.5	
8	 70	 44	(62.9%)	 56.8	
	 Males		
Weeks	
Total	number	
of	VOCs	
identified	
Number	of	VOCs	
present	in	50%	of	
samples	(%	of	total	
VOCs)	
%	of	these	VOCs	
within	±3SD	of	the	
mean	abundance	
1	 88	 50	(56.8%)	 72.0	
2	 78	 43	(55.1%)	 61.7	
3	 85	 46	(54.1%)	 71.7	
4	 79	 48	(60.8%)	 68.8	
5	 49	 32	(65.3%)	 65.6	
6	 94	 66	(70.2%)	 74.2	
7	 44	 26	(59.1%)	 42.3	
8	 85	 55	(64.7%)	 43.6	
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Table	3.2	Master	 list	of	VOCs	 identified	 in	HS	gas	of	 faecal	 samples	 from	healthy	male	and	 female	C57BL/6	mice	across	8	experimental	
weeks	from	age	5	weeks	to	12	weeks	old	(n=6/gender).	Data	presented	as	the	percentage	occurrence	at	each	week	and	ordered	according	to	
13	chemical	classes;	alcohols,	acids,	esters,	aldehydes,	alkanes,	alkenes,	alicyclic	compounds,	benzenoid	compounds,	heterocyclic	compounds,	
ketones,	nitrogen-,	sulphur-containing	and	unidentified	VOCs	(w1	=	week	1,	etc).		
	 %	occurrence	at	each	week	
	 Females	 Males	
RT_compound	 w1	 w2	 w3	 w4	 w5	 w6	 w7	 w8	 w1	 w2	 w3	 w4	 w5	 w6	 w7	 w8	
6.61_ethanol	 100	 100	 100	 100	 100	 100	 83	 100	 100	 100	 100	 100	 100	 100	 100	 100	
7.61_isopropanol	 100	 100	 100	 100	 100	 100	 100	 100	 83	 100	 100	 100	 100	 100	 100	 100	
9.57_1-propanol	 100	 0	 100	 0	 17	 100	 0	 50	 100	 67	 100	 17	 0	 100	 0	 100	
10.77_2-butanol	 33	 0	 17	 0	 0	 50	 0	 17	 17	 0	 17	 0	 0	 80	 0	 100	
11.19_2-methyl-3-buten-2-ol	 0	 0	 0	 0	 0	 0	 0	 0	 17	 33	 0	 33	 0	 60	 0	 20	
11.90_1-propanol,	2-methyl-	 100	 0	 100	 0	 0	 100	 0	 33	 50	 0	 100	 0	 0	 100	 0	 80	
13.44_1-butanol	 0	 0	 33	 0	 0	 0	 0	 0	 0	 0	 0	 0	 0	 40	 0	 0	
16.08_3-buten-1-ol,	3-methyl-	 0	 0	 33	 0	 0	 17	 17	 0	 0	 0	 0	 0	 0	 0	 0	 0	
14.00_1-penten-3-ol	 0	 0	 0	 0	 0	 0	 0	 0	 0	 0	 67	 0	 0	 0	 0	 0	
17.45_1-pentanol	 0	 0	 100	 0	 0	 0	 0	 0	 0	 0	 67	 0	 0	 0	 0	 0	
21.19_1-hexanol	 0	 0	 83	 0	 0	 0	 0	 0	 0	 0	 100	 0	 0	 0	 0	 0	
25.12_1-octen-3-ol	 0	 0	 83	 0	 0	 0	 0	 0	 0	 0	 33	 0	 0	 0	 0	 0	
28.14_phenol	 17	 17	 67	 0	 33	 67	 17	 17	 83	 17	 33	 17	 17	 60	 20	 40	
12.51_acetic	acid	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	
16.29_propanoic	acid	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	
18.26_2-methyl-propanoic	acid	 83	 67	 100	 83	 83	 50	 67	 67	 83	 33	 83	 33	 67	 60	 60	 100	
19.62_butanoic	acid	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	
19.84_2,2-dimethyl-propanoic	acid	 83	 83	 67	 83	 50	 83	 17	 83	 100	 100	 67	 100	 83	 60	 60	 80	
21.51_3-methyl-butanoic	acid	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 83	 100	 100	 100	
21.73_2-methyl-butanoic	acid	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 83	 83	 100	 80	 100	
23.14_pentanoic	acid	 100	 67	 100	 100	 100	 100	 83	 100	 100	 100	 100	 67	 83	 100	 60	 100	
26.38_hexanoic	acid	 83	 33	 50	 0	 0	 50	 0	 67	 100	 33	 50	 50	 0	 60	 0	 20	
34.02_propanoic	acid,	2,2-dimethyl-,	sodium	salt	 0	 0	 50	 17	 17	 0	 33	 17	 0	 0	 33	 0	 17	 20	 40	 0	
7.94_methyl	acetate	 33	 17	 67	 17	 0	 50	 0	 50	 50	 0	 67	 17	 0	 60	 0	 60	
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Table	3.2	continued.		 	
	 %	occurrence	at	each	week	
	 Females	 Males	
RT_compound	 w1	 w2	 w3	 w4	 w5	 w6	 w7	 w8	 w1	 w2	 w3	 w4	 w5	 w6	 w7	 w8	
10.53_ethyl	Acetate	 33	 17	 0	 17	 33	 17	 0	 17	 17	 50	 0	 17	 17	 40	 0	 0	
10.74_acetic	acid	ethenyl	ester	 17	 50	 67	 50	 17	 50	 17	 33	 0	 50	 33	 33	 17	 0	 20	 20	
11.21_methyl	propionate	 67	 17	 17	 0	 0	 50	 0	 33	 50	 33	 50	 17	 0	 80	 0	 80	
12.22_isopropyl	acetate	 0	 17	 33	 67	 17	 67	 50	 17	 0	 0	 17	 17	 0	 80	 20	 60	
14.69_methyl	butyrate	 83	 17	 33	 50	 17	 100	 33	 67	 100	 67	 50	 33	 50	 100	 0	 100	
17.72_ethyl	butyrate	 50	 67	 83	 83	 67	 100	 17	 67	 33	 100	 50	 83	 83	 100	 0	 100	
19.08_butanoic	acid,	1-methylethyl	ester	 0	 17	 33	 33	 17	 67	 17	 0	 17	 0	 33	 17	 0	 100	 0	 80	
28.90_butyric	acid,	p-fluorophenyl	ester	 0	 0	 33	 0	 0	 0	 0	 0	 0	 0	 0	 0	 0	 0	 0	 0	
5.12_acetylaldehyde	 33	 83	 50	 67	 67	 33	 50	 33	 17	 50	 17	 33	 50	 0	 0	 20	
7.11_2-propenal	 17	 33	 50	 0	 0	 0	 0	 17	 17	 0	 67	 17	 0	 40	 0	 20	
7.21_propanal	 100	 100	 100	 100	 100	 100	 67	 100	 100	 100	 100	 100	 100	 100	 100	 100	
9.01_2-methyl-propanal	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 83	 100	 100	 100	
10.16_butanal	 50	 33	 0	 0	 0	 33	 0	 0	 67	 33	 17	 33	 0	 80	 0	 40	
12.49_3-methyl-butanal	 67	 33	 33	 50	 17	 83	 50	 50	 83	 33	 17	 50	 17	 80	 0	 40	
12.81_2-methyl-butanal	 100	 83	 33	 100	 67	 67	 83	 100	 100	 67	 50	 83	 33	 100	 40	 80	
14.20_pentanal	 83	 100	 83	 100	 67	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	
18.43_hexanal	 100	 100	 50	 100	 83	 83	 100	 100	 100	 100	 83	 100	 100	 100	 100	 100	
18.51_2-butenal,	3-methyl-	 0	 0	 50	 33	 33	 17	 33	 33	 0	 0	 0	 0	 0	 0	 0	 0	
20.96_2-hexanal	 0	 0	 0	 0	 0	 0	 0	 0	 0	 33	 0	 50	 0	 80	 0	 40	
21.97_2-methyl-pentanal	 0	 0	 0	 0	 0	 0	 0	 0	 33	 0	 17	 17	 17	 0	 0	 0	
22.33_heptanal	 100	 67	 33	 83	 0	 100	 0	 67	 100	 100	 17	 100	 50	 100	 0	 100	
24.89_2-heptanal	 17	 33	 0	 0	 0	 17	 0	 33	 50	 83	 17	 50	 0	 80	 0	 60	
26.08_octanal	 0	 33	 0	 0	 0	 33	 0	 0	 67	 33	 17	 67	 0	 60	 0	 0	
27.67_5-ethylcyclopent-1-enecarboxaldehyde	 0	 33	 0	 0	 0	 17	 0	 0	 17	 50	 33	 33	 0	 60	 0	 0	
28.62_2-octenal	 0	 0	 0	 0	 0	 0	 0	 0	 17	 17	 0	 50	 0	 40	 0	 0	
29.57_nonanal	 67	 17	 0	 83	 0	 67	 0	 67	 100	 17	 0	 100	 0	 100	 0	 40	
5.92_butane,	2-methyl-	 17	 33	 33	 17	 50	 50	 0	 17	 0	 50	 0	 50	 33	 0	 0	 40	
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Table	3.2	continued.	 	
	 %	occurrence	at	each	week	
	 Females	 Males	
RT_compound	 w1	 w2	 w3	 w4	 w5	 w6	 w7	 w8	 w1	 w2	 w3	 w4	 w5	 w6	 w7	 w8	
6.42_pentane	 83	 83	 17	 67	 17	 83	 17	 67	 83	 100	 33	 100	 83	 60	 20	 40	
12.63_hexane,	3-methyl-	 0	 0	 0	 0	 0	 0	 0	 0	 17	 17	 0	 33	 0	 20	 0	 0	
16.64_octane	 0	 0	 0	 0	 0	 0	 0	 0	 17	 33	 0	 33	 0	 20	 0	 0	
22.77_a-pinene	 0	 0	 0	 0	 0	 100	 0	 17	 0	 17	 0	 0	 0	 100	 0	 80	
24.38_2,2,4,6,6-pentamethyl-heptane	 100	 100	 83	 100	 83	 100	 67	 100	 83	 100	 17	 100	 33	 80	 60	 100	
27.01_6,8-dioxabicyclo[3.2.1]octane,	7-ethyl-5-methyl-,	(1R-exo)-	 0	 0	 0	 0	 0	 0	 0	 0	 33	 0	 0	 17	 0	 20	 0	 20	
27.68_undecane,	2,8-dimethyl-	 50	 0	 17	 0	 0	 50	 0	 0	 33	 17	 0	 0	 0	 40	 0	 40	
27.84_heptane,	3,3-dimethyl-	 67	 0	 0	 0	 0	 50	 0	 17	 50	 0	 0	 0	 0	 80	 0	 60	
28.93_diiodomethane	 50	 33	 33	 33	 17	 83	 67	 33	 67	 67	 67	 67	 50	 60	 60	 80	
30.96_dodecane	 100	 50	 67	 0	 0	 83	 0	 67	 83	 33	 33	 0	 0	 100	 0	 100	
16.58_toluene	 0	 33	 0	 33	 83	 0	 0	 0	 0	 33	 17	 33	 50	 0	 40	 0	
22.67_bicyclo[3.1.0]hex-2-ene,	2-methyl-5-(1-methylethyl)-	 33	 33	 0	 0	 17	 0	 0	 17	 0	 0	 0	 50	 0	 0	 0	 20	
27.53_7-exo-ethyl-5-methyl-6,8-dioxabicyclo[3.2.1]oct-3-ene	 0	 0	 67	 33	 33	 33	 33	 50	 33	 17	 67	 33	 0	 80	 60	 100	
8.32_cyclopentane	 83	 50	 100	 50	 67	 83	 0	 83	 50	 100	 100	 33	 100	 100	 60	 60	
17.94_oxirane,	2-methyl-2-(1-methylethyl)-	 0	 0	 0	 0	 0	 0	 0	 0	 33	 0	 0	 0	 0	 40	 0	 0	
22.16_pentyl-oxirane	 0	 0	 0	 0	 0	 0	 0	 0	 17	 17	 0	 33	 0	 20	 0	 0	
20.22_ethylbenzene	 50	 50	 50	 50	 83	 67	 33	 67	 33	 100	 17	 100	 17	 40	 0	 60	
20.53_1,3-xylene	 67	 50	 67	 17	 17	 83	 0	 50	 50	 50	 100	 50	 17	 80	 0	 40	
20.56_N-benzyloxy-2-carbomethoxyaziridine	 0	 0	 0	 0	 0	 0	 0	 0	 0	 17	 0	 0	 0	 40	 0	 40	
25.73_benzaldehyde	 83	 67	 100	 83	 67	 83	 50	 83	 100	 67	 100	 100	 67	 80	 0	 100	
33.74_benzene,	1,	3-bis(1,1-dimethylethyl)-	 100	 100	 100	 33	 100	 100	 67	 100	 100	 83	 100	 67	 83	 100	 80	 100	
6.92_furan	 0	 0	 0	 0	 0	 0	 0	 0	 17	 0	 17	 0	 0	 20	 0	 40	
10.32_furan,	3-methyl-	 0	 0	 0	 0	 0	 0	 0	 0	 17	 0	 17	 0	 0	 60	 0	 0	
13.51_2-ethyl-furan	 50	 0	 0	 0	 0	 17	 0	 0	 33	 17	 0	 0	 0	 0	 0	 20	
21.07_2-n-butyl	furan	 0	 0	 0	 0	 0	 0	 0	 0	 17	 33	 0	 0	 0	 0	 0	 0	
24.93_2-pentyl-furan	 50	 50	 17	 33	 0	 67	 0	 33	 100	 83	 33	 100	 0	 100	 0	 60	
7.41_acetone	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	
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Table	3.2	continued.		 	
	 %	occurrence	at	each	week	
	 Females	 Males	
RT_compound	 w1	 w2	 w3	 w4	 w5	 w6	 w7	 w8	 w1	 w2	 w3	 w4	 w5	 w6	 w7	 w8	
10.28_2,3-butanedione	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	
10.56_2-butanone	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	 100	
13.98_2-pentanone	 100	 100	 100	 100	 100	 100	 100	 100	 100	 83	 83	 100	 83	 100	 100	 100	
14.16_2,3-pentanedione	 100	 67	 83	 100	 100	 100	 0	 100	 67	 50	 67	 67	 83	 80	 60	 80	
14.65_2-propanone,	1-hydroxy-	 33	 0	 83	 0	 0	 33	 0	 17	 17	 0	 100	 0	 0	 40	 0	 40	
16.13_3-hydroxy-2-butanone	 100	 100	 100	 100	 100	 100	 100	 83	 100	 83	 100	 100	 100	 100	 100	 100	
16.46_3-penten-2-one	 0	 0	 0	 0	 17	 0	 33	 0	 33	 17	 17	 50	 0	 60	 0	 40	
16.98_1-propanone,	1-cyclopropyl-	 17	 17	 50	 0	 0	 17	 0	 17	 0	 0	 0	 0	 0	 0	 0	 0	
18.10_methyl	isobutyl	ketone	 0	 0	 33	 0	 0	 17	 0	 0	 33	 0	 0	 0	 0	 0	 0	 20	
19.73_2-hydroxy-3-pentanone	 0	 0	 0	 0	 0	 0	 0	 0	 0	 0	 0	 0	 0	 20	 0	 40	
23.99_3-hepten-2-one	 0	 0	 33	 17	 17	 0	 0	 0	 0	 0	 0	 0	 0	 0	 0	 0	
24.10_3-heptanone,	6-methyl-	 0	 0	 33	 17	 33	 0	 33	 33	 33	 17	 17	 50	 0	 60	 20	 60	
25.79_2(5H)-furanone	 67	 50	 83	 0	 33	 0	 0	 0	 100	 67	 33	 0	 0	 20	 0	 20	
22.11_2-heptanone	 50	 50	 67	 33	 33	 100	 50	 100	 83	 33	 33	 50	 0	 100	 0	 80	
26.79_2(3H)-furanone,	dihydro-5-methyl-	 0	 0	 33	 0	 0	 0	 0	 0	 33	 17	 33	 0	 0	 40	 0	 20	
27.97_3-octen-2-one	 0	 0	 0	 0	 0	 0	 0	 0	 0	 0	 0	 17	 0	 40	 0	 0	
28.15_1,3-difluoro-2-propanone	 33	 0	 33	 17	 0	 17	 17	 33	 17	 0	 33	 0	 0	 20	 0	 60	
29.09_5-azacytosine	 17	 0	 50	 0	 0	 0	 0	 0	 0	 0	 33	 0	 0	 0	 0	 0	
5.59_trimethylamine	 0	 0	 0	 0	 0	 0	 0	 0	 17	 17	 17	 17	 0	 40	 40	 40	
7.82_thiourea	 17	 17	 50	 33	 33	 50	 0	 50	 83	 0	 17	 33	 0	 20	 0	 20	
7.90_acetonitrile	 50	 100	 67	 83	 67	 67	 0	 67	 50	 100	 83	 83	 67	 60	 0	 60	
10.40_nitromethane	 0	 0	 0	 0	 0	 0	 0	 0	 17	 17	 33	 17	 0	 60	 40	 60	
14.33_hydrogen	azide	 0	 0	 33	 0	 0	 17	 0	 0	 0	 0	 0	 0	 0	 0	 0	 0	
22.56_pyrazine,	2,5-dimethyl-	 0	 0	 17	 17	 33	 0	 33	 17	 50	 17	 17	 0	 0	 0	 0	 20	
23.37_2-acetyl-1-pyrroline	 0	 0	 0	 0	 0	 0	 0	 0	 0	 17	 17	 17	 0	 60	 40	 60	
24.80_1,3,5-triazine	 0	 33	 0	 0	 17	 50	 0	 17	 0	 33	 33	 0	 50	 20	 20	 20	
38.66_indole	 33	 50	 67	 50	 50	 100	 50	 83	 100	 50	 83	 50	 33	 80	 20	 80	
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Table	3.2	continued.		 	
	 %	occurrence	at	each	week	
	 Females	 Males	
RT_compound	 w1	 w2	 w3	 w4	 w5	 w6	 w7	 w8	 w1	 w2	 w3	 w4	 w5	 w6	 w7	 w8	
26.66_dimethyl	sulfone	 33	 17	 100	 33	 50	 83	 50	 83	 83	 50	 83	 83	 0	 100	 80	 100	
23.27_unidentified	 67	 83	 50	 67	 67	 83	 0	 83	 33	 67	 100	 67	 17	 60	 20	 100	
25.63_unidentified	 33	 0	 17	 0	 17	 0	 0	 17	 17	 0	 67	 0	 17	 0	 20	 20	
25.82_unidentified	 0	 0	 0	 0	 0	 0	 0	 0	 33	 17	 17	 67	 0	 60	 0	 60	
29.71_unidentified	 0	 0	 0	 0	 0	 0	 0	 0	 17	 17	 17	 50	 0	 100	 40	 60	
 
 
	 102	
3.5.2	Chemical	composition	of	murine	faecal	pellets		
	
Faecal	 pellets	 from	C57BL/6	mice	were	 rich	 in	 compounds	 at	 RTs	 between	10-30	
mins	 with	 fewer	 VOCs	 identified	 before	 10	 or	 after	 30	mins	 (Figures	 3.2	 –	 3.9).	
Inevitably,	some	compounds	can	belong	to	more	than	one	chemical	class	therefore	
the	 VOCs	 present	 in	 Table	 3.2	 were	 sorted	 according	 to	 the	 following	 list	 of	
compound	categories	(Table	3.3).		
	
Table	 3.3	 The	 number	 of	 VOCs	 grouped	 into	 each	 chemical	 class	 identified	 in	 at	
least	30%	of	samples	from	at	least	1	time	point	from	healthy	C57BL/6	mice.	
Chemical	class	of	compounds	 Number	of	VOCs	
1:	Alcohols	 13	
2:	Acids	 10	
3:	Esters	 9	
4:	Aldehydes	 18	
5:	Alkanes	 11	
6:	Alkenes	 3	
7:	Alicyclic	compounds	 3	
8:	Benzenoid	compounds	 5	
9:	Heterocyclic	compounds	 5	
10:	Ketones	 19	
11:	Nitrogen-containing	compounds	 9	
12:	Sulphur-containing	compounds	 1	
13:	Unidentified	compounds	 4	
 
The	 most	 common	 group	 of	 compounds	 identified	 in	 the	 headspace	 of	 faecal	
pellets	 from	 C57BL/6	 mice	 were	 ketones	 with	 19	 in	 total.	 Acetone,	 2,	 3-
butanedione,	2-butanone,	2-pentanone	and	3-hydroxy-2-butanone	were	identified	
in	>80%	of	samples	from	male	and	female	mice	at	every	time	point.	There	were	18	
aldehydes	 identified	 with	 propanal,	 2-methylpropanal,	 3-methylbutanal,	 2-
methylbutanal,	 pentenal	 and	 hexanal	 being	 common	 to	 every	 week	 in	 >60%	 of	
samples	 from	 males	 and	 females.	 The	 next	 most	 frequently	 identified	 chemical	
classes	were	alcohols,	alkanes	and	acids.	There	were	only	2	out	of	the	13	alcohols	
(ethanol,	isopropanol)	present	at	every	time	point	for	both	genders	and	3	out	of	11	
alkanes.	Eight	out	of	 the	10	acids	 identified	were	present	 in	>60%	of	 samples	 for	
males	and	females	at	every	time	point.		
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3.5.3	Composition	of	mouse	feed	
	
Mice	 were	 fed	 a	 standard	 pelleted	 diet	 suitable	 for	 short	 term	 maintenance	
supplied	 by	 Special	 Diets	 Services	 (SDS),	 Essex,	 UK.	 Ingredients	 include	 wheat,	
wheatfeed,	barley,	de-hulled	extracted	 toasted	soya,	maize,	macro	minerals,	 soya	
oil,	 potato	 protein,	 hydrolised	 wheat	 gluten,	 full	 fat	 soya,	 maize	 gluten	 meal,	
vitamins,	micro	minerals	and	amino	acids.	Aliquots	of	feed	were	run	in	triplicate	to	
determine	 the	 VOCs	 present	 in	 it	 and	 were	 compared	 with	 the	 VOC	 profiles	
produced	from	analysis	of	murine	faeces.	Acetic	acid,	3-methylbutanal,	hexanal,	1-
propanol	 and	 isopropanol	 were	 the	 VOCs	 emitted	 from	 the	 food	 at	 the	 highest	
abundance.	A	master-list	of	VOCs	 found	 in	 this	 food	 is	 included	 in	Table	3.4.	This	
masterlist	was	produced	 to	allow	 the	author	 to	make	note	of	 any	 common	VOCs	
throughout	 all	 future	 studies	 that	 may	 be	 present	 within	 the	 mouse	 chow.					
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Table	3.4	List	of	VOCs	found	in	the	chow	fed	to	all	mice	housed	in	Liverpool
	
6.42_pentane	
6.61_ethanol	
6.92_furan	
7.11_2-propenal	
7.21_propanal	
7.41_acetone	
7.49_dimethyl	sulfide	
7.61_isopropanol	
7.94_methyl	acetate	
8.12_pentane,	2-methyl-	
8.61_3-methyl-pentane	
9.01_2-methyl-propanal	
9.07_hexane	
9.57_1-propanol	
9.89_2,2-dimethylpentane	
10.16_butanal	
10.28_2,3-butanedione	
10.31_cyclopentane,	methyl-	
10.32_furan,	3-methyl-	
10.56_2-butanone	
10.77_2-butanol	
11.19_2-methyl-3-buten-2-ol	
11.64_cyclohexane	
11.90_1-propanol,	2-methyl-	
12.49_3-methyl-butanal	
12.51_acetic	acid	
12.63_hexane,	3-methyl-	
12.70_heptane	
12.81_2-methyl-butanal	
13.51_2-ethyl-furan	
14.00_1-penten-3-ol	
14.20_pentanal	
15.94_dimethyl	disulfide	
16.05_cyclobutanone,	2,2,3-trimethyl-	
16.06_1-butanol,	3-methyl-	
16.29_propanoic	acid	
16.46_3-penten-2-one	
16.58_toluene	
16.64_octane	
17.45_1-pentanol	
18.10_methyl	isobutyl	ketone	
18.43_hexanal	
19.42_hydroxymethyl	2-hydroxy-2-
methylpropionate	
19.62_butanoic	acid	
19.84_2,2-dimethyl-propanoic	acid	
20.53_1,3-xylene	
20.56_N-benzyloxy-2-
carbomethoxyaziridine	
20.96_2-hexanal	
21.07_2-n-butyl	furan	
21.19_1-hexanol	
21.51_3-methyl-butanoic	acid	
21.73_2-methyl-butanoic	acid	
22.11_2-heptanone	
22.33_heptanal	
22.67_bicyclo[3.1.0]hex-2-ene,	2-methyl-5-
(1-methylethyl)-	
22.77_a-pinene	
23.14_pentanoic	acid	
23.27_unknown	
23.62_3-(methylthio)-propanal	
24.36_pentane,	2,	2,	3-trimethyl	
24.38_2,2,4,6,6-pentamethyl-heptane	
24.89_2-heptanal	
24.93_2-pentyl-furan	
25.12_1-octen-3-ol	
25.34_dimethyltrisulphide	
25.54_butyrolactone	
25.63_(1H)pyrrole-3-carbonitrile,	2-methyl-	
25.63_unknown		
25.73_benzaldehyde	
26.08_octanal	
26.38_hexanoic	acid	
26.79_2(3H)-furanone,	dihydro-5-methyl-	
27.67_5-ethylcyclopent-1-
enecarboxaldehyde	
28.14_phenol	
28.62_2-octenal,	(E)	
28.66_benzeneacetaldehyde	
29.57_nonanal	
30.27_2(3H)-furanone,	5-ethyldihydro-	
30.96_dodecane	
31.81_2-nonenal	
33.74_benzene,	1,	3-bis(1,1-dimethylethyl)-	
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3.5.4	Significant	effect	of	age	and	gender	on	the	presence	of	VOCs	
	
A	two-way,	repeated	measures	ANOVA	was	performed	on	the	average	number	of	
VOCs	 identified	 across	 time	 for	 male	 and	 female	 C57BL/6	 mice.	 There	 was	 a	
significant	 main	 effect	 of	 time,	 F	 (7,	 35)	 =	 23.12,	 p<0.001.	 This	 means	 if	 other	
dependent	variables	(gender)	are	ignored,	the	average	number	of	VOCs	identified	is	
different	across	time.	There	was	also	a	significant	main	effect	of	gender,	F	(1,	5)	=	
36.68,	 p<0.01.	 This	 effects	 means	 if	 time	 is	 ignored,	 the	 number	 of	 VOCs	 were	
different	 between	 males	 and	 females.	 In	 addition,	 there	 was	 a	 significant	
interaction	between	 the	 two	variables,	 time	and	gender,	 F	 (7,	35)	=	4.21,	p<0.01.	
This	means	that	the	number	of	VOCs	identified	for	both	male	and	female	mice	were	
different	for	the	different	time	points	(Figure	3.10).	There	was	a	 lower	number	of	
VOCs	 identified	 at	weeks	 5	 and	 7,	 compared	 to	 all	 other	weeks,	 and	 the	moving	
average	was	plotted	to	smooth	out	these	small	fluctuations	in	the	data.		
	
Figure	3.10	Number	of	VOCs	identified	in	the	HS	of	murine	faecal	samples	collected	
during	 8	 consecutive	 weeks	 in	 both	 female	 (n=6)	 and	 male	 (n=6)	 C57BL/6	 mice	
(data	expressed	as	mean±SEM).	The	pink	line	is	the	rolling	average	for	female	mice	
and	 the	blue	 line	 is	 the	 rolling	average	 for	male	mice,	both	 showing	 the	 trend	of	
number	of	VOCs	over	time	for	both	genders.	
	
	
	 106	
3.5.5	The	effect	of	gender	on	murine	faecal	volatile	metabolomic	profiles	
	
The	 effect	 of	 gender	 on	 the	 HS	 faecal	 pellet	 VOC	metabolomic	 profile	 was	 then	
investigated	 in	 healthy	 WT	 C57BL/6	 mice.	 A	 PCA	 derived	 from	 compound	
concentrations	 in	 murine	 faecal	 pellets	 collected	 weekly	 for	 8	 weeks	 revealed	
separation	between	male	and	female	mice	at	most	time	points,	with	the	exception	
of	weeks	2	and	5	(Figure	3.11).	The	largest	degree	of	separation	between	males	and	
females	appeared	at	weeks	1,	4,	6	and	8.	Therefore,	at	ages	5,	8,	10	and	12	weeks	
old,	respectively,	the	faecal	metabolome	of	male	and	female	mice	appear	to	be	the	
most	different.		
	
In	 order	 to	 investigate	 which	 individual	 VOCs	 contributed	 to	 this	 separation,	 the	
PCA	biplot	was	examined	 for	each	 time	point	and	univariate	statistical	 tests	were	
performed.	There	were	7,	 1,	 4,	 6,	 3,	 5,	 5	 and	4	 compounds	 found	 to	 significantly	
vary	between	male	and	female	mice	at	weeks	1,	2,	3,	4,	5,	6,	7	and	8,	respectively	
(Student’s	t-test,	p<0.05).	The	majority	of	these	significant	compounds	were	either	
increased	in	males	at	each	time	point	compared	to	females,	or	absent	 in	females.	
The	compounds	 included	2-pentanone,	3-methylbutanoic	acid,	phenol,	 indole	and	
thiourea	at	week	1;	propanoic	acid	at	week	3;	pentanal,	hexanal,	2-pentylfuran	and	
propanal	 at	 week	 4;	 pentane	 and	 propanal	 at	 week	 5;	 pentanoic	 acid	 and	 2-
heptanal	 at	 week	 6;	 propanoic	 acid,	 acetone	 and	 isopropanol	 at	 week	 7	 and	 2-
butanol	 and	 propanal	 at	 week	 8.	 There	 was	 one	 compound	 unique	 to	 males	
(octanal)	 at	 week	 1	 and	 week	 4	 and	 one	 unique	 to	 females	 (2(5H)-furanone)	 at	
week	1	and	week	3.	1-propanol	was	unique	to	males	at	week	2	and	week	6	and	1-
penten-3-ol	at	week	3.	One	compound	was	found	exclusively	in	males	at	week	6	(1-
hexanal)	 and	 week	 8	 (butanoic	 acid,	 1-methylethyl	 ester)	 and	 two	 in	 females	 at	
week	7	(3-penten-2-one	and	3-methyl-2-butenal).		
	
There	are	a	number	of	compounds	responsible	 for	 the	separation	between	males	
and	 females	 at	 each	 time	 point,	 thus	 creating	 a	 unique	 profile	 for	 male	 versus	
female	 C57BL/6	 mice	 between	 the	 ages	 of	 5	 to	 12	 weeks	 old.
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Figure	3.11	A	PCA	for	the	VOC	metabolomic	profiles	of	male	and	female	C57BL/6	mice	at	each	experimental	week	tested,	weeks	1-8	(A-H,	
respectively).	All	PCAs	were	performed	on	compounds	present	in	at	least	30%	of	one	gender	with	missing	data	substituted	with	the	value	1	
and	data	were	log	transformed	(circles	=	female	(n=6),	triangles	=	male	(n=6)).		
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3.5.6	The	effect	of	age	on	murine	faecal	volatile	metabolomic	profiles		
	
The	 C57BL/6	 faecal	 VOC	profile	 can	 separate	males	 from	 females	 at	 certain	 time	
points	 and	 the	 longitudinal	 VOC	 profiles	 for	 males	 and	 females	 were	 examined	
individually.	A	one-way	ANOVA	was	performed	on	 the	 time	 series	data	 for	males	
and	 females,	 in	 order	 to	 identify	 those	 compounds	 that	 significantly	 varied	
according	to	time.		
	
This	analysis	 identified	29	and	25	compounds	which	significantly	varied	over	 time	
for	males	and	 females,	 respectively	 (ANOVA	with	Bonferroni	multiple	 comparison	
correction,	 p<0.05).	 A	 PCA	 of	 these	 significantly	 different	 compounds	 showed	 a	
tight	clustering	pattern	at	all	8	time	points	for	both	male	(Figure	3.12)	and	female	
(Figure	 3.13)	 mice,	 which	 appeared	 very	 similar	 between	 males	 and	 females.	
Similarities	 between	 the	 two	were	 evident	with	week	 3	 (green)	 having	 complete	
separation	from	the	rest	of	the	data	points.	Weeks	1,	6	and	8	(blue,	black	and	pink)	
appeared	to	overlap	for	both	genders,	as	do	weeks	2	and	4	(red	and	orange).	It	was	
observed	 earlier	 that	 weeks	 5	 and	 7	 had	 the	 lowest	 number	 of	 compounds	
identified	for	males	and	females	(Figure	3.10),	it	seems	these	two	weeks	are	most	
alike.		
	
The	 ten	most	 significant	 compounds	 that	were	 found	 to	 vary	 over	 time	 for	male	
C57BL/6	mice	were	1-hexanol,	pinene,	2-butanone,	1-propanol,	nonanal,	2-methyl-
1-propanol,	 ethanol,	 heptanal,	 2,	 3-butandione	and	propanoic	 acid	 (p<0.001).	 For	
females,	 the	 ten	 most	 significantly	 different	 compounds	 were	 1-pentanol,	
isopropanol,	 pinene,	 2-methyl-1-propanol,	 1-propanol,	 1-octen-3-ol,	 1-hexanol,	 2-
butanone,	 propanoic	 acid	 and	 acetic	 acid	 (p<0.001).	 Six	 of	 these	were	 shared	 for	
male	and	 female.	 It	was	concluded	that	 the	VOC	metabolomic	profile	 from	faecal	
pellets	of	C57BL/6	changes	according	to	time,	but	the	time-dependent	metabolites	
appear	to	be	similar	in	male	and	female	mice.		
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Figure	3.12	A	PCA	for	 the	 faecal	samples	 from	healthy	male	C57BL/6	mice	 (n=6)	
collected	over	time	from	the	age	of	5	to	12	weeks	old.	The	first	PC	(26.71%)	has	
been	plotted	against	the	second	PC	(13.51%).	The	PCA	was	performed	using	the	54	
VOCs	 that	 were	 found	 to	 be	 significantly	 different	 over	 time	 (missing	 data	
substituted	 with	 the	 value	 1,	 data	 were	 log	 transformed,	 n=12/groups,	 ANOVA	
followed	by	Tukey’s	HSD	Bonferroni	correction	(p<0.05)).	 	
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Figure	3.13	A	PCA	for	the	faecal	samples	from	healthy	female	C57BL/6	mice	(n=6)	
collected	over	time	from	the	age	of	5	to	12	weeks	old.	The	first	PC	(31.75%)	has	
been	plotted	against	the	second	PC	(14.65%).	The	PCA	was	performed	using	the	54	
VOCs	 that	 were	 found	 to	 be	 significantly	 different	 over	 time	 (missing	 data	
substituted	 with	 the	 value	 1,	 data	 were	 log	 transformed,	 n=12/groups,	 ANOVA	
followed	by	Tukey’s	HSD	Bonferroni	correction	(p<0.05)).	 	
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3.5.7	Significantly	different	VOC	profiles	according	to	location	of	GI	tract	
	
Faecal	 content	 was	 collected	 at	 the	 end	 of	 the	 experiment	 (week	 8)	 from	 the	
proximal	(ascending)	and	distal	(descending)	colon	and	the	small	 intestine	(SI)	and	
was	compared	to	the	faecal	pellet	collected	earlier	the	same	day	from	each	mouse.	
Due	to	the	very	minor	differences	identified	earlier	between	male	and	female	mice,	
data	was	not	separated	according	to	gender	for	this	comparison.		
	
The	number	of	compounds	identified	was	compared.	A	significantly	lower	number	
of	VOCs	were	identified	in	the	SI	content	(26.2±1.5)	compared	to	the	faecal	pellet	
(44.1±2.0),	 distal	 colon	 content	 (41.0±2.9)	 and	 the	 proximal	 colon	 content	
(45.9±2.0)	(mean±SEM;	ANOVA	followed	by	Tukey’s	HSD,	p<0.001)	(Figure	3.14A).		
The	 chemical	 composition	 of	 VOCs	 emitted	 from	 all	 four	 groups	 of	 faecal	matter	
appeared	 relatively	 similar.	 Ester	 compounds	 were	 responsible	 for	 8.7,	 13.4	 and	
14.5%	 of	 total	 VOC	 composition	 in	 the	 faecal	 pellet,	 distal	 and	 proximal	 colon,	
respectively.	However,	no	esters	were	identified	in	the	small	intestine	content.	This	
could	explain	 the	 significant	 reduction	 in	 the	number	of	VOCs	 identified	 in	 the	 SI	
content.	One	alicyclic	compound,	cyclopentane,	was	 identified	 in	 the	 faecal	pellet	
(72%	 of	 samples)	 and	 the	 proximal	 colon	 content	 (18%	 of	 samples)	 but	 it	 was	
absent	 in	the	small	 intestine	content	and	the	distal	colon	content.	Similarly,	there	
were	 no	 sulphur-containing	 compounds	 found	 in	 the	 distal	 colon	 content	 (Figure	
3.14B).		
	
A	total	of	86	compounds	were	identified	across	all	four	groups	(present	in	at	least	
30%	of	 samples	 in	at	 least	one	group).	To	 further	 investigate	differences	 in	 these	
VOC	 profiles,	 the	 abundances	 of	 these	 86	 VOCs	 were	 compared,	 resulting	 in	 74	
significantly	different	VOCs	(ANOVA,	p<0.05).	A	PCA	plot	using	these	74	VOCs	shows	
the	differences	between	 the	VOC	 constituents	 identified	and	 their	 abundances	 in	
the	HS	of	samples	taken	from	different	locations	of	the	small	and	large	bowel.	The	
clustering	of	similar	samples	is	evident	showing	reproducibility	between	individual	
C57BL/6	mice.	The	PCA	shows	that	the	faecal	content	collected	from	the	proximal	
(green)	 and	 distal	 colon	 (red)	 overlap;	 therefore	 they	 have	 the	most	 similar	 VOC	
	 112	
profiles	 in	 this	 comparison.	 There	 is	 a	 clear	 separation	 between	 the	 pellet	 (blue)	
and	the	small	 intestine	content	(orange)	from	each	other	and	the	combined	colon	
content	 groups.	 There	 was	 an	 increase	 in	 the	 levels	 of	 most	 esters	 in	 the	 distal	
colon	 content	 combined	 with	 other	 compounds	 such	 as	 2-nonanone,	 phenol,	 3-
pent-2-one,	 butanal	 and	 furan,	 3-methyl	 being	 responsible	 for	 the	 separation	
between	the	faecal	pellet	samples	and	the	distal	and	proximal	colon	content,	where	
they	 were	most	 abundant.	 Dimethyl	 sulfone,	 2,2-dimethyl	 propanoic	 acid	 and	 2-
butanol	were	most	abundant	in	the	pellet	with	pyrrole	influencing	the	separation	of	
the	 small	 intestine	 samples	 (Figure	 3.15).	 Understanding	 these	 apparent	
differences	will	 be	 useful	when	 analyzing	 samples	 from	murine	models	 of	 the	GI	
disease.	
	
 
	 113	
 
Figure	3.14	The	faecal	pellet	was	compared	to	the	faecal	content	taken	from	the	
distal	 and	 proximal	 colon	 and	 the	 small	 intestine.	 There	 was	 a	 significant	
difference	 between	 the	 number	 of	 compounds	 identified	 when	 comparing	 the	
pellet,	 distal	 and	proximal	 colon	 content	 to	 the	 small	 intestine	 content	 (A.)	 (Data	
expressed	 as	 mean±SEM,	 n=12/group,	 ANOVA	 followed	 by	 Tukey’s	 HSD	 test	
***p<0.001).	 The	 chemical	 composition	 of	 VOCs	 across	 the	 different	 groups	
appears	similar	with	an	absence	of	esters	 identified	 in	 the	small	 intestine	content	
(B).		
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Figure	3.15	A	PCA	for	the	faecal	samples	from	healthy	female	and	male	C57BL/6	
mice	 sampled	 at	 the	 different	 regions	 of	 the	 GI	 tract:	 cage	 pellet,	 distal	 colon	
contents,	 proximal	 colon	 contents	 and	 small	 intestine	 contents.	 The	 first	 PC	
(30.88%)	has	been	plotted	against	the	second	PC	(27.29%).	The	PCA	was	performed	
using	 the	 74	 VOCs	 that	 were	 found	 to	 be	 significantly	 different	 across	 the	 four	
groups	(data	were	log	transformed,	n=12/groups,	ANOVA	followed	by	Tukey’s	HSD	
(p<0.05)).		
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3.5.8	Impact	of	a	germ-free	VOC	metabolome	
	
In	this	study,	the	impact	of	the	intestinal	microbiota	on	the	VOC	faecal	metabolome	
of	laboratory	mice	from	MRC	Harwell,	Oxford	was	investigated	using	SPME	coupled	
to	GC-MS.	Specifically,	the	impact	of	the	host	VOC	on	the	faecal	metabolome	was	
investigated.	Samples	collected	from	GF	animals	were	from	a	mixture	of	C3H/HeN	
and	Junbo	(on	a	C3H/HeN	background)	male	and	female	mice.	GF	and	their	non-GF	
strain	matched	 SPF	 animal	 groups	were	 of	 the	 same	 age	 and	 fed	 the	 same	 diet.	
Analysis	 of	 the	 headspace	 gas	 emitted	 from	 faecal	 pellets	 of	 GF	 and	 non-GF	
equivalent	 mice	 (SPF	 housed)	 identified	 54.3±1.3	 and	 77.0±1.9	 compounds,	
respectively	 (mean±SEM);	 thus,	 there	 were	 significantly	 more	 VOCs	 identified	 in	
SPF	non-GF	mice,	compared	to	GF	mice	(Student’s	t-test,	p<0.001)	(Figure	3.16).		
	
	
Figure	3.16	Number	of	VOCs	identified	in	the	HS	of	murine	faecal	samples	collected	
from	a	mixture	of	 Junbo	 and	C3H/HeN	GF	mice	 (n=6),	and	non-GF	SPF	equivalent	
(n=6),	provided	by	MRC	Harwell,	Oxford	(data	expressed	at	mean±SEM,	Student’s	t-
test	***p<0.001).		
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The	 quantitative	 differences	 between	 the	 two	 groups	 were	 then	 explored;	 there	
were	 64	 significantly	 different	 VOCs	 (Student’s	 t-test	 with	 Bonferroni	 multiple	
comparison	 correction,	 p<0.05).	 Of	 these	 64	 VOCs,	 35	 were	 absent	 in	 GF	 faecal	
samples	and	were	found	exclusively	in	the	faecal	samples	of	the	non-GF	equivalent	
mice,	of	which	the	majority	were	acid	and	ester	compounds.	There	were	12	VOCs	
unique	 to	GF	 faecal	 samples	 including	8	alkanes.	The	abundance	of	5	compounds	
was	significantly	greater	in	GF	compared	to	non-GF,	of	which	3	were	aldehydes.	In	
contrast,	 7	 out	 of	 the	 12	 VOCs	which	were	 significantly	 less	 abundant,	 in	 the	GF	
compared	 to	 non-GF	 samples,	 were	 ketones.	 A	 PCA	 showed	 a	 remarkable	
difference	 observed	 in	 the	 VOCs	 emitted	 from	 the	 faecal	 pellet	 between	GF	 and	
non-GF	mice	(Figure	3.17).			
	
	
Figure	3.17	A	PCA	for	the	faecal	samples	from	healthy	GF	C3H/HeN	and	Junbo	mice	
compared	 to	 non-GF	 SPF	 C3H/HeN	 (n=6/group),	 collected	 from	 MRC	 Harwell,	
Oxford.	The	 first	PC	 (80.4%)	has	been	plotted	against	 the	second	PC	 (5.03%).	The	
PCA	was	performed	using	the	64	VOCs	that	were	found	to	be	significantly	different	
between	GF	and	SPF	mice	(data	were	log	transformed,	Student’s	t-test	followed	by	
Bonferroni	correction	(p<0.05)).	
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The	 faecal	 samples	 used	 for	 the	 investigation	 of	 the	 impact	 of	 a	 GF	 VOC	
metabolome	were	 housed	 in	 a	 different	 geographical	 location	 and	 of	 a	 different	
strain	to	the	samples	from	mice	used	for	the	work	 in	this	thesis.	The	chow	fed	to	
the	C3H/HeN	SPF	and	GF	mice	from	MRC	Harwell	was	also	supplied	from	SDS	and	
contained	 the	 same	 ingredients	 as	 the	 chow	 fed	 to	 the	 SPF	 mice	 at	 Liverpool.	
Therefore,	 the	 VOC	 metabolome	 of	 GF	 and	 their	 non-GF	 SPF	 equivalent	 were	
compared	to	that	of	 the	mice	housed	 in	SPF	conditions	at	University	of	Liverpool.	
The	 VOC	 faecal	 metabolome	 was	 significantly	 different	 between	 healthy	 GF	 and	
non-GF	SPF	of	two	different	strains	and	 locations	(Figure	3.18).	Butyl-	and	propyl-	
acid	and	ester	compounds	were	significantly	different	between	the	faecal	pellets	of	
mice	from	MRC	Harwell	SPF	conditions	compared	to	Liverpool.	Butanal,	2-methyl-,	
2-heptanone,	 propanal,	 2-methyl-,	 2-pentanone	and	heptanal	were	 a	 selection	of	
the	compounds	that	were	significantly	different	between	GF	mice	and	the	healthy	
SPF	 C57BL/6	 mice	 housed	 at	 Liverpool	 (ANOVA	 followed	 by	 Tukey’s	 HSD	 test,	
p<0.01).	
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Figure	 3.18	 A	 PCA	 for	 the	 faecal	 samples	 from	 healthy	 GF	 mice	 from	 Oxford,	
compared	 to	 non-GF	 SPF	 from	 Oxford	 (C3H/HeN),	 and	 Liverpool	 (C57BL/6)	
(n=6/group).	The	first	PC	(42.67%)	has	been	plotted	against	the	second	PC	(35.59%).	
The	 PCA	 was	 performed	 using	 the	 66	 VOCs	 that	 were	 found	 to	 be	 significantly	
different	 over	 time	 (data	 were	 log	 transformed,	 ANOVA	 followed	 by	 Bonferroni	
correction	(p<0.05)).	
	
Germ	free
C3H/HeN SPF
C57BL/6	SPF
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3.6	SUMMARY	OF	RESULTS	
	
1. Investigation	 of	 the	 healthy	murine	 faecal	 VOC	 profile	 using	HS-SPME-GC-
MS	found	little	biological	variation	between	individual	WT	C57BL/6	mice.		
	
2. Analysis	 of	 chromatograms	 produced	 from	 female	 and	 male	 mice	 weekly	
from	5	to	12	weeks	identified	90	and	103	VOCs	in	total,	respectively.	There	
was	 a	 variety	 of	 different	 compound	 classes	 identified	 with	 ketones,	
aldehydes	and	alcohols	being	the	most	commonly	observed	compounds.	
	
3. There	was	a	significant	effect	of	age	and	gender	on	the	average	number	of	
VOCs	identified	in	the	HS	of	faecal	pellets	collected	from	WT	C57BL/6	mice.	
For	 the	 age	 range	 tested,	 there	 are	 clear	 differences	 between	 male	 and	
female	 mice	 when	 comparing	 the	 abundance	 of	 all	 significantly	 different	
VOCs.	
	
4. There	were	29	and	25	VOCs	that	varied	significantly	over	time	for	male	and	
female	mice,	respectively.		
	
5. The	faecal	VOC	profile	varied	significantly	between	the	different	regions	of	
the	murine	lower	GI	tract,	and	the	faecal	pellet.	
	
6. The	 VOC	 profile	 from	 the	 faecal	 pellet	 of	 GF	mice	was	 compared	 to	 their	
non-GF	strain	equivalent,	 resulting	 in	 significant	differences	 in	 the	number	
of	VOCs	identified	and	the	abundance	of	a	large	number	of	specific	VOCs.	
	
7. Preliminary	data	may	suggest	that	there	is	an	effect	of	geographical	location	
and	 genetic	 background	 on	 the	 faecal	 VOC	 profile	 of	 mice	 but	 further	
investigation	is	required	to	separate	these	differences.		
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3.7	DISCUSSION	
	
This	study	has	investigated	the	faecal	VOC	metabolome	of	healthy	C57BL/6	mice	by	
detecting	VOCs	in	the	HS	gas	using	SPME-GC-MS.	The	gas	chromatograms	produced	
from	 the	 faecal	 pellets	 were	 abundant	 in	 compounds	 at	 RT	 10-30	minutes.	 Very	
little	were	detected	before	10	minutes;	those	after	30	mins	appeared	to	originate	
from	 the	 food	 remains	 in	 the	 faecal	 pellets.	 More	 than	 50%	 of	 compounds	
identified	 in	50%	of	samples	tested	 longitudinally	over	a	period	of	8	weeks	varied	
very	 little	 between	 individual	 mice.	 However,	 upon	 examining	 the	 coefficient	 of	
variation	 (CV),	 also	 known	 as	 the	 relative	 standard	 deviation,	 between	 individual	
mice,	it	was	above	the	statistically	acceptable	range	of	30%	[231].	In	order	to	have	a	
low	 CV	 between	 individual	 samples,	 it	 would	 require	 at	 least	 10	 biological	
replicates.	However,	this	is	beyond	the	scope	of	this	study	as	we	aimed	to	establish	
the	VOC	metabolome,	taking	into	consideration	the	ethical	guidelines	underpinning	
the	humane	use	of	animals	in	scientific	research,	the	three	Rs	(replace,	reduce	and	
refine)	[228,	232].	
	
Stable	 establishment	 of	 the	 microbial	 groups	 requires	 cooperation	 in	 food	
networks,	 such	 as	 cross-feeding	 where	 metabolites	 from	 one	 organism	 act	 as	 a	
substrate	 for	 another	 [233].	 In	 the	 intestinal	 environment,	 one	 of	 the	 most	
important	roles	of	microbial	activity	 is	the	fermentation	of	dietary	or	host-derived	
components,	 including	 the	 conversion	of	 non-digestible	 carbohydrates	 into	 SCFAs	
[234].	The	presence	of	SCFAs,	as	identified	in	the	faecal	pellet	and	bowel	contents,	
causes	activation	of	the	G-protein	coupled	receptor	43	which	has	been	proposed	to	
constitute	 a	 molecular	 link	 between	 diet,	 microbiota	 and	 immune	 modulation	
[235],	 and	 also	 plays	 a	 major	 role	 in	 the	 regulation	 of	 energy	 balance	 [236].	 In	
particular,	the	SCFA,	butyrate,	is	important	in	the	large	bowel	as	a	source	of	energy	
for	colonocytes	and	is	produced	by	beneficial	colonic	bacteria	[237].	There	were	4	
butyrates	 yielded	 in	 the	murine	 faecal	 pellet,	methyl	 butyrate,	 ethyl	 butyrate,	 1-
methylethyl	butyrate	and	fluorophenyl	butyrate.	The	 latter	 is	rare	as	 it	was	found	
only	 at	 week	 3	 in	 33%	 of	 female	 mice,	 therefore	 is	 more	 likely	 to	 be	 an	
environmental	 contaminant	 rather	 than	 a	 biologically	 relevant	 compound.	 Upon	
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inspection	 of	 the	 chromatograms	 at	 this	 time	 point	 of	 other	 animals,	 a	 siloxane	
contaminant	is	present,	thereby	confirming	our	suspicions	of	fluorophenyl	butyrate	
possibly	being	an	environmental	contaminant.		
	
Ketones	were	 the	most	 common	 class	 of	 VOCs	 identified	 in	 the	 gas	 surrounding	
healthy	murine	 faecal	 pellets.	 It	 is	 likely	 that	 acetone	 and	 2-butanone	 arise	 from	
fatty	 acid	 carbohydrate	 metabolism	 [238].	 The	 universal	 presence	 of	 2,	 3-
butanedione	 is	 important	 as	 it	 has	 been	 reported	 to	 have	 potential	 health	
implications	 by	 impacting	 on	 the	 growth	 of	 yeast	 and	 some	 bacteria,	 either	
increasing	or	decreasing	the	growth	[239],	but	does	occur	naturally	as	a	by-product	
of	 fermentation	 [240].	 The	 aldehydes,	 propanal,	 2-methylpropanal,	 3-
methylpropanal,	 2-methylbutanal,	 pentanal	 and	 hexanal	 were	 predominantly	
observed.	 Their	 presence	 suggests	 that	 their	 respective	 acids	 have	 undergone	
reduction	 or	 that	 their	 origin	may	 be	 dietary	 as	 there	 have	 been	 reports	 of	 such	
compounds	found	in	potatoes	and	carrots	[241,	242].	Hexanal	and	3-methylbutanal	
were	 amongst	 the	 most	 abundant	 compounds	 identified	 in	 the	 mouse	 feed;	 3-
methylbutanal	has	reportedly	been	included	in	feed	for	mice	and	rats	as	a	feeding	
stimulant	[243].		
	
The	 faecal	 pellet	 VOC	 composition	 of	 C57BL/6	mice	 was	 assessed	 for	 eight	 time	
points	 from	 the	 age	 of	 5	 to	 12	 weeks	 old	 in	 male	 and	 female	 mice.	 It	 was	
demonstrated	that	healthy	male	and	female	mice	form	distinct	clusters	and	further	
investigation	 also	 revealed	 a	 change	 in	 VOC	metabolomic	 profiles	 as	 mice	 aged.	
C57BL/6	mice	 reach	 sexual	 maturity	 at	 6-8	 weeks	 old	 (experimental	 weeks	 2-4),	
and,	 because	 of	 the	 hormonal	 changes	 occurring	 in	 both	 male	 and	 female	 mice	
(such	 as	 oestrogens	 and	 progesterone	 in	 female	 and	 androgen	 in	 males),	 the	
metabolites	may	vary.	Won	et	al.	 investigated	the	metabolomics	urinary	profile	of	
obese	mice	 using	NMR	 and	 reported	 significant	 gender-related	 differences	 [244].	
This	 highlights	 the	 importance	 of	 the	 gender-specific	 differences	 and	 metabolic	
pathways	for	future	studies.		
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Dissection	 of	 these	 known	 pathways	 and	 investigation	 into	 the	 mechanisms	 by	
which	 these	 differences	 arise	 will	 potentially	 lead	 to	 new	 diagnostic	 tests	 and	
understanding	of	the	pathogenesis	of	health	and	disease.	For	example,	it	has	been	
reported	that	certain	metabolites	related	to	mitochondrial	energy	metabolism	were	
found	 to	be	different	between	gender	and	age	 [245].	 It	 is	 important	 to	note	 that	
dietary	components	may	vary	according	to	the	time	of	day	the	faecal	pellets	were	
collected.	This	is	something	that	was	considered	in	preparation	for	this	experiment,	
and	controlled	for.		
	
Efficient	 absorption	 and	metabolism	 of	 nutrients	 is	 the	 primary	 role	 of	 the	 small	
intestine.	 Here,	 various	 nuclear	 receptors	 have	 an	 important	 regulatory	 role	 in	
keeping	 homeostatic	 control	 of	 the	 digestive	 system	 [246].	 This	 is	 achieved	 by	
mixing	 food	 with	 the	 digestive	 enzymes	 to	 increase	 contact	 with	 the	 absorptive	
cells	of	the	luminal	mucosa	[247].	The	small	intestine	secretes	signalling	molecules,	
such	 as	 gut	 hormones	 and	 cytokines,	 resulting	 in	 the	 liver	 and	 muscle	 tissue	
responding	by	modulating	their	own	metabolism.	There	was	a	significant	decrease	
in	the	number	of	VOCs	identified	in	this	study	of	the	luminal	content	from	the	small	
intestine,	 compared	 to	 the	 faecal	 pellet	 and	 the	 luminal	 content	 from	 the	 large	
intestine.	 There	 was	 also	 an	 absence	 of	 ester	 compounds	 in	 the	 SI	 contents,	
perhaps	 explaining	 the	 significant	 decrease	 in	 number	 of	 VOCs.	 The	 number	 of	
bacteria	 in	 the	 gut	 increases	 distally,	 from	 the	 stomach	 to	 the	 large	 bowel,	 with	
microbial	 densities	 relatively	 low	 in	 the	 small	 intestine.	 Esters	 are	produced	 from	
the	metabolism	of	carbohydrates	by	the	interaction	of	the	gut	bacteria	with	these	
complex	 polysaccharides	 [196],	 providing	 a	 possible	 explanation	 for	 this	
observation.		
	
This	study	has	investigated	the	faecal	VOC	metabolome	from	GF	and	non-GF	mice	
using	a	non-invasive	method,	HS-SPME-GC-MS,	and	consequently,	established	very	
significant	 and	 reproducible	 profiles.	 It	 found	 specific	 groups	 of	 compounds	
responsible	for	these	distinct	VOC	profiles.	A	number	of	alkanes	were	unique	to	GF	
faecal	 pellets	 in	 combination	 with	 an	 increase	 in	 the	 levels	 of	 aldehydes	 and	 a	
decrease	 in	the	 levels	of	ketones,	with	a	notable	absence	of	acids	and	esters.	The	
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synthesis	 of	 esters	 may	 be	 mediated	 by	 enzymes	 derived	 from	 the	 intestinal	
mucosa	 [248],	which	GF	mice	 lack	as	demonstrated	 in	 this	 study.	 In	addition,	 it	 is	
well-known	 that	 the	 gut	 microbiota	 is	 responsible	 for	 the	 degradation	 of	 most	
amino	acids	to	synthesise	SCFAs	[249]	[250].	The	gut	microbiota	 is	responsible	for	
the	synthesis	of	essential	vitamins	(e.g.	vitamin	K	and	B)	therefore	GF	mice	have	to	
be	 given	 these	 vitamins	 supplemented	 in	 their	 food	 [196];	 a	possible	 explanation	
for	 these	 differences	 noted	 between	 GF	 and	 non-GF	 animals.	 A	 reduction	 in	 the	
level	of	ketones	is	observed	in	fasted	GF	mice	in	this	study,	which	may	be	explained	
by	 the	 lack	of	nutrients	available	 to	 these	mice.	The	colon	 is	 the	most	prominent	
site	of	microbial	colonisation	therefore	it	is	no	surprise	that	the	faecal	metabolome	
of	 GF	 mice	 is	 different	 from	 that	 of	 conventionally	 housed	 mice	 [233].	 The	
microbiota	 of	 mice	 housed	 in	 SPF	 conditions	 is	 composed	 of	 well-established	
resident	bacteria	resulting	from	the	long-term	associations	with	the	host	from	birth	
[251].		
	
By	comparing	the	colonic	 luminal	metabolome	of	GF	mice	and	non-GF	mice	using	
capillary	electrophoresis-time	of	flight	mass	spectrometry	(CE-TOFMS),	Matsumoto	
et	al.	were	able	 to	obtain	a	novel	profile	of	numerous	metabolites	present	 in	 the	
intestinal	 lumen	 unique	 to	 GF	 mice,	 which	 supports	 our	 findings	 [252].	
Furthermore,	 Schwende	 et	 al.	 was	 able	 to	 show	 that	 by	 analysing	 urinary	 VOCs	
from	mice	of	one	strain	may	differ	both	quantitatively	and	qualitatively	from	those	
of	another	[253].	Here,	 it	has	been	shown	that	the	VOCs	present	 in	the	HS	gas	of	
faecal	pellets	from	mice	of	different	strains,	and	geographical	locations,	differ.		
	
Dysbiosis	of	the	intestinal	microbiota	has	been	associated	with	a	variety	of	diseases	
such	 as	 IBD	 and	 CRC	 [254].	 This	 highlights	 the	 importance	 of	 improving	 our	
understanding	 of	 the	 molecular	 basis	 and	 metabolic	 pathways	 involved	 in	 host-
microbe	interactions	and	will	increase	the	awareness	of	possible	disease-associated	
shifts.	 These	 studies	 will	 aid	 future	 studies	 of	 chemically-induced	 IBD	 and	 CRC	
murine	models,	where	one	gender	of	mice	will	be	used,	taking	into	account	these	
age-related	VOC	changes	during	the	development	of	disease.	
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Chapter	4	
	
Comparison	of	the	Healthy	Murine	
and	Human	Faecal	Metabolome
125	
	
4.1	INTRODUCTION	
	
The	 GI	 tracts	 of	 mouse	 and	 human	 are	 similar	 in	 physiology	 and	 anatomical	
structure.	Both	species	have	a	GI	tract	composed	of	a	mouth,	oesophagus,	stomach,	
small	intestine,	large	intestine	and	anus,	and	are	also	composed	of	the	same	cells	in	
the	 small	 intestine	 e.g.	 enterocytes,	 goblet	 cells,	 Paneth	 cells,	 and	 the	 colon	 e.g.	
colonocytes,	 goblet	 cells,	 enteroendocrine	 cells	 [255].	 However,	 due	 to	 the	
different	diets,	feeding	patterns,	body	sizes	and	metabolic	requirements,	there	are	
also	 prominent	 anatomical	 differences.	 Although	 the	 average	 ratio	 of	 intestinal	
surface	area:	body	surface	area	is	similar	[256],	the	ratio	differs	along	the	length	of	
the	 GI	 tract	 such	 that	 the	 small	 intestine:	 colon	 surface	 area	 ratio	 is	 18	 in	mice	
versus	400	in	humans	and	also	the	average	small	intestine:	colon	length	ratio	is	2.5	
in	mice	compared	to	7	in	humans	[255,	256].	Mice	have	a	large	caecum,	relative	to	
the	rest	of	their	GI	tract	(Figure	4.1),	whereas	the	human	caecum	is	relatively	small	
with	no	 clear	 function.	 The	mouse	 caecum	 illustrates	 the	adaption	of	 the	murine	
gut	 to	 digest	 larger	 amounts	 of	 ‘indigestible’	 foods	 from	 the	 diet,	 such	 as	 the	
fermentation	 of	 plant	 materials	 and	 the	 production	 of	 vitamins	 K	 and	 B;	 mice	
reabsorb	these	nutrients	through	coprophagy	[257].	Another	significant	difference	
is	 that	 humans	 have	 an	 appendix,	 but	mice	 do	not.	 In	 addition,	 the	 human	 large	
intestine	 contains	 sub-compartments	 made	 by	 haustral	 folds	 that	 support	 the	
fermentation	of	dietary	carbohydrates	in	the	human	colon,	which	are	absent	in	the	
mouse	colon	and	are	not	observed	in	the	caecum	or	appendix	[255].		
	
In	 addition,	 an	 example	 of	 the	 differences	 at	 cellular	 level	 between	 human	 and	
mouse	 includes	 the	 distribution	 of	 Paneth	 cells	 along	 the	 GI	 tract;	 they	 secrete	
antimicrobial	compounds	and	are	present	along	the	small	 intestine,	the	colon	and	
caecum	of	humans,	but	are	uniquely	found	in	the	small	intestine	of	mice	[255].	The	
principal	defence	molecules	secreted	by	Paneth	cells	are	α-defensins,	cells	located	
in	 the	mouse	 small	 intestine	 secrete	 >20,	 compared	with	 two	 in	 human	 [258].	 A	
consequence	 of	 cellular	 differences	 may	 suggest	 differences	 in	 local	 immune	
responses,	 also	 having	 a	 role	 to	 play	 in	 shaping	 the	 composition	 of	 the	 gut	
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microbiota.	Such	differences	in	the	anatomical	structure	and	cellular	distribution	of	
the	 GI	 tract	 may	 have	 an	 impact	 on	 the	 diversity	 and	 composition	 of	 the	 gut	
microbial	 communities	 of	 the	 colon,	 in	 turn	 affecting	 the	 breakdown	 of	 food	
components	 and	 the	 production	 of	 essential	 complements	 to	 the	 host,	 including	
SCFAs.		
	
	
Figure	4.1	Gross	anatomy	of	the	human	and	mouse	GI	tract.	The	human	colon	 is	
divided	 into	 ascending,	 transverse	 and	 descending	 colon	 sections,	 whereas	 the	
mouse	 colon	 is	 not	 [255].	 Copyright	 has	 been	 granted	 and	 figure	 is	 used	 with	
permission.	
	
The	 gut	microbiota	 of	 both	 human	 and	mouse	 are	 dominated	 by	 the	 two	major	
phyla,	 Bacteroidetes	 and	 Firmicutes	 [259,	 260].	 However,	 although	 there	 is	
considerable	 similarity	 at	 divisional	 level,	 85%	 of	 genera	 and	 microbial	 species	
found	in	mice	are	not	seen	in	humans	[261].	A	recent	analysis	using	16S	rDNA	found	
79	 genera	occurring	 in	both	human	and	mouse	 gut	microbiota.	Dominant	 genera	
with	 high	 abundance	 in	 humans	 included	 Prevotella,	 Faecalibacterium	 and	
Ruminococcus,	 whereas	 Lactobacillus,	 Alistipes	 and	 Turicibacter	 were	 more	
abundant	 in	mouse	 [255].	 In	 contrast,	 Clostridium,	 Bacteroides	 and	Blautia	were	
present	at	a	 similar	 relative	abundance	 in	both	organisms.	A	possible	explanation	
for	 these	 differences	 may	 be	 that	 most	 human	 studies	 include	 the	 use	 of	 stool	
samples,	 whereas	 caecal	 contents	 are	 usually	 used	 in	 murine	 studies,	 with	 the	
exception	of	 longitudinal	 studies	when	pellets	 are	used.	Other	 influencing	 factors	
include	the	age	of	the	mice/human	subjects,	mouse	strains/human	populations,	the	
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different	microbiota	 pools	 in	 different	 laboratories	 and	 technological	 differences.	
Also,	 the	 presence	 of	 an	 SPF	 environment	 in	 murine	 studies	 may	 reduce	 the	
diversity	 of	 the	 mouse	 gut	 microbiota	 compared	 to	 wild	 mice,	 as	 evidenced	 by	
Linnenbrink	 et	 al.	 [262].	 In	 conclusion,	 the	 observed	 differences	 may	 either	 be	
caused	 by	 intrinsic	 biological	 differences,	 or,	 by	 various	 confounding	 factors	
including	diet,	pathogen	exposure	and	environment.		
	
4.2	HYPOTHESIS	
	
The	hypotheses	were:	
• There	will	be	notable	similarities	 in	the	number	and	occurrence	of	VOCs	in	
humans	and	mice.		
• The	 differences	 between	 the	 human	 and	 murine	 faecal	 metabolome	 will	
reflect	a	varied	diet	and	more	complex	 intestinal	microbiota	 in	 the	human	
samples.			
	
4.3	AIMS	
	
1. Perform	a	qualitative	comparison	of	the	VOCs	present	 in	the	headspace	of	
faecal	samples	from	healthy	humans	and	mice.	
2. Determine	those	VOCs	that	are	unique	to	both	humans	and	mice,	and	those	
that	are	shared	between	the	two	species.			
	
4.4	METHODS	
	
4.4.1	Experimental	design	
	
For	 the	 qualitative	 comparison	 of	 the	 faecal	 VOC	 profile	 from	humans	 and	mice,	
human	 samples	 were	 donated	 from	 a	 single	 healthy	 volunteer	 with	 informed	
consent	collected	as	part	of	a	method	development	study	by	Dr	David	Sawbridge	in	
the	in	the	Department	of	Gastroenterology,	University	of	Liverpool.		Samples	(n=6)	
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used	for	this	comparison	were	from	a	male	aged	between	30-40	years,	who	ate	ad	
lib	with	 no	 dietary	 restrictions.	 For	 the	murine	 group,	 faecal	 pellet	 samples	 from	
male	C57BL/6	mice	at	week	3	of	the	baseline	study	(Chapter	3)	were	used.		
	
4.4.2	HS-SPME-GC-MS	sample	preparation	and	analysis	
	
In	 brief,	 10	 pellets	 of	murine	 stool	 sample	was	 collected	 and	 stored	 in	 2ml	 glass	
vials	at	-20°C.	For	human	samples,	2g	of	faeces	were	collected	and	stored	in	a	10ml	
glass	vial	at	-20°C.	Prior	to	VOC	extraction,	samples	were	pre-incubated	for	30	mins	
at	60°C	before	compound	extraction	using	the	solvent	free	SPME	technique	with	a	
CAR/PDMS/DVB	 fibre	 for	20	mins	prior	 to	desorption	 into	 the	GC	oven	 [219].	 For	
GC-MS	conditions,	please	refer	to	section	2.6.1.		
	
4.4.3	Data	processing	and	statistical	analysis		
	
All	raw	data	were	processed	and	analysed	as	described	in	Chapter	2.	Briefly,	a	batch	
report	was	produced	in	AMDIS	and	new	compounds	were	added	to	the	murine	VOC	
library	 prior	 to	 batch	 report	 generation.	 A	 list	 of	 all	 compounds	 present	 and	 the	
corresponding	 corrected	 peak	 abundances	 were	 generated	 using	 Metab.	 As	 the	
volume	 of	 faeces	 differed	 between	 human	 and	mouse	 in	 this	 comparison,	 there	
was	no	statistical	analysis	performed	on	the	abundances	of	peaks.	The	presence	or	
absence	of	each	compound	was	determined	for	all	samples,	those	VOCs	unique	to	
human	or	mouse,	and	those	shared	were	also	studied.		
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4.5	RESULTS	
	
Generation	of	a	report	from	the	chromatograms	of	healthy	human	(n=6)	and	mouse	
(n=6)	 faecal	 samples	 containing	VOCs	present	 in	 the	headspace	yielded	a	 total	of	
151	 individual	 VOCs.	Of	 these	 151,	 112	were	 present	 in	 humans	 and	 89	 in	mice.	
There	 were	 62	 VOCs	 unique	 to	 the	 human	 samples,	 39	 unique	 to	 the	 mouse	
samples	and	50	shared	between	 the	 two	giving	a	33%	overlap	correlation	 (Figure	
4.2)	(Table	4.1).		
	
	
Figure	 4.2	 Venn	 diagram	 presenting	 the	 number	 of	 VOCs	 identified	 in	 the	 HS	 of	
human	and	mouse	faecal	samples.		
	
4.5.1	Similarities	in	the	faecal	VOC	metabolome	between	human	and	mice	
	
The	50	VOCs	 shared	between	 the	human	and	murine	 samples	 include	aldehydes,	
alcohols,	 ketones,	 acids,	 esters,	 alkanes,	heterocyclic	 furan,	benzene	 ring,	 sulphur	
and	nitrogen	containing	compounds	(Table	4.1).	Aldehydes,	acids	and	ketones	were	
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the	most	commonly	occurring	compounds	amongst	humans	and	mice	with	11,	10	
and	8	present	in	each	group,	respectively.	Acetone,	2-methyl	propanal,	2-butanone,	
butanoic	acid,	xylene	and	benzaldehyde	were	present	 in	100%	of	samples	 in	both	
the	human	and	mouse	group	(n=6/group).	Although	the	VOCs	discussed	here	were	
all	 shared	 amongst	 humans	 and	 mice,	 the	 compounds	 present	 at	 high	
concentrations	 in	 each	 group	 differed.	 The	 5	most	 abundant	 VOCs	 in	 the	 human	
group,	 present	 in	 more	 than	 65%	 of	 samples,	 were	 indole	 (1,050,315,435	
±241,701,172),	 hexanoic	 acid	 (429,148,928	 ±227,212,721),	 pentanoic	 acid	
(418,416,435	 ±205,678,082),	 heptanoic	 acid	 (296,822,016	 ±131,542,496),	 and	 3-
methyl	 butanoic	 acid	 (203,146,496	 ±98,772,864)	 (mean	 abundance	 ±SEM).	 In	
comparison,	 the	5	most	 abundant	VOCs	 in	 the	murine	group,	present	 in	100%	of	
samples,	were	acetic	acid	(1,260,126,208	±48,441,145),	butanoic	acid	(538,432,853	
±108,426,586),	 acetone	 (414,821,035	 ±115,810,948),	 propanoic	 acid	 (241,188,864	
±28,876,877),	 and	 2,3-butanedione	 (156,672,683	 ±25,434,050)	 (mean	 abundance	
±SEM).	 The	 shared	 compounds	 probably	 reflect	 a	 combination	 of	 the	 metabolic	
effluvia	of	common	intestinal	microbiota	and	mammalian	physiology.		
	
4.5.2	Differences	in	the	faecal	VOC	metabolome	between	human	and	mice	
	
There	were	39	VOCs	identified	to	be	unique	to	the	murine	group,	and	62	unique	to	
the	human	group.	Most	notable	in	the	murine	group	were	ethanol,	isopropanol,	1-
propanol,	 1-hydroxy-2-propanone,	 3-hydroxy-2-butanone,	 2,2,4,6,6-penta-methyl	
heptane,	 present	 in	 100%	 of	 samples	 and	 absent	 from	 the	 human	 group.	
Furthermore,	four	of	these	commonly	occurring	VOCs	were	also	amongst	the	most	
abundant	VOCs	 specific	 to	 the	murine	group;	3-hydroxy-2-butanone	 (743,945,557	
±156,656,618),	 isopropanol	 (627,630,080	 ±101,172,143),	 ethanol	 (89,643,008	
±7,839,467),	and	1-hydroxy-2-propanone	(11,339,051	±988,069)	(mean	abundance	
±SEM).	Trimethylamine,	acetic	acid	ethenyl	ester	and	acetonitrile	were	also	present	
at	very	high	concentrations	compared	to	the	other	VOCs	unique	to	mouse,	but	only	
present	in	17%,	33%	and	83%	of	samples,	respectively.	Whereas	alcohols,	acids	and	
ketones	 were	 the	 most	 commonly	 occurring	 compounds	 shared	 by	 humans	 and	
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mice,	nitrogen-containing	compounds	were	the	most	common	group	unique	to	the	
murine	group	with	8	identified	in	total,	 including	trimethylamine,	acetonitrile,	and	
hydrogen	 azide.	 Several	 compounds	 found	 in	 the	murine	 samples,	 that	were	 not	
identified	 in	 the	 human	 samples	 probably	 reflect	 urine	 contamination	 from	
incontinent	mice.		
	
Chief	 compounds	 identified	 in	 the	 human	 group	 included	 4-methyl	 phenol	
(2,140,809,899	 ±141,657,253),	 D-limonene	 (1,918,599,168	 ±201,023,554),	 2,2-
dimethyl-3-methylene-bicyclo[2.2.1]heptane	 (330,735,616	 ±68,785,368),	 1-(1,5-
dimethyl-4-hexenyl)-4-methyl-benzene	 (291,588,779	 ±49,118,453),	 dimethyl	
disulfide	 (265,988,779	 ±60,329,640),	 3-methylene-6-(1-methylethyl)-cyclohexene	
(256,698,778	 ±62,613,587),	 benzeneacetaldehyde	 (233,732,779	 ±80,361,107),	 α-
pinene	 (223,176,021±70,508,920),	 4-ethenyl-1,2-dimethyl-benzene	 (198,322,688	
±101,294,027),	 and	 β-pinene	 (153,371,989	 ±27,116,088);	 all	 present	 in	 >80%	 of	
samples	 at	high	 concentrations.	 Complex	 cycloalkenes	 such	as	 terpenes	were	 the	
most	 commonly	 occurring	 compounds	 with	 ketones	 and	 benzene-based	
compounds	 present	 in	 abundance.	 There	 was	 an	 absence	 of	 nitrogen-containing	
compounds	identified	specific	to	the	human	samples,	only	shared	compounds	e.g.	
indole.	Figure	4.3	 shows	 representative	 chromatograms	 from	healthy	human	and	
mouse	 faecal	 samples.	 The	 human	 chromatogram	 appears	 to	 be	 busier	 than	 the	
murine	chromatogram,	which	appears	to	be	 lacking	peaks	towards	the	tail	end	of	
the	 run,	 after	 30	minutes.	 These	 findings	 are	 in	 agreement	with	 the	 VOC	 report	
produced	from	the	analysis	of	samples.	
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Figure	 4.3	 Representative	 chromatograms	 of	 healthy	 human	 (A)	 and	mouse	 (B)	
faecal	samples.	Samples	were	run	using	the	optimised	HS-SPME-GC-MS	method	for	
the	detection	of	VOCs.		
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Table	4.1	List	of	151	VOCs	identified	in	the	HS	of	faecal	samples	from	human	(n=6)	
and	mouse	(n=6),	by	SPME-GC-MS.		
	 Presence	(+)	or	absence	(-)	 	
RT_compound	 Human	 Mouse	 Occurrence	(%)	
VOCs	unique	to	human	
7.49_dimethyl	sulfide	 +	 -	 100	 0	
13.44_1-butanol	 +	 -	 17	 0	
13.51_2-ethyl-furan	 +	 -	 17	 0	
15.94_dimethyl	disulfide	 +	 -	 100	 0	
16.06_1-butanol,	3-methyl-	 +	 -	 67	 0	
16.19_1-butanol,	2-methyl-	 +	 -	 33	 0	
18.03_2-hexanone	 +	 -	 17	 0	
18.10_methyl	isobutyl	ketone	 +	 -	 83	 0	
18.51_2-butenal,	3-methyl-	 +	 -	 17	 0	
18.60_methyl	valerate	 +	 -	 33	 0	
20.64_methyl	vinyl	ketone	 +	 -	 17	 0	
20.96_2-hexanal	 +	 -	 17	 0	
21.07_2-n-butyl	furan	 +	 -	 33	 0	
21.83_styrene		 +	 -	 50	 0	
22.66_1,6-octadiene,	3,7-
dimethyl-	 +	 -	 100	 0	
22.77_ β-pinene +	 -	 100	 0	
23.59_2,2-dimethyl-3-
methylene-
bicyclo[2.2.1]heptane	
+	 -	 100	 0	
23.62_3-(methylthio)-
propanal	 +	 -	 67	 0	
24.04_2-octene,	2-methyl-6-
methylene-	 +	 -	 100	 0	
24.26_2,6-dimethyl-2-trans-6-
octadiene	 +	 -	 100	 0	
24.42_α-phellandrene +	 -	 67	 0	
24.68_α-pinene +	 -	 100	 0	
24.83_1,3-hexadiene,	3-ethyl-
2,5-dimethyl-	 +	 -	 100	 0	
24.94_butanoic	acid,	butyl	
ester	 +	 -	 33	 0	
25.25_2,3-octanedione	 +	 -	 33	 0	
25.34_dimethyltrisulphide	 +	 -	 67	 0	
25.49_1,3-cyclohexadiene,	2-
methyl-5-(1-methylethyl)-	 +	 -	 83	 0	
25.52_3-octanone	 +	 -	 17	 0	
25.57_2-octanone	 +	 -	 83	 0	
26.34_D-limonene	 +	 -	 100	 0	
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Table	4.1	continued.	 	 	
26.45_benzene,	1-methyl-2-
(1-methylethyl)-	 +	 -	 100	 0	
26.63_cyclohexene,	3-
methylene-6-(1-methylethyl)-	 +	 -	 83	 0	
27.19_butanoic	acid,	2-
methylbutyl	ester	 +	 -	 17	 0	
27.25_butanoic	acid,	3-
methylbutyl	ester	 +	 -	 17	 0	
27.31_γ-terpinene	 +	 -	 100	 0	
27.97_3-octen-2-one	 +	 -	 33	 0	
28.32_pentanoic	acid,	pentyl	
ester	 +	 -	 17	 0	
28.40_cyclohexene,	1-
methyl-4-(1-
methylethylidene)-	
+	 -	 100	 0	
28.66_benzeneacetaldehyde	 +	 -	 100	 0	
28.98_benzene,	4-ethenyl-
1,2-dimethyl-	 +	 -	 100	 0	
29.06_2-nonanone	 +	 -	 100	 0	
29.34_acetophenone	 +	 -	 100	 0	
29.57_nonanal	 +	 -	 67	 0	
31.04_4-methyl-phenol	 +	 -	 100	 0	
31.25_phenylethyl	alcohol	 +	 -	 17	 0	
31.73_hexyl	ester,	acid		 +	 -	 17	 0	
31.81_2-nonenal	 +	 -	 50	 0	
32.87_decanal	 +	 -	 83	 0	
33.14_p-menth-1-en-8-ol	 +	 -	 100	 0	
33.89_butane,	2,2-dimethyl-	 +	 -	 33	 0	
33.91_4-ethyl-phenol	 +	 -	 17	 0	
35.29_butanimidamide	 +	 -	 50	 0	
36.42_benzeneacetaldehyde,	
a-ethylidene-	 +	 -	 17	 0	
37.06_undecane,	4,7-
dimethyl-	 +	 -	 100	 0	
37.84_ α-copaene +	 -	 100	 0	
38.01_zingiberene	 +	 -	 33	 0	
39.56_benzene,	(1,1-
dimethylnonyl)-	 +	 -	 100	 0	
39.63_hexadecane	 +	 -	 50	 0	
39.71_cyclopentadecane	 +	 -	 100	 0	
39.84_caryophyllene	 +	 -	 100	 0	
40.23_1-pentadecene	 +	 -	 50	 0	
40.99_benzene,	1-(1,5-
dimethyl-4-hexenyl)-4-methy	 +	 -	 100	 0	
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Table	4.1	continued.		 	 	 	 	
VOCs	unique	to	mouse	
5.59_trimethylamine	 -	 +	 0	 17	
6.42_pentane	 -	 +	 0	 50	
6.61_ethanol	 -	 +	 0	 100	
7.11_2-propenal	 -	 +	 0	 67	
7.61_isopropanol	 -	 +	 0	 100	
7.90_acetonitrile	 -	 +	 0	 83	
9.57_1-propanol	 -	 +	 0	 100	
10.40_nitromethane	 -	 +	 0	 33	
10.74_acetic	acid	ethenyl	
ester	 -	 +	 0	 33	
10.77_2-butanol	 -	 +	 0	 17	
11.21_methyl	propionate	 -	 +	 0	 50	
12.22_isopropyl	acetate	 -	 +	 0	 17	
14.00_1-penten-3-ol	 -	 +	 0	 67	
14.33_hydrogen	azide	 -	 +	 0	 17	
14.65_2-propanone,	1-
hydroxy-	 -	 +	 0	 100	
16.13_3-hydroxy-2-butanone	 -	 +	 0	 100	
16.98_1-propanone,	1-
cyclopropyl-	 -	 +	 0	 17	
19.08_butanoic	acid,	1-
methylethyl	ester	 -	 +	 0	 33	
19.84_2,2-dimethyl-
propanoic	acid	 -	 +	 0	 67	
20.82_2-pentanone,	4-
hydroxy-	 -	 +	 0	 17	
21.97_2-methyl-pentanal	 -	 +	 0	 17	
22.56_pyrazine,	2,5-dimethyl-	 -	 +	 0	 17	
23.37_2-acetyl-1-pyrroline	 -	 +	 0	 17	
23.99_3-hepten-2-one	 -	 +	 0	 17	
24.10_3-heptanone,	6-
methyl-	 -	 +	 0	 17	
24.22_heptane,	2,2,4,6,6-
pentamethyl-	 -	 +	 0	 100	
24.36_pentane,	2,	2,	3-
trimethyl	 -	 +	 0	 17	
24.80_1,3,5-triazine	 -	 +	 0	 33	
24.96_1-hexene,	3,5-
dimethyl-	 -	 +	 0	 17	
25.12_1-octen-3-ol	 -	 +	 0	 50	
25.63_(1H)pyrrole-3-
carbonitrile,	2-methyl-	 -	 +	 0	 83	
25.79_2(5H)-furanone	 -	 +	 0	 33	
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Table	4.1	continued.		 	 	 	 	
25.82_unknown		 -	 +	 0	 17	
26.66_dimethyl	sulfone	 -	 +	 0	 83	
26.79_2(3H)-furanone,	
dihydro-5-methyl-	 -	 +	 0	 33	
27.53_7-exo-ethyl-5-methyl-
6,8-dioxabicyclo[3.2.1]oct-3-
ene	
-	 +	 0	 67	
28.90_butyric	acid,	p-
fluorophenyl	ester	 -	 +	 0	 17	
29.09_5-azacytosine	 -	 +	 90	 33	
30.96_dodecane	 -	 +	 0	 33	
VOCs	shared	between	human	and	mouse	
5.12_acetylaldehyde	 +	 +	 17	 17	
6.92_furan	 +	 +	 33	 17	
7.21_propanal	 +	 +	 17	 100	
7.41_acetone	 +	 +	 100	 100	
7.82_thiourea	 +	 +	 100	 50	
7.94_methyl	acetate	 +	 +	 33	 67	
8.32_cyclopentane	 +	 +	 17	 100	
9.01_2-methyl-propanal	 +	 +	 100	 100	
10.16_butanal	 +	 +	 33	 17	
10.28_2,3-butanedione	 +	 +	 83	 100	
10.32_furan,	3-methyl-	 +	 +	 100	 17	
10.56_2-butanone	 +	 +	 100	 100	
11.90_1-propanol,	2-methyl-	 +	 +	 17	 100	
12.49_3-methyl-butanal	 +	 +	 100	 17	
12.51_acetic	acid	 +	 +	 67	 100	
12.81_2-methyl-butanal	 +	 +	 100	 50	
13.98_2-pentanone	 +	 +	 100	 83	
14.16_2,3-pentanedione	 +	 +	 100	 67	
14.20_pentanal	 +	 +	 100	 83	
14.69_methyl	butyrate	 +	 +	 50	 50	
16.29_propanoic	acid	 +	 +	 33	 100	
16.47_2-pentanone,	3-methyl	 +	 +	 17	 17	
16.58_toluene	 +	 +	 100	 17	
17.45_1-pentanol	 +	 +	 50	 67	
17.72_ethyl	butyrate	 +	 +	 33	 50	
18.26_2-methyl-propanoic	
acid	 +	 +	 50	 83	
18.43_hexanal	 +	 +	 100	 83	
19.62_butanoic	acid	 +	 +	 100	 100	
20.22_ethylbenzene	 +	 +	 33	 17	
20.53_1,3-xylene	 +	 +	 100	 100	
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Table	4.1	continued.	 	 	 	 	
21.19_1-hexanol	 +	 +	 67	 100	
21.51_3-methyl-butanoic	acid	 +	 +	 67	 100	
21.73_2-methyl-butanoic	acid	 +	 +	 83	 100	
22.11_2-heptanone	 +	 +	 100	 33	
22.33_heptanal	 +	 +	 50	 17	
23.14_pentanoic	acid	 +	 +	 83	 100	
23.27_unknown	 +	 +	 17	 100	
24.89_1-heptanol	 +	 +	 50	 17	
24.93_2-pentyl-furan	 +	 +	 17	 33	
25.73_benzaldehyde	 +	 +	 100	 100	
26.08_octanal	 +	 +	 67	 17	
26.38_hexanoic	acid	 +	 +	 83	 50	
27.67_5-ethylcyclopent-1-
enecarboxaldehyde	 +	 +	 17	 33	
28.14_phenol	 +	 +	 83	 67	
28.93_diiodomethane	 +	 +	 17	 67	
29.72_heptanoic	acid	 +	 +	 67	 17	
30.27_2(3H)-furanone,	5-
ethyldihydro-	 +	 +	 17	 17	
33.74_benzene,	1,	3-bis(1,1-
dimethylethyl)-	 +	 +	 17	 100	
34.02_propanoic	acid,	2,2-
dimethyl-,	sodium	salt	 +	 +	 17	 33	
38.66_indole	 +	 +	 100	 83	
There	 are	 62	 VOCs	 unique	 to	 human	 samples,	 39	 unique	 to	 mouse	 and	 50	 VOCs	 are	
shared	between	the	two	species.	The	%	occurrence	is	the	number	of	times	the	VOC	was	
present	in	the	sample	group.	
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4.6	SUMMARY	OF	RESULTS	
	
1. A	 total	 of	 151	VOCs	were	 identified	 in	 this	 comparison	of	 the	 human	 and	
mouse	faecal	metabolome,	by	HS-SPME-GC-MS.	There	were	50	VOCs	shared	
between	 the	 two	 species	 giving	 a	 33%	overlap	of	 total	 VOCs	 amongst	 the	
two	species.	Of	these	shared	VOCs,	aldehydes,	acids	and	ketones	were	the	
most	 commonly	 occurring	 compounds.	 Indole	 and	 hexanoic	 acid	 were	
amongst	 the	VOCs	present	 at	 high	 concentration	 in	 the	human	group	and	
acetic	acid	and	butanoic	acid	in	the	murine	group.		
	
2. There	were	89	of	the	total	151	VOCs	found	in	the	mouse	faecal	metabolome	
and	 39	were	 unique	 to	 this	 species.	 Alcohol	 and	 ketone	 compounds	were	
the	most	abundant	VOCs	in	the	murine	metabolome	being	present	in	100%	
of	samples.		
	
3. 112	 VOCs	 were	 identified	 in	 the	 human	 faecal	 metabolome	 compared	 to	
mouse	and	62	were	unique	to	this	species.	Terpene	and	complex	aromatic	
and	 cyclic	 benzenoid	 compounds	 were	 the	 most	 commonly	 occurring	
compounds	 in	 the	 human	 metabolome.	 Chromatograms	 highlighted	 the	
increased	number	of	VOCs	after	30	minutes	in	the	human	group,	compared	
to	the	murine	group.		
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4.7	DISCUSSION	
	
This	 study	has	compared	the	 faecal	VOC	profile	emitted	 from	healthy	human	and	
murine	 samples.	 There	 is	 a	 notable	 correlation	between	 the	 two	 species	 and	 the	
differences	in	number	and	complexity	of	the	VOCs	found	in	the	human,	compared	
to	the	mouse,	may	reflect	a	varied	diet	and	a	more	complex	intestinal	microbiome.		
	
Terpenes	are	a	 large	and	diverse	class	of	organic	compounds	and	a	number	were	
found	 exclusively	 in	 human	 samples,	 including	 caryophyllene,	 γ-terpinene	 and	 D-
limonene.	 They	 are	 often	 strong,	 yet	 pleasant	 smelling	 compounds,	 and	 are	
reportedly	 produced	 by	 a	 variety	 of	 plants,	 particularly	 conifers.	 Terpenes	 are	
constituents	of	the	essential	oils	of	many	types	of	plants	and	flowers,	which	are	also	
used	 as	 fragrances	 in	 perfumery,	 and	 in	 alternative	 medicines	 such	 as	
aromatherapy.	Odorous	plants,	 or	 parts	 of	 plants,	 including	 conifer	wood	 (e.g.	 β-
pinene),	 citrus	 fruits	 (e.g.	 D-limonene),	 eucalyptus,	 lavender,	 lemon	 grass,	
peppermint	 species,	 rosemary	 (e.g.	 α-pinene),	 coriander,	 sage	 and	 thyme	 all	
contain	 terpenes	 which	 are	 extracted	 and	 used	 to	 create	 fine	 perfumes	 (e.g.	 β-
phellandrene	and	γ-terpinene),	refine	flavours	and	aromas	of	food	and	drink	and	to	
produce	medicines	[263].		
	
Another	example	of	the	varied	and	diverse	diet	consumed	by	the	human	group	 is	
the	 identification	 of	 zingiberene,	 a	 monocyclic	 sesquiterpene	 that	 is	 the	
predominant	constituent	of	the	oil	of	ginger	[264].	Zingiberene	is	also	an	ingredient	
in	an	herbal	dietary	supplement	for	weight	loss	in	humans,	along	with	rhubarb,	red	
saga	root,	astragalus,	and	turmeric	[265].	Derivatives	of	phenol	were	also	detected	
exclusively	 in	 the	human	group,	 including	4-methyl	phenol	and	4-ethyl	phenol.	P-
Cresol	 is	 another	 name	 for	 4-methyl	 phenol,	 which	 has	 been	 reported	 as	 a	
component	 in	 human	 sweat	 [266],	 but	 has	 also	 been	measured	 in	 the	 urine	 and	
faeces	of	humans	[267].		
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Compounds	 shared	 between	 mouse	 and	 human	 include	 acetone,	 2-methyl	
propanal,	2-butanone,	butanoic	acid,	xylene	and	benzaldehyde.	Acetone,	2-methyl	
propanal	 and	 2-butanone	 probably	 arise	 from	 fatty	 acid	 and	 carbohydrate	
metabolism	 [268].	 Traces	 of	 2-methyl	 propanal	 has	 also	 been	 found	 in	 alcoholic	
beverages,	 tea,	 fresh	 fruits,	 breads,	 cooked	 pork	 and	 spearmint	 [268].	
Benzaldehyde	 is	occasionally	 found	as	 a	 volatile	 component	of	urine	 [269],	 but	 is	
also	used	as	an	aromatic	aldehyde	in	cosmetics	as	a	denaturant,	a	flavouring	agent,	
and	 a	 fragrance	 [270].	 Butanoic	 acid	 is	 a	 SCFA	 and	 is	 a	 product	 of	 anaerobic	
bacterial	 fermentation	 of	 dietary	 carbohydrates	 in	 the	 colon,	 providing	 an	
explanation	for	the	presence	of	butanoic	acid	in	both	humans	and	mice.	Incubation	
of	 labelled	butanoic	 acid	with	 faeces	by	Garner	et	al.	 [242]	 found	 that	 esters	 are	
generated	 from	 acids,	which	may	 be	mediated	 by	 a	 bacterial	 esterase	 such	 as	 is	
present	 in	 E.	 coli	 [271],	 or	 by	 the	 intestinal	 mucosa	 enzyme,	 ethanol-O-
acyltransferase	 (AEAT)	 [272].	 This	 may	 explain	 the	 increase	 in	 number	 of	 esters	
identified	specific	to	the	human	group,	compared	to	acids.		
	
Fermentation	of	the	aromatic	amino	acids,	tyrosine	and	tryptophan,	in	human	stool	
has	been	 shown	 to	produce	 the	VOCs	phenol	and	 indole,	 respectively	 [242,	273].		
Indole	 and	 phenol	 were	 shared	 between	 humans	 and	 mice	 suggesting	 a	 similar	
metabolism	of	amino	acids	by	human	and	mouse	colonic	bacteria.	 It	 is	 likely	 that	
the	 presence	 of	 trimethylamine	 (TMA)	 in	 the	 murine	 group	 is	 from	 the	 urinary	
contamination	of	the	stool	samples.	It	is	generally	thought	that	the	origin	of	urinary	
TMA	is	via	the	action	of	intestinal	microbiota	on	precursors	within	the	food	such	as	
choline.	This	has	been	confirmed	by	the	absence	of	urinary	TMA	in	germ-free	mice	
and	the	significant	reduction	in	antibiotic-treated	mice.	Subsequently,	cohabitation	
of	 germ-free	mice	 with	 conventional	 mice	 restored	 their	 ability	 to	 excrete	 TMA,	
suggesting	an	important	role	of	the	gut	microbiota	in	the	production	of	TMA	[274].	
	
Despite	 the	 notable	 differences	 between	 the	 faecal	 metabolome	 of	 human	 and	
mice	outlined	in	this	study,	there	are	considerable	similarities.	Therefore,	although	
the	results	from	this	thesis	are	primarily	from	murine	models	of	human	GI	disease,	
141	
	
the	translation	of	results	to	human	disease	and	any	conclusions	will	be	made	with	
caution.
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Chapter	5	
	
VOC	Profiling	of	Chemically-Induced	
Acute	Intestinal	Inflammation
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5.1	INTRODUCTION	
	
IBD	 has	 two	 major	 phenotypes,	 CD	 and	 UC,	 and	 is	 characterised	 by	 chronic	
inflammation	of	the	GI	tract.	Symptoms	include	severe	abdominal	pain,	diarrhoea,	
rectal	bleeding	and	weight	 loss	and	predominantly	affects	the	younger	population	
[5].	 Currently,	 the	 pathogenesis	 of	 IBD	 is	 unknown	 but	 is	 hypothesised	 to	 result	
from	 an	 interaction	 of	 environmental	 factors	 (e.g.	 smoking,	 oral	 contraceptives,	
high-fat	 diet)	 affecting	 the	 intestinal	microbiota,	 combined	with	 an	 inappropriate	
immune	 response	 often,	 but	 not	 only,	 in	 a	 genetically	 predisposed	 person.	 The	
chronic	 inflammation	 in	 IBD	 is	 caused	 by	 activation	 of	 effector	 immune	 cells,	
producing	pro-inflammatory	cytokines,	resulting	in	colonic	tissue	damage.	The	NFκB	
has	been	identified	as	one	of	the	key	regulators	of	the	immunological	setting	in	IBD	
[275].	Therefore,	until	we	understand	the	cause	of	IBD,	the	diagnosis	and	treatment	
will	remain	difficult	for	clinicians.	
	
The	 diagnosis	 and	 care	 of	 IBD	 patients	 remains	 difficult	 for	 clinicians	 due	 to	 the	
non-specific	diagnostic	methods	currently	used.	They	lack	sensitivity	and	are	often	
invasive,	expensive	and	are	found	unpleasant	by		patients.	Non-invasive	methods	of	
assessing	the	disease	process,	such	as	measuring	faecal	calprotectin	concentration,	
are	becoming	 increasing	preferred.	However,	 there	 is	 still	 room	 for	 improvement	
with	regards	to	finding	a	non-invasive	test	with	higher	specificity	and	sensitivity	for	
IBD.	Faecal	calprotectin	is	raised	in	other	conditions,	not	just	IBD	[276,	277].	Recent	
studies	 strongly	 suggest	 that	 the	 accurate	 reproducible	 detection	 of	 VOCs	 from	
biological	samples	has	great	potential	to	develop	into	a	non-invasive	diagnostic	test	
for	 IBD	 [131,	242,	278-280].	The	untargeted	analysis	of	VOCs	 in	 the	 faeces	of	 IBD	
patients	 has	 potential	 as	 a	 non-invasive	 diagnostic	 method	 because	 of	 what	 the	
human	stool	represents;	the	end-product	of	diet,	digestive	and	excretory	processes,	
and	colonic	bacterial	metabolism	[185].		
	
Oral	 administration	 of	 DSS	 is	 the	 most	 commonly	 used	 rodent	 model	 to	 induce	
colitis	 in	 experimental	 animals	 since	 1990	 [281]	 and	 to	 date	 there	 have	 been	
around	1000	papers	published	using	this	model	[130].	DSS	is	administered	orally	in	
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sterile	drinking	water	at	a	dose	between	1-5%	for	5	days,	followed	by	7	days	normal	
drinking	water	to	induce	colitis.	This	experimental	model	shares	clinical	(diarrhoea,	
bloody	stools	and	weight	loss)	and	histological	(crypt	erosion,	goblet	cell	depletion,	
ulceration)	features	with	human	ulcerative	colitis	[108].	The	typical	features	appear	
by	day	5,	are	maximally	expressed	by	day	8	and	present	with	signs	of	recovery	by	
day	11.	 	Depending	on	 the	 concentration,	 the	duration	and	 the	 frequency	of	DSS	
administration,	 the	 animals	 may	 develop	 acute	 or	 chronic	 colitis.	 However,	 the	
exact	 mechanism	 of	 action	 of	 DSS-induced	 intestinal	 inflammation	 remains	
unknown.	 Mice	 lacking	 the	 NFκB2	 gene	 are	 resistant	 to	 DSS-induced	 colitis,	
compared	to	wild-type	mice	[54]		
	
Quantitative	 profiling	 of	 the	 VOCs	 emitted	 from	 the	 faeces	 of	mice	 administered	
DSS	 is	 a	 promising	 method	 to	 investigate	 the	 pathogenic	 mechanisms	 involved	
during	 the	 development	 of	 colitis	 by	 characterising	 the	 changes	 occurring	 in	 the	
levels	 of	 metabolites.	 In	 spite	 of	 this,	 there	 are	 currently	 a	 limited	 number	 of	
studies	using	a	metabolomics	approach	 to	explore	 these	metabolic	 changes	 [282-
285].	Also,	these	studies	primarily	focus	on	the	metabolite	profile	of	plasma,	urine	
and	tissue	using	1H-NMR-based	metabolomics,	rather	than	the	volatile	component	
of	the	metabolomic	profile	emitted	from	the	headspace	of	the	faeces	of	these	DSS-
treated	mice.		
	
5.2	HYPOTHESIS	
	
The	hypotheses	were:	
• The	presence	and	levels	of	VOCs	detected	in	the	HS	of	faeces	by	GC-MS	will	
change	during	the	development	of	murine	colitis.			
• The	examination	of	these	changes	will	achieve	a	detailed	understanding	of	
the	pathogenesis	of	murine	colitis	on	a	metabolite	 level,	and	consequently	
human	IBD.		
• The	faecal	VOC	profile	from	colitic	mice	will	be	significantly	different	to	the	
profile	from	osmotic	diarrhoea	mice.		
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• NFκB2	 null	mice	will	 be	 resistant	 to	 colitis	 by	 DSS	 administration	 and	will	
have	a	 faecal	VOC	profile	similar	 to	untreated	control	animals,	 rather	than	
DSS	treated	animals.		
	
5.3	AIMS	
	
1. To	 induce	 acute	 intestinal	 colitis	 in	 C57BL/6	 WT	 female	 mice	 by	 oral	
administration	of	DSS.	
2. To	compare	metabolic	differences	in	the	development	of	acute	DSS-induced	
experimental	colitis	model	to	untreated	controls.	
3. To	 investigate	 the	 impact	of	an	absence	of	 the	NFκB2	 gene	on	acute	DSS-
induced	 colitis,	 and	 the	 subsequent	 metabolic	 changes	 in	 the	 faecal	 VOC	
profile,	compared	to	untreated	controls	and	treated	WT	mice.		
4. To	 induce	 secretory	 diarrhoea	 in	WT	mice	 by	 oral	 gavage	 of	MgSO4,	 and	
establish	 change	 in	 faecal	 VOC	 profile	 compared	 to	 healthy	 control	 and	
acute	DSS-colitis.	
	
5.4	METHODS	
	
5.4.1	Experimental	design	
	
5.4.1.1	Induction	of	acute	colitis	by	DSS	administration	
	
C57BL/6	female	mice	were	administered	4.25%	DSS	(wt/vol)	in	their	drinking	water	
for	5	days	followed	by	6	days	of	normal	water.	Clinical	parameters	of	body	weight	
loss,	stool	consistency	and	the	presence	of	rectal	bleeding	were	assessed	daily.	This	
procedure	aims	to	induce	a	mild	to	moderate	form	of	colitis.	Therefore,	to	ensure	
procedure	and	ethical	guidelines	were	adhered	to	this	experiment	was	split	over	3	
separate	experiments,	each	time	increasing	the	number	of	mice	used.	Experiments	
were	reproducible	and	data	was	combined	to	produce	results.	Mice	were	sacrificed	
at	experimental	days	0	(n=11),	5	(n=11),	8	(n=11)	and	11	(n=8);	colonic,	caecal,	small	
intestine	contents	and	mid-large	bowel	and	distal	small	bowel	tissue	sections	were	
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taken	 from	each	mouse	and	stored	at	 -20°C	prior	 to	analysis	by	HS-SPME-GC-MS.	
The	 entire	 small	 and	 large	 intestine	 tissues	 were	 taken	 for	 histological	 analysis.	
Samples	collected	from	mice	euthanized	at	day	0	were	treated	as	untreated	control	
to	be	compared	to	days	5,	8	and	11.		
	
This	experiment	was	conducted	to	investigate	the	susceptibility	of	colitis	in	NFκB2-/-	
mice	(n=6),	mice	were	administered	2%	DSS	in	their	drinking	water	for	5	days	and	
were	euthanized	at	day	8.	Three	control	groups	were	used:	C57BL/6	untreated	(WT)	
(n=4),	 C57BL/6	 2%	 DSS	 treated	 (WT)	 (n=6)	 and	 NFκB2-/-	 untreated	 (n=4).	 Colon	
content	collected	upon	necropsy	was	stored	at	-20°C	prior	to	analysis	by	HS-SPME-
GC-MS.	Dr	Jonathan	Williams	performed	this	experiment	with	the	assistance	of	the	
author.		
	
5.4.1.2	Induction	of	osmotic	diarrhoea	by	MgSO4		
	
C57BL/6	mice	were	 fasted	overnight	 and	were	administered	magnesium	sulphate	
(2mg/kg)	by	oral	gavage	(n=5)	with	a	control	group	receiving	distilled	water	(n=3).	
Following	the	administration	of	the	MgSO4,	the	animals	were	placed	on	filter	paper	
which	 was	 changed	 every	 hour.	 The	 amount	 and	 consistency	 of	 the	 faeces	 was	
assessed	each	hour	 for	6	hours.	Faecal	 samples	were	collected	every	hour	and	at	
termination	of	the	experiment.	All	samples	were	stored	at	-20°C	prior	to	analysis	by	
GC-MS.	 The	 VOC	 profile	 identified	 by	 HS-SPME-GC-MS	 of	 the	 resulting	 diarrhoea	
samples	 was	 compared	 to	 the	 colon	 content	 samples	 collected	 at	 day	 8	 of	 DSS-
induced	acute	colitis.		
	
5.4.2	HS-SPME-GC-MS	sample	preparation	and	analysis		
	
In	brief,	where	possible,	130mg	(maximum	volume)	of	stool	sample	was	collected	
and	stored	 in	2ml	glass	vials	at	 -20°C.	Prior	 to	VOC	extraction,	 samples	were	pre-
incubated	for	30	mins	at	60°C	before	compound	extraction	using	the	solvent	 free	
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SPME	technique	with	a	CAR/PDMS/DVB	fibre	 for	20	mins	prior	 to	desorption	 into	
the	GC	oven	[221].	For	GC-MS	conditions,	please	refer	to	section	2.6.1.		
	
5.4.3	Data	processing	and	statistical	analysis	
	
All	raw	data	were	processed	and	analysed	as	described	in	Chapter	2.	Briefly,	batch	
reports	are	produced	for	each	dataset	in	AMDIS	and	a	list	of	all	compounds	present	
and	 their	 corresponding	 corrected	 peak	 abundances	 was	 then	 generated	 using	
Metab.	Compounds	present	in	less	than	30%	of	at	least	one	condition	are	removed.	
Chi-square	test	is	used	to	determine	compounds	significantly	more	prevalent	in	one	
condition.	NA	was	replaced	with	1	and	peak	abundance	was	 log	transformed,	and	
appropriate	statistical	analysis	(Student’s	t-test	or	two-way	ANOVA)	was	applied:	all	
p-values	are	corrected	for	multiple	comparison	(Bonferroni).	Hierarchical	clustering	
and	PCA	was	applied	to	illustrate	the	variation	present	between	groups.		
	
5.5	RESULTS	
	
5.5.1	Clinical	and	histological	symptoms	confirm	acute	DSS-induced	colitis	
	
Acute	colitis	was	induced	by	oral	administration	of	4.25%	DSS	in	the	drinking	water	
of	C57BL/6	female	mice	for	5	days	followed	by	6	days	of	normal	water.	A	moderate	
to	severe	colitis	was	observed,	characterized	by	a	significant	weight	loss	and	bloody	
diarrhoea	appearing	at	day	5,	being	most	severe	by	day	8	and	with	signs	of	recovery	
by	day	11.	There	was	a	significant	decrease	in	relative	body	weight	at	day	5	with	a	
loss	 of	 3.8±1.3%	 (n=11,	 ANOVA	 with	 Tukey,	 p<0.001),	 and	 27.3±1.6%	 at	 day	 8	
(n=10,	ANOVA	with	Tukey,	p<0.001),	compared	to	a	start	weight	of	19.1±0.7g	at	day	
0	 (mean±SEM,	 n=11).	 At	 day	 11	 (n=8),	 the	 relative	 body	 weight	 significantly	
increased	compared	to	day	8	 (ANOVA	with	Tukey,	p<0.001)	with	a	 final	weight	of	
20.2±0.6g	(mean±SEM)	(Figure	5.1).		
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A	 daily	 disease	 activity	 index	 (DAI)	 score	was	 given	 to	 each	 animal	 based	 on	 the	
change	 in	body	weight,	presence	of	diarrhoea	and	rectal	bleeding	to	evaluate	the	
general	 condition	 of	 the	mice.	 The	 DAI	markedly	 increased	 from	 day	 5	 to	 day	 8	
(Kruskal-Wallis,	p<0.001)	 followed	by	 a	 significant	decrease	 from	day	8	 to	day	11	
(Kruskal-Wallis,	p<0.001)	at	which	point	 the	experiment	was	 finished	 (Figure	5.2).	
The	 DAI	 scores	 for	 the	 animals	 culled	 at	 days	 5,	 8	 and	 11	 were	 all	 significantly	
different	compared	to	the	day	0	group	(Kruskal-Wallis,	p<0.01).		
	
Histological	examination	of	the	distal	colon	with	H&E	staining	found	the	degree	of	
microscopic	 injury	 to	be	different	according	to	 the	stage	of	colitis	at	 the	different	
time	points.	Day	0	showed	an	intact	epithelial	layer	and	crypts,	signifying	a	healthy	
murine	 intestine.	 In	 contrast,	day	5	and	8	 samples	 showed	 inflammatory	changes	
characterised	 by	 damaged	 crypts	 and	 a	 sub-mucosal	 layer	 with	 oedema	 and	 an	
infiltration	of	inflammatory	cells	such	as	neutrophils.	Day	11	pathology	showed	the	
re-formation	of	 the	 crypt	 infrastructure	and	a	 reduction	 in	 tissue	 inflammation	 in	
comparison	 to	 that	 observed	 at	 days	 5	 and	 8.	 Significantly	 different	 histological	
scores	 between	 days	 5	 and	 8,	 and	 8	 and	 11	 provide	 quantification	 of	 the	
pathological	damage	(p<0.001)	(Figure	5.3	&	5.4).	
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Figure	 5.1	Weight	 loss.	The	 change	 in	 the	 body	weight	 (%)	 of	 C57BL/6	mice	was	
measured	daily	 to	assess	 the	degree	of	 colitis.	Data	 from	3	 separate	experiments	
combined	and	represented	as	mean±SEM,	n=11,	11,	10,	8	for	days	0,	5,	8	and	11,	
respectively.	Statistical	differences	were	assessed	by	one-way	ANOVA	followed	by	
Tukey’s	 HSD	 test,	 p<0.001***	 compared	 to	 day	 0,	 ###	 compared	 to	 day	 5,	 ^^^	
compared	to	day	11.	
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Figure	5.2	DAI.	Assessment	of	disease	activity	index	(DAI)	daily	for	each	animal	(DAI	
=	 (combined	 score	 of	 weight	 loss,	 stool	 consistency	 and	 bleeding)/3).	 Data	
represented	 as	mean±SEM,	n=11,	 11,	 10,	 8	 for	 days	 0,	 5,	 8	 and	 11,	 respectively.	
Statistical	 differences	 were	 assessed	 by	 Kruskal-Wallis	 Test	 followed	 by	 Mann-
Whitney	U	tests	between	pairs	of	groups,	p<0.01**,	p<0.001***	compared	to	day	
0,	###	compared	to	day	5,	^^^	compared	to	day	11.		
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Figure	 5.3	Representative	 images	 of	H&E	 stained	distal	 colonic	 sections	 at	 each	
time	 point.	 Mice	 were	 euthanized	 at	 days	 0,	 5,	 8	 and	 11	 since	 the	 start	 of	 DSS	
treatment	 at	 day	 0.	 Arrows	 indicate	 damaged	 crypts;	 triangles	 indicate	 the	
submucosal	layer	with	oedema	and	an	infiltrate	of	inflammatory	cells.		
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Figure	 5.4	 Histological	 (inflammation)	 scores	 of	 DSS-induced	 colitis	 in	 mice.	
Inflammation	score	of	distal	colon	taken	from	C57BL/6	mice	at	day	0	(blue),	day	5	
(red),	day	8	(green)	and	day	11	(orange)	of	a	5	day	4.25%	DSS	treatment.	Each	dot	
represents	 a	 score	 from	 one	 mouse	 and	 data	 are	 presented	 as	 mean±SEM,	
***p<0.001	 compared	 to	 day	 0,	 ###p<0.001	 compared	 to	 day	 5,	 ^^p<0.01	
compared	to	day	11	by	Kruskal-Wallis	test	followed	by	follow-up	Mann-Whitney	U	
tests.		
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5.5.2	Variation	in	the	faecal	VOC	metabolome	of	acute	DSS-induced	colitis	
	
Mice	were	sacrificed	at	days	0,	5,	8	and	11	of	experiment,	tissues	excised	and	colon	
contents	collected	for	extraction	of	VOCs	by	HS-SPME-GC-MS.	This	has	enabled	the	
direct	comparison	of	VOCs	present	in	the	headspace	of	the	colonic	luminal	content	
during	the	development	of	acute	DSS-induced	colitis	at	days	0,	5,	8	and	11.		
	
A	total	of	95	low	molecular	weight	VOCs	were	identified	across	the	four	time	points	
analysed	present	in	at	least	30%	of	samples	in	at	least	one	group.	40%	of	these	95	
VOCs	were	present	in	at	least	50%	of	all	samples	at	every	time	point,	day	0,	5,	8	and	
11,	with	 acid,	 alcohol	 and	 aldehyde	 compounds	 as	 the	most	 common	 compound	
classes.	 Ethanol,	 acetone,	 2-methyl-propanal,	 1-propanol,	 2-methyl-butanal,	
butanoic	 acid,	 xylene,	 3-methyl-butanoic	 acid	 and	 indole	 were	 ubiquitous	
compounds	 (Table	 5.1).	 Of	 these	 95	 compounds,	 there	were	 59.1±2.5,	 54.9±2.3,	
47.9±2.6	 and	 49.6±4.2	 VOCs	 identified	 at	 days	 0,	 5,	 8	 and	 11,	 respectively	
(mean±SEM).	 The	 average	 number	 of	 VOCs	 identified	 decreased	 with	 the	
development	 of	 colitis,	 with	 a	 significant	 decrease	 at	 day	 8	 compared	 to	 day	 0	
(p<0.05).	During	the	recovery	phase	of	colitis,	there	was	a	minor	increase	between	
day	8	and	11	(Figure	5.5).		
	
The	 chemical	 composition	 of	 the	 colon	 contents	 collected	 at	 the	 different	 time	
points	 of	 acute	DSS-colitis	was	 investigated.	 This	was	 achieved	 by	 calculating	 the	
total	 number	 of	 alcohol,	 acid,	 ester,	 aldehyde,	 alkane,	 alicyclic,	 benzenoid,	 ether,	
heterocyclic,	 ketone,	 nitrogen	 containing,	 sulphur	 containing	 and	 unidentified	
compounds	 found	 in	 all	 samples	 and	determining	 the	presence	of	 each	 group	by	
percentage	at	each	time	point.	Although	the	chemical	composition	does	not	appear	
to	vary	dramatically,	there	is	a	slight	decrease	in	the	number	of	ester	compounds	at	
day	8	 (11%)	 compared	 to	day	5	 (14%).	 There	 is	 also	a	noticeable	decrease	 in	 the	
number	of	alkane	compounds	 (e.g.	3-methylpentane,	hexane),	 and	an	 increase	 in	
aldehydes	and	ketones	in	the	presence	of	colitis	at	days	5	and	8,	compared	to	days	
0	and	11	(Figure	5.6).	
	
	154	
	
Table	 5.1	 List	 of	 95	 compounds	 detected	 in	 the	HS	 of	 colonic	 luminal	 content	 of	
DSS-treated	mice	at	different	time	points,	by	SPME-GC-MS	(n=11,	11,	10,	8	for	days	
0,	5,	8	and	11,	respectively).		
	 Presence	(%)	
RT_compound	 Day	0	 Day	5	 Day	8	 Day	11	
5.12_acetylaldehyde	 0	 0	 40	 0	
6.42_pentane	 55	 45	 0	 63	
6.61_ethanol	 100	 100	 100	 100	
6.92_furan	 45	 18	 30	 50	
7.21_propanal	 0	 100	 100	 0	
7.41_acetone	 100	 100	 100	 100	
7.49_dimethyl	sulfide	 91	 82	 40	 75	
7.61_isopropanol	 100	 64	 90	 75	
7.82_thiourea	 91	 91	 60	 75	
7.94_methyl	acetate	 91	 100	 50	 88	
8.61_3-methyl-pentane	 36	 0	 0	 38	
9.01_2-methyl-propanal	 100	 100	 100	 100	
9.07_hexane	 36	 0	 0	 25	
9.57_1-propanol	 100	 100	 100	 100	
10.16_butanal	 18	 100	 70	 25	
10.28_2,3-butanedione	 82	 100	 100	 100	
10.32_furan,	3-methyl-	 100	 45	 30	 100	
10.53_ethyl	acetate	 82	 100	 70	 100	
10.56_2-butanone	 82	 73	 90	 75	
10.77_2-butanol	 100	 0	 20	 75	
11.21_methyl	propionate	 55	 100	 50	 88	
11.90_1-propanol,	2-methyl-	 82	 82	 60	 88	
12.49_3-methyl-butanal	 91	 100	 90	 88	
12.51_acetic	acid	 91	 100	 100	 100	
12.81_2-methyl-butanal	 100	 100	 100	 100	
13.44_1-butanol	 73	 73	 50	 88	
13.51_2-ethyl-furan	 36	 9	 10	 0	
13.98_2-pentanone	 91	 100	 80	 88	
14.00_1-penten-3-ol	 64	 36	 30	 38	
14.08_propanoic	acid,	ethyl	ester	 73	 91	 40	 75	
14.16_2,3-pentanedione	 18	 27	 60	 25	
14.20_pentanal	 9	 36	 10	 13	
14.26_propyl	acetate	 100	 100	 50	 88	
14.41_2-pentanol	 64	 9	 0	 75	
14.69_methyl	butyrate	 91	 100	 50	 88	
16.08_1-butanol,	3-methyl-	 73	 45	 30	 38	
16.13_3-hydroxy-2-butanone	 9	 55	 90	 63	
16.19_1-butanol,	2-methyl-	 45	 9	 40	 25	
16.29_propanoic	acid	 100	 100	 90	 100	
16.47_2-pentanone,	3-methyl	 91	 45	 10	 50	
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Table	5.1	continued.		 	
	 Presence	(%)	
RT_compound	 Day	0	 Day	5	 Day	8	 Day	11	
16.98_1-propanone,	1-cyclopropyl-	 45	 18	 30	 25	
17.45_1-pentanol	 55	 55	 60	 38	
17.72_ethyl	butyrate	 100	 100	 60	 88	
17.93_propanoic	acid,	propyl	ester	 45	 18	 40	 63	
17.94_oxirane,	2-methyl-2-(1-
methylethyl)-	 73	 55	 20	 25	
18.10_methyl	isobutyl	ketone	 0	 36	 10	 38	
18.26_2-methyl-propanoic	acid	 100	 100	 100	 88	
18.43_hexanal	 64	 82	 50	 63	
18.51_2-butenal,	3-methyl-	 18	 36	 50	 0	
18.60_methyl	valerate	 45	 9	 0	 0	
19.62_butanoic	acid	 100	 100	 100	 100	
19.73_2-hydroxy-3-pentanone	 0	 9	 60	 13	
20.22_ethylbenzene	 64	 73	 80	 50	
20.53_xylene	 100	 100	 100	 100	
20.56_N-benzyloxy-2-
carbomethoxyaziridine	 27	 18	 40	 0	
21.35_butanoic	acid,	propyl	ester	 64	 45	 10	 13	
21.49_1-hexanol	 64	 55	 60	 50	
21.51_3-methyl-butanoic	acid	 100	 100	 100	 100	
21.73_2-methyl-butanoic	acid	 100	 100	 100	 88	
22.11_2-heptanone	 100	 82	 90	 100	
22.16_2-heptanol	 55	 0	 0	 25	
22.33_heptanal	 9	 82	 80	 13	
23.14_pentanoic	acid	 100	 100	 100	 88	
23.27_unknown	 27	 9	 40	 0	
23.62_3-(methylthio)-propanal	 36	 64	 70	 25	
24.05_oxime-,	methoxy-phenyl-	 55	 36	 20	 13	
24.73_2-heptanone,	5-methyl-	 91	 73	 30	 63	
24.80_1,3,5-triazine	 9	 36	 30	 13	
24.89_1-heptanol	 45	 45	 40	 38	
24.93_2-pentyl-furan	 82	 36	 0	 50	
24.94_butanoic	acid,	butyl	ester	 55	 45	 0	 0	
25.12_1-octen-3-ol	 55	 55	 60	 88	
25.52_3-octanone	 91	 73	 30	 63	
25.73_benzaldehyde	 91	 100	 100	 88	
26.38_hexanoic	acid	 55	 73	 30	 25	
26.50_1-propanol,	3-(methylthio)-	 9	 18	 50	 0	
26.66_dimethyl	sulfone	 45	 18	 10	 0	
26.99_1-hexanol,	2-ethyl-	 55	 55	 60	 38	
27.25_butanoic	acid,	3-methylbutyl	ester	 36	 18	 0	 0	
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Table	5.1	continued.		
	 Presence	(%)	
RT_compound	 Day	0	 Day	5	 Day	8	 Day	11	
27.67_5-ethylcyclopent-1-
enecarboxaldehyde	 82	 73	 20	 63	
28.14_phenol	 100	 91	 90	 50	
28.62_2-octenal	 82	 73	 50	 50	
28.64_benzyl	alcohol	 9	 9	 40	 0	
28.66_benzeneacetaldehyde	 91	 100	 100	 75	
28.93_diiodomethane	 36	 0	 20	 25	
29.06_2-nonanone	 55	 45	 30	 50	
29.24_5-hydroxy-4-octanone	 36	 0	 0	 13	
29.57_nonanal	 36	 36	 50	 13	
29.77_benzenamine,	2-methyl-	 73	 45	 20	 0	
31.25_phenylethyl	alcohol	 55	 55	 60	 50	
31.41_2-decanone	 0	 55	 50	 50	
31.62_1-nonanol	 55	 0	 0	 25	
31.81_2-nonenal	 9	 27	 20	 50	
33.74_benzene,	1,	3-bis(1,1-
dimethylethyl)-	 64	 9	 0	 13	
38.66_indole	 100	 100	 100	 100	
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Figure	 5.5	 Variation	 in	 the	 presence	 of	 faecal	 VOCs	 during	 the	 development	 of	
acute	colitis.	The	number	of	VOCs	identified	in	the	headspace	of	the	colon	contents	
collected	at	days	0,	5,	8	and	11	of	the	induction	of	acute	colitis	by	administration	of	
4.25%	DSS	(data	represented	as	mean±SEM,	n	=11,	11,	10,	8	for	days	0,	5,	8	and	11,	
respectively;	ANOVA	followed	by	Tukey’s	test,	*p<0.05).		
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Figure	 5.6	 Variation	 in	 the	 chemical	 composition	 by	 percentage	 of	 faecal	 VOCs	
according	 to	 development	 of	 colitis.	 Bar	 plots	 demonstrating	 the	 compound	
chemical	composition	by	percentage	across	all	time	points.		
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5.5.3	Quantitative	VOC	profile	variation	during	the	development	of	acute	colitis	
	
In	 order	 to	 further	 investigate	 the	 differences	 in	 faecal	 VOC	 profiles	 of	 colon	
content	samples	collected	at	days	0,	5,	8	and	11	of	this	experimental	colitis	murine	
model,	 the	 concentrations	 of	 the	 95	 identified	 VOCs	 in	 the	 colonic	 content	were	
examined.		
	
The	peak	abundances	for	all	compounds	in	all	samples	were	collated	and	a	one-way	
ANOVA	 was	 performed	 on	 log-transformed	 data	 to	 identify	 those	 compounds	
significantly	varying	with	the	development	of	colitis.	In	the	colonic	luminal	contents	
of	 DSS-treated	 mice,	 there	 were	 46	 compounds	 whose	 levels	 were	 significantly	
different	 between	 days	 0,	 5,	 8	 and	 11	 of	 treatment	 (Table	 5.2).	 Of	 these	 46	
compounds,	32	significantly	decreased	at	days	5	and	8,	compared	to	day	0	and	11;	
in	most	cases	the	levels	were	seen	to	increase	at	day	11,	to	levels	similar	to	those	
observed	 at	 day	 0.	 In	 contrast,	 there	 were	 14	 compounds	 that	 significantly	
increased	at	days	5	and	8	when	compared	to	the	levels	at	days	0	and	11.	The	levels	
of	 nitrogen	 containing	 (e.g.	 indole),	 sulphur	 containing	 (e.g.	 dimethyl	 sulphide),	
fatty	 acids	 (e.g.	 2-methyl-butanoic	 acid),	 esters	 (e.g.	 butanoic	 acid,	 propyl	 ester)	
and	alcohols	 (e.g.	 2-butanol)	were	 all	 decreased	during	 the	 acute	phase	of	 colitis	
(days	5	and	8).	Figure	5.7	 shows	each	of	 the	46	significantly	different	compounds	
presented	 as	 a	 boxplot;	 a	 standardised	way	of	 displaying	 the	 distribution	 of	 data	
based	 on	 the	 minimum,	 first	 quartile,	 median,	 third	 quartile,	 and	 maximum.	
Presenting	 each	 significantly	 different	 compound	 in	 the	 form	 of	 a	 boxplot	 was	 a	
good	 way	 to	 visually	 identify	 outliers	 and	 to	 compare	 the	 distribution	 of	
presence/absence,	abundance	and	spread	of	data	across	each	time	point.		
	
Some	of	the	46	significantly	different	compounds	may	be	significant	with	p-values	
less	than	0.05	purely	by	chance.	Therefore,	these	p-values	were	then	corrected	for	
multiple	 comparisons	 using	 the	 Bonferroni	 correction,	 resulting	 in	 9	 compounds	
being	 significantly	 different	 between	 days	 0,	 5,	 8	 and	 11.	 A	 Tukey	 HSD	 test	
identified	where	these	differences	lie	(Table	5.3).	Propanal	was	identified	in	100%	
of	samples	at	days	5	and	8	at	concentrations	of	5,850,711±790,709	and	3,213,638	
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±495,214,	 respectively,	 but	 absent	 at	 days	 0	 and	 11.	 A	 significant	 difference	was	
therefore	 found	 when	 comparing	 days	 5	 and	 8	 to	 days	 0	 and	 11	 (p<0.001).	 2-
butanol	was	present	in	100%	and	75%	of	samples	in	days	0	and	11,	respectively;	it	
was	absent	at	day	5	and	showed	a	22-fold	significant	decrease	between	day	0	and	
day	8	(only	20%	of	samples)	(p<0.001),	with	a	subsequent	6-fold	increase	between	
day	8	and	day	11	 (p<0.01).	Butanal	was	detected	 in	18%	of	samples	at	day	0	and	
showed	 a	 significant	 29-fold	 increase	 compared	 to	 day	 5	 (100%	 of	 samples)	
(p<0.001).	 The	 concentration	 of	 butanal	 then	 significantly	 decreased	 from	
5,655,360	 ±1,048,855	 at	 day	 5	 to	 1,485,786	 ±630,022	 at	 day	 8	 with	 a	 14-fold	
decrease	between	day	8	and	11,	 resulting	 in	a	 level	 similar	 to	 that	seen	at	day	0.	
Heptanal	behaved	similar	to	propanal,	significantly	increasing	at	days	5	and	8	when	
compared	to	days	0	and	11,	but	was	present	at	lower	concentrations	at	days	0	and	
11	unlike	propanal.	Ethanol	was	identified	in	100%	of	samples	at	every	time	point	
with	 its	 concentration	 significantly	decreasing	at	day	5	and	8	 compared	 to	day	0.	
Ethanol	 also	 significantly	 increased	 2-fold	 between	 day	 8	 and	 11	 to	 a	 final	
concentration	of	202,669,568	±22,678,375,	reverting	back	to	levels	more	similar	to	
that	at	day	0	(307,124,410	±50,827,323),	suggestive	of	signs	of	recovery.		There	was	
also	a	significant	decrease	in	the	levels	of	2-pentanol	when	comparing	days	5	(24-
fold	decrease)	 and	8	 (absent)	with	days	0	and	11.	 The	 level	of	3-methyl-butanoic	
acid	started	at	144,108,079	±19,162,470	on	day	0,	 increased	slightly	at	day	5	then	
gradually	 decreased	 from	 day	 5	 to	 day	 8	 with	 a	 final	 concentration	 of	
31,745,896±8,629,142	 at	 day	 11	 and	 was	 also	 identified	 in	 100%	 of	 samples	 at	
every	time	point	(mean±SEM).	3-hydroxy-2-butanone	was	identified	in	the	majority	
(90%)	of	 samples	 at	day	8	 at	 a	noticeably	higher	 concentration	 than	 identified	at	
days	 5	 (10-fold	 increase)	 and	 11	 (8-fold	 increase),	 but,	 interestingly,	 it	 was	 only	
present	in	one	sample	at	day	0	at	very	low	concentrations	2,846,628.	Finally,	furan,	
3-methyl-	showed	a	significant	decrease	in	both	the	concentration	and	occurrence	
at	days	5	and	8	compared	to	days	0	and	11.		
	
It	is	also	important	to	note	that	there	are	no	significant	differences	between	days	0	
and	day	11	with	only	one	compound	showing	a	significant	difference	between	days	
5	and	8	(Table	5.3).		
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To	 summarise,	 propanal,	 butanal,	 heptanal	 and	 3-hydroxy-2-butanone	 were	
present	 in	 samples	at	day	8	at	higher	 levels	 than	at	days	0	and	11.	On	 the	other	
hand,	 ethanol,	 2-butanol,	 2-pentanol,	 3-methyl-furan	 and	 3-methyl-butanoic	 acid	
were	 either	 absent	 or	 detected	 at	 significantly	 lower	 levels	 at	 day	 8	 than	 day	 0	
(Figure	5.8).	At	this	point,	it	was	noted	that	propanal,	butanal,	heptanal,	ethanol,	2-
butanol,	 3-methyl-furan	 and	 3-methyl-butanoic	 acid	 were	 also	 identified	 in	 the	
mouse	chow	(Table	3.4).		
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Table	5.2	List	of	the	46	significantly	different	compounds	across	time	detected	in	the	HS	of	colonic	luminal	content	of	DSS-treated	mice,	by	
SPME-GC-MS	 (n=11,	 11,	 10,	 8	 for	 days	 0,	 5,	 8	 and	 11,	 respectively).	Highlighted	 in	 bold	 are	 those	 VOCs	 still	 significant	 after	 Bonferroni	
correction.		
	 Abundance	(mean±SEM)	 P-value	
RT_compound	 Day	0	 Day	5	 Day	8	 Day	11	
10.16_butanal	 194,951±130,834	 5,655,360±1,048,855	 1,485,786±630,022	 380,257±305,951	 P<0.00	
10.32_furan,	3-
methyl-	 1,119,436±75,840	 725,662±274,024	 207,343±108,584	 1,192,496±248	 P<0.00	
10.77_2-butanol	 10,206,231±2,279,081	 NA	 462,670±314,178	 2,944,264±937,262	 P<0.00	
14.26_n-propyl	
acetate	 5,949,300±894,811	 13,097,356±2,713,452	 6,344,653±2,846,939	 7,083,712±1,690,712	 P<0.00	
14.41_2-pentanol	 7,799,971±2,785,378	 319,070±319,069	 NA	 4,141,792±1,772,331	 P<0.00	
16.13_3-hydroxy-2-
butanone	 2,846,628±2,846,627	 42,097,758±20,626,200	 423,418,778±150,622,215	 52,067,712±21,943,052	 P<0.00	
16.47_2-pentanone,	
3-methyl	 4,971,730±954,199	 1,023,145±406,099	 392,423±392,422	 2,099,873±992,904	 P<0.00	
17.72_ethyl	butyrate	 33,141,132±9,759,791	 4,486,156±1,050,183	 1,892,808±662,034	 6,974,176±2,829,829	 P<0.00	
19.73_2-hydroxy-3-
pentanone	 NA	 290,235±290,234	 6,097,357±2,168,733	 194,177±194,176	 P<0.00	
20.53_1,3-xylene	 2,030,627±155,608	 1,722,624±172,033	 2,026,496±238,410	 1,080,292±240,972	 P<0.00	
21.51_3-methyl-
butanoic	acid	
144,108,079±19,162,
470	 192,230,493±56,667,181	 74,954,650±15,587,067	 31,745,896±8,629,143	 P<0.00	
22.16_2-heptanol	 1,763,142±540,439	 NA	 NA	 565,513±387,504	 P<0.00	
22.33_heptanal	 42,824±42,823	 531,098±129,452	 664,903±275,435	 88,065±88,064	 P<0.00	
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Table	5.2	continued.		 	 	
	 Abundance	(mean±SEM)	 P-value	RT_compound	 Day	0	 Day	5	 Day	8	 Day	11	
24.93_2-pentyl-
furan	 1,566,790±271,019	 691,137±348,215	 NA	 1,259,609±536,636	 P<0.00	
24.94_butanoic	acid,	
butyl	ester	 2,520,384±1,204,729	 746,834±334,510	 NA	 NA	 P<0.00	
31.62_1-nonanol	 269,426±82,907	 NA	 NA	 124,717±81,845	 P<0.00	
33.74_benzene,	1,	3-
bis(1,1-
dimethylethyl)-	
543,654±155,274	 78,762±78,761	 NA	 160,177±160,176	 P<0.00	
5.12_acetylaldehyde	 NA	 NA	 20,740,097±11,322,651	 NA	 P<0.00	
6.61_ethanol	 307,124,410±50,827,323	 122,771,642±14,804,044	 75,989,709±13,431,387	 202,669,568±22,678,375	 P<0.00	
7.21_propanal	 NA	 5,850,711±790,709	 3,213,638±495,214	 NA	 P<0.00	
7.41_acetone	 218,915,654±57,501,895	 181,642,705±51,242,452	 72,877,875±22,236,808	 53,674,496±12,930,049	 P<0.00	
9.57_1-propanol	 113,671,075±19,233,946	 70,583,761±11,031,622	 46,356,378±14,653,938	 43,409,408±6,024,092	 P<0.00	
11.21_methyl	
propionate	 866,374±316,465	 6,592,291±1,647,556	 1,637,863±635,804	 6,046,552±1,868=3,814	 0.01	
14.69_methyl	
butyrate	 4,475,805±957,096	 1,992,919±354,263	 513,972±195,107	 1,764,420±544,620	 0.01	
18.60_methyl	
valerate	 452,987±168,084	 111,826±111,825	 NA	 NA	 0.01	
21.35_butanoic	acid,	 7,277,429±2,414,777	 1,594,555±639,061	 132,987±132,986	 119,065±119,064	 0.01	
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propyl	ester	
	
Table	5.2	continued.		 	 	
	 Abundances	(mean±SEM)	 P-value	RT_compound	 Day	0	 Day	5	 Day	8	 Day	11	
21.73_2-methyl-
butanoic	acid	
105,170,665±13,459,
797	 103,931,439±27,846,126	 32,463,053±6,459,924	 12,501,568±2,638,618	 0.01	
24.73_2-heptanone,	
5-methyl-	 2,504,035±376,554	 1,205,661±296,457	 236,871±126,365	 957,864±401,046	 0.01	
25.52_3-octanone	 1,425,460±333,004	 2,072,371±1,112,261	 236,193±121,533	 906,280±314,466	 0.01	
28.14_phenol	 11,601,437±4,188,859	 17,074,810±7,664,201	 67,305,715±26,344,602	 1,339,153±723,287	 0.01	
29.77_benzenamine,	
2-methyl-	 679,919±203,564	 687,490±349,396	 241,095±168,891	 NA	 0.01	
7.94_methyl	acetate	 13,298,548±2,856,056	 15,561,356±2,664,082	 3,878,068±1,578,805	 9,981,696±2,172,581	 0.01	
10.28_2,3-
butanedione	 7,194,496±2,182,163	 20,330,566±3,575,995	 62,987,162±20,049,708	 13,116,448±3,853,211	 0.02	
19.62_butanoic	acid	 999,817,216±160,950,090	
797,625,251±128,372,77
2	 443,548,058±109,004,878	
501,849,216±123,912,53
0	 0.02	
27.67_5-
ethylcyclopent-1-
enecarboxaldehyde	
499,292±79,691	 503,912±135,476	 100,442±69,121	 572,130±230,400	 0.02	
31.41_2-decanone	 NA	 1,949,126±876,603	 1,169,735±538,749	 710,657±301,527	 0.02	
6.42_pentane	 1,397,196±441,984	 774,051±342,704	 NA	 1,634,438±649,195	 0.02	
8.61_3-methyl-
pentane	 471,942±250,342	 NA	 NA	 218,723±109,612	 0.02	
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Table	5.2	continued.		 	 	
	 Abundances	(mean±SEM)	 P-value	RT_compound	 Day	0	 Day	5	 Day	8	 Day	11	
26.50_1-propanol,	
3-(methylthio)-	 27,271±27,270	 81,498±60,370	 526,474±263,553	 NA	 0.03	
29.24_5-hydroxy-4-
octanone	 312,001±138,112	 NA	 NA	 63,289±63,288	 0.03	
7.49_dimethyl	
sulfide	 2,052,841±359,095	 1,395,596±374,376	 410,797±231,724	 1,604,312±531,780	 0.03	
17.94_oxirane,	2-
methyl-2-(1-
methylethyl)-	
2,345,036±608,508	 1,164,224±358,382	 364,334±255,319	 426,633±293,537	 0.04	
18.26_2-methyl-
propanoic	acid	
66,311,633±11,822,9
25	 68,957,370±17,949,426	 30,914,842±7,055,699	 14,576,256±3,446,318	 0.04	
28.66_benzeneaceta
ldehyde	 2,224,093±551,654	 8,800,047±1,413,856	 7,669,888±1,755,801	 2,723,560±1,352,426	 0.04	
9.07_hexane	 1,178,815±974,180	 NA	 NA	 443,097±294,567	 0.04	
38.66_indole	 96,823,575±17,540,940	 53,867,520±8,293,595	 77,596,774±22,680,947	 37,622,368±7,390,657	 0.05	
P-values	were	calculated	according	to	a	one-way	ANOVA	with	the	significant	level	of	p<0.05.		Compounds	are	ordered	according	to	p-values	(lowest	to	
highest)	with	those	compounds	showing	a	larger	significant	difference	across	time	at	the	top	of	the	list.	These	p-values	have	not	been	corrected	for	
multiple	comparisons.	
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Figure	5.7	Box	plots	of	the	peak	abundance	(log	scale)	of	the	significantly	different	
compounds.	 A	 one-way	 ANOVA	 was	 performed	 across	 the	 four	 time	 points	 and	
found	46	compounds	to	significantly	vary	across	time	(p<0.05).	These	p-values	are	
shown	in	Table	5.2	and	have	not	been	corrected	for	multiple	comparisons.	
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Figure	 5.7	 (continued).	 Box	 plots	 of	 the	 peak	 abundance	 (log	 scale)	 of	 the	
significantly	 different	 compounds.	A	 one-way	 ANOVA	was	 performed	 across	 the	
four	time	points	and	found	46	compounds	to	significantly	vary	across	time	(p<0.05).	
These	p-values	 are	 shown	 in	 Table	 5.2	 and	 have	 not	 been	 corrected	 for	multiple	
comparisons.		
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Figure	 5.7	 (continued).	 Box	 plots	 of	 the	 peak	 abundance	 (log	 scale)	 of	 the	
significantly	 different	 compounds.	A	 one-way	 ANOVA	was	 performed	 across	 the	
four	time	points	and	found	46	compounds	to	significantly	vary	across	time	(p<0.05).	
These	p-values	 are	 shown	 in	 Table	 5.2	 and	 have	 not	 been	 corrected	 for	multiple	
comparisons.	
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Figure	 5.7	 (continued).	 Box	 plots	 of	 the	 peak	 abundance	 (log	 scale)	 of	 the	
significantly	 different	 compounds.	A	 one-way	 ANOVA	was	 performed	 across	 the	
four	time	points	and	found	46	compounds	to	significantly	vary	across	time	(p<0.05).	
These	p-values	 are	 shown	 in	 Table	 5.2	 and	 have	 not	 been	 corrected	 for	multiple	
comparisons.		
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Table	5.3	List	of	the	9	significantly	different	compounds	as	a	result	of	adjusting	the	p-values	shown	in	Table	5.2	for	multiple	comparisons	by	
Bonferroni	correction.		
RT_compound	 P-values	Bonferroni	 Day	0	vs.	5	 Day	0	vs.	8	 Day	0	vs	11	 Day	5	vs.	8	 Day	5	vs.	11	 Day	8	vs.	11	
7.21_propanal	 0.0000	 0.0000	 0.0000	 1.0000	 0.0230	 0.0000	 0.0000	
10.16_butanal	 0.0008	 0.0000	 0.0159	 0.9798	 0.1327	 0.0002	 0.0711	
16.13_3-hydroxy-2-
butanone	 0.0446	 0.0799	 0.0002	 0.0451	 0.1172	 0.9673	 0.3552	
22.33_heptanal	 0.0016	 0.0003	 0.0006	 0.9964	 0.9995	 0.0018	 0.0031	
6.61_ethanol	 0.0030	 0.0144	 0.0000	 0.7767	 0.1402	 0.2120	 0.0017	
10.32_furan,	3-methyl-	 0.0070	 0.0081	 0.0005	 1.0000	 0.6937	 0.0185	 0.0014	
10.77_2-butanol	 0.0000	 0.0000	 0.0000	 0.1448	 0.4332	 0.0000	 0.0016	
14.41_2-pentanol	 0.0063	 0.0052	 0.0015	 0.9813	 0.9489	 0.0041	 0.0013	
21.51_3-methyl-butanoic	
acid	 0.0353	 1.0000	 0.2475	 0.0007	 0.2649	 0.0008	 0.0874	
P-values	were	calculated	according	to	a	one-way	ANOVA	(Table	5.2),	adjusted	for	multiple	comparisons	using	Bonferroni	correction,	
followed	by	Tukey’s	HSD	test.	Red	indicates	p<0.05,	blue	p<0.01	and	green	p<0.001.		
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Figure	5.8	Bar	plots	of	the	peak	abundance	of	9	significantly	different	compounds.	Table	5.3	shows	the	significant	differences	identified	by	a	
one-way	ANOVA	performed	across	the	four	time	points	and	adjusted	for	multiple	comparisons	using	Bonferroni	correction	(p<0.05).	Data	are	
expressed	 as	mean±SEM	peak	 abundance	 for	 each	 significant	 compound	with	 the	percentage	occurrence	of	 each	 compound	 at	 each	 time	
point	presented.		
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5.5.4	 Pattern	 recognition	using	multivariate	 statistics	 visually	 confirms	 variation	
during	development	of	colitis	
	
The	patterns	of	variation	 in	 the	 levels	of	 the	46	significantly	different	compounds	
detected	 in	 the	 HS	 of	 the	 colon	 contents	 of	 DSS-treated	 mice	 were	 analysed	 to	
examine	the	clustering	of	each	time	point	according	to	multivariate	statistics	using	
PCA.	This	was	performed	using	the	abundance	of	the	46	significant	compounds	and	
showed	distinct	clustering	and	clear	separation	of	the	four	time	points	(Figure	5.9).	
It	 is	apparent	from	closer	 inspection	of	this	analysis	that	the	VOC	profile	from	the	
colon	contents	of	DSS-treated	mice	changes	according	to	the	different	time	points	
tested	during	the	development	of	acute	DSS-colitis.	Specifically,	samples	from	day	0	
are	grouped	in	the	upper	right	hand	quadrant	of	the	plot,	day	5	centre,	day	8	to	the	
left	and	day	11	grouped	in	the	lower	right	hand	quadrant	with	very	little	variation	
between	day	0	and	11.	These	results	visually	suggest	that	the	pathogenesis	of	DSS-
induced	 colitis	 leads	 to	 variation	 in	 the	 faecal	 metabolome.	 Inspection	 of	 the	
variable	 factor	 map	 produced	 alongside	 the	 biplot	 of	 the	 PCA	 shows	 that	 the	
significant	 VOCs	 (p<0.05,	 Bonferroni)	 are	 responsible	 for	 the	 separation	 between	
the	different	time	points.	For	example,	butanal	and	3-methylbutanoic	acid	are	chief	
compounds	at	day	5,	heptanal	and	3-hydroxy-2-butanone	at	day	8,	and	2-butanol	
and	ethanol	at	day	0	and	11.		
	
In	order	to	further	explore	the	differences	between	these	significant	VOC	emissions	
from	the	different	time	points	of	DSS-colitis,	a	heat	map	was	produced	using	cluster	
analysis	according	to	the	abundance	of	the	9	compounds	selected	(p<0.05,	ANOVA	
followed	by	Bonferroni)	 (Figure	5.10).	The	resulting	plots	showed	similar	patterns	
with	days	0	(control)	and	11	(black)	grouped	together,	and	days	5	and	8	(red).	It	also	
visually	shows	how	each	of	the	9	significantly	different	compounds	change	between	
the	 time	points.	For	example,	Figure	5.8	shows	 that	 the	concentration	of	ethanol	
decreases	at	days	5	and	8	compared	to	day	0	and	11.	This	decrease	is	represented	
by	 the	 heatmap	 with	 shades	 of	 red	 and	 shades	 of	 yellow	 representing	 higher	
concentrations	of	each	compound.		
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To	 summarise,	 a	 one-way	 ANOVA	 followed	 by	 Tukey’s	 HSD	 test,	 corrected	 for	
multiple	 comparison	 using	 the	 Bonferroni	 method,	 identified	 9	 significantly	
different	compounds.	Of	 these	9,	 there	were	3	aldehydes,	3	alcohols,	1	ketone,	1	
acid	and	1	 furan	compound.	All	aldehydes	and	3-hydroxy-2-butanone	significantly	
increased	in	the	presence	of	colitis	and	all	alcohols,	3-methyl-butanoic	acid	and	the	
furan	 compound	 significantly	 decreased.	 The	 visual	 cluster	 analyses	 confirm	 that	
these	 compounds	 are	 responsible	 for	 the	 differences	 observed	 according	 to	 the	
degree	of	colitis.		
	
	
	
	
Figure	 5.9	 A	 PCA	 biplot	 for	 the	 colonic	 luminal	 content	 samples	 of	 DSS-treated	
mice.	The	first	principal	component	has	been	plotted	against	the	second	principal	
component.	 The	 PCA	 was	 performed	 using	 the	 abundance	 of	 the	 46	 significant	
compounds	from	Table	5.2.		
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Figure	5.10	Hierarchical	clustering.	A	heat	map	representing	hierarchical	clustering	
of	 the	 significantly	 different	 9	 compounds	 (ANOVA	 followed	 by	 Bonferroni	
correction)	 across	 the	 four	 different	 time	 points	 of	 DSS-induced	 colitis.	 Sample	
classes	are	indicated	by	the	coloured	bars	(day	0	&	day	11	=	black,	day	5	&	day	8	=	
red).	Columns	represent	individual	murine	faecal	samples	and	rows	refer	to	distinct	
compounds.	 Shades	 of	 yellow	 represent	 an	 increase	 in	 concentration	 of	 a	
compound	and	shades	of	red	represent	a	decrease	in	concentration	of	a	compound,	
grouping	similar	rows/columns	using	the	complete-linkage	clustering	method.		
	
	175	
	
5.5.5	Metabolomic	effect	of	deleting	NFκB2	in	acute	DSS-induced	colitis	
	
This	study	specifically	investigates	the	VOCs	that	may	be	associated	with	the	role	of	
the	 alternative	 NFκB	 pathway	 in	 the	 development	 of	 acute	 DSS-induced	 colitis.	
Clinical	 (weight	 loss	 and	 DAI)	 and	 histological	 features	 (Figure	 5.11C&D)	 were	
assessed	 and	 confirmed	 the	 resistance	 of	 NFκB2-/-	 compared	 to	WT	 treated	mice	
following	treatment	with	DSS.	WT	DSS	treated	mice	lost	19.5±1.15%	of	their	body	
weight	at	day	8,	which	was	significantly	more	than	NFκB2-/-	treated	mice	(1.8±0.9%	
weight	 loss)	 and	 also	 the	 WT	 and	 NFκB2-/-	 untreated	 groups	 (p<0.001,	 ANOVA	
followed	by	Tukey’s	HSD	test)	(Figure	5.11A).	The	WT	DSS	treated	mice	were	also	
significantly	more	physically	unwell	compared	to	WT	untreated,	NFκB2-/-	untreated,	
and	NFκB2-/-	 DSS	 treated	 animals	 (p<0.01,	 Kruskal	Wallis	 Test	 followed	 by	Mann-
Whitney	U)	(Figure	5.11B).		
	
A	total	of	100	VOCs	were	identified	in	the	headspace	of	the	colonic	luminal	content	
of	the	mice	in	all	four	groups.	Univariate	statistical	analysis	found	26	of	these	VOCs	
to	be	present	at	significantly	different	concentrations	between	the	different	groups	
(p<0.05,	ANOVA	and	Bonferroni)	(Table	5.4).	Of	these,	15	VOCs	were	absent	in	the	
WT	and	NFκB2-/-	DSS	treated	group	and	were	commonly	alcohols.	Inspection	of	the	
PCA	 (Figure	 5.12)	 shows	 that	 based	 on	 the	 abundance	 of	 the	 26	 significant	
compounds,	 WT	 and	 NFκB2-/-	 untreated	 mice	 appear	 to	 have	 a	 similar	 faecal	
metabolome.	The	WT	DSS-treated	group	appears	 to	be	very	different	 to	both	 the	
control	 groups	 with	 the	 NFκB2-/-	 DSS	 treated	 group	 lying	 in	 between	 the	 two	
clusters	on	the	PCA.	Although,	clinically	the	NFκB2-/-	DSS	treated	group	behaved	like	
the	untreated	control	groups,	the	faecal	VOC	metabolome	is	significantly	different,	
suggesting	a	role	of	NFκB2	in	the	pathogenesis	of	DSS-induced	colitis.		
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Figure	 5.11	 Clinical	 and	 histological	 features	 of	 acute	 DSS-induced	 colitis	 in	WT	
and	NFκB2-/-	mice.	A.	Weight	loss.	B.	Disease	activity	index	(DAI);	Data	represented	
as	mean±SEM,	n=4,	6,	4,	6	for	WT	(unt.),	WT	DSS,	NFκB2-/-	(unt.)	and	NFκB2-/-	DSS,	
respectively.	Statistical	differences	were	assessed	by	one-way	ANOVA	followed	by	
Tukey’s	 test	 for	weight	 loss	and	Kruskal-Wallis	 Test	 followed	by	Mann-Whitney	U	
for	DAI,	p<0.01	**,	p<0.001	***,	^^^,	###	compared	to	WT	(unt.),	NFκB2-/-	(unt.),	
NFκB2-/-	 DSS,	 respectively.	 C.	 &	 D.	 Representative	 images	 of	 H&E	 stained	 distal	
colonic	sections	for	WT	and	NFκB2-/-	DSS	treated	mice.		
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Table	5.4	List	of	the	26	significantly	different	compounds	between	WT	and	NFκB2-
/-	mice	treated	with	and	without	2%	DSS.   
	 Abundance	(mean±SEM)	
P-value	RT_Compound	 WT	DSS-treated	
WT	
untreated	
NFκB2-/-	
DSS-
treated	
NFκB2-/-	
untreated	
26.99_1-hexanol,	2-
ethyl-	 NA	
4,293,824±
461,077	 NA	
2,823,744±
111,612	 0.0000	
40.10_5,9-
undecadien-2-ol,	6,10-
dimethyl-	
NA	 6,320,576±773,170	 NA	
24,114,944
±4,747,307	 0.0000	
16.19_1-butanol,	2-
methyl-	 NA	
25,662,464
±6,962,638	 NA	
14,029,568
±2,975,937	 0.0000	
11.90_1-propanol,	2-
methyl-	 NA	
5,085,568±
1,051,529	 NA	
3,859,904±
990,037	 0.0000	
17.45_1-pentanol	 NA	 4,209,088±1,034,285	 NA	
4,133,056±
337,640	 0.0000	
31.25_phenylethyl	
alcohol	 NA	
13,751,552
±3,973,018	 NA	
7,011,520±
310,868	 0.0000	
21.19_1-hexanol	 NA	 26,988,224±6,589,116	 NA	
20,873,984
±2,822,093	 0.0000	
25.12_1-octen-3-ol	 NA	 12,283,328±2,769,442	 NA	
15,430,144
±4,198,912	 0.0000	
10.77_2-butanol	 NA	 6,767,104±1,555,738	 NA	
4,950,256±
1,495,925	 0.0000	
14.41_2-pentanol	 NA	 6,107,472±2,132,947	 NA	
4,357,104±
1,735,014	 0.0000	
24.89_1-heptanol	 NA	 1,612,816±363,086	 NA	
1,554,645±
249,402	 0.0002	
26.50_1-propanol,	3-
(methylthio)-	 NA	
1,772,395±
535,956	 NA	
1,498,592±
120,772	 0.0002	
31.62_1-nonanol	 NA	 658,683±90,728	 NA	
452,368±48
,434	 0.0002	
13.44_1-butanol	 NA	 4,323,952±1,888,453	 NA	
8,490,837±
1,647,241	 0.0003	
28.64_benzyl	alcohol	 NA	 6,632,976±3,331,760	 NA	 1,428,736	 0.0003	
20.53_1,3-xylene	
7,996,03
2±484,93
8	
2,173,168±
159,663	
7,894,613±
484,386	
4,869,248±
702,532	 0.0000	
35.82_1,2-
benzisothiazole	
1,783,80
8	
5,888,640±
1,658,803	
7,309,653±
1,606,850	
6,075,136±
1,299,329	 0.0006	
21.73_2-methyl-
butanoic	acid	
9,474,13
3±2,895,
488	
93,830,656
±24,504,66
7	
37,910,699
±9,004,976	
69,857,024
±16,370,36
5	
0.0249	
19.62_butanoic	acid	
125,237,
931±40,1
54,797	
611,123,20
0±164,712,
772	
647,350,95
5±94,764,9
49	
663,744,51
2±167,684,
275	
0.0272	
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Table	5.4	continued.	 	 	 	 	 	
33.74_benzene,	1,	3-
bis(1,1-
dimethylethyl)-	
NA	 422,480	 2,241,909±235,028	
1,790,784±
576,388	 0.0000	
14.20_pentanal	 NA	 1,147,776	 NA	 1,663,568±287,732	 0.0006	
14.69_methyl	
butyrate	 NA	
2,612,780±
1,035,401	
1,570,672±
363,524	
1,590,560±
478,802	 0.0105	
9.57_1-propanol	 5,640,448	
24,012,032
±6,126,457	 6,414,848	
27,009,792
±7,682,815	 0.0153	
18.60_methyl	valerate	 NA	 1,057,493±155,322	 NA	 NA	 0.0162	
7.21_propanal	
3,415,76
5±473,66
8	
NA	 2,326,784	 1,082,752	 0.0228	
24.10_3-heptanone,	
6-methyl-	 NA	
807,787±15
3,411	
1,401,088±
98,362	
1,261,152±
299,611	 0.0369	
P-values	were	calculated	according	to	a	one-way	ANOVA	adjusted	for	multiple	comparisons	
using	Bonferroni	correction,	followed	by	Tukey’s	HSD	test.		
	
	
	
	
Figure	 5.12	 A	 PCA	 biplot	 for	 the	 colonic	 luminal	 content	 samples	 of	 WT	 and	
NFκB2-/-	 control	 and	 DSS-treated	 mice.	 The	 first	 principal	 component	 has	 been	
plotted	against	the	second	principal	component.	The	PCA	was	performed	using	the	
abundance	 of	 the	 26	 significant	 compounds	 (p<0.05,	 ANOVA	 followed	 by	
Bonferroni).		
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5.5.6	Administration	of	MgSO4	induces	a	quick	onset	of	diarrhoea		
	
Diarrhoea	was	induced	by	oral	administration	of	magnesium	sulphate	at	the	dose	of	
2g/kg.	Faecal	samples	were	collected	every	hour	and	the	amount	and	consistency	
of	 the	 faeces	 were	 assessed.	 Each	 animal	 was	 assigned	 a	 FOI	 (FOI	 =	 sum	 of	
consistency	scores	of	all	motions	passed	within	3	hours	[286]).	A	mouse	passing	a	
stool	of	score	2	at	 least	once	was	counted	as	suffering	 from	diarrhoea.	Diarrhoea	
was	observed	between	1	and	2	hours	after	administration	of	MgSO4,	peaking	at	3	
hours	with	a	significantly	different	FOI	between	control	and	treated	groups	of	mice	
(Figure	5.13).	All	faecal	samples	collected	were	analysed	using	the	HS-SPME-GC-MS	
method	 of	 VOC	detection	 and	were	 later	 used	 as	 controls	 against	 the	DSS	 colitis	
samples	to	isolate	compounds	changing	or	produced	as	a	result	of	an	inflammatory	
response.		
	
	
Figure	5.13	FOI	 for	MgSO4-induced	diarrhoea	at	3	hours.	The	FOI	was	defined	as	
the	sum	of	the	consistency	scores	of	all	the	motions	passes	within	the	observation	
period	of	3	hours.	A	mouse	passing	a	stool	of	score	2	at	least	once	was	counted	as	
suffering	 from	 diarrhoea.	 Data	 expressed	 as	 mean±SD	 of	 FOI	 of	 each	mouse	 for	
both	control	(n=3)	and	MgSO4	group	(n=5);	t-test	***p<0.001.	
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5.5.7	 Significantly	 different	 VOCs	 present	 with	 the	 onset	 of	 MgSO4-induced	
diarrhoea	
	
The	 detection	 of	 the	 VOCs	 emitted	 from	 the	 diarrhoea	 samples	 of	mice	 3	 hours	
after	being	 treated	with	MgSO4	and	 their	untreated	controls	yielded	a	 total	of	69	
compounds	with	an	average	of	33.0±4.0	and	37.2±4.0	found	in	untreated	controls	
and	MgSO4-treated	mice,	respectively	(mean±SEM,	p>0.05)	(Figure	5.14).		Of	these,	
ketones,	 aldehydes,	 acids	 and	 alkanes	 were	 among	 the	 commonest	 groups	 of	
compounds	 across	 both	 groups	 with	 the	 number	 of	 ketones	 and	 aldehydes	
identified	 increasing	 in	the	diarrhoea	group,	compared	to	control.	Phenol	was	the	
only	compound	found	to	be	significantly	more	prevalent	in	the	MgSO4	group	(5/5),	
compared	to	control	(0/3)	(Fisher’s	Exact,	p<0.05).		
	
Figure	5.14	Administration	of	MgSO4	causes	in	increase	the	number	of	 identified	
VOCs.	 The	 number	 of	 VOCs	 identified	 in	 the	 HS	 of	 stool	 samples	 from	 mice	
administered	 with	 2mg/kg	 MgSO4	 (n=5)	 increased	 slightly	 compared	 to	 those	
identified	 from	 untreated	 controls	 (n=3).	 Data	 expressed	 as	 mean±SEM;	 t-test	
p>0.05	N.S.	
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Univariate	 statistical	 analysis	 resulted	 in	 6	 significantly	 different	 compounds	
(Student’s	t-test,	p<0.05)	(Table	5.5).	Isopropanol	was	identified	in	100%	of	samples	
from	both	the	MgSO4	and	control	groups	but	at	a	significantly	lower	concentration	
in	 MgSO4	 samples	 (p=0.01)	 with	 a	 4.3-fold	 decrease.	 3-hydroxy-2-butanone	
behaved	in	a	similar	way,	but	only	had	a	prevalence	of	20%	in	MgSO4	compared	to	
control	(100%)	with	a	1.3-fold	significant	decrease	(p=0.02).	2-methyl-propanal	and	
2-methyl-butanal	were	also	found	in	100%	of		MgSO4		samples	and	both	significantly	
increasing	in	MgSO4	samples	(p<0.01)	by	a	12.3	and	36.4-fold	increase,	respectively.	
Phenol	and	3-(methylthio)-propanal	were	absent	in	the	control	group	with	100	and	
80%	prevalence	in	the	MgSO4	group,	respectively.	These	changes	in	abundance	can	
be	observed	by	inspection	of	the	box	and	whisker	plots	in	Figure	5.15.		Phenol	was	
the	 only	 compound	 to	 remain	 significantly	 different	 after	 undergoing	 the	
Bonferroni	correction.		
	
Furthermore,	 PCA	 illustrated	 the	 separation	 of	MgSO4-treated	mice	 compared	 to	
the	 control	 group	 based	 on	 these	 significantly	 different	 VOCs	 (Figure	 5.16).	 This	
suggests	 that	 the	 detection	 and	 analysis	 of	 VOCs	 is	 capable	 of	 distinguishing	
between	healthy	and	diarrhoea	faecal	samples.		
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Table	5.5	List	of	the	6	significantly	different	compounds	detected	in	the	HS	of	diarrhoea	samples	from	MgSO4-treated	mice	compared	to	
untreated	controls,	by	SPME-GC-MS.			
RT_compound	
Presence	(%)	 Abundance	(mean±SEM)	 	 	
control	(n=3)	 MgSO4(n=5)	 control	(n=3)	 MgSO4(n=5)	 Fold	change	 P-value	
7.61_isopropanol	 100	 100	 92,575,061±19,183,304	 21,470,617±7,927,192	 4.3	↓	 0.0125	
9.01_2-methylpropanal	 100	 100	 2,761,514±652,764	 33,999,974±12,072,443	 12.3	↑	 0.0118	
12.81_2-methylbutanal	 100	 100	 2,027,776±570,594	 73,876,428±30,147,287	 36.4	↑	 0.0035	
16.13_3-hydroxy-2-
butanone	 100	 20	 69,043,712±57,917,128	 51,949,568	 1.3	↓	 0.0167	
23.62_3-(methylthio)-
propanal	 0	 80	 NA	 1,730,448±849,691	
Absent	in	
control	 0.0168	
28.14_phenol	 0	 100	 NA	 10,213,824±4,825,243	 Absent	in	control	 0.0000*	
P-values	were	calculated	according	to	a	Student’s	t-test	and	performed	on	log-transformed	data	(p<0.05).	Fold	change	shows	an	increase	(↑)	or	decrease	
(↓)	of	the	average	peak	abundance	of	each	compound	in	the	MgSO4	group,	compared	to	untreated	control.	*Bonferroni	correction.		
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Figure	5.15	Box	plots	of	the	peak	abundance	(log	scale)	of	the	significantly	different	compounds.	A	Student’s	t-test	was	performed	between	
the	abundance	of	the	92	VOCs	identified	in	the	HS	of	stool	samples	from	both	groups.	There	were	6	compounds	found	to	significantly	vary	and	
the	p-values	are	shown	in	Table	5.5.		
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Figure	5.16	A	PCA	biplot	for	the	diarrhoea	faecal	samples	collected	at	3	hours	post	
MgSO4	administration.	The	first	principal	component	(76.19%	of	the	total	variation)	
has	 been	 plotted	 against	 the	 second	 principal	 component	 (11.56%	 of	 the	 total	
variation).	The	PCA	was	performed	using	 the	6	 significant	 compounds	 from	Table	
5.5.		
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5.5.8	VOC	comparison	of	DSS-induced	colitis	and	MgSO4-induced	diarrhoea	
	
In	order	to	identify	compounds	specific	to	the	acute	DSS-induced	colitis	faecal	VOC	
profile,	the	colon	contents	collected	at	day	8	of	acute	DSS-colitis	were	compared	to	
those	produced	from	mice	administered	MgSO4.	The	consistency	of	diarrhoea	was	
scored	 hourly	 after	 administration	 of	 MgSO4	 with	 3	 hours	 receiving	 the	 highest	
score.	 Therefore,	 the	 samples	 collected	 at	 3	 hours	 (n=5)	were	 directly	 compared	
with	the	samples	from	day	8	of	the	third	and	final	acute	DSS-colitis	model	(n=6).		
	
Administration	 of	 MgSO4	 causes	 diarrhoea	 by	 accelerating	 the	 small	 intestinal	
transit	 time	 and	 reducing	 the	 intestinal	 absorption	 of	 fat,	 protein	 and	
carbohydrates,	 therefore	 acting	 as	 an	 osmotic	 laxative	 [287].	 The	 onset	 of	 this	
watery	diarrhoea	is	fast	with	a	quick	transit	time	through	the	intestine,	resulting	in	
a	significantly	lower	number	of	VOCs	identified	(38.2±4.4)	when	compared	to	DSS-
colitis	(50.5±2.9)	(mean±SEM,	p<0.05)	(Figure	5.17).		
	
	
Figure	5.17	The	number	of	VOCs	identified	from	diarrhoea	samples	decreases	for	
MgSO4-treated	 mice	 compared	 to	 DSS-treated	 mice.	 The	 number	 of	 VOCs	
identified	 in	 the	HS	of	 colon	 contents	 of	mice	 culled	 at	 day	8	of	DSS-colitis	 (n=6)	
development	significantly	 increased	compared	 to	MgSO4-treated	mice	 (n=5).	Data	
expressed	as	mean±SEM;	*p<0.05.		
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Of	92	compounds	found	in	at	least	30%	of	faecal	samples	in	either	group,	21	were	
noted	 to	 be	 significantly	 more	 prevalent	 in	 either	 the	 DSS-colitis	 or	 the	 MgSO4-
diarrhoea	 group	 (Table	 5.6).	 The	most	 significantly	 different	 compounds	were	 1-
pentanol,	2-ethyl-1-hexanol	and	phenylethyl	alcohol	which	were	all	present	in	100%	
of	 DSS-colitis	 samples	 but	 absent	 from	MgSO4-diarrhoea	 samples	 (p<0.001).	 The	
majority	 of	 these	 significant	 compounds	 were	 more	 prevalent	 in	 the	 DSS-colitis	
group	with	alcohols	appearing	most	frequently.	These	compounds	were	present	in	
60%	of	samples	at	day	8	of	the	acute	colitis	experiment,	compared	to	38%	at	day	
11.	This	 implies	that	the	presence	of	these	compounds	may	indicate	the	presence	
of	 inflammation-driven	 diarrhoea,	 or	 the	 absence	may	 indicate	 osmotic	 laxative-
induced	diarrhoea.			
	
In	addition,	there	were	20	compounds	found	to	significantly	vary	 in	concentration	
between	 the	 two	 groups	 (t-test;	 p<0.05).	 There	 were	 12	 compounds	 found	
exclusively	 in	 the	 DSS-colitis	 group	 (abundant	 in	 alcohols	 and	 ketones),	 1	 in	 the	
MgSO4	 (pentanal)	 and	 7	 compounds	 common	 to	 both	 groups	 (Table	 5.7).	 The	
concentration	 of	 ethanol	 and	 2-butanol	 significantly	 decreased	 at	 day	 8	 of	 DSS-
colitis	when	compared	to	day	0,	5	and	11,	whereas	heptanal,	butanal	and	propanal	
significantly	 increased	 at	 day	 8.	 All	 mentioned	 compounds	 were	 present	 in	 the	
MgSO4-diarrhoea	 group	 (>30%	 of	 samples)	 but	 with	 no	 significant	 difference	 in	
concentration	to	day	8	DSS-colitis.	2-pentanol	was	present	at	day	0,	5	and	11	of	the	
DSS-colitis	 but	 absent	 at	 day	 8	 and	 also	 the	 MgSO4-diarrhoea	 groups.	 These	
similarities	 indicate	 that	 these	 compounds	 are	 potential	 biomarkers	 for	 the	
presence	of	diarrhoea,	not	specific	to	IBD.	Whereas,	3-hydroxy-2-butanone,	which	
was	present	at	day	8	DSS-colitis	at	a	significantly	higher	concentration	than	day	0	
(T-test,	p<0.001),	was	present	in	only	1/5	samples	in	the	MgSO4	group	(Table	5.6	&	
5.7).	A	PCA	plot	using	the	abundances	of	these	20	significantly	different	compounds	
clearly	demonstrates	this	separation	(PC1	=	67.32%	variation)	of	samples	from	mice	
administered	either	4.25%	DSS	or	2mg/kg	MgSO4	based	on	their	VOC	profile	(Figure	
5.18).	 This	 shows	 that	 the	 faecal	 VOC	 profiles	 are	 significantly	 different	 between	
the	different	causes	of	murine	diarrhoea.		
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Table	5.6	List	of	21	compounds	with	a	significantly	different	prevalence	between	
DSS-induced	colitis	and	MgSO4-induced	diarrhoea.	
RT_compound	 Present	in	DSS-colitis	(%)	
Present	in	
MgSO4-diarrhoea	(%)	
Chi2	test	
p-value	
17.45_1-pentanol	 100	 0	 0.0009	
26.99_1-hexanol,	2-ethyl-	 100	 0	 0.0009	
31.25_phenylethyl	alcohol	 100	 0	 0.0009	
13.44_1-butanol	 83	 0	 0.0057	
19.73_2-hydroxy-3-pentanone	 83	 0	 0.0057	
25.33_1-octen-3-ol	 83	 0	 0.0057	
26.50_1-propanol,	3-(methylthio)-	 83	 0	 0.0057	
14.20_pentanal	 0	 80	 0.0060	
16.13_3-hydroxy-2-butanone	 100	 20	 0.0060	
21.49_1-hexanol	 100	 20	 0.0060	
25.12_1-nonen-3-ol	 100	 20	 0.0060	
16.19_1-butanol,	2-methyl-	 67	 0	 0.0221	
20.56_N-benzyloxy-2-
carbomethoxyaziridine	 67	 0	 0.0221	
24.89_1-heptanol	 67	 0	 0.0221	
28.64_benzyl	alcohol	 67	 0	 0.0221	
31.41_2-decanone	 67	 0	 0.0221	
11.90_1-propanol,	2-methyl-	 100	 40	 0.0261	
24.93_2-pentyl-furan	 0	 60	 0.0261	
26.34_D-limonene	 0	 60	 0.0261	
29.34_acetophenone	 0	 60	 0.0261	
26.66_dimethyl	sulfone	 17	 80	 0.0357	
P-values	were	calculated	according	to	the	Chi-Square	test	to	determine	compounds	significantly	more	or	
less	prevalent	in	MgSO4-treated	(n=5)	or	DSS-treated	mice	(n=6)	(p<0.05).		
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Table	5.7	List	of	20	significantly	different	compounds	between	diarrhoea	samples	at	3	hours	post	MgSO4	administration	and	day	8	acute	DSS-
colitis.	Peak	abundance	of	each	compound	expressed	as	mean±SEM	and	percentage	occurrence	of	each	compound	in	each	group.	
RT_compound	
DSS	(n=10)	 MgSO4	(n=4)	 	
mean±SEM	 Prevalence	(%)	 mean±SEM	 Prevalence	(%)	 P-value	
17.45_1-pentanol	 1,773,515±267,525	 6/6	(100)	 NA	 0	 0.0000	
26.99_1-hexanol,	2-ethyl-	 1,032,523±86,273	 6/6	(100)	 NA	 0	 0.0000	
31.25_phenylethyl	alcohol	 9,522,837±3,708,046	 6/6	(100)	 NA	 0	 0.0000	
19.73_2-hydroxy-3-pentanone	 11,492,915±2,229,163	 5/6	(83)	 NA	 0	 0.0042	
25.33_1-octen-3-ol	 18,029,005±5,578,158	 5/6	(83)	 NA	 0	 0.0042	
26.50_1-propanol,	3-(methylthio)-	 1,052,947±380,771	 5/6	(83)	 NA	 0	 0.0042	
13.44_1-butanol	 15,762,330±8,775,427	 5/6	(83)	 NA	 0	 0.0045	
25.12_1-nonen-3-ol	 19,264,213±5,304,469	 6/6	(100)	 1,086,784	 1/5	(20)	 0.0074	
21.49_1-hexanol	 9,815,680±1,630,312	 6/6	(100)	 1,390,976	 1/5	(20)	 0.0094	
16.13_3-hydroxy-2-butanone	 586,330,283±228,375,228	 6/6	(100)	 51,949,568	 1/5	(20)	 0.0102	
14.20_pentanal	 NA	 0	 3,171,936±948,957	 4/5	(80)	 0.0164	
28.14_phenol	 94,737,920±38,409,969	 6/6	(100)	 10,213,824±4,825,243	 5/5	(100)	 0.0213	
20.56_N-benzyloxy-2-
carbomethoxyaziridine	 1,950,768±208,789	 4/6	(67)	 NA	 0	 0.0251	
16.19_1-butanol,	2-methyl-	 15,589,760±3,725,321	 4/6	(67)	 NA	 0	 0.0252	
28.64_benzyl	alcohol	 900,372±244,350	 4/6	(67)	 NA	 0	 0.0252	
24.89_1-heptanol	 1,750,160±470,750	 4/6	(67)	 NA	 0	 0.0253	
31.41_2-decanone	 2,483,344±817,373	 4/6	(67)	 NA	 0	 0.0253	
26.66_dimethyl	sulfone	 477,776	 1/6	(17)	 1,608,052±508,239	 4/5	(80)	 0.0371	
19.62_butanoic	acid	 493,524,992±176,378,555	 6/6	(100)	 120,535,603±91,190,829	 5/5	(100)	 0.0440	
11.90_1-propanol,	2-methyl-	 4,374,101±1,094,815	 6/6	(100)	 1,078,432±323,635	 2/5	(40)	 0.0465	
P-values	were	calculated	according	to	Student’s	t-test	with	the	significant	level	of	p<0.05.	These	p-values	have	not	been	corrected	for	multiple	comparisons.		
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Figure	 5.18	 A	 PCA	 biplot	 for	 the	 diarrhoea	 samples	 from	 MgSO4-treated	 mice	
compared	 to	 the	 colon	 contents	 from	 day	 8	 of	 DSS-colitis.	 The	 first	 principal	
component	 (67.32%	 of	 the	 total	 variation)	 has	 been	 plotted	 against	 the	 second	
principal	 component	 (9.92%	of	 the	 total	variation).	The	PCA	was	performed	using	
the	20	significant	compounds	from	Table	5.6.	
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5.6 SUMMARY	OF	RESULTS	
	
1. Significant	weight	loss	combined	with	a	significant	increase	in	both	DAI	and	
histological	 inflammation	score	at	day	8	confirmed	the	onset	of	acute	DSS-
induced	colitis.	This	was	followed	by	a	recovery	at	day	11	characterised	by	
an	increase	in	body	weight	and	a	significant	decrease	in	DAI	and	histological	
inflammation	score.		
	
2. There	were	 a	 total	 of	 95	VOCs	 identified	 in	 the	HS	 of	 the	 colonic	 content	
collected	upon	necropsy	at	days	0	(n=11),	5	(n=11),	8	(n=10)	and	11	(n=8)	of	
acute	 DSS-colitis.	 Acid,	 alcohol	 and	 aldehydes	 compounds	 were	 the	 most	
common	 compound	 classes	 identified	 across	 all	 time	 points	 with	 the	
chemical	 composition	 not	 appearing	 to	 vary	 dramatically	 between	 the	
different	time	points.	A	significant	decrease	in	the	average	number	of	VOCs	
at	day	8	compared	to	day	0	was	also	found.		
	
3. Using	these	46	VOCs,	a	PCA	was	plotted	to	examine	the	clustering	of	each	
time	point	according	to	the	abundance	of	these	significant	compounds.	This	
PCA	provided	results	that	suggest	that	the	VOC	profile	changes	according	to	
the	different	time	points	tested	during	the	development	of	acute	DSS	colitis.		
	
4. A	 one-way	 ANOVA	 found	 46	 compounds	 that	 significantly	 varied	 in	
abundance	during	the	development	of	acute	colitis.	Of	these,	32	significantly	
decreased	in	the	presence	of	colitis	(days	5	&	8),	compared	to	days	0	and	11,	
and	14	significantly	increased.	Multiple	comparison	p-value	correction	found	
9	 compounds	 which	 remained	 significantly	 different:	 propanal,	 2-butanol,	
butanal,	 heptanal,	 ethanol,	 2-pentanol,	 3-methyl-butanoic	 acid,	 3-hydroxy-
2-butanone	and	3-methyl-furan.	A	heatmap	presented	these	differences	 in	
abundance	of	VOCs	visually.		
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5. NFκB2	null	mice	were	resistant	 to	acute	DSS-induced	colitis.	Unexpectedly,	
the	faecal	VOC	profile	of	these	mice	was	dissimilar	to	both	the	DSS	treated	
C57BL/6	mice,	and	the	untreated	control	groups.		
	
6. MgSO4-induced	diarrhoea	was	observed	1-2	hours	after	administration	with	
a	high	FOI	at	3	hours	which	was	significantly	higher	than	untreated	controls.	
However,	 there	 was	 no	 significant	 difference	 found	 between	 the	 average	
number	of	VOCs	 identified	 in	untreated	 controls	 and	MgSO4-treated	mice.	
Based	on	the	significantly	different	VOCs	by	abundance,	a	PCA	was	able	to	
clearly	separate	untreated	and	MgSO4-treated	faecal	samples.		
	
7. Day	 8	 acute	 DSS-colitis	 compared	 to	 3-hour	 post-	 MgSO4	 administration	
found	a	 significant	decrease	 in	 average	number	of	VOCs	 in	MgSO4	 treated	
mice.	 There	were	 a	number	of	VOCs	 absent	 in	MgSO4-diarrhoea	but	were	
ubiquitous	 to	 the	 DSS-diarrhoea	 samples,	 implying	 potential	 markers	 of	
inflammation-driven	diarrhoea.	When	considering	the	abundance	of	specific	
VOCs,	 comparison	 between	 these	 two	 groups	 also	 indicate	 VOCs	 as	
potential	markers	for	the	presence	of	diarrhoea,	not	specific	to	 IBD.	A	PCA	
demonstrated	this	separation	based	on	the	VOC	profiles.		
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5.7	DISCUSSION	
	
There	 have	 been	 several	 studies	 that	 have	 applied	 a	 metabolomics	 approach	 to	
discriminate	 IBD	 patients	 from	 healthy	 controls,	 CD	 from	 UC	 and	 patients	 with	
active	 disease	 from	 patients	 in	 remission	 [131,	 242,	 280].	 As	 a	 result,	 the	
involvement	 of	 the	 gut	 microbiota	 in	 the	 chronic	 mucosal	 immune	 activation	
underlying	the	pathogenesis	of	IBD	has	become	more	acceptable	and	has	led	to	an	
increased	 interest	 and	 use	 of	 faecal	 samples	 to	 apply	 to	 metabolomics	 profiling	
studies.	 However,	 to	 date	 there	 have	 been	 few	 studies	 investigating	 the	 VOCs	
present	in	the	faeces	of	IBD	patients	and	murine	models	[65].	
	
HS-SPME-GC-MS	was	performed	using	the	colonic	luminal	contents	from	mice	with	
DSS-induced	colitis.	The	clinical	and	histological	features	observed	in	this	study	are	
consistent	 	 earlier	 studies	 of	 this	 model	 of	 IBD	 [132,	 133].	 The	 pathological	
appearance	of	the	colon	tissue	at	days	5	and	8	represented	the	damage	induced	by	
oral	administration	of	the	DSS	molecules.	An	increase	in	body	weight,	an	absence	of	
diarrhoea	and	pathological	 improvements	between	day	8	and	11	suggest	that	this	
model	 of	 colitis	 also	 has	 a	 recovery	 phase.	 This	 study	 has	 detected	 compounds	
whose	levels	significantly	vary	along	the	development	of	colitis,	indicating	that	the	
pathogenesis	 of	 colitis	 causes	 variations	 in	 the	murine	 faecal	metabolome.	 It	 has	
been	 shown	 that	 the	 faecal	 volatile	 metabolomic	 profiles	 significantly	 vary	
according	 to	 the	 stage	 of	 colitis	 with	 specific	 compounds	 responsible	 for	 these	
differences	being	grouped	into	the	organic	compound	classes,	aldehydes,	alcohols	
and	 furans.	 In	 addition,	 the	 levels	 of	 nitrogen	 and	 sulphur	 containing,	 fatty	 acids	
and	esters	are	all	at	significantly	lower	levels	with	the	presence	of	colitis,	compared	
to	 the	 untreated	 and	 recovery	 phases	 of	 colitis.	 These	 VOC	 profile	 changes	
correspond	with	the	clinical	and	pathological	differences.		
	
A	PCA	plot	based	on	the	46	significant	compounds	illustrated	differences	among	the	
normal	(day	0),	acute	(days	5-8)	and	recovery	(day	11)	phases	of	DSS-induced	colitis	
(Figure	5.9).	Upon	dissection	of	the	PCA	plot,	it	was	revealed	from	the	loadings	plot	
that	 several	 compounds	 strongly	 influenced	 the	 separation	 of	 each	 time	 point,	
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including	 2-butanol,	 methyl-ketones	 and	 esters.	 Furthermore,	 based	 on	 the	 9	
compounds	identified	as	highly	significant	between	healthy	and	colitis	(Table	5.3),	a	
heatmap	using	a	hierarchical	clustering	method	provided	visual	evidence	for	these	
differences	between	the	time	points	tested	of	acute	DSS-colitis.			
	
It	 has	 been	 reported	 that	 the	 characteristic	 changes	 in	 the	 levels	 of	 compounds	
occurring	 during	 acute	DSS-induced	 colitis	 are	 a	 result	 of	 the	 disturbance	 of	 lipid	
and	energy	metabolism.	Shiomi	et	al.	 found	a	significant	decrease	 in	 the	 levels	of	
tricarboxylic	 acid	 (TCA)	 cycle	 intermediates	 in	 the	 serum	and	colon	 tissue	of	DSS-
treated	mice	 as	 a	 result	 of	 a	 higher	 energy	 demand	 due	 to	 a	 decline	 in	 nutrient	
absorption	through	the	damaged	intestine	[282].	The	TCA	cycle,	 lying	at	the	heart	
of	 cellular	 metabolism,	 occurs	 within	 the	 mitochondria	 and	 is	 a	 sequence	 of	
chemical	 reactions	used	by	all	 aerobic	organisms	 to	 generate	energy	 through	 the	
oxidation	 of	 acetate	 derived	 from	 carbohydrates,	 fats	 and	 proteins	 into	 CO2	 and	
chemical	energy	in	the	form	of	ATP.	This	study	has	resulted	in	a	significant	decrease	
in	 the	 levels	of	alcohols	 in	combination	with	a	significant	 increase	 in	 the	 levels	of	
aldehydes	 in	 the	 presence	 of	 colitis.	 The	 higher	 energy	 demand	 during	 the	
development	of	DSS-colitis	will	see	an	increase	in	glucose	breakdown	to	pyruvate,	
releasing	free	energy	to	form	the	required	high	energy	compounds	ATP	and	NADH.	
Consequently,	 there	 is	 an	 increased	 breakdown	 of	 pyruvate	 into	 acetate	 with	
aldehydes	occurring	as	biproducts	of	this	reaction,	offering	an	explanation	for	the	
observed	increase	in	levels	of	aldehydes	in	the	presence	of	colitis.		
	
Glutamine	is	considered	one	of	the	primary	sources	of	amino	acids	in	the	intestinal	
mucosa,	 having	 a	 central	 role	 in	 colonocyte	 nutrition	 and	 integrity	 [288].	 It	 has	
recently	 been	 reported	 that	 the	 oral	 administration	 of	 glutamine	 after	 the	
pathogenesis	of	DSS-colitis	significantly	decreases	the	severity	of	disease,	therefore	
exerting	 a	 therapeutic	 effect	 on	 colitis	 [282].	 Under	 normal	 conditions,	 it	 is	 a	
precursor	for	the	synthesis	of	amino	acids,	proteins	and	nucleotides,	conversely,	it	
has	been	demonstrated	that	the	tissue	glutamine	metabolism	increases	markedly	in	
many	stressful	disease	states.	A	decrease	 in	 the	nitrogen-	and	sulphur-containing,	
fatty	acids,	esters	and	alcohol	compounds	could	be	explained	by	the	decrease	in	the	
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essential	 amino	 acids,	 including	 glutamine.	 This	 decrease	 in	 amino	 acids	 is	
demonstrated	 by	 a	 recent	 study	 investigated	 the	 metabolic	 effects	 of	 DSS	 on	
intestinal	 epithelial	 cells	using	 1H-NMR.	They	were	able	 to	 show	 that	Caco-2	 cells	
incubated	with	DSS	 inhibits	alanine	synthesis	with	a	3	fold	decrease,	compared	to	
untreated	cells	[289].	Glutamine	is	converted	to	alanine	in	the	intestine,	therefore	
the	 decrease	 in	 glutamine	 identified	 in	 the	 colon	 tissue	 explains	 the	 observed	
decrease	of	alanine	[290].			
	
Additionally,	the	levels	of	ROS	are	increased	in	the	presence	of	DSS-induced	colitis,	
therefore	playing	a	vital	role	in	the	pathogenesis	of	this	disease	[291].	Damiani	et	al.	
made	the	interesting	finding	that	a	marker	of	lipoperoxidation	is	increased	in	DSS-
treated	rats	[292].	Lipid	peroxidation	is	a	chain	reaction,	initiated	by	the	removal	of	
hydrogen	 atoms	 via	 the	 production	 of	 ROS,	 resulting	 in	 end-products	 including	
hydrocarbons	such	as	ethane	and	pentane,	but	also	aldehydes	[293].	The	number	
and	 levels	of	aldehydes	compounds	 identified	 in	 the	headspace	of	colon	contents	
from	DSS-treated	mice	 in	 this	 study	 increased	 at	 day	 5/8.	 However,	 there	was	 a	
noticeable	decrease	in	the	number	of	alkanes	detected	at	day	5/8,	ethane	was	not	
identified	and	pentane	was	significantly	decreased	at	day	5/8,	compared	to	day	0.		
	
The	distal	colon	is	characterised	by	an	anaerobic	microbiota	with	an	abundance	of	
metabolically	active	bacteria,	 constantly	 interacting	with	 the	host’s	epithelial	 cells	
and	mucosal	immune	system.	An	altered	microbial	composition	and	function	in	the	
presence	of	 IBD	will	result	 in	an	 increased	 immune	stimulation,	an	epithelial	 layer	
dysfunction	leading	to	enhanced	mucosal	permeability	[294].	It	has	been	postulated	
that	changes	in	the	composition	of	the	microbiota	contributes	to	the	pathogenesis	
of	DSS-induced	colitis	[108].	Hence,	the	differences	noted	in	this	study	according	to	
stage	of	colitis	may	be	a	direct	result	of	the	changes	in	the	gut	luminal	environment.		
	
NFκB2	 null	 mice	 have	 previously	 shown	 a	 significant	 reduction	 in	 the	 pro-
inflammatory	 cytokine,	 TNF-α,	 and	 a	 significant	 increase	 in	 the	 levels	 of	 the	 anti-
inflammatory	 cytokine,	 IL-4,	 following	 DSS	 treatment,	 compared	 to	 treated	 WT	
mice	 ([295]	 [54]).	 Therefore,	 the	 resistance	 of	 DSS-induced	 colitis	 observed	 in	
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NFκB2	null	mice	might	be	mediated	by	the	significant	down-regulation	of	TNF-α	and	
the	 up-regulation	 of	 IL-4,	 exerting	 a	 protective	 effect	 against	 inflammation.	 The	
similarity	 of	 the	 faecal	 VOC	 metabolome	 in	 the	 WT	 and	 NFκB2	 null	 untreated	
groups	suggest	that	the	absence	of	the	NFκB2	gene	does	not	significantly	affect	the	
faecal	 metabolome	 during	 health,	 whereas	 the	 administration	 of	 DSS	 to	 mice	
lacking	the	NFκB2	induces	a	significant	change	to	the	faecal	VOC	metabolome.	The	
DSS-treated	NFκB2	 null	 group	behaved	 similarly	when	 considering	 that	 there	was	
no	 significant	 weight	 loss	 and	 an	 absence	 of	 bloody	 diarrhoea.	 However,	 the	
significantly	different	faecal	VOC	metabolome	suggest	that	at	a	metabolite	level	the	
NFκB2	 gene	 has	 a	 role	 to	 play	 in	 the	 pathogenesis	 of	 DSS-induced	 colitis,	 and	
appears	 to	 be	 in	 agreement	 with	 previous	 findings	 [54]	 that	 this	 role	 may	 be	
protective.	This	study	provides	evidence	to	support	the	hypothesis	that	NFκB	does	
have	a	role	to	play	in	the	pathogenesis	of	DSS-induced	colitis,	and	human	IBD.	Using	
experimental	 murine	 models	 of	 colitis	 macrophages	 and	 epithelial	 cells	 isolated	
from	 inflamed	gut	were	positive	 for	 the	 expression	 and	 activation	of	NFκB	 [296].	
The	amount	of	NFκB	 activation	has	also	been	 found	 to	be	 significantly	 correlated	
with	the	severity	of	intestinal	inflammation	[297].		
	
Diarrhoea	 results	 from	 an	 imbalance	 between	 the	 absorptive	 and	 secretory	
mechanisms	in	the	intestinal	tract,	which	is	accompanied	by	an	excess	loss	of	fluid	
in	the	faeces.	MgSO4	is	an	osmotic-acting	laxative	and	has	been	reported	to	induce	
diarrhoea	 by	 increasing	 the	 volume	 of	 intestinal	 content	 through	 prevention	 of	
reabsorption	 of	 water	 [298].	 The	 significant	 decrease	 identified	 between	 the	
average	number	of	VOCs	in	the	day	8	DSS	diarrhoea	and	MgSO4	diarrhoea	samples	
may	be	explained	by	the	higher	content	of	water	and	an	increase	in	colonic	transit	
time	 of	 the	 MgSO4	 samples.	 Through	 the	 identification	 of	 VOCs	 and	 a	 direct	
comparison	between	metabolomic	profiles	of	 faeces	 from	DSS-induced	colitis	and	
MgSO4,	 these	 results	 highlight	 the	 differences	 between	 the	mechanism	 of	 which	
diarrhoea	occurs,	and	the	metabolic	pathways	 involved.	To	our	knowledge,	 this	 is	
the	first	time	this	comparison	has	been	reported.		
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The	extraction	of	VOCs	from	the	HS	of	colonic	luminal	content	of	mice	collected	at	
varying	 times	 during	 the	 development	 of	 DSS-induced	 acute	 colitis	 has	 revealed	
significant	 metabolomic	 profiles.	 This	 has	 provided	 evidence	 that	 this	 method	 is	
capable	 of	 producing	 reproducible	 and	 reliable	 results.	 Together	with	 the	 clinical	
and	 histological	 confirmation,	 these	VOC	 faecal	 profiles	 aid	 investigation	 into	 the	
pathogenesis	of	the	acute	DSS-colitis	murine	model.		
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Chapter	6	
	
VOC	Profiling	of	a	Mouse	Model	of	
Inflammation-Associated	Colorectal	
Cancer	
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6.1	INTRODUCTION	
	
IBD	 is	 a	 chronic	 condition,	 characterised	 by	 acute	 inflammation	 of	 the	 intestine	
followed	 by	 periods	 of	 remission.	 It	 is	 likely	 to	 result	 from	 an	 interaction	 of	
environmental	 risk	 factors	 (e.g.	 smoking,	 diet)	 affecting	 the	 intestinal	microbiota,	
with	 an	 inappropriate	 immune	 response	 often	 but	 not	 only,	 in	 a	 genetically	
predisposed	person.	Despite	many	years	of	extensive	research,	 its	pathogenesis	 is	
poorly	 understood.	 There	 have	 been	 numerous	 animal	 models	 developed	 to	
characterise	the	complexity	of	 IBD.	Oral	exposure	to	DSS	 is	 the	most	widely	used,	
inducing	a	colitis	resembling	UC.	A	single	cycle	of	DSS	induces	acute	inflammation,	
whereas	multiple	cycles	of	DSS	induce	chronic	inflammation	[299].	It	has	previously	
been	reported	that	bacteria	play	a	major	role	in	initiation	of	inflammation	in	acute	
DSS	colitis	but	not	in	chronic	DSS	colitis	[300].	
	
Individuals	 with	 chronic	 IBD	 are	 at	 increased	 risk	 for	 colorectal	 cancer	 (CRC).	
Although	IBD-related	CRC	is	only	responsible	for	less	than	2%	of	all	CRC	cases,	the	
risk	of	developing	CRC	in	IBD	patients	increases	by	0.5-1%	each	year	depending	on	
the	duration	and	extent	of	the	disease	[301].	Furthermore,	 individuals	with	either	
UC	or	CD	and	who	have	a	family	history	of	CRC	have	a	relative	risk	of	2.5	and	3.7	of	
developing	CRC,	respectively,	when	compared	to	IBD	patients	with	no	family	history	
[302].	The	mean	age	of	developing	CRC	in	the	setting	of	IBD	(40	to	50	years)	is	lower	
than	it	is	for	sporadic	CRC	(60	years)	[303].	The	risk	of	developing	CRC	in	the	setting	
of	 IBD	 is	 increased;	 a	 possible	 explanation	 for	 this	 may	 be	 due	 to	 chronic	
inflammation	leading	to	significant	tissue	damage.	This	enhances	the	epithelial	cell	
turnover	of	the	colonic	mucosa,	increasing	the	chance	of	errors	in	DNA	repair	[304].	
The	mechanisms	that	mediate	the	transition	from	intestinal	inflammation	to	cancer	
have	 not	 been	 well	 identified.	 Clinical	 symptoms	 of	 IBD-associated	 CRC	 are	 not	
specific	so	prognosis	is	poor	because	of	delayed	diagnosis.	CRC	usually	arises	from	
dysplasia-associated	 lesions	 following	 a	 progressive	 scenario	 from	 non-dysplastic	
lesions	to	low-grade,	then	to	high-grade	dysplasia	and	ultimately	to	invasive	CRC.		
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Patients	 with	 IBD	 are	 currently	 screened	 for	 dysplasia	 after	 10	 years	 of	 IBD	
diagnosis	and	due	to	the	relatively	young	age	of	such	patients,	attempts	have	been	
made	 to	 stratify	 patients	 at	 the	 greatest	 risk.	 A	 number	 of	 cohort	 studies	 have	
demonstrated	improved	survival	in	patients	with	IBD	undergoing	colonoscopy	[305,	
306].	A	recent	review	of	the	literature	states	that	surveillance	is	now	recommended	
by	 the	 American	 Gastroenterological	 Association	 (AGA),	 the	 American	 College	 of	
Gastroenterology	 (ACG),	 the	 American	 Society	 for	 Gastrointestinal	 Endoscopy	
(ASGE),	and	 the	British	Society	of	Gastroenterology	 (BSG)	 [303].	The	main	goal	of	
surveillance	is	to	detect	the	presence	of	dysplasia,	which	is	associated	with	a	high	
risk	of	CRC.	Therefore,	an	ideal	surveillance	strategy	would	include	a	cost-effective	
and	sensitive	detection	system.	It	is	evident	that	surveillance	significantly	improves	
patient	 survival.	 For	 instance,	 149	 patients	 with	 IBD-associated	 CRC	 included	 23	
who	had	undergone	colonoscopic	surveillance	prior	to	the	discovery	of	CRC,	while	
126	patients	had	not.	When	considering	the	five-year	survival,	100%	of	patients	in	
the	 prior	 surveillance	 group	 survived	 compared	 to	 74%	 in	 the	 non-surveillance	
group	 [307].	 However,	 the	 colonoscopy	 approach	 generally	 suffers	 from	 poor	
patient	compliance,	thus	a	non-invasive	diagnostic	tool	is	desirable.		
	
Increasing	 availability	 of	 high-throughput	 methodologies	 has	 opened	 up	 new	
possibilities	and	has	led	to	the	development	of	a	metabolomics-based	approach	for	
the	early	detection	of	CRC.	The	use	of	metabolomics	applied	in	the	field	of	oncology	
has	the	potential	to	identify	marker	metabolites	specific	for	the	diagnosis	of	certain	
cancers.	In	addition,	metabolomics	may	be	able	to	differentiate	between	harmless	
changes	and	abnormalities	that	precede	the	disease,	allowing	the	detection	of	the	
disease	at	an	early	stage.	Nishiumi	et	al.	recently	performed	a	serum	metabolome	
analysis	using	GC-MS:	the	resulting	model	for	the	prediction	of	CRC	was	composed	
of	 2-hydroxybutyrate,	 aspartic	 acid,	 kynurenine,	 and	 cystamine	 and	 had	 85%	
sensitivity,	specificity	and	accuracy	[308].		
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6.2	HYPOTHESIS	
	
The	 onset	 of	 IBD	 causes	 dysbiosis	 and	 a	 change	 to	 the	 normal	 metabolic	 state.	
Dysplasia	will	lead	to	a	further	change	in	the	metabolome.	This	change	may	be	used	
to	detect	dysplasia	and	offer	a	novel,	cheaper,	non-invasive	method	of	diagnosing	
IBD	and	also	an	effective	screening	tool	for	early	CRC	detection.		
	
6.3	AIMS	
	
1. To	 induce	 chronic	 intestinal	 inflammation	 in	 C57BL/6	WT	 female	mice	 by	
cyclic	oral	administration	of	DSS.	
2. To	 induce	 inflammation-associated	 colorectal	 cancer	 in	 WT	 mice	 by	 i.p.	
administration	of	AOM	and	cycles	of	DSS.		
3. To	investigate	metabolic	differences	by	detecting	VOCs	in	the	headspace	of	
faecal	 samples	 from	murine	models	of	colitis,	 colitis-associated	cancer	and	
untreated	controls.		
	
6.4	METHODS	
	
6.4.1	Experimental	design	
	
6.4.1.1	Induction	of	chronic	colitis	by	DSS	administration	
	
Mice	 were	 administered	 0.75%	 DSS	 (wt/vol)	 in	 their	 drinking	 water	 for	 5	 days,	
followed	by	7	days	of	normal	water.	This	cycle	was	repeated	three	further	times	to	
induce	 chronic	 colitis;	 the	 DSS	 concentration	 increased	 slightly,	 to	 1%,	 for	 cycles	
two	and	three	and	to	1.25%	for	cycle	four.	The	control	group	of	mice	remained	on	
normal	drinking	water	throughout	the	course	of	the	experiment	(n=6	control;	n=6	
treated).	 Clinical	 parameters	 of	 body	 weight	 loss,	 stool	 consistency	 and	 the	
presence	of	rectal	bleeding	were	assessed	daily.	Faecal	samples	were	collected	on	
experimental	days	5,	8	and	11	of	each	cycle.	Animals	were	sacrificed	on	day	45	with	
colonic,	 caecal,	 small	 intestine	 contents	 collected	 and	 stored	 at	 -20°C	 prior	 to	
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analysis	by	GC-MS	and	intestinal	tissues	taken	for	histological	analysis.	MT	stain	was	
used	to	evaluate	the	degree	of	fibrosis,	as	a	method	to	distinguish	between	acute	
and	chronic	colitis.		
	
6.4.1.2	Induction	of	inflammation-associated	colorectal	cancer	using	AOM/DSS		
	
As	described	in	detail	in	Chapter	2,	mice	were	administered	one	dose	of	12.5mg/kg	
AOM	i.p.	Mice	were	then	orally	exposed	to	1.5%	DSS	for	5	days	followed	by	16	days	
of	 ordinary	 water.	 This	 DSS	 cycle	 was	 repeated	 twice	 more	 (or	 just	 twice)	 with	
animals	 sacrificed	12	days	 after	 final	 cycle.	 Faecal	 samples	were	 collected	weekly	
and	stored	at	-20°C	prior	to	analysis	by	GC-MS.	Tissues	were	taken	for	histological	
analysis	 following	 necropsy.	 HID-AB	 staining	 was	 used	 to	 visualise	 pre-malignant	
lesions	in	the	form	of	MDF,	in	sections	of	distal	colonic	tissues.		
	
6.4.2	HS-SPME-GC-MS	sample	preparation	and	analysis		
	
In	 brief,	where	possible,	 130mg	or	 10	pellets	 (maximum	volume)	of	 stool	 sample	
was	 collected	 and	 stored	 in	 2ml	 glass	 vials	 at	 -20°C.	 Prior	 to	 VOC	 extraction,	
samples	were	pre-incubated	for	30	mins	at	60°C	before	compound	extraction	using	
the	solvent	free	SPME	technique	with	a	CAR/PDMS/DVB	fibre	for	20	mins	prior	to	
desorption	 into	 the	GC	oven	 [221].	 For	GC-MS	conditions,	please	 refer	 to	section	
2.6.1.		
	
6.4.3	Data	processing	and	statistical	analysis	
	
All	raw	data	were	processed	and	analysed	as	described	in	Chapter	2.	Briefly,	batch	
reports	are	produced	for	each	dataset	in	AMDIS	and	a	list	of	all	compounds	present	
and	 their	 corresponding	 corrected	 peak	 abundances	 are	 then	 generated	 using	
Metab.	 Compounds	 present	 in	 less	 than	 30%	 of	 at	 least	 one	 condition	 were	
removed.	NA	was	replaced	with	1	and	peak	abundance	was	 log	 transformed,	and	
appropriate	statistical	analysis	(Student’s	t-test	or	two-way	ANOVA)	was	applied:	all	
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p-values	are	corrected	for	multiple	comparison	(Bonferroni).	Hierarchical	clustering	
and	PCA	was	applied	to	illustrate	variation	present	between	groups.	
	
6.5	RESULTS	
	
6.5.1	Clinical	and	histological	confirmation	of	chronic	DSS-induced	colitis	
	
Mice	 were	 administered	 0.75%	 DSS	 (wt/vol)	 in	 their	 drinking	 water	 for	 5	 days,	
followed	by	6	days	of	normal	water.	This	cycle	was	repeated	three	further	times	to	
induce	chronic	colitis	[309].	The	DSS	concentration	was	increased	slightly	to	1%	for	
cycles	two	and	three	and	to	1.25%	for	cycle	four.			
	
Mice	 were	 weighed	 daily	 to	 assess	 the	 degree	 of	 colitis.	 Weight	 loss	 was	 first	
observed	 in	 the	 fourth	 and	 final	 cycle	of	DSS	and	was	 accompanied	by	diarrhoea	
and	rectal	bleeding	(Figure	6.1).	At	necropsy,	the	colons	of	DSS	treated	mice	were	
white	 with	 extreme	 mucosal	 thickening	 and	 decreased	 length	 compared	 to	
untreated	 controls.	 H&E	 stained	 distal	 colon	 tissue	 sections	 showed	 an	
inflammatory	 cell	 infiltrate	 into	 the	 submucosal	 layer	 and	 a	 breakdown	 of	 the	
epithelial	layer	and	crypt	structure	in	the	DSS	treated	mice	(Figure	6.2).	Figure	6.3	
shows	 that	 the	untreated	 controls	were	 free	 from	 inflammation,	 compared	 to	an	
average	 inflammation	 score	 of	 3	 for	 the	 DSS-treated	 group	 (p<0.001,	 Mann-
Whitney	U	test).		
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Figure	6.1	Weight	change	in	mice	undergoing	chronic	DSS	treatment	and	controls.	The	percentage	change	in	the	body	weight	was	
used	to	assess	the	degree	of	colitis.	Data	represented	as	mean±SEM,	n=6/group.	Statistical	differences	at	day	43	were	assessed	by	
Student’s	t-test,	p<0.001***	for	weight	loss	in	the	DSS	treated	group	at	day	43	compared	to	untreated	control.		
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Figure	 6.2	 Representative	 images	 of	 H&E	 stained	 distal	 colonic	 sections	 of	
untreated	controls	and	DSS	 treated	mice.	Mice	were	euthanized	at	experimental	
day	45	since	the	start	of	DSS	treatment	at	day	0.	Arrows	indicate	damaged	crypts	in	
the	 DSS	 treated	 group	 accompanied	 by	 a	 damaged	 epithelium,	 compared	 to	
untreated	controls.		
	
	
Figure	 6.3	 Histological	 (inflammation)	 scores	 of	 DSS-induced	 chronic	 colitis	 in	
mice.	 Inflammation	score	of	distal	colon	taken	from	C57BL/6	mice	at	day	45	from	
chronic	DSS	 treated	and	untreated	 control	 groups.	 Each	dot	 represents	 the	 score	
from	 one	 mouse	 and	 data	 are	 presented	 as	 mean±SEM,	 **p<0.01	 by	 Mann-
Whitney	U	test.		
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6.5.2	Longitudinal	VOC	analysis	of	the	development	of	chronic	colitis	
	
Mice	 were	 sacrificed	 on	 day	 45	 of	 the	 experiment,	 tissues	 excised	 and	 colon	
contents	were	 collected	 for	 extraction	 of	 VOCs	 by	HS-SPME-GC-MS.	 This	 enabled	
the	 direct	 comparison	 of	 VOCs	 present	 in	 the	 headspace	 of	 the	 colon	 luminal	
content	of	chronic	DSS-treated	mice.	Faecal	samples	were	also	collected	during	the	
experiment	 on	 days	 5,	 8	 and	 11	 of	 each	 cycle.	 The	 faecal	 VOC	 profiles	 from	
experimental	days	0,	8,	20,	31,	42	and	45	from	both	untreated	control	and	the	DSS	
treated	groups	were	compared.		
	
One	hundred	and	seventy	VOCs	were	identified	in	two	treatment	groups	during	the	
experiment.	There	was	no	difference	in	the	average	number	of	VOCs	identified	on	
experimental	days	0,	8,	20,	31,	42	and	45	between	the	untreated	control	and	DSS-
treated	 C57BL/6	 mice	 assessed	 by	 a	 two-way	 ANOVA.	 No	 significant	 interaction	
effect	was	found,	indicating	that	when	considering	both	group	and	time,	there	were	
no	significant	differences	with	the	effect	of	time	on	the	number	of	VOCs	for	control	
or	DSS-treated	mice,	F	(5,58)	=	1.44,	p>0.05).	There	was	no	significant	main	effect	
of	group,	F	 (1,	58)	=	2.09,	p>0.05.	This	means	 if	other	dependent	variables	 (time)	
are	 ignored,	 the	 average	 number	 of	 VOCs	 identified	 did	 not	 vary	 significantly	
according	to	disease	group.	There	was,	however,	a	significant	main	effect	of	time,	F	
(5,	58)	=	2.92,	p<0.05.	This	effect	means	 if	 group	 is	 ignored,	 the	number	of	VOCs	
were	different	between	days	0,	8,	20,	31,	42	and	45.	In	order	to	further	investigate	
where	 this	 time	 related	 significant	 difference	 occured,	 a	 Tukey	 HSD	 test	 was	
performed	irrespective	of	group.	The	number	of	VOCs	identified	were	significantly	
lower	at	day	42	compared	to	day	8	(Figure	6.4).		
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Figure	 6.4	 Variation	 in	 the	 presence	 of	 faecal	 VOCs	 during	 the	 development	 of	
chronic	colitis.	The	number	of	VOCs	identified	in	the	headspace	of	the	faecal	pellets	
collected	at	days	0,	 8,	 20,	 31,	 42	and	45	 from	untreated	 control	 and	DSS-treated	
mice.	 Data	 represented	 as	 mean±SEM,	 n=6/group.	 Statistical	 differences	 were	
assessed	 by	 two-way	 ANOVA,	 p<0.05*	 for	 combined	 number	 of	 VOCs	 at	 day	 8	
compared	to	day	42.	 	The	blue	line	 is	the	rolling	average	for	control	mice	and	the	
red	 line	 is	 the	 rolling	 average	 for	 DSS-treated	 mice,	 both	 showing	 the	 trend	 of	
number	of	VOCs	over	time	for	both	groups.	
	
Next,	 the	concentrations	each	compound	were	compared.	Of	the	170	compounds	
identified	across	the	6	time	points	tested,	165	were	found	in	the	DSS	treated	group,	
167	 in	 the	 untreated	 control	 group	 with	 3	 and	 5	 being	 unique	 to	 the	 DSS	 and	
untreated	 group,	 respectively.	 In	 the	 DSS	 treated	 group,	 19	 VOCs	 varied	
significantly	in	abundance	across	days	0,	8,	20,	31,	42	and	45	(ANOVA	followed	by	
Bonferroni,	p<0.05).	A	PCA	plot	using	these	19	compounds	showed	clear	separation	
of	each	time	point,	in	particular	on	day	45	(Figure	6.5).	Eight	of	the	19	compounds	
also	 significantly	 varied	 over	 time	 in	 the	 untreated	 control	 group	 (1-pentanol,	 1-
penten-3-ol,	 2-methyl-propanal,	 1-butanol,	 1-hexanol,	 α-pinene,	 nonanal,	
dodecane);	therefore,	it	was	concluded	that	these	compounds	were	not	specific	to	
chronic	colitis	and	were	dismissed	for	further	analysis	into	VOC	markers	of	chronic	
inflammation.	 In	 addition,	 a	 number	 of	 these	 significant	 compounds	 were	 also	
found	to	significantly	vary	as	healthy	mice	aged	(section	3.5.6).	Consequently,	the	
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11	 remaining	 compounds	 found	 to	 vary	 significantly	 exclusively	 in	 the	DSS	 group	
were	 considered	 as	 potential	 markers	 of	 inflammation	 (Figure	 6.6).	 The	
concentration	 of	 each	 compound	was	 plotted	 to	 illustrate	 how	 the	 profile	 varied	
during	the	development	of	chronic	colitis	in	both	untreated	control	mice	and	DSS-
treated	mice.	Clinically,	the	DSS	treated	mice	showed	signs	of	colitis	between	days	
40	 and	 45	 (time	 points	 10-12);	 acetone,	 propanoic	 acid	 propyl	 ester,	 5-methyl-2-
heptanone,	 2-octanone,	 tetra-methyl-pyrazine,	 1,3-xylene,	 2-acetoxy-3-butanone	
and	 2-decanone	 were	 all	 present	 at	 higher	 concentrations,	 whereas	 2-methyl-
propanal,	hexanal	and	benzene,	1,3-bis	(1-1-dimethylethyl)-	were	present	at	lower	
concentrations	in	the	DSS	treated	faeces	compared	to	the	untreated	control	group.			
	
Figure	 6.5	 A	 PCA	 biplot	 for	 the	 faecal	 pellets	 of	 DSS	 treated	 mice	 from	
experimental	days	0,	8,	20,	31,	42	and	45.	The	PCA	shows	the	variation	within	the	
DSS	group	and	was	performed	using	the	abundance	of	the	19	significant	different	
compounds	over	time	(ANOVA	followed	by	Bonferroni,	p<0.05).	The	last	time	point	
tested,	day	45,	is	circled.		
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Figure	 6.6	 Time	 series	 abundance	 plots	 of	 prominent	 VOCs	 from	 chronic	 DSS-
induced	 colitis	 and	 untreated	 controls.	 The	 mean	 peak	 abundance	 of	 the	 11	
compounds	 found	to	vary	significantly	over	 time	 is	plotted	at	12	time	points	over	
the	space	of	45	days	of	which	mice	were	administered	four	cycles	of	DSS	(red	lines)	
(p<0.05;	ANOVA	followed	by	Bonferroni).	The	concentration	of	each	compound	 in	
the	untreated	control	group	is	also	included	to	compare	VOC	profiles	(black	lines).	
Dashed	lines	represent	the	standard	deviation	(n=6/treatment	group).		
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Figure	 6.6	 continued.	 Time	 series	 abundance	 plots	 of	 prominent	 VOCs	 from	
chronic	DSS-induced	colitis	and	untreated	controls.	The	mean	peak	abundance	of	
the	11	compounds	found	to	vary	significantly	over	time	is	plotted	at	12	time	points	
over	the	space	of	45	days	of	which	mice	were	administered	four	cycles	of	DSS	(red	
lines)	 (p<0.05;	 ANOVA	 followed	 by	 Bonferroni).	 The	 concentration	 of	 each	
compound	in	the	untreated	control	group	is	also	included	to	compare	VOC	profiles	
(black	lines).	Dashed	lines	represent	the	standard	deviation	(n=6/treatment	group).		
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The	distinct	cluster	of	the	DSS	treated	faecal	samples	at	day	45	in	the	top	right	hand	
quarter	 of	 the	 PCA	 plot	 (Figure	 6.5)	 suggests	 that	 the	 VOC	 profile	 is	 capable	 of	
representing	 a	 change	 in	 disease	 state.	 We	 have	 identified	 potential	 markers	 of	
both	 acute	 and	 chronic	 inflammation	 during	 the	 development	 of	 colitis	 by	
administration	of	1-4	cycles	of	DSS,	therefore,	the	VOC	profile	observed	at	day	45	
was	 then	 directly	 compared	 to	 the	 untreated	 control	 group	 (Figure	 6.7	 and	 6.8).	
Although	there	appears	to	be	more	variation	within	each	sample	group,	there	were	
14	 significantly	 different	 compounds	 between	 the	 two	 groups	 and	 when	 plotted	
using	 a	 PCA,	 the	 separation	 was	 clear	 (Student’s	 t-test	 followed	 by	 Bonferroni,	
p<0.05).	 Eight	 of	 these	 14	 were	 present	 at	 significantly	 higher	 levels	 in	 the	 DSS	
treated	group	compared	to	untreated	controls,	4	were	absent	in	the	DSS	group,	and	
2	were	 absent	 in	 the	 untreated	 control	 group	 (Figure	 6.8).	 Benzene,	 1,	 3-bis(1,1-
dimethylethyl)-	significantly	varied	over	time	in	the	DSS-treated	group	and	was	also	
found	to	be	significantly	different	at	day	45	between	the	DSS-treated	group	and	the	
control	group.		
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Figure	 6.7	 A	 PCA	 biplot	 for	 the	 faecal	 pellets	 of	 DSS	 treated	mice	 compared	 to	
untreated	control	mice	at	experimental	day	45.	The	first	principal	component	has	
been	 plotted	 against	 the	 second	 principal	 component.	 The	 PCA	 was	 performed	
using	 the	 abundance	of	 the	 14	 significant	 different	 compounds	 between	 the	 two	
groups	(Student’s	t-test	followed	by	Bonferroni,	p<0.05)	(Figure	6.8).		
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Figure	 6.8	 Bar	 plots	 of	 the	 peak	 abundance.	 Comparison	 of	 compound	
concentrations	at	day	45	between	untreated	control	and	DSS	treated	mice	resulted	
in	 14	 significantly	 different	 compounds	 (Student’s	 t-test	 followed	 by	 Bonferroni,	
(p<0.05)).	 Data	 are	 expressed	 as	mean±SEM	peak	 abundance	 for	 each	 significant	
compound.		
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6.5.3	Histological	differences	between	acute	and	chronic	DSS-induced	colitis		
	
Clinical	 and	 histological	 analyses	 have	 previously	 confirmed	 the	 presence	 of	 both	
acute	(section	5.5.1)	and	chronic	 (section	6.5.1)	DSS-induced	colitis.	Distal	colonic	
sections	taken	from	mice	induced	with	both	acute	and	chronic	mice	were	evaluated	
for	 the	degree	of	 fibrosis	using	 the	MT	method.	A	 tissue	section	was	also	stained	
with	H&E	at	the	same	time	to	directly	compare	the	degree	of	inflammation	(Figure	
6.10).		In	order	to	quantify	the	amount	of	fibrosis	in	acute	colitis,	chronic	colitis	and	
untreated	 control	mice,	 an	 accredited	murine	 pathologist	 assessed	 each	 slide	 for	
the	degree	of	 fibrosis	and	the	percent	of	tissue	 in	which	 it	was	present;	a	 fibrosis	
score	was	 then	given	 to	each	animal	based	on	 the	sum	of	 these	 two	parameters.	
The	 fibrosis	 score	 was	 higher	 in	 the	 chronic	 colitis	 mice	 compared	 to	 the	 acute	
colitis	mice	and	significantly	higher	than	the	untreated	control	group	(p<0.01,	Mann	
Whitney	U).	
	
Figure	6.9	Histological	fibrosis	score.	Fibrosis	score	of	distal	colonic	tissue	sections	
stained	 with	 MT	 stain	 from	 mice	 induced	 with	 acute	 and	 chronic	 colitis,	 also	
compared	to	untreated	controls.	The	fibrosis	score	for	each	animal	is	the	sum	of	the	
degree	of	fibrosis	score	and	the	percent	involvement.	Each	dot	represents	a	score	
from	one	mouse	and	data	are	presented	as	mean±SEM	**p<0.01	by	Mann-Whitney	
U	test.	
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Figure	 6.10	 Evaluation	 of	 fibrosis.	Representative	 images	 of	 distal	 colon	 sections	
from	 untreated	 controls	 and	 DSS	 treated	 mice	 with	 either	 chronic	 or	 acute	
inflammation.	Slides	were	stained	using	the	MT	method	to	evaluate	the	amount	of	
fibrosis,	and	H&E	to	assess	the	degree	of	inflammation.		
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6.5.4	 Significantly	different	 faecal	VOC	profiles	between	acute	 and	 chronic	DSS-
induced	colitis	
	
Clinical	and	histological	analysis	confirmed	induction	of	acute	and	chronic	colitis	in	
the	 respective	 groups.	 Significantly	 different	 VOC	 profiles	 were	 found	 in	 each	
condition.	 The	 specific	 VOCs	 responsible	 for	 the	 differences	 observed	 during	 the	
development	of	acute	colitis	and	between	control	and	chronic	colitis	were	not	the	
same.	With	acute	colitis,	there	was	a	significant	increase	in	the	levels	of	aldehydes	
and	a	decrease	in	alcohols.	Chronic	colitis	was	associated	with	a	significant	increase	
in	 the	 bacterial	 products,	 methyl-ketones,	 and	 also	 carboxylic	 acids.	 A	 direct	
comparison	between	day	11	acute	and	day	45	chronic	colitis	showed	a	significant	
increase	 in	 the	number	of	 compounds	 identified	 in	 chronic	 (75±1.5)	 compared	 to	
acute	colitis	(49±4.0)	(mean±SEM,	t-test,	p<0.001)	(Figure	6.11A).	The	levels	of	2,3-
butandione	 (FC=49.2),	 2-heptanone	 (FC=37.8)	 and	 acetone	 (FC=20.7)	 were	 all	
significantly	increased	in	chronic	compared	to	acute	colitis	with	a	notable	absence	
of	 1-butanol	 in	 chronic	 colitis	 and	 an	 absence	 of	 2-acetoxy-3-butanone,	 2,4,6-
trimethyl-octane	 and	 7-ethyl-5-methyl-6,8-dioxabicyclo[3.2.1]oct-3-ene	 in	 acute	
colitis.	 Nonanal	 and	 2-octanone	were	 identified	 in	 only	 one	 sample	 of	 the	 acute	
colitis	group	compared	to	100%	of	the	chronic	colitis	group	with	109.7	and	93.4	fold	
increase,	 respectively,	 in	 chronic	 compared	 to	 acute	 colitis	 (Table	 6.1).	 A	 PCA	
showed	 the	 separation	of	 acute	and	 chronic	 colitis	 based	on	 the	 significant	VOCs	
present	in	the	headspace	of	the	colonic	content	(Figure	6.11B).		
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Figure	6.11	Comparison	of	VOC	profiles	from	mice	with	acute	and	chronic	colitis.	
(A)	The	number	of	VOCs	identified	in	the	headspace	of	the	colon	contents	collected	
at	 the	 final	 day	 of	 the	 acute	 (n=8)	 and	 chronic	 (n=6)	 colitis	 experiments	
(mean±SEM,	Student’s	t-test,	***p<0.001).	(B)	A	PCA	biplot	with	the	first	principal	
component	 plotted	 against	 the	 second	 principal	 component	 representing	 88.32%	
and	 4.2%	 of	 the	 variation,	 respectively.	 The	 PCA	 was	 performed	 using	 the	 11	
significant	compounds	from	Table	6.1.		
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Table	6.1	List	of	the	11	significantly	different	compounds	detected	in	the	HS	of	colon	content	samples	from	mice	with	acute	(day	11)	and	
chronic	(day	45)	colitis,	by	SPME-GC-MS.			
RT_compound	
Presence	(%)	 Abundance	(mean±SEM)	
	 	Acute	
(n=8)	
Chronic	
(n=6)	 Acute	 Chronic	 Fold	change	 P-value	
7.41_acetone	 100	 100	 53,674,496±2,930,049	 1,111,553,365±453,789,761	 20.7	↑	 0.0002	
10.28_2,3-butanedione	 100	 100	 13,116,448±3,853,211	 645,977,429±263,719,181	 49.2	↑	 0.0002	
10.32_furan,	3-methyl-	 100	 100	 1,192,496±248,478	 7,458,304±3,044,840	 6.3	↑	 0.0069	
13.44_1-butanol	 87.5	 NA	 22,807,776±13,397,620	 NA	 Absent	in	chronic	 0.0289	
20.53_1,3-xylene	 100	 100	 1,080,292±240,972	 6,910,976±2,821,394	 6.4	↑	 0.0018	
22.11_2-heptanone	 100	 100	 5,919,840±1,607,085	 223,645,696±91,302,973	 37.8	↑	 0.0014	
22.61_2-acetoxy-3-butanone	 NA	 100	 NA	 41,806,037±17,067,243	 Absent	in	acute	 0.0000	
25.57_2-octanone	 12.5	 100	 266,689	 24,915,968±10,171,901	 93.4	↑	 0.0078	
27.53_7-ethyl-5-methyl-6,8-
dioxabicyclo[3.2.1]oct-3-ene	 NA	 100	 NA	 17,735,040±7,240,300	 Absent	in	acute	 0.0000	
29.57_nonanal	 12.5	 100	 62,867	 6,893,781±2,814,374	 109.7	↑	 0.0058	
39.63_octane,	2,4,6-trimethyl-	 NA	 100	 NA	 3,434,837±1,402,266	 Absent	in	acute	 0.0000	
P-values	were	calculated	according	to	a	Student’s	t-test,	corrected	for	multiple	comparison	by	Bonferroni	and	performed	on	log-transformed	data	(p<0.05).	Fold	
change	shows	an	increase	(↑)	or	decrease	(↓)	of	the	average	peak	abundance	of	each	compound	in	the	acute	colitis	group,	compared	to	chronic	colitis.	
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6.5.5	Pre-malignant	changes	in	an	inflammation-associated	CRC	model	
	
C57BL/6	 female	mice	 (n=6)	were	 housed	 individually	 and	were	 administered	 one	
dose	of	12.5mg/kg	AOM.	This	was	followed	by	oral	exposure	to	1.5%	DSS	for	5	days	
followed	 by	 16	 days	 of	 ordinary	 water.	 This	 DSS	 cycle	 was	 repeated	 twice	 with	
animals	 being	 sacrificed	 12	 days	 after	 final	 cycle.	 There	 were	 2	 control	 groups	
included	 in	 the	 analysis:	 an	 untreated	 control	 group	 (n=6)	 and	mice	 treated	with	
cycles	of	DSS	alone	(chronic	colitis)	(n=6).	Faecal	samples	were	collected	weekly	and	
tissues	were	 taken	 for	 histological	 analysis	 upon	 necropsy.	 After	 treatment,	 DSS-
treated	mice	weighed	significantly	less	than	the	untreated	mice	with	a	difference	of	
17.7±4.3%,	9.1±2.7%	and	11.2±1.6%	on	days	13,	34	and	57,	respectively	(Student’s	
t-test;	 mean±SEM)	 (Figure	 6.12).	 This	 weight	 loss	 was	 accompanied	 by	 mild	
diarrhoea.	 The	 AOM/DSS	 inflammation-associated	 CRC	 model	 is	 expected	 to	
produce	 large	 colonic	 tumours,	 however	 inspection	 of	 the	 colon	 at	 necropsy	
showed	no	tumours.	Tissues	were	prepared	for	histological	examination	for	signs	of	
pre-malignancy.		
	
All	 animals	 treated	with	 AOM/DSS	 showed	 signs	 of	 pre-malignancy,	 visualised	 by	
HID/AB	 staining	 of	 colonic	 sections.	 Signs	 included	 hyperplasic	 and	 occasionally	
dysplastic	crypts	and	were	assessed	for	the	number	of	MDF	by	both	the	author	and	
an	accredited	murine	pathologist	(Figure	6.13).	The	criterion	used	to	define	an	MDF	
is	described	 in	section	2.4.6.	There	were	significantly	more	MDF	 in	 the	AOM/DSS	
treated	group	compared	to	the	DSS-alone	treated	group	with	3.7±0.7	and	1.2±0.2	
MDF	 identified	 respectively	 (mean±SEM,	 Student’s	 t-test,	 p<0.05);	 no	MDF	 were	
identified	in	untreated	control	mice	(Figure	6.14).	
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Figure	6.12	Weight	loss	of	DSS/AOM	treated	mice	compared	to	untreated	control.	
The	 change	 in	 the	 body	weight	 (%)	 of	mice	was	measured	 daily	 during	 each	DSS	
cycle.	Data	are	represented	as	mean±SEM,	n=6/group.	Statistical	differences	were	
assessed	 by	 Student’s	 t-test,	 p<0.01**	 for	 weight	 loss	 in	 the	 AOM/DSS	 treated	
group	at	days	13	and	57,	p<0.001***	at	day	34	compared	to	untreated	control.		
	
	
	
Figure	 6.13	 Representative	 images	 of	 HID/AB	 stained	 distal	 colonic	 section	 for	
untreated	 controls,	 AOM/DSS	 and	 DSS-alone	 treated	 mice	 (x20	 magnification).	
The	untreated	control	group	and	the	AOM/DSS	treated	group	were	euthanized	at	
experimental	 day	 64	 and	 the	 DSS-alone	 treated	mice	were	 euthanized	 at	 day	 45	
since	the	start	of	DSS/AOM	treatment	at	day	0.	The	arrow	indicates	damaged	crypts	
in	the	AOM/DSS	treated	group	accompanied	by	a	damaged	epithelium,	compared	
to	untreated	controls.		
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Figure	 6.14	 Number	 of	 MDF/colon.	 Identification	 of	 morphologically	 distinctive	
pre-invasive	 mucosal	 lesions,	 MDF,	 characterised	 by	 dysplastic	 crypts	 devoid	 of	
mucins.	The	number	of	MDF/colon	was	significantly	higher	in	the	AOM/DSS	treated	
mice	 compared	 to	 the	 DSS-alone	 treated	 mice	 (n=6/group;	 Student’s	 t-test,	
p<0.05*).		
	
6.5.6	VOC	profiles	as	indicators	of	early	lesions	in	murine	colitis	associated		CRC		
	
In	the	first	instance,	the	faecal	VOC	profiles	were	compared	between	the	AOM/DSS	
group	and	untreated	controls.	Faecal	pellet	samples	collected	from	each	animal	and	
samples	 from	experimental	weeks	 1,	 4,	 7	 and	 10	were	 compared.	 A	 total	 of	 138	
VOCs	 were	 identified	 across	 the	 four	 time	 points	 from	 both	 groups;	 the	 largest	
number	of	VOCs	identified	was	at	week	4,	in	both	groups,	and	the	lowest	at	week	
10.	A	two-way	ANOVA	found	a	significant	effect	of	time,	F(3,	40)	=	29.20,	p<0.001,	
but	 no	 significant	 interaction	 effect	 or	 main	 effect	 of	 group	 was	 found.	 This	
suggests	that	if	group	is	ignored,	the	number	of	VOCs	was	different	between	weeks	
1,	 4,	 7	 and	 10.	 In	 order	 to	 further	 investigate	where	 this	 time	 related	 significant	
difference	 occurs,	 a	 Tukey	 HSD	 test	 was	 performed	 irrespective	 of	 group.	 The	
number	of	VOCs	identified	were	significantly	lower	at	week	1	and	week	7	compared	
to	week	4,	and	week	10	compared	to	weeks	1,	4	and	7	(Figure	6.15).				
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The	 abundance	 of	 47	VOCs	 varied	 significantly	with	 time,	 in	 the	AOM/DSS	 group	
(ANOVA	 followed	 by	 Bonferroni,	 p<0.05).	 A	 PCA	 using	 these	 47	 VOCs	 shows	 the	
difference	between	week	1	and	week	10	(Figure	6.16).			
	
	
Figure	 6.15	 Variation	 in	 the	 number	 of	 faecal	 VOCs	 identified	 during	 the	
development	of	 inflammation-driven	CRC.	 The	number	 of	 VOCs	 identified	 in	 the	
headspace	of	 the	 faecal	pellets	 collected	at	weeks	1,	 4,	 7	 and	10	 from	untreated	
control	 and	AOM/DSS	 treated	mice.	Data	 represented	 as	mean±SEM,	n=6/group.	
Statistical	 differences	were	 assessed	 by	 two-way	ANOVA,	p<0.01**	 for	 combined	
number	of	VOCs	from	the	untreated	control	and	AOM/DSS	treated	groups	between	
weeks	1,	4,	7	and	10.	The	green	line	is	the	rolling	average	for	the	untreated	control	
group	 and	 the	 blue	 line	 is	 the	 rolling	 average	 for	 AOM/DSS	 treated	 mice,	 both	
showing	the	trend	of	number	of	VOCs	over	time	for	both	groups.	
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Figure	 6.16	 A	 PCA	 biplot	 for	 the	 faecal	 pellets	 of	 AOM/DSS	 treated	mice	 from	
weeks	1,	4,	7	and	10.	The	PCA	shows	the	variation	within	the	AOM/DSS	group	and	
was	 performed	 using	 the	 abundance	 of	 the	 47	 significantly	 different	 compounds	
(p<0.05;	 ANOVA	 followed	 by	 Bonferroni).	 The	 last	 time	 point	 tested,	week	 10,	 is	
circled.	
	
Faecal	 VOC	 analysis	 at	 week	 10	 yielded	 93	 compounds,	 11	 of	 which	 were	
significantly	different	between	the	two	groups	(Student’s	t-test,	p<0.01).	A	PCA	plot	
was	able	to	clearly	distinguish	between	untreated	and	treated	mice	based	on	VOCs	
present	in	the	HS	of	faecal	samples,	using	all	VOCs	and	when	just	using	those	VOCs	
that	significantly	varied	between	the	two	groups,	as	shown	in	Figure	6.17.		Of	these	
significantly	 different	 compounds	 found	 to	 vary	 between	 treated	 and	 untreated	
mice	at	the	end	time	point,	10	were	increased	and	one	(propanoic	acid,	2-methyl-,	
anhydride)	decreased	 (Figure	6.18).	 The	10	compounds	 found	 to	be	higher	 in	 the	
AOM/DSS	treated	group	were	either	aldehydes,	or	ketones.		
	223	
	
	
	
Representative	chromatograms	from	week	10	clearly	show	these	differences	in	the	
presence	 or	 levels	 of	 peaks,	 which	 correlate	 to	 the	 11	 significantly	 different	
compounds	and	 their	 absence	or	decrease	 in	untreated	 controls.	 For	example,	 2-
heptanone,	 5-methyl-2-heptanone,	 6-methyl-2-heptanone,	 2H-pyran-2-one,	
tetrahydro-	and	benzeneacetaldehyde	(Figure	6.19).		
	
	
	
Figure	6.17	A	PCA	biplot	for	the	faecal	pellets	of	AOM/DSS	treated	mice	compared	
to	untreated	control	mice	at	experimental	week	10.	The	PCA	was	performed	using	
the	abundance	of	the	11	significantly	different	compounds	between	the	two	groups	
(Student’s	t-test	followed	by	Bonferroni,	p<0.05).	
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Figure	6.18	Box	plots	of	the	peak	abundance	(log	scale)	of	the	significantly	different	compounds.	A	Student’s	t-test,	followed	by	Bonferroni	
multiple	 comparison	 correction,	 was	 performed	 between	 AOM/DSS	 treated	 and	 untreated	 control	 groups	 and	 found	 11	 compounds	 to	
significantly	vary	across	time	(p<0.05).		
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Figure	6.19	Representative	chromatograms	from	experimental	week	10.	This	demonstrates	the	differences	in	peaks	between	an	untreated	
control	faecal	sample	compared	to	a	AOM/DSS	mouse	sample.	A	number	of	the	significant	VOCs	are	highlighted	(Student’s	t-test,	p<0.05).		
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In	order	to	further	explore	the	differences	between	the	VOC	profiles	from	weeks	1,	
4,	 7	 and	 10	 of	 untreated	 and	AOM/DSS	 treated	mice,	 a	 heat	map	was	 produced	
using	 cluster	 analysis	using	 the	75	 significantly	different	VOCs	 (found	by	 two-way	
ANOVA,	using	the	time-series	metabolomics	online	tool,	MetAtt	[225]	(Figure	6.20).	
	
Figure	 6.20	 Heat	 map	 representing	 hierarchical	 clustering	 of	 75	 compounds	
identified	 in	 the	 faeces	of	 untreated,	 and	AOM/DSS	 treated	mice	 at	 4	 different	
time	points	(weeks	1,	4,	7,	and	10).	The	untreated	control	group	is	indicated	by	the	
purple	 left-hand	 panel	 and	 the	 AOM/DSS	 treated	 group	 is	 indicated	 by	 the	 blue	
right-hand	 side	 panel.	 Columns	 represent	 individual	 murine	 faecal	 samples	 and	
rows	 refer	 to	 distinct	 compounds.	 Shades	 of	 red	 represent	 an	 increase	 in	
concentration	 of	 a	 compound	 and	 shades	 of	 blue	 represent	 a	 decrease	 in	
concentration	of	a	compound.	
	
	 	
High	
concentration
Low	
concentration
Untreated	control AOM/DSS	treated
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In	 order	 to	 demonstrate	 that	 the	 markers	 of	 pre-malignancy	 are	 specific	 to	 the	
presence	of	malignant	changes,	and	are	not	markers	of	chronic	 inflammation,	the	
VOC	profiles	from	week	10	of	AOM/DSS	treated	mice	was	directly	compared	to	day	
45	 chronic	 DSS	 only	 treated	mice.	 26	 compounds	were	 significantly	 different;	 10	
were	increased	in	the	chronic	colitis	group	and	16	in	the	 inflammation-carcinogen	
group	(Table	6.2).	A	PCA	plotted	using	these	significant	compounds	is	able	to	clearly	
distinguish	between	the	two	groups	(Figure	6.21).		
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Table	6.2	List	of	the	26	significantly	different	compounds	detected	in	the	HS	of	faecal	pellet	samples	from	mice	treated	with	AOM/DSS	by	
SPME-GC-MS.			
RT_compound	 Presence	(%)	 Abundance	(mean±SEM)	 	DSS		 AOM/DSS		 DSS	 AOM/DSS	 P-value	
6.61_ethanol	 100	 100	 480,156,331±159,522,185	 61,950,123±15,761,211	 0.0085	
7.21_propanal	 33.3	 100	 12,402,048±4,704,010	 9,047,637±2,182,796	 0.0264	
7.49_dimethyl	sulfide	 66.7	 0	 8,266,224±3,912,603	 NA	 0.0256	
7.61_isopropanol	 100	 100	 66,871,467±14,796,772	 24,212,651±4,510,725	 0.0098	
9.57_1-propanol	 100	 100	 49,677,483±21,472,805	 12,274,517±2,101,616	 0.0373	
10.56_2-butanone	 100	 100	 843,795,797±206,663,769	 214,717,099±26,504,314	 0.0231	
11.90_1-propanol,	2-methyl-	 100	 33.3	 4,458,453±618,098	 6,742,400±2,252,276	 0.0275	
14.20_pentanal	 0	 100	 NA	 53,717,504±23,817,831	 0.0000	
16.46_3-penten-2-one	 0	 66.7	 NA	 9,268,224±4,831,905	 0.0255	
16.58_toluene	 16.7	 83.3	 1,805,056	 7,846,246±1,360,117	 0.0132	
17.57_2,3-hexanedione	 0	 66.7	 NA	 140,064,768±17,121,344	 0.0251	
18.51_2-butenal,	3-methyl-	 83.3	 16.7	 3,547,341±331,371	 6,165,248±2,097,536	 0.0206	
20.53_1,3-xylene	 100	 100	 6,910,976±893,127	 37,793,621±6,930,503	 0.0003	
20.96_2-hexanal	 33.3	 100	 4,039,168±275,946	 4,722,987±1,232,157	 0.0248	
21.07_2-n-butyl	furan	 0	 66.7	 NA	 6,226,656±2,097,536	 0.0253	
21.49_4-heptanone,	3-methyl-	 16.7	 83.3	 9,399,296	 39,231,693±12,556,693	 0.0142	
22.61_2-acetoxy-3-butanone	 100	 33.3	 41,806,037±16,909,092	 23,981,056±2,528,000	 0.0237	
24.10_3-heptanone,	6-methyl-	 66.	7	 0	 27,705,344±14,418,736	 NA	 0.0259	
25.25_2,3-octanedione	 16.7	 100	 4,801,536	 23,892,480±5,321,259	 0.0025	
25.52_3-octanone	 83.3	 16.7	 23,896,883±5,517,636	 20,142,080	 0.0179	
27.01_6,8-dioxabicyclo[3.2.1]octane,	7-ethyl-5-
methyl-,	(1R-exo)-	 66.7	 0	 6,995,456±319,122	 NA	 0.0250	
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Table	6.2	continued.		 	 	 	 	 	
28.14_phenol	 100	 16.7	 45,255,168±29,198,521	 2,038,038,52	 0.0130	
30.96_dodecane	 0	 100	 NA	 20,571,605±8,629,327	 0.0000	
31.41_2-hexanone,	5-methyl-	 0	 83.3	 NA	 2,467,853±707,320	 0.0251	
33.74_benzene,	1,	3-bis(1,1-dimethylethyl)-	 0	 100	 NA	 75,492,864±35,440,076	 0.0000	
37.06_Undecane,	4,7-dimethyl-	 50	 100	 1,919,808±276,549	 7,936,299±2,148,834	 0.0456	
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Figure	6.21	A	PCA	biplot	for	the	faecal	pellets	of	AOM/DSS	treated	mice	compared	
to	DSS	alone	treated	mice.	The	PCA	was	performed	using	the	abundance	of	the	26	
significantly	 different	 compounds	 between	 the	 two	 groups	 (Student’s	 t-test	
followed	by	Bonferroni,	p<0.05).	
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6.6	SUMMARY	OF	RESULTS	
	
1. After	 4	 cycles	 of	 DSS,	 chronic	 colitis	 was	 induced	 as	 characterised	 by	
significant	weight	loss	and	histological	changes.	Analysis	of	the	longitudinal	
faecal	 VOC	 profile	 found	 significant	 differences	 compared	 to	 untreated	
healthy	 control	 mice.	 There	 were	 specific	 VOCs	 associated	 with	 chronic	
colitis;	these	were	5-methyl-2-heptanone,	2-octanone	and	2-decanone.		
	
2. There	 was	 significantly	 more	 fibrosis	 in	 mice	 treated	 with	 chronic	 DSS	
compared	 to	 those	given	acute	DSS	 treatment	only.	The	clinical	difference	
was	associated	with	significantly	different	VOC	profiles.		
	
3. Administration	of	a	single	dose	of	AOM	followed	by	3	cycles	of	1.5%	DSS	did	
not	result	in	the	induction	of	distal	colonic	tumours,	but	was	associated	with	
pre-malignant	MDF	lesions,	as	visualised	by	HID/AB.		
	
4. There	was	a	significant	increase	in	the	abundance	and	prevalence	of	methyl	
ketones	 and	 aldehydes	 in	 AOM/DSS	 treated	mice	 compared	 to	 untreated	
controls.	Furthermore,	the	specific	compounds	were	associated	with	either	
the	AOM/DSS	or	the	DSS	groups	and	may	be	markers	of	pre-malignancy.	
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6.7	DISCUSSION	
	
This	 study	 has	 demonstrated	 that	 HS-SPME-GC-MS	 analysis	 can	 be	 used	 to	
differentiate	VOC	profiles	 of	 healthy	untreated,	 chronic	 colitis	 and	CRC	AOM/DSS	
treated	 murine	 faecal	 samples.	 Potential	 markers	 for	 chronic	 intestinal	
inflammation	and	the	presence	of	very	early	stage	CRC	as	well	as	possible	markers	
of	disease	progression	were	 identified.	Even	early	 lesions	of	colitis-associated	CRC	
were	associated	with	significant	metabolic	alterations	in	the	faeces	of	mice	treated	
with	AOM/DSS.		
	
Among	 the	 chemically-induced	 CRC	models,	 the	 combination	 of	 a	 single	 dose	 of	
AOM	with	1-week	exposure	 to	DSS	 in	 rodents	has	proven	to	dramatically	shorten	
the	latency	time	for	induction	of	CRC	and	to	rapidly	recapitulate	the	aberrant	crypt	
foci–adenoma–carcinoma	sequence	that	occurs	in	human	CRC.	This	study	used	this	
CRC	model	 and	 identified	morphologically	distinctive	pre-invasive	mucosal	 lesions	
to	help	elucidate	the	early	steps	of	CRC,	which	included	the	characterisation	of	so-
called	MDF,	formed	by	dysplastic	crypts	devoid	of	mucins	[310].	
	
There	 were	 specific	 VOCs	 identified	 in	 AOM/DSS	 treated	 mice,	 which	 had	
premalignant	changes	in	the	colon,	including	3-(methylthio)-propanal,	2-nonenal,	3-
hexanone	and	6-methyl-2-heptanone.	In	addition,	markers	of	chronic	inflammation	
were	found,	including	ethanol,	3-methyl-2-butenal,	3-octanone,	2-butanone	and	2-
acetoxy-3-butanone.	Overproduction	of	ROS	combined	with	the	occurrence	of	lipid	
peroxidation	 has	 been	 widely	 proposed	 as	 a	 possible	 mechanism	 for	 intestinal	
inflammation	 of	 the	mucosa	 and	 intestinal	 lumen.	 An	 increase	 in	 the	 number	 of	
ROS	 causes	 an	 increase	 in	 toxic	 VOCs,	 including	 aldehydes	 and	 alkanes,	which	 in	
turn	have	a	toxic	effect	on	the	surrounding	tissue	[311].	Further	work	to	investigate	
whether	 or	 not	 these	 markers	 that	 we	 have	 identified	 are	 markers	 of	 oxidative	
stress	or	markers	of	alternative	metabolic	pathways	associated	with	CRC	(e.g.	those	
involved	in	the	transformation	from	normal	epithelium	to	benign	neoplasia	[312]),	
would	 include	 taking	 an	 in	 vitro	 approach.	A	 recent	 review	has	 identified	 current	
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challenges	 in	 the	 investigations	 of	 VOCs	 as	 potential	 cancer	 biomarkers	 and	 this	
approach	shows	the	rationale	for	further	study	[313].		
	
A	 recent	 study	 was	 able	 to	 demonstrate	 the	 use	 of	 travelling	 wave	 ion	mobility	
mass	 spectrometry	 (TWIMMS)	 technology	 as	 a	 fast	 and	 efficient	 method	 for	
metabolomics	profiling	of	human	CRC	[314].	The	authors	discovered	alterations	 in	
fatty	 acid	 biosynthesis	 and	 oxidative,	 glycolytic,	 and	 polyamine	 pathways	 that	
distinguish	 tumours	 from	 non-malignant	 colonic	 epithelium	 as	 well	 as	 various	
stages	of	CRC.	In	addition,	 it	has	been	shown	recently	that	a	study	using	selected-
ion	 flow-tube	mass	 spectrometry	 (SIFT-MS)	was	 able	 to	 correctly	 classify	 samples	
into	either	high	 risk	or	 low	risk	of	developing	CRC	with	a	 specificity	of	78%	and	a	
sensitivity	of	72%	[315].		
	
Overall,	data	produced	from	this	study	combined	with	previous	studies	suggest	that	
a	 difference	 can	be	predicted	between	 faecal	 samples	 from	 individuals	 or	 animal	
models	with	CRC	compared	to	healthy	control	samples,	based	on	their	VOC	profile.	
A	 multivariate	 predictive	 method	 of	 modelling	 this	 data	 may	 enable	 the	
development	 of	 a	 predictive	 tool	 to	 be	 used	 in	 a	 clinical	 setting	 to	 determine	
whether	 or	 not	 individuals	 are	may	 already	 have	 preneoplasia,	 and	 are	 at	 risk	 of	
developing	CRC.		
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Chapter	7	
	
VOC	Profiling	of	a	Sporadic	Colon	
Cancer	Murine	Model
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7.1	INTRODUCTION	
	
CRC	 is	 the	 fourth	most	common	cancer	 [67]	and,	with	more	 than	600,000	deaths	
annually,	 it	 is	 the	 second	 leading	 cause	of	 cancer	 related	death	 in	 both	men	and	
women	 in	 the	 UK	 [316].	 CRC	 often	 evolves	 over	 a	 number	 a	 years,	 therefore	
providing	a	window	of	opportunity	 for	early	detection.	However,	 the	prognosis	of	
CRC	 for	 many	 patients	 is	 poor	 due	 to	 late	 detection	 and,	 despite	 the	 growing	
evidence	 to	 support	 an	 increased	 understanding	 of	 the	 pathogenesis	 of	 CRC,	
reliable	 disease-specific	 biomarkers	 for	 screening	 and	 surveillance	 are	 lacking.	
There	are	currently	no	reliable	markers	 for	early	diagnosis	of	CRC	or	 its	precursor	
lesions,	and	therefore	this	remains	an	overwhelming	challenge	[317].		
	
As	 previously	 described,	 there	 is	 an	 increased	 risk	 of	 developing	 CRC	 associated	
with	the	duration	and	extent	of	IBD	[56].	However,	most	CRC	occurs	independent	of	
IBD	 and	 is	 directly	 influenced	 by	 diet,	 genetic	 and	 environmental	 factors	 [318].	
Individuals	who	do	not	have	a	 family	history	of	CRC	or	adenomas,	or	a	history	of	
non-polyposis	 syndromes	 or	 IBD	 are	 classified	 as	 having	 sporadic	 CRC.	
Approximately	 75%	of	 patients	 have	 sporadic	 CRC	with	 no	 known	 risk	 factors	 for	
their	disease	[319].	
	
In	England,	all	men	and	women	aged	60-74	are	invited	to	carry	out	an	FOB	test	at	
home	to	check	for	the	presence	of	blood	in	a	stool	sample	as	a	way	of	screening	for	
early	signs	of	CRC	[320].	While	non-invasive	stool-based	screening	tests	are	used	for	
the	 early	 detection	 of	 CRC	 concerns	 have	 been	 raised	 about	 their	 sensitivity	 and	
specificity.	 Thus,	 as	 previously	 mentioned,	 there	 is	 an	 opportunity	 for	 the	
development	of	 a	metabolomics-based	approach	 to	 the	non-invasive	diagnosis	 of	
CRC.	Metabolomics	 involves	 the	 comprehensive	 profiling	 of	 low	MW	 compounds	
emitted	from	biological	samples	or	fluids,	and	has	been	used	to	classify	CRC	on	the	
basis	 of	 tumour	 classification	 [321],	 to	 identify	 new	 diagnostic	 or	 prognostic	
markers	 [322]	 and	 to	 discover	 new	 targets	 for	 future	 therapeutic	 interventions	
[323].		
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Understanding	 the	metabolome	 of	 human	 CRC	will	 also	 provide	 insights	 into	 the	
critical	metabolic	pathways	 involved	 in	CRC.	Montrose	et	al.	 determined	whether	
metabolic	changes	can	be	detected	in	the	faeces	and	plasma	during	AOM-induced	
CRC	 using	 ultra-performance	 liquid	 chromatography	 tandem	 mass	 spectrometry	
(UPLC/MS/MS)	 and	 GC/MS.	 They	 were	 able	 to	 provide	 evidence	 that	 CRC	 was	
associated	 with	 significant	 metabolic	 alterations	 in	 both	 the	 faeces	 and	 plasma,	
including	 elevated	 levels	 of	 sarcosine	 in	 the	 faeces,	 and	 increased	 levels	 of	 2-
hydroxyglutarate	in	the	plasma	[324].	Here,	we	use	HS-SPME-GC-MS	to	investigate	
the	metabolic	odorous	‘smell’	emitted	from	faeces	of	a	AOM-induced	CRC	model.		
	
7.2	HYPOTHESIS	
	
The	hypotheses	were:	
• The	induction	of	sporadic	CRC	will	cause	a	significant	change	to	the	faecal	
VOC	profile	of	mice	compared	to	untreated	controls.	
• The	VOCs	responsible	for	these	changes	will	be	different	to	those	identified	
as	markers	of	inflammation-associated	CRC.		
	
7.3	AIMS	
	
1. To	determine	the	appropriate	dose	of	AOM	to	induce	sporadic	CRC.		
2. To	determine	whether	metabolic	changes	can	be	detected	in	the	faeces	
during	AOM-induced	CRC.		
3. To	investigate	whether	the	tumour	was	a	potential	source	for	altered	levels	
of	metabolites	in	faeces.		
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7.4	METHODS	
	
7.4.1	Experimental	design		
 
7.4.1.1	Induction	of	sporadic	colorectal	cancer	using	AOM	
	
Briefly,	 female	 C57BL/6	 mice	 were	 given	 6	 injections	 (I.P.)	 of	 12.5mg/kg	 AOM	
solution	once	a	week	over	the	first	6	weeks	of	the	experiment.	Faecal	samples	were	
collected	once	a	week	until	week	30	when	mice	were	 sacrificed	and	 colons	were	
assessed	 for	 tumours.	 A	 pilot	 study	 was	 performed	 using	 a	 control	 and	 AOM-
treated	group	(n=4/group)	in	order	to	investigate	the	outcome	of	using	12.5mg/kg	
of	AOM	(ended	at	week	20	due	to	profuse	rectal	bleeding).	This	was	followed	by	a	
subsequent	study	using	n=6	mice	in	each	group	as	a	repeat	study	which	continued	
until	week	30.				
	
7.4.2	HS-SPME-GC-MS	
	
In	brief,	where	possible,	10	pellets	of	stool	sample	was	collected	and	stored	in	2ml	
glass	 vials	 at	 -20°C.	 Prior	 to	 VOC	 extraction,	 samples	 were	 pre-incubated	 for	 30	
mins	at	60°C	before	compound	extraction	using	 the	 solvent	 free	SPME	 technique	
with	a	CAR/PDMS/DVB	fibre	for	20	mins	prior	to	desorption	into	the	GC	oven	[221].	
For	GC-MS	conditions,	please	refer	to	section	2.6.1.		
	
7.4.3	Data	processing	and	statistical	analysis		
	
All	raw	data	were	processed	and	analysed	as	described	in	Chapter	2.	Briefly,	batch	
reports	 were	 produced	 for	 each	 dataset	 in	 AMDIS	 and	 a	 list	 of	 all	 compounds	
present	and	 their	 corresponding	corrected	peak	abundances	was	generated	using	
Metab.	 Compounds	 present	 in	 less	 than	 30%	 of	 at	 least	 one	 condition	 were	
removed.	NA	was	replaced	with	1	and	peak	abundance	was	 log	 transformed,	and	
appropriate	statistical	analysis	(Student’s	t-test	or	two-way	ANOVA)	was	applied:	all	
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p-values	are	corrected	for	multiple	comparison	(Bonferroni).	Hierarchical	clustering	
and	PCA	was	applied	to	illustrate	variation	present	between	groups.		
	
7.5	RESULTS	
	
7.5.1	Pilot	Study:	measurement	of	distal	colonic	tumours	
	
In	 order	 to	 monitor	 the	 health	 of	 the	 animals,	 mice	 were	 weighed	 daily	 and	
percentage	 body	 weight	 loss	 was	 determined.	 Unlike	 the	 observations	 of	 mice	
treated	with	DSS	alone	and	 in	combination	with	AOM,	 in	which	mice	 lost	weight,	
the	weight	 of	 AOM-alone	 treated	mice	 remained	 stable	 or	 increased	 throughout	
the	experiment	(Figure	7.1).	Between	weeks	14	and	20,	the	weight	of	the	untreated	
control	 group	 continued	 to	 increase	 whereas	 the	 weight	 plateaued	 in	 the	 AOM	
treated	group	with	a	significant	difference	at	week	16	(p<0.05,	t-test).	At	week	16,	
rectal	bleeding	was	also	observed	in	the	AOM	treated	animals,	which	may	explain	
the	 difference	 in	 weight,	 so	 the	 decision	 was	 made	 to	 end	 the	 experiment	
prematurely	at	week	20,	before	the	planned	end	at	week	30.		
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Figure	 7.1	 Weight	 change	 in	 mice	 undergoing	 sporadic	 AOM	 treatment	 and	
controls	 (Pilot	 Study).	 Data	 represented	 as	 mean±SEM,	 n=4/group.	 Statistical	
differences	were	assessed	by	Student’s	t-test	at	each	week,	p<0.05*	for	weight	loss	
in	the	AOM	treated	group	at	week	16	only	compared	to	untreated	control.		
	
In	 this	 pilot	 study,	 all	 mice	 in	 the	 AOM	 treated	 group	 (n=4)	 received	 6	 doses	 of	
12.5mg/kg	AOM;	3	mice	developed	colonic	tumours	but	in	1	no	tumour	was	found	
(Table	7.1).	Tumours	were	mainly	located	within	the	distal	and	middle	thirds	of	the	
colon,	as	shown	in	Figure	7.2.	These	locations	correlate	with	previous	findings	[325]	
and	 imply	 that	 the	protocol	was	effective	 [144].	Microscopic	examination	of	H&E	
stained	 colonic	 sections	 found	 that	 the	 tumours	 were	 mainly	 broad-based	
adenomas	and	they	did	not	penetrate	the	muscularis	mucosa	(Figure	7.3).	
	
Table	7.1	Tumour	load	analysis.		
Animal	I.D.	 Treatment	 Number	of	tumours	
Average	tumour	size	
(mm)	
5	 6	x	i.p.	12.5	mg/kg	 1	 3	
6	 6	x	i.p.	12.5	mg/kg	 0	 0	
7	 6	x	i.p.	12.5	mg/kg	 5	 2.6	
8	 6	x	i.p.	12.5	mg/kg	 2	 5	
Number	of	visible	colonic	tumours	per	mouse	following	sporadic	tumour	induction	using	
AOM	and	the	average	tumour	size.		
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Figure	7.2	Representative	 gross	 images.	Macroscopic	 view	of	 longitudinally	 open	
colon	mice	following	tumour	induction	by	AOM	treatment.	A	scaled	ruler	was	used	
to	 measure	 the	 size	 of	 the	 formed	 tumours	 (yellow	 arrows	 indicate	 visible	
tumours).		
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Figure	 7.3	 Representative	 H&E	 stained	 colonic	 sections	 from	 mice	 following	
tumour	induction	using	AOM.	Histology	of	colonic	tumours	in	sections	(Swiss	roll)	
at	20x	objective	magnification	(arrows	indicate	the	formed	polyps).		
 
7.5.2	Pilot	Study:	metabolomics	VOC	profile	of	AOM-induced	colonic	tumours	
	
A	 total	of	208	VOCs	were	 identified	 in	 the	 faecal	pellets	 from	both	groups	across	
weeks	1,	5,	10,	15	and	20.	Comparison	of	 the	average	number	of	VOCs	 identified	
across	time,	and	between	treatment	group,	found	no	significant	interaction	effect,	
indicating	 that	 there	 is	 no	 significant	 differences	 in	 the	 effect	 of	 time	 on	 the	
number	of	VOCs	 for	control	or	AOM-treated	mice,	F	 (4,20)	=	0.30,	p>0.05).	There	
was	 also	 no	 significant	 main	 effect	 of	 group,	 F	 (1,	 20)	 =	 3.24,	 p>0.05.	 However,	
there	was	a	significant	main	effect	of	time,	F	(4,	20)	=	8.45,	p<0.001;	the	number	of	
VOCs	identified	were	significantly	lower	at	weeks	15	and	20	compared	to	weeks	1,	5	
and	10	in	both	groups	(ANOVA	followed	by	Tukey	HSD	test,	p<0.01)	(Figure	7.4).		
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Figure	7.4	Number	of	faecal	VOCs	identified	during	the	treatment	of	AOM	in	the	
Pilot	Study.	The	number	of	VOCs	 identified	 in	 the	headspace	of	 the	 faecal	pellets	
collected	 at	weeks	 1,	 5,	 10,	 15	 and	 20	 from	 untreated	 control	 and	 AOM	 treated	
mice.	 Data	 represented	 as	 mean±SEM,	 n=6/group.	 Statistical	 differences	 were	
assessed	by	 two-way	ANOVA,	p<0.01**	 for	 combined	number	of	VOCs	 compared	
between	weeks	1	and	15,	1	and	20,	5	and	15,	5	and	20,	10	and	15,	and	10	and	20.		
The	green	line	is	the	rolling	average	for	the	untreated	control	group	and	the	orange	
line	is	the	rolling	average	for	AOM-treated	mice,	both	showing	the	trend	of	number	
of	VOCs	over	time	for	both	groups.	
	
A	two-way	ANOVA	was	then	performed	to	identify	variations	between	groups	over	
time	according	 to	 the	 concentration	of	 each	of	 the	208	VOCs.	 There	were	only	 8	
compounds	 found	 to	 vary	 significantly	 over	 time	 when	 comparing	 the	
concentrations	 between	 the	 untreated	 control	 and	 the	 AOM-treated	 groups.	 Of	
these	significant	VOCs,	2,2,4,-tetramethyloctane,	2,2,4,6,6-pentamethylheptane,	D-
limonene	and	cyclopentane	were	only	present	 in	the	AOM-treated	group	at	week	
10	 (p<0.001),	 isopropanol	 (p<0.001)	 and	 5-hydroxy-4-octanone	 (p<0.05)	 were	
present	at	 significantly	higher	 concentrations,	whereas	1,3-xylene	 (p<0.01)	and	2-
ethyl-1-hexanol	 (p<0.05)	were	present	at	 significantly	 lower	concentrations	 in	 the	
untreated	 control	 group	 at	 week	 10	 (MetAtt).	 A	 heat	 map	 illustrates	 the	 total	
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variation	of	 the	208	VOC	 identified	between	both	groups	and	how	they	vary	over	
time	 from	week	 1	 to	week	 20	 (Figure	 7.5).	 These	 results	 indicate	 that	 there	 is	 a	
change	in	VOC	profile	at	week	10,	which	also	corresponds	with	the	plateau	in	the	
weight	loss	in	the	AOM-treated	group.		
	
Analysis	 of	 the	 VOCs	 present	 across	 both	 groups	 at	 the	 end	 time	 point	 was	
performed.	 At	 week	 20	 one	 compound	 was	 significantly	 different	 between	 the	
untreated	 control	 and	AOM-treated	groups;	 1,3-difluoro-2-propanone	was	 absent	
in	the	control	group	and	in	all	four	samples	at	24,909,824±12,511,196	in	the	AOM-
treated	 group	 (mean±SEM,	 Student’s	 t-test).	 A	 PCA	was	produced	using	 the	 total	
208	 VOCs	 but	 resulted	 in	 poor	 separation	 of	 the	 two	 groups,	 which	 may	 be	
explained	by	 the	 small	 n	 number	 (n=3	untreated	control,	 n=4	AOM-treated	mice)	
(Figure	7.6).		
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Figure	7.5	Hierarchical	clustering.	A	heat	map	representing	hierarchical	clustering	
of	 the	VOCs	 identified	 across	 the	 five	different	 time	points	of	AOM-induced	CRC.	
Sample	 classes	 are	 indicated	 by	 the	 coloured	 bars	 (AOM-treated	 mice	 =	 yellow,	
untreated	control	=	grey).	Columns	represent	individual	murine	faecal	samples	and	
rows	 refer	 to	 distinct	 compounds.	 Shades	 of	 red	 represent	 an	 increase	 in	
concentration	 of	 a	 compound	 and	 shades	 of	 blue	 represent	 a	 decrease	 in	
concentration	of	a	compound.		
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Figure	7.6	A	PCA	biplot	 for	 the	 faecal	pellets	of	AOM-treated	mice	compared	to	
untreated	 control	 mice	 at	 experimental	 week	 20	 in	 the	 Pilot	 Study.	 The	 first	
principal	 component	 has	 been	 plotted	 against	 the	 second	 principal	 component	
representing	30.87%	and	20.53%	of	 the	 total	variation,	 respectively.	The	PCA	was	
performed	using	the	abundance	of	the	136	VOCs	present	at	week	20.		
	
7.5.3	Repeat	Study:	measurement	of	distal	colonic	tumours	
	
As	the	Pilot	Study	resulted	in	the	successful	induction	of	distal	colonic	tumours,	the	
method,	including	the	AOM	concentration,	used	for	the	repeat	study	was	an	exact	
replica	 of	 the	 Pilot	 Study	 but	 with	 n=6	 mice	 in	 each	 group.	 The	 only	 difference	
between	the	two	studies	was	that	the	repeat	study	continued	until	week	30,	rather	
than	week	20.		
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The	 weight	 of	 the	 AOM-treated	 group	 continued	 to	 increase	 alongside	 the	
untreated	control	group.	There	was	a	significant	difference	in	body	weight	at	weeks	
18,	20	and	24;	however	this	was	not	accompanied	by	rectal	bleeding	(Figure	7.7).	
Upon	dissection	of	the	intestines,	there	was	an	absence	of	distal	colonic	tumours,	
which	was	unexpected.	Possible	reasons	to	explain	this	may	be	that	the	AOM	dose	
was	too	low	or	that	there	was	variation	between	the	different	litters	of	the	C57BL/6	
mouse	strain	causing	one	to	have	a	low	susceptibility.		
	
	
Figure	 7.7	 Weight	 change	 in	 mice	 undergoing	 sporadic	 AOM	 treatment	 and	
controls	 (Repeat	 Study).	 Data	 represented	 as	 mean±SEM,	 n=6/group.	 Statistical	
differences	were	assessed	by	Student’s	t-test	at	each	week,	p<0.05*	for	weight	loss	
in	the	AOM	treated	group	at	weeks	18,	20	and	24	compared	to	untreated	control.		
	
7.5.4	Repeat	Study:	metabolomics	VOC	profile	of	AOM-induced	colonic	tumours	
	
Although	 this	 study	 did	 not	 result	 in	 the	 induction	 of	 distal	 colonic	 tumours,	 as	
expected,	 the	 faecal	 samples	 still	 underwent	 analysis	 for	 the	 detection	 of	 VOCs.	
There	were	207	VOCs	were	identified	in	the	faecal	pellets	from	both	groups	across	
weeks	1,	8,	15,	23	and	30,	similar	to	the	208	in	the	Pilot	Study.	The	number	of	VOCs	
at	 each	 group	 also	 followed	 a	 similar	 pattern	 with	 the	 lowest	 number	 of	 VOCs	
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identified	towards	the	end	of	the	experiment.	Comparison	of	the	average	number	
of	 VOCs	 produced	 the	 same	 pattern	 as	 found	 in	 the	 Pilot	 Study;	 there	 was	 no	
significant	 interaction	effect,	F	 (4,30)	=	0.39,	p>0.05),	no	significant	main	effect	of	
group,	F	(1,	30)	=	0.99,	p>0.05,	and	a	significant	main	effect	of	time,	F	(4,	30)	=	3.83,	
p<0.01.	When	grouping	 the	untreated	 control	 and	AOM	 treated	groups	 together,	
the	 number	 of	 VOCs	 identified	 were	 significantly	 lower	 at	 week	 1	 compared	 to	
week	15,	week	8	compared	to	week	15,	week	30	compared	to	week	15,	and	week	
30	compared	to	week	23	(ANOVA	followed	by	Tukey	HSD	test,	p<0.01)	(Figure	7.8).		
	
	
Figure	7.8	Number	of	faecal	VOCs	identified	during	the	treatment	of	AOM	in	the	
Repeat	Study.	The	number	of	VOCs	identified	in	the	headspace	of	the	faecal	pellets	
collected	 at	weeks	 1,	 8,	 15,	 23	 and	 30	 from	 untreated	 control	 and	 AOM	 treated	
mice.	 Data	 represented	 as	 mean±SEM,	 n=6/group.	 Statistical	 differences	 were	
assessed	by	 two-way	ANOVA,	p<0.01**	 for	 combined	number	of	VOCs	 compared	
between	weeks	1	and	15,	8	and	15,	15	and	30,	and	23	and	30.		The	green	line	is	the	
rolling	 average	 for	 the	 untreated	 control	 group	 and	 the	 orange	 line	 is	 the	 rolling	
average	 for	 AOM-treated	mice,	 both	 showing	 the	 trend	 of	 number	 of	 VOCs	 over	
time	for	both	groups.	
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Unlike	 the	 Pilot	 Study,	 a	 multivariate	 quantitative	 analysis	 performed	 on	 this	
dataset	 showed	no	 significant	differences	between	 the	 concentrations	of	 the	207	
VOCs	between	the	untreated	control	and	AOM-treated	groups	(MetAtt).	The	heat	
map	demonstrates	this	by	showing	similar	VOC	profiles	over	time	for	both	groups	
(Figure	 7.9).	 Furthermore,	 the	 analysis	 of	 VOCs	 at	week	 30	 resulted	 in	 only	 four	
significantly	 different	 compounds;	 1-cyclopropyl-1-propanone	 and	 3-methylbutyl	
ester-butanoic	 acid	 are	 absent	 in	 the	 AOM-treated	 group,	 and	 toluene	 and	 2-
butanol	 were	 increased	 in	 AOM	 compared	 to	 the	 untreated	 control	 group	
(Student’s	 t-test,	 p<0.05).	 A	 PCA	 was	 produced	 using	 the	 total	 207	 VOCs,	 which	
were	not	able	to	differentiate	samples	according	to	AOM	treatment	(Figure	7.10).		
	
	
Figure	7.9	Hierarchical	clustering.	As	with	the	Pilot	Study,	a	heat	map	representing	
hierarchical	clustering	of	 the	VOCs	 identified	across	 the	 five	different	 time	points.	
Sample	 classes	 are	 indicated	 by	 the	 coloured	 bars	 (AOM-treated	 mice	 =	 yellow,	
untreated	control	=	grey).	Columns	represent	individual	murine	faecal	samples	and	
rows	 refer	 to	 distinct	 compounds.	 Shades	 of	 red	 represent	 an	 increase	 in	
concentration	 of	 a	 compound	 and	 shades	 of	 blue	 represent	 a	 decrease	 in	
concentration	of	a	compound.		
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Figure	7.10	A	PCA	biplot	for	the	faecal	pellets	of	AOM-treated	mice	compared	to	
untreated	 control	mice	 at	 experimental	week	 30	 in	 the	 Repeat	 Study.	 The	 first	
principal	 component	 has	 been	 plotted	 against	 the	 second	 principal	 component	
representing	26.43%	and	18.59%	of	 the	 total	variation,	 respectively.	The	PCA	was	
performed	using	the	abundance	of	the	163	VOCs	present	at	week	30.		
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7.6	SUMMARY	OF	RESULTS	
	
1. Following	AOM	administration	mice	developed	distal	 colonic	 tumours	with	
slightly	different	faecal	VOC	profiles	from	week	15	to	week	20.		
2. Unfortunately	the	repeat	study	did	not	yield	the	anticipated	results	as	there	
were	 no	 distal	 colonic	 tumours	 present.	 Therefore,	 a	 more	 susceptible	
mouse	strain	would	ideally	be	used	in	future	experiments	to	produce	more	
reliable	 results	when	 using	AOM	 to	 induce	 CRC	with	 high	 penetrance	 and	
low	mortality.		
	
7.7	DISCUSSION	
	
The	objective	of	this	study	was	to	provide	strong	rationale	for	carrying	out	human	
studies	with	the	goal	of	both	defining	the	metabolic	changes	that	occur	in	tumour	
tissue	 during	 CRC	 and	 possibly	 identifying	metabolites	 in	 faeces	 that	 reflect	 CRC.	
However,	the	study	did	not	produce	the	expected	results.	AOM	is	known	for	being	
very	 reliable	 in	 inducing	 CRC	 with	 high	 penetrance	 in	 highly	 susceptible	 mouse	
strains	with	3-10	tumours	 in	80-100%	of	animals	with	a	mortality	rate	below	10%	
[144].	There	are	a	number	of	factors	reported	to	influence	tumourigenesis	such	as	
genetic	predisposition	[325]	and	the	colonic	microflora	[326],	both	of	which	play	a	
role	 in	 the	 activation	 cascade	 of	 AOM.	 Consequently,	 the	 genetic	 heterogeneity	
within	 inbred	 strains	 and	 variation	 in	 the	 intestinal	 microbiota	 between	 animal	
facilities	 will	 influence	 the	 development	 of	 tumours	 after	 AOM	 administration.	
C57BL/6	mice	have	a	lower	susceptibility	to	AOM-induced	CRC	compared	to	those	
strains	 less	 resistant	 to	 AOM	 such	 as	 C3H/HeN	 and	 Balb/c	 [327].	 It	 was	 for	 this	
reason	 that	 the	 dose	 of	 AOM	was	 increased	 from	 10	 to	 12.5	mg/kg.	 It	 has	 been	
recommended	 to	 perform	 dose-response	 experiments	 to	 optimise	 conditions	 for	
the	specific	mouse	strain,	animal	facility	and	preparation	of	AOM	that	is	used	[144].	
However,	as	each	experiment	lasted	up	to	6	months	there	was	insufficient	time	to	
dose	optimise	the	AOM.		
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Metabolomic	profiling	has	previously	been	shown	to	 identify	biomarkers	of	AOM-
induced	 colorectal	 neoplasia	 in	 mice	 using	 ultra-performance	 liquid	
chromatography	tandem	mass	spectrometry	and	GC-MS	[324].	Haem,	changed	with	
disease	 progression,	 increasing	 over	 time,	 which	 is	 consistent	 with	 enhanced	 GI	
bleeding.	However,	haem	may	also	be	increased	in	non-cancerous	conditions.	Wang	
et	 al.	 collected	 blood	 from	 16	 CRC	 patients	 and	 20	 healthy	 controls,	 and	 using	
SPME-GC-MS	they	found	that	phenyl	methylcarbamate,	ethylhexanol	and	6-t-butyl-
2,2,9,9-tetramethyl-3,5-decadien-7-yne	were	at	 significantly	 lower	 concentrations,	
and	1,1,4,4-tetramethyl-2,5-dimethylene-cyclohexane	at	a	higher	 concentration	 in	
the	 CRC	 group	 compared	 to	 the	 normal	 group	 [328].	 In	 addition,	 tumour	 growth	
also	involves	several	metabolic	changes	leading	to	the	production	of	specific	VOCs	
that	 have	 been	 detected	 in	 exhaled	 breath.	 Altomare	 et	 al.	 used	 mathematical	
modelling	 to	 identify	 a	 pattern	 of	 VOCs	 emitted	 from	 exhaled	 breath	 to	
discriminate	between	CRC	patients	 and	healthy	 controls	with	an	accuracy	of	 85%	
[329].	 Furthermore,	 detection	 of	 CRC	 by	 urinary	 VOC	 analysis	 using	 ion	 mobility	
spectroscopy	(FAIMS)	has	also	shown	potential	as	a	novel	screening	tool	[330].		
	
There	 is	 increasing	 evidence	 to	 suggest	 that	 CRC	 exhibits	 a	 distinct	 faecal,	 blood,	
urine	and	breathe	metabolic	profile	with	respect	to	VOCs.	Further	investigation	and	
optimisation	 of	 AOM	 to	 induce	 CRC	 in	 mice	 will	 aid	 the	 development	 of	 VOC	
profiling	as	a	potential	clinical	application	for	human	CRC	screening,	and	diagnosis.		
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Chapter	8	
	
Faecal	Calprotectin	as	a	Non-Specific	
Marker	of	Inflammatory	Diseases
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8.1	INTRODUCTION	
	
Calprotectin	is	a	calcium-binding	protein	found	in	neutrophils.	Faecal	calprotectin	is	
a	 substance	 that	 is	 released	 into	 the	 intestinal	 lumen	 by	 an	 influx	 of	 neutrophils	
when	 there	 is	 any	 inflammation	 present	 and	 so	 can	 act	 as	 a	 marker	 for	
inflammatory	conditions	of	 the	 lower	GI	 tract.	 Its	presence	may	suggest	a	person	
has	 active	 IBD.	 As	 the	 symptoms	 of	 IBD	 and	 some	 non-inflammatory	 bowel	
conditions	 such	 as	 IBS	 are	 similar,	 people	 with	 IBS	 may	 undergo	 unnecessary	
invasive	 hospital	 investigations	 before	 their	 condition	 is	 diagnosed.	 Therefore,	
faecal	calprotectin	testing	 is	recommended	by	NICE	as	an	option	to	help	clinicians	
distinguish	between	IBD	and	non-inflammatory	bowel	diseases,	such	as	IBS.		
	
Several	 technologies	 that	measure	 the	 level	of	 calprotectin	 in	 stool	 samples	have	
been	evaluated,	including	fully	quantitative	laboratory-based	tests	(e.g.	an	enzyme-
linked	 immunosorbent	 assay	 (ELISA)	 platform),	 fully	 quantitative	 rapid	 tests	 and	
semi-quantitative	 point-of-care	 tests	 (POCTs).	 Due	 to	 the	 fact	 that	 faecal	
calprotectin	concentration	correlated	with	the	level	of	bowel	inflammation,	results	
are	 interpreted	 in	 the	context	of	a	 cut-off	 value,	below	which	 the	 test	 is	deemed	
negative	and	above	which	is	deemed	positive,	thereby	supporting	an	IBD	diagnosis.	
The	most	common	cut-off	recommended	by	test	manufacturers	is	50μg/g	[331].		
	
Advantages	of	using	the	faecal	calprotectin	test	 in	the	diagnosis	and	management	
of	IBD	include	the	fact	that	it	is	a	simple,	relatively	cheap	non-invasive	test	and	has	
increased	 specificity	 by	 the	 more	 direct	 assessment	 of	 intestinal	 inflammation,	
compared	 to	 serum	 markers.	 However,	 there	 are	 a	 number	 of	 disadvantages,	
including	the	poor	assessment	of	ileal	inflammation,	detection	of	neutrophil-related	
inflammation	 only	 and	 the	 inability	 to	 distinguish	 IBD	 from	 infections	 and	
pathologies	that	bleed	[332].		
	
Diagnostic	tests	are	often	carried	out	to	exclude	conditions	rather	than	to	diagnose	
them,	leading	to	repeat	visits	and	unpleasant	investigations.	Faecal	calprotectin	still	
has	some	disadvantages	and	can	only	be	used	as	a	complementary	test.		Here,	we	
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used	 stool	 samples	 from	murine	models	 of	GI	 disease	 to	 assess	 the	 sensitivity	 of	
faecal	calprotectin	concentration	as	a	diagnostic	marker	for	IBD.		
	
8.2	HYPOTHESIS	
	
The	faecal	calprotectin	test	will	be	positive	in	stool	samples	from	murine	models	of	
IBD	and	CRC.		
	
8.3	AIMS	
	
1. Detection	of	calprotectin	 in	the	stool	samples	from	murine	models	of	DSS-
induced	colitis,	and	AOM/DSS-induced,	and	AOM-induced	CRC.		
2. Quantification	 of	 the	 calprotectin	 concentration,	 and	 test	 for	 differences	
between	groups.		
	
8.4	METHODS	
	
8.4.1	Faecal	samples	
	
Faecal	samples	used	in	this	study	were	collected	during	the	experiments	performed	
throughout	this	project:	acute	DSS-induced	colitis	(Chapter	5),	chronic	DSS-induced	
colitis	(Chapter	6),	AOM/DSS-induced	CRC	(Chapter	6),	and	AOM-induced	CRC	(Pilot	
Study)	(Chapter	7).	Each	group	was	run	in	triplicate	(n=3)	and	each	sample	was	run	
in	duplicate	wells.	For	the	acute	and	chronic	DSS-induced	colitis	groups,	the	faecal	
samples	were	 in	the	form	of	colon	contents,	whereas	the	faecal	samples	used	for	
the	AOM±DSS-induced	CRC	were	faecal	pellets.		
	
8.4.2	Calprotectin	mouse	ELISA	
	
Quantitative	 determination	 of	 calprotectin	 was	 performed	 using	 a	 sandwich	
S100A8/S100A9	 (Calprotectin)	 ELISA	 technique	 in	 a	 96-well	 plate	 format	 with	 a	
commercial	kit	supplied	by	Biohit	Healthcare,	UK	who	are	the	UK	suppliers	for	the	
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manufacturers,	Immundiagnostik,	Germany.	A	detailed	protocol	for	the	calprotectin	
mouse	ELISA	is	included	in	section	2.5	of	Chapter	2.	Samples	were	extracted	1:50	in	
extraction	 buffer	 and	 centrifuged	 for	 5	minutes	 at	 13000g	prior	 to	 beginning	 the	
ELISA.		
	
8.4.3	Statistical	analysis	
	
The	average	concentration	of	calprotectin	 in	each	sample	 (n=2)	was	calculated	by	
finding	the	mean	of	each	replicate	(n=2)	using	the	standard	curve,	subsequently	the	
average	concentration	 for	each	group	 (n=3)	and	differences	between	 the	average	
calprotectin	 concentrations	 of	 the	 different	 treatment	 groups	 were	 determined.	
Statistical	 analysis	was	 performed	 in	 SPSS.	 For	 normally	 distributed	 data,	 a	 t-test	
was	used	to	test	for	differences	 in	the	concentration	of	calprotectin	between	two	
groups.	A	one-way	ANOVA	was	used	when	 there	were	more	 than	 two	groups.	P-
values	less	than	0.05	were	considered	statistically	significant.		
	
8.5	RESULTS	
	
8.5.1	Measurement	of	calprotectin	in	acute	DSS-induced	colitis	
	
Faecal	 calprotectin	 concentration	 during	 induction	 and	 resolution	 of	 acute	 DSS-
colitis	 was	 measured	 to	 examine	 the	 level	 of	 inflammation	 in	 DSS-treated	 mice.	
DSS-induced	 colitis	 can	 be	 in	 the	 form	 of	 an	 acute,	 or	 chronic	 colitis.	 First,	 we	
assessed	the	concentrations	of	calprotectin	 in	the	colonic	 luminal	content	of	mice	
treated	 with	 4.25%	 DSS	 in	 an	 acute	 model	 of	 colitis	 (chapter	 5).	 Mice	 were	
sacrificed	via	cervical	dislocation	at	experimental	days	0	(n=11),	5	(n=11),	8	(n=10)	
and	11	(n=8);	samples	from	three	mice	in	each	group	were	used	in	duplicate	for	this	
experiment.	As	 expected,	 the	 concentration	of	 faecal	 calprotectin	 increased	 from	
48.0±5.9	ng/ml	at	day	0	(prior	to	DSS	treatment),	to	62.6±25.9	ng/ml	at	day	5	and	
84.9±34.2	 ng/ml	 at	 day	 8	 when	 mice	 were	 clinically	 unwell	 (mean±SEM).	 The	
amount	of	 inflammation	appeared	to	decrease	at	day	11	due	to	the	improvement	
in	histological	and	clinical	parameters,	therefore	the	calprotectin	concentration	was	
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expected	 to	 decrease.	 However,	 the	 levels	 at	 day	 11	 (127.6±62.0	 ng/ml)	 were	
higher	 than	 those	at	day	8,	but	no	 significant	difference	was	 found	which	 can	be	
explained	by	 the	 variability	between	 the	 individual	mice	 (p>0.05,	ANOVA)	 (Figure	
8.1).		
	
	
Figure	 8.1	 Faecal	 calprotectin	 concentration	 [ng/ml]	 in	 the	 colonic	 luminal	
contents	from	mice	of	an	acute	DSS-induced	colitis	model.	Female	C57BL/6	mice	
were	administered	4.25%	DSS	in	their	drinking	water	for	5	days	followed	by	6	days	
of	 ordinary	water.	Mice	were	 sacrificed	on	 experimental	 days	 0,	 5,	 8	 and	11	 and	
colonic	 luminal	 contents	were	 collected	 and	 stored	 at	 -20°C	 until	 analysis	 by	HS-
SPME-GC-MS	 and	 then	 detection	 of	 calprotectin	 by	 ELISA	 (data	 expressed	 as	
mean±SD,	n=3/group;	p>0.05,	ANOVA).		
	
8.5.2	Measurement	 of	 faecal	 calprotectin	 concentration	 in	 chronic	 DSS-induced	
colitis	
	
Following	 the	 assessment	 of	 acute	 DSS-induced	 colitis,	 the	 concentration	 of	
calprotectin	was	assessed	in	the	colonic	luminal	content	of	mice	(n=6)	treated	with	
four	cycles	of	0.75-1.25%	DSS	in	a	chronic	model	of	colitis	(Chapter	6).	There	was	an	
untreated	 control	 group	 (n=6).	 All	mice	were	 sacrificed	 via	 cervical	 dislocation	 at	
day	 45;	 samples	 from	 three	 mice	 in	 each	 group	 were	 used	 in	 duplicate	 for	 this	
experiment.	The	concentration	of	faecal	calprotectin	increased	from	15.7±3.7	ng/ml	
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in	 the	 control	 group	 to	45.2±23.8	ng/ml	 in	 the	DSS	 treated	group	 (p=0.37,	 t-test)	
(Figure	8.2).	
	
Figure	 8.2	 Faecal	 calprotectin	 concentration	 [ng/ml]	 in	 the	 colonic	 luminal	
contents	from	mice	of	a	chronic	DSS-induced	colitis	model.	Female	C57BL/6	mice	
were	 administered	 four	 cycles	 of	DSS	 in	 their	 drinking	water	 at	 doses	 from	0.75-
1.25%.	Each	cycle	 included	5	days	of	DSS	 followed	by	6	days	of	ordinary	water.	A	
control	and	treated	group	were	included	and	all	mice	were	sacrificed	on	day	45	at	
the	end	of	the	experiment	and	colonic	luminal	contents	were	collected	and	stored	
at	 -20°C	 until	 analysis	 by	 HS-SPME-GC-MS	 and	 then	 detection	 of	 calprotectin	 by	
ELISA	(data	expressed	as	mean±SD,	n=3/group;	p>0.05,	t-test).	
	
8.5.3	 Measurement	 of	 faecal	 calprotectin	 concentration	 in	 inflammation-
associated	CRC	
	
A	 murine	 model	 of	 inflammation-associated	 CRC	 included	 one	 injection	 of	 a	
carcinogen,	12.5mg/kg	AOM	followed	by	3	cycles	of	1.5%	DSS	(Chapter	6).	Animals	
were	sacrificed	at	day	64	and	due	to	the	presence	of	cancerous	lesions	within	the	
mucosal	 surface	 of	 the	 distal	 colon,	 fresh	 faecal	 pellets	 were	 collected	 from	 the	
cages	 instead	of	colonic	 luminal	contents;	samples	from	three	mice	 in	each	group	
were	used	in	duplicate	for	this	experiment.	The	concentration	of	faecal	calprotectin	
increased	 from	 18.1±1.8	 ng/ml	 in	 the	 control	 group	 to	 42.2±13.6	 ng/ml	 in	 the	
AOM/DSS	treated	group	(p=0.22,	t-test)	(Figure	8.3).	
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Figure	 8.3	 Faecal	 calprotectin	 concentration	 [ng/ml]	 in	 the	 faecal	 pellets	 from	
mice	 of	 an	 inflammation-associated	 CRC	 model.	 Female	 C57BL/6	 mice	 received	
one	injection	(i.p.)	of	12.5mg/kg	AOM	and	were	administered	three	cycles	of	1.5%	
DSS	in	their	drinking	water.	A	control	and	treated	group	were	included	and	all	mice	
were	 sacrificed	 at	 week	 10	 at	 the	 end	 of	 the	 experiment	 and	 colonic	 luminal	
contents	were	collected	and	stored	at	-20°C	until	analysis	by	HS-SPME-GC-MS	and	
then	 detection	 of	 calprotectin	 by	 ELISA	 (data	 expressed	 as	mean±SD,	n=3/group;	
p>0.05,	t-test).	
	
8.5.4	Measurement	of	faecal	calprotectin	concentration	in	sporadic	CRC	
	
A	murine	 model	 of	 sporadic	 CRC	 included	 six	 weekly	 injections	 of	 a	 carcinogen,	
12.5mg/kg	AOM	and	lasted	6	months	for	the	growth	of	colonic	adenomas	(Chapter	
7).	 Animals	 were	 sacrificed	 at	 the	 end	 of	 week	 20	 (Pilot	 Study)	 and	 similar	 to	
samples	 from	 the	 AOM/DSS	 study,	 fresh	 faecal	 pellets	 were	 collected	 from	 the	
cages	 instead	of	colonic	 luminal	contents;	samples	from	three	mice	 in	each	group	
were	used	in	duplicate	for	this	experiment.	The	concentration	of	faecal	calprotectin	
increased	from	22.6±5.1	ng/ml	in	the	control	group	to	68.7±27.3	ng/ml	in	the	AOM	
treated	group	(p=0.25,	t-test)	(Figure	8.4).	
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Figure	 8.4	 Faecal	 calprotectin	 concentration	 [ng/ml]	 in	 the	 faecal	 pellets	 from	
mice	of	a	sporadic	CRC	model.	Female	C57BL/6	mice	received	six	weekly	injections	
(i.p.)	of	12.5mg/kg	AOM.	A	control	and	 treated	group	were	 included	and	all	mice	
were	 sacrificed	 at	 week	 20	 at	 the	 end	 of	 the	 experiment	 and	 colonic	 luminal	
contents	were	collected	and	stored	at	-20°C	until	analysis	by	HS-SPME-GC-MS	and	
then	 detection	 of	 calprotectin	 by	 ELISA	 (data	 expressed	 as	mean±SD,	n=3/group;	
p>0.05,	t-test).	
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8.6	DISCUSSION	
	
Calprotectin	 constitutes	 60%	 of	 neutrophil	 proteins	 and	 is	 abundant	 in	 all	 bodily	
fluids	at	 levels	dependent	on	 the	neutrophil	migration	 toward	 the	 intestinal	 tract	
and	thus,	the	degree	of	 inflammation.	Faecal	calprotectin	has	a	number	of	clinical	
advantages,	which	makes	it	a	robust	test.	It	is	resistant	to	bacterial	degradation	in	
the	gut	and	is	also	stable	 in	stool	samples	at	room	temperature	for	up	to	a	week,	
therefore	tolerating	any	interruption	or	delay	in	the	transportation	of	the	sample	to	
the	laboratory	[333].		
	
The	measurement	of	faecal	calprotectin	in	both	the	acute,	and	chronic	DSS-induced	
colitis	model	 yielded	 expected	 results.	 The	 levels	 of	 calprotectin	 increased	 in	 the	
presence	 of	 inflammation,	 illustrated	 by	 the	 clinical	 and	 histological	 data	 and	
demonstrated	by	the	step-wise	increase	in	faecal	calprotectin.	However,	the	levels	
were	not	 significantly	different	due	 to	 the	wide	error	bars;	 future	 repeats	 should	
include	a	larger	n	number	to	achieve	tighter	error	bars	and	a	significant	difference.	
		
These	results	are	in	agreement	with	human	studies.	Measurement	of	calprotectin	in	
stool	samples	from	healthy,	chronic	IBD,	and	IBS	patients	showed	that	it	was	able	to	
differentiate	between	chronic	IBD	and	IBS	[334].	Additionally,	a	second	study	found	
that	faecal	calprotectin	was	strongly	associated	with	colorectal	inflammation	[335],	
providing	 strong	evidence	 for	 the	clinical	use	of	 the	 faecal	 calprotectin	 test	when	
distinguishing	between	IBS	and	IBD.	It	is	also	useful	for	monitoring	disease	activity	
by	reliably	discriminating	between	inactive	disease	from	mild,	moderate	and	highly	
active	 diseases,	 demonstrated	 by	 the	 overall	 accuracy	 for	 the	 detection	 of	
endoscopically	 active	 disease	 being	 89%	 for	 calprotectin	 [336].	 Furthermore,	
evidence	shows	 it	might	also	be	useful	 in	predicting	an	 impending	clinical	 relapse	
[337].		
	
In	humans,	 the	sensitivity	and	specificity	of	calprotectin	 in	distinguishing	between	
CD	and	IBD	is	67.7%	and	66.7%,	respectively	[338].	Although	this	is	high,	there	may	
still	be	 room	for	 improvement	with	a	novel	diagnostic	 test.	The	 lack	of	 sensitivity	
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and	 specificity	 may	 be	 caused	 by	 the	 occurrence	 of	 false	 positive	 results.	 False	
positive	 calprotectin	 readings	may	be	 the	 result	of	any	bleeding	 in	 the	body	over	
100ml,	 e.g.	 menstrual	 bleeding.	 Also,	 the	 presence	 of	 non-steroidal	 anti-
inflammatory	 drugs	 (NSAIDs)	 may	 cause	 an	 increase	 in	 calprotectin	 levels	 in	
patients	without	 IBD	 [270].	 Likewise,	 levels	 of	 faecal	 calprotectin	 increase	 in	 any	
condition	 that	 causes	 neutrophil	 migration	 to	 the	 gut,	 including	 neoplasms	 and	
infections,	 therefore	 the	 sensitivity	 and	 specificity	of	 faecal	 calprotectin	 is	 limited	
and	is	not	as	high	as	desired.		
	
Faecal	 calprotectin	 in	 stool	 samples	 from	 murine	 models	 of	 inflammation-
associated,	and	sporadic	CRC	also	produced	positive	results,	compared	to	untreated	
control	 groups.	 Kristinsson	 et	 al.	 showed	 that	 the	 majority	 of	 patients	 with	 CRC	
have	 increased	 faecal	 concentrations	 of	 calprotectin	 [276].	 They	 recruited	 155	
patients	with	newly	diagnosed	CRC	and	found	that	87%	of	all	patients	had	elevated	
faecal	calprotectin	concentrations;	79%	had	levels	above	15mg/l	and	74%	had	levels	
above	20mg/l.	Furthermore,	the	calprotectin	levels	in	faecal	samples	collected	after	
bowel	 resection	 surgery	 fell	 significantly	 from	a	 preoperative	median	 value	 of	 45	
mg/l	 to	 14	 mg/l	 after	 the	 resection.	 Although	 this	 study	 suggests	 that	 the	
measurement	 of	 faecal	 calprotectin	 may	 be	 a	 marker	 for	 CRC,	 similar	 to	 FOBT,	
faecal	calprotectin	is	non-specific	for	colorectal	pathology.		
	
These	 results	 provide	 evidence	 that	 the	 faecal	 calprotectin	 test	 may	 not	 be	 a	
specific	IBD	or	CRC	diagnostic	marker	in	murine	models	and	are	in	agreement	with	
current	studies	testing	the	effectiveness	of	faecal	calprotectin	in	human	GI	disease.	
However,	the	assay	was	only	performed	once	and	in	order	to	validate	these	results	
further,	it	would	need	to	be	repeated	on	a	larger	scale.	Furthermore,	there	appears	
to	 be	 a	 lack	 of	 evidence	 to	 support	 the	 use	 of	 this	 assay	 to	 specifically	measure	
colonic	 inflammation	 in	 the	 faeces	 of	 colitis	 murine	models.	 Investigation	 of	 the	
variability	of	the	healthy	mouse	microbiota	of	five	common	lab	mouse	strains	using	
16S	 rDNA	 pyrosequencing	 found	 the	 murine	 enterotype	 to	 show	 a	 striking	
resemblance	 to	 human,	which	was	 also	 associated	with	 calprotectin	 levels	 [339].	
Mice	 expressing	 an	 increase	 in	 Enterobacteriaceae,	 which	 has	 previously	 been	
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associated	with	 induction	of	 low	grade	 inflammation,	also	had	 increased	 levels	of	
caecal	calprotectin;	providing	confirmation	that	 low-grade	inflammation	can	occur	
in	healthy	SPF	mice.	In	addition,	calprotectin	is	also	reportedly	increased	in	plaques	
from	a	diabetic	murine	model	 [340],	brain	hemispheres	of	an	Alzheimer’s	disease	
model	[341],	and	in	the	serum	of	LPS-induced	septic	shock	mice	[342].	Therefore,	as	
with	 human	 studies,	 the	 specificity	 of	 faecal	 calprotectin	 as	 a	 marker	 of	 colonic	
inflammation	in	mice	is	questioned.		
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9.1	CONCLUDING	DISCUSSION	
	
The	 different	 ‘omic’	 approaches,	 including	 genomics,	 transcriptomics	 and	
proteomics,	 are	 currently	 applied	 to	 identifying	 novel	 diagnostic,	 disease-specific	
biomarkers.	 These	 approaches	 also	 aim	 to	 characterise	 the	 link	 between	 the	 gut	
microbiota	and	host	metabolism	and	to	investigate	the	pathophysiology	underlying	
diseases.	 Metabolomics	 can	 be	 defined	 as	 ‘the	 non-biased	 identification	 and	
quantification	of	all	metabolites	in	a	biological	system’	[343],	integrating	the	effects	
of	 gene	 regulation,	 post-transcriptional	 regulation	 and	 the	 resulting	 pathway	
interactions	 [344].	 This	 approach,	 ultimately,	 provides	 us	with	 a	 direct	molecular	
readout	 of	 the	 cell	 status,	 reflecting	 the	 physiological	 phenotype.	 Furthermore,	
metabolomic	 profiling	 reflects	 the	 environmental	 and	 dietary	 factors	 of	 the	 host,	
which	do	not	affect	the	genome.		
	
Here,	we	have	characterised	the	healthy	murine	faecal	metabolome	and	assessed	
the	effect	of	 inducing	disease	of	 the	GI	 tract	 for	 the	first	 time	using	HS-SPME-GC-
MS.	 As	 a	 result,	 our	 analysis	 of	 the	 murine	 faecal	 metabolome	 has	 enabled	 the	
isolation	 and	 detection	 of	 specific	 VOCs,	 and	 certain	 groups	 of	 VOCs,	 that	 are	
associated	 with	 both	 health	 and	 disease	 states.	 Only	 subtle	 differences	 were	
identified	between	individual	mice	therefore	providing	confidence	in	the	use	of	this	
species	 for	 subsequent	 studies.	 This	 also	 demonstrated	 the	 robustness	 of	 our	
optimised	HS-SPME-GC-MS	method.	Furthermore,	comparison	of	the	human	faecal	
VOC	profile	with	the	murine	profile	highlighted	the	diversity	of	the	human	intestinal	
microbiota	with	62	VOCs	found	to	be	unique	to	this	group	compared	to	39	 in	the	
murine	group.	This	 is	 likely	due	to	a	more	varied	human	diet	and	changes	 in	their	
environment.	 The	 consequent	 focus	 on	 the	 murine	 VOC	 metabolome	 found	
significant	effects	of	age	and	gender;	which	were	expected,	and	 led	 to	 the	use	of	
one	 gender	 (females)	 in	 future	 experiments	 to	 decrease	 variation,	 and	 to	 ensure	
that	time	related	differences	in	VOC	profiles	of	GI	disease	were	already	recognised.	
Differences	between	males	and	females	were	most	notable	when	mice	were	5,	8,	
10	and	12	weeks	old	where	the	majority	of	VOCs	were	significantly	higher	in	males	
compared	 to	 females,	or	 completely	absent	 in	 females.	This	may	be	explained	by	
	265	
	
hormonal	differences.	Female	was	the	chosen	gender	for	future	experiments	due	to	
the	 slightly	 lower	 variation	 in	 abundance	 of	 VOCs	 over	 time;	 27.8%	 of	 VOCs	
significantly	 varied	 over	 time	 for	 females,	 compared	 to	 28.2%	 for	 males.	 A	
significant	 decrease	 in	 both	 the	 number	 of	 VOCs	 and	 the	 abundance	 of	 specific	
VOCs	in	the	small	intestine	was	found	compared	to	the	large	bowel	and	the	faecal	
pellet	of	healthy	mice	which	could	be	explained	by	the	increase	in	the	numbers	of	
bacteria	 from	 the	 stomach	 to	 the	 colon.	 This	 was	 also	 considered	 an	 important	
finding	 to	 take	 into	 account	 when	 planning	 future	 experiments;	 for	 instance,	
making	sure	to	not	directly	compare	the	VOC	profiles	of	samples	obtained	directly	
from	the	large	bowel	with	faecal	pellets.		
	
IBD	 is	 often	 difficult	 for	 clinicians	 to	 diagnose.	 It	 can	 also	 be	 traumatic	 and	
unpleasant	 for	 a	 patient	 to	 have	 to	 undergo	 unnecessary	 invasive	 tests.	 This	 can	
also	 be	 said	 for	 the	 diagnosis	 of	 cancer,	 in	 particular,	 IBD-associated	 CRC.	 The	
earlier	the	cancer	is	detected,	the	better	the	chances	of	the	patient	recovering,	as	
prognosis	 is	 better	 and	 appropriate	 treatment	 can	 be	 started	 sooner.	 Earlier	
diagnosis	 and	 screening	 would	 therefore	 result	 in	 a	 better	 prognosis	 for	 CRC	
patients	of	all	types.	This	thesis	thus	far	has	discussed	the	underlying	need	for	the	
development	 of	 new	 methods	 for	 the	 early	 detection	 of	 CRC	 as	 current	 non-
invasive	 tests	 lack	 sensitivity	 and	 specificity,	 and	 a	 colonoscopy	 is	 required	 to	
confirm	a	positive	result.	Ideally,	a	novel	screening	tool	would	have	100%	accuracy	
with	 fewer	 false	 positives	 than	 FOBT,	 thus	 reducing	 the	 number	 of	 unnecessary	
colonoscopies.	 The	 focus	 of	 this	 work	 has	 been	 a	 metabolomics	 approach,	
specifically,	the	analysis	of	VOCs	emitted	from	the	faeces	of	mice	with	or	without	GI	
diseases	with	 the	 aim	of	 producing	 results	 that	may	 aid	 future	 studies	 of	 human	
disease.		
	
A	mouse	model	mimicking	human	UC	was	used	and,	after	performing	a	number	of	
DSS	dose	response	studies,	a	reproducible	protocol	was	established	that	resulted	in	
weight	 loss,	 rectal	 bleeding	 and	 diarrhoea.	 A	 VOC	 profile	 was	 identified	 that	
changed	significantly	during	 the	onset	and	 recovery	of	acute	colitis,	 characterised	
by	 an	 increase	 in	 aldehydes,	 specifically,	 propanal,	 butanal,	 and	 heptanal,	 and	 a	
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decrease	 in	 alcohols,	 namely	 2-butanol,	 2-pentanol	 and	 ethanol	 at	 days	 5	 and	 8	
compared	to	days	0	and	11.	A	similar	pattern	with	an	increase	in	aldehydes	and	a	
decrease	in	alcohols	was	also	found	in	a	mouse	model	of	osmotic	diarrhoea	when	
compared	 to	 untreated	 controls,	 but	 different	 marker	 compounds,	 including	 2-
methyl-propanal,	 2-methyl-butanal	 and	 phenol	 were	 found.	 Phenol	 was	 the	 only	
compound	 to	 remain	 significantly	 different	 between	 MgSO4-treated	 mice	 and	
untreated	controls	after	p-values	were	corrected	 for	multiple	comparisons;	 this	 is	
believed	 to	 originate	 from	 the	microbial	 degradation	 of	 tyrosine	 in	 the	 intestinal	
tract	[345].	This	similarity	indicates	that	a	combination	of	increased	aldehydes	and	
decreased	alcohols	may	be	a	marker	of	acute	diarrhoea	 in	mice.	A	comparison	of	
DSS-treated	mice	 with	MgSO4-treated	mice	 showed	 a	 significantly	 lower	 average	
number	 of	 VOCs	 in	 the	 MgSO4-treated	 group	 (38.2)	 compared	 to	 DSS-treated	
(50.5);	 possibly	 due	 to	 the	 decreased	 intestinal	 transit	 time	 and	 the	 increased	
amount	 of	 water	 present	 in	 the	 faeces	 in	 MgSO4-treated	 mice.	 Previous	 results	
have	shown	alcohol	compounds	to	be	indicative	of	a	healthy	murine	gut	due	to	the	
significant	 decrease	 observed	 in	 diarrhoea	 samples	 obtained	 from	 both	 MgSO4-
treated	and	DSS-treated	mice.	A	DSS	vs	MgSO4	comparison	found	that	a	number	of	
alcohols	were	either	absent	 (12)	 from	or	 significantly	decreased	 (6)	 in	 the	MgSO4	
group,	 and	 based	 on	 these	 significant	 compounds,	 a	 PCA	 was	 able	 to	 clearly	
distinguish	between	these	two	groups.	This	suggests	 that	 the	metabolic	pathways	
involved	in	the	pathogenesis	of	colitis	are	independent	from	those	involved	in	the	
onset	of	diarrhoea	that	was	not	associated	with	colitis,	which	is	also	supported	by	
previous	findings	[346].	Decreased	bacterial	diversity	characterises	the	altered	gut	
microbiome	 present	 in	 IBD;	 the	 observed	 decrease	 in	 ‘health’-associated	 alcohol	
compounds	 and	 the	 reported	 role	 that	 these	 compounds	 play	 in	 providing	 an	
ecological	 niche	 [242]	 therefore	 fits	 with	 this	 hypothesis.	 The	 differences	 in	 the	
levels	 of	 specific	 alcohols	 associated	 with	 health,	 colitis	 and	 osmotic	 diarrhoea	
suggests	 that	 identification	 of	 disease-associated	 VOC	 concentration	 ranges	
combined	 with	 specific	 marker	 compounds	 would	 potentially	 increase	 the	
likelihood	of	finding	an	IBD-specific	faecal	VOC	marker	profile.		
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Administration	of	DSS	induces	an	acute	or	chronic	form	of	colitis,	depending	on	its	
dose	and	duration	of	administration,	and	it	has	been	postulated	that	the	initiation	
of	these	disease	types	may	be	caused	by	different	mechanisms	[138].	In	addition	to	
identification	of	 individual	VOC	profiles	 for	acute	and	chronic	DSS	colitis,	we	have	
shown	that	metabolomic	faecal	VOC	profiling	is	capable	of	distinguishing	between	
chemically-induced	murine	 acute	 and	 chronic	 colitis.	 Ten	 VOCs	were	 detected	 at	
significantly	 higher	 concentrations	 in	 chronic	 colitis	 compared	 to	 acute	 colitis,	
amongst	 them	 were	 5	 ketones	 (acetone,	 2,3-butanedione,	 2-heptanone,	 2-
octanone,	 2-acetoxy-3-butanone).	 The	 immune	 system	 is	 essential	 to	 prevent	
infection	but	is	also	important	in	the	process	of	repair	and	recovery	from	any	type	
of	injury,	such	as	intestinal	inflammation.	It	has	a	role	to	play	in	the	control	of	the	
resident	 microbiota	 which	 is	 essential	 to	 metabolic	 health	 and	 is	 highly	 energy	
demanding	 on	 all	 immune	 cells	 [347].	 It	 has	 been	 reported	 that	 the	 adaptive	
immune	system	 is	not	 required	 for	acute	colitis,	but	 is	 likely	 to	play	an	 important	
role	 in	the	pathogenesis	of	chronic	colitis,	 therefore	 indicating	the	 involvement	of	
different	 immune	responses.	 In	addition,	ketones	were	the	most	common	type	of	
VOC	found	 in	healthy	mice,	and	were	found	to	significantly	decrease	 in	germ	free	
samples	 suggesting	 that	 the	 origin	 of	 ketones	 in	 the	 gut	 is	 likely	 to	 be	 from	 the	
presence	 of	 bacteria.	 Samples	 from	 another	 pre-clinical	 chronic	 colitis	 murine	
model,	the	CD4+CD62L+	T	cell	transfer-mediated	colitis,	were	kindly	provided	by	Dr	
Jim	Wilson,	 Epistem,	Manchester.	 Similar	 to	 the	 DSS-induced	 chronic	 colitis,	 our	
method	 was	 able	 to	 also	 distinguish	 between	 VOC	 profiles	 of	 healthy	 and	 T	 cell	
transfer-mediated	colitis	(Appendix	2)	with	marker	compounds	including	3-methyl-
2-pentanone	and	2,5-dimethyl-3-hexanone	being	decreased	in	colitic	mice	28	days	
after	T-cell	transfer.	Methyl	ketones	may	therefore	be	a	marker	of	chronic	colitis	as	
this	 group	 of	 compounds	 were	 also	 responsible	 for	 the	 different	 VOC	 profile	
between	untreated	controls	and	the	DSS-induced	chronic	colitis	model	used	in	this	
thesis,	 and	 have	 interestingly	 been	 reported	 to	 be	 produced	 by	many	 species	 of	
bacteria	and	fungi	[242].		
	
Colorectal	 tumours	 shed	cells	 and	 sometimes	bleed,	 therefore	 faeces	provide	 the	
ideal	matrix	for	identifying	markers	of	intestinal	changes.	However,	the	induction	of	
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CRC	using	AOM±DSS	is	a	time-consuming	experiment	and	requires	troubleshooting	
to	ensure	the	correct	doses	of	both	AOM	and	DSS	are	used.	Unfortunately,	this	was	
not	 achieved	 in	 the	 timeframe	 that	 the	 work	 in	 this	 thesis	 was	 performed.	 That	
said,	 the	 absence	 of	 distal	 colonic	 tumours	 from	 the	 AOM±DSS	 experiment	 was	
surprising	due	to	the	clinical	GI	symptoms	noted	throughout.	Significant	weight	loss	
and	the	presence	of	mild	diarrhoea	suggested	that	the	DSS	was	administered	at	the	
correct	dose	and	 that	 there	may	have	been	 further	dose	 studies	 required	 for	 the	
AOM	in	order	to	initiate	the	CRC	cascade.	The	pilot	study	using	12.5mg/kg	resulted	
in	3	out	of	4	mice	developing	tumours,	but	repeating	this	with	and	without	DSS,	did	
not.	 Interpreting	 this	 result	 in	 terms	 of	 the	method	 suggests	 that	 batch-to-batch	
variation	may	exist	for	AOM	(obtained	from	Sigma	Aldrich).		
	
The	premalignant	lesions,	MDF,	are	associated	with	the	future	development	of	CRC	
and	can	be	visualised	by	staining	with	HID-AB,	as	reported	by	[327].	Although	there	
were	 no	 invasive	 tumours,	 the	 administration	 of	 AOM/DSS	 did	 promote	 MDF	
development	 in	 this	 study.	 Therefore,	 we	 demonstrated	 that	 VOC	 profiling	 is	
capable	 of	 detecting	metabolic	 differences	 at	 an	 earlier	 stage	 than	 we	 originally	
anticipated.	MDF	were	 first	 described	 in	 2003,	 and	 like	most	 colorectal	 tumours,	
also	 show	 constitutive	 activation	 of	 the	Wnt-signalling	 pathway	with	 cytoplasmic	
and	nuclear	accumulation	of	β-catenin	[348].	They	are	also	characterised	by	an	APC	
mutation	 [349].	 Specific	 VOCs	 were	 identified	 in	 AOM/DSS	 treated	 compared	 to	
untreated	 mice,	 which	 provides	 evidence	 that	 they	 may	 be	 markers	 for	 the	
presence	of	MDF,	including	3-(methylthio)-propanal,	2-nonenal,	3-hexanone	and	6-
methyl-2-heptanone.	In	addition,	by	comparison	of	AOM/DSS	vs	DSS	alone	treated	
mice,	markers	of	chronic	 inflammation	were	found,	 including	ethanol,	3-methyl-2-
butenal,	 3-octanone,	 2-butanone	 and	 2-acetoxy-3-butanone,	 in	 agreement	 with	
previous	 findings	 when	 comparing	 chronic	 DSS-induced	 colitis	 to	 untreated	
controls.	Investigation	of	the	VOCs	produced	by	cancerous	cells	in	vitro	would	help	
with	determining	the	true	origin	of	these	identified	marker	compounds.		
	
Current	non-invasive	markers	for	IBD	include	the	measurement	of	calprotectin	in	a	
patient’s	 stool	 sample.	However,	 the	 specificity	 for	 IBD	has	been	questioned.	The	
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levels	 of	 faecal	 calprotectin	 were	 therefore	 tested	 in	 samples	 from	 acute	 and	
chronic	 DSS-induced	 colitis,	 and	 AOM±DSS-induced	 CRC.	 As	 expected,	 faecal	
calprotectin	 concentration	was	 increased	compared	 to	healthy	 control	 samples	 in	
all	 groups.	 Raised	 faecal	 calprotectin	 concentration	 is	 a	 direct	 consequence	 of	
neutrophil	 degranulation	 due	 to	 mucosal	 damage	 and	 can	 also	 be	 increased	 in	
some	patients	with	IBS.	The	same	can	be	said	of	the	FOBT	which	is	currently	used	
for	CRC	screening.	Taken	together,	the	lack	of	specificity	of	current	non-invasive	IBD	
diagnostic	 tests	 and	 CRC	 screening	 tests	 combined	 with	 our	 method	 showing	
capabilities	of	distinguishing	between	health	and	disease	based	on	a	VOC	profile,	
suggests	that	there	may	be	a	need	to	develop	a	novel	non-invasive	test	that	is	cost-
efficient	with	a	high	level	of	specificity.	Furthermore,	the	lack	of	characteristic	early	
clinical	signs	in	most	forms	of	cancer	highlights	the	importance	of	investigating	new	
methods	for	early	tumour	detection.		
	
Although	 MS-based	 metabolomics	 is	 being	 increasingly	 used	 to	 characterise	 the	
complex	metabolic	 interactions	 involved	 in	disease	pathogenesis,	 and	as	we	have	
shown,	 also	 as	 a	 method	 of	 detecting	 odorous	 disease	 markers,	 there	 are	 still	
limitations	which	slow	down	the	progress	of	this	innovative	area.	For	instance,	the	
lack	of	well	established	and	standardised	methods	and	protocols	between	different	
laboratories	 and	 research	 groups.	 Therefore,	 I	 firstly	 set	 out	 to	 establish	 a	
reproducible,	robust	method	for	the	untargeted	detection	of	HS	VOCs	emitted	from	
murine	 faecal	 samples.	 This	 method,	 along	 with	 the	 detection	 of	 HS	 VOCs	 from	
human	 faecal	 samples,	has	 since	been	peer-reviewed	and	 shared	 [221].	Care	was	
taken	 throughout	 all	 studies	 performed	 in	 this	 thesis	 with	 regards	 to	 sample	
collection	 and	 storage,	 the	 quality	 performance	 of	 all	 instruments	 used	 (e.g.	 GC-
MS),	 the	 extraction	 of	 raw	data	 and	 the	 identification	 and	 interpretation	 of	 both	
individual	VOCs,	and	disease	specific	VOC	profiles.	The	analysis	of	data	in	this	thesis	
was	performed	by	the	author	but	under	the	guidance	of	a	bioinformatician.	Similar	
to	a	lack	of	standardised	protocol	for	the	extraction	of	VOCs,	there	is	currently	no	
standardised	method	for	both	the	univariate	or	multivariate	analysis	of	these	data.	
It	 is	well	 known	 that	altering	even	one	step	of	a	protocol	may	cause	a	 significant	
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change	in	results,	further	highlighting	the	importance	of	establishing	a	standardised	
method.		
	
Limitations	 such	 as	 these	 mean	 that	 results	 from	 different	 research	 groups	 are	
currently	 difficult	 to	 compare	 and	 thus,	 the	 interpretation	 of	 results	 between	
studies	needs	to	be	done	with	caution.	That	said,	the	increased	levels	of	aldehydes	
in	the	presence	of	colitis	seen	in	this	work	may	be	explained	by	the	higher	energy	
demand	due	to	a	decline	in	nutrient	absorption	through	the	damaged	intestine;	this	
was	 also	 demonstrated	 by	 the	 observed	 decrease	 in	 levels	 of	 TCA	 cycle	
intermediates	in	a	study	performed	by	Shiomi	et	al	[282].		
	
9.2	IMPLICATIONS	FOR	FUTURE	STUDIES	
	
VOCs	are	reportedly	emitted	from	the	HS	of	body	specimens,	such	as	blood	[328],	
urine	 [186],	 faeces	 [242],	 and	 breath	 [329].	 However,	 currently	 none	 of	 these	
matrices	 are	 ideal	 for	 looking	 for	 potential	 disease	 biomarkers	 because	 of	 the	
uncertainty	with	regards	to	the	origin	of	the	detected	VOCs.	This	may	be	explained	
by	the	fact	that	the	patterns	of	VOCs	identified	may	depend	not	only	on	the	disease	
state,	but	also	on	other	 contributing	variables	 such	as	genetics,	 the	environment,	
age	 and	 gender.	 A	 relatively	 newer	 matrix	 is	 the	 HS	 of	 cells	 in	 vitro	 [350].	
Advantages	 of	 in	 vitro	 studies	 over	 other	 commonly	 used	matrices,	 in	 particular	
breath	 or	 faeces,	 include	 easier	 control	 of	 experimental	 variables	 and	 perhaps,	
more	easily	interpreted	results,	due	to	less	biological	variation	as	a	result	of	factors	
such	as	gender,	age	or	diet.	Investigations	of	the	VOC	profiles	produced	by	tumours	
at	 the	 microcellular	 level	 by	 sample	 preparation	 of	 cells	 or	 tumours	 have	 been	
reported	 to	 be	 a	 valuable	 tool	 in	 advancing	 the	 aim	 of	 cancer	 diagnosis	 [313].	
Future	studies	should	therefore	use	complementary	 in	vivo	and	 in	vitro	studies	to	
provide	possible	explanations	for	the	presence	of	particular	compounds	found	in	a	
chromatogram.	 This	 may	 also	 enable	 the	 identification	 of	 markers	 of	 oxidative	
stress	and	metabolic	pathways.		
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Preliminary	 investigations	 performed	 as	 part	 of	 this	 thesis	 consisted	 of	 the	 VOC	
analysis	 by	 HS-SPME-GC-MS	 analysis	 of	 isolated	 colonic	 epithelial	 cells	 incubated	
with	and	without	DSS,	and	also	the	analysis	of	colonic	tissue	from	mice	treated	with	
and	 without	 DSS.	 Results	 included	 chromatograms	 with	 no	 peaks,	 indicating	 the	
lack	 of	 VOCs	 emitted	 from	 these	matrices.	Optimisation	of	 sample	 preparation	 is	
therefore	required	for	further	analysis	into	the	VOC	profiles	by	this	method.	These	
results	 did	 lead	 to	 the	 conclusion,	 however,	 that	 the	VOCs	 identified	 from	 faecal	
samples	are	likely	to	originate	from	the	presence	of	the	intestinal	microbiota.	That	
said,	 this	 study	 has	 also	 investigated	 the	 faecal	 VOC	metabolome	 from	GF	mice,	
resulting	in	the	isolation	of	compounds	specific	to	this	profile	when	compared	to	a	
non-GF	control	group.	These	findings	are	in	agreement	with	previous	studies	[252]	
and	emphasise	the	importance	of	microbial	colonisation	in	the	metabolism	of	food	
and	the	production	of	waste	matter.	Due	to	the	increasing	awareness	of	the	role	of	
the	microbiota	in	the	pathogenesis	of	IBD	[197],	metabolomics	studies	using	murine	
models	of	colitis	in	GF	mice	may	provide	further	evidence	for	this.		
	
As	 previously	 stated,	murine	models	 are	 a	 crucial	 component	 of	 gut	microbiome	
research.	Having	established	the	healthy	murine	faecal	metabolome	of	WT	C57BL/6	
mice	and	NFκB2-/-	mice,	studies	leading	on	from	this	work	should	therefore	include	
murine	 models	 using	 strains	 of	 a	 multitude	 of	 genetic	 backgrounds	 and	
experimental	 setups.	 Specifically,	 genetic	 variation	 contributes	 to	 19%	 to	 the	
variance	 in	 the	murine	 gut	microbiota	 composition	 [339].	 Future	 identification	 of	
the	 faecal	metabolome	 of	 genetically	 engineered	murine	 colitis	models	 including	
the	 IL-10-/-	spontaneous	colitis	model	with	or	without	the	addition	of	Helicobacter	
hepaticus	 (previously	 shown	 to	 develop	 severe	 colitis	 when	 IL-10-/-	 mice	 are	
reconstituted	 with	 H.	 hepaticus	 [351]),	 would	 deepen	 our	 understanding	 of	 the	
complex	pathogenesis	of	colitis.	Calprotectin	is	raised	in	the	blood	and	faeces	as	a	
marker	 of	 inflammation	 [352],	 therefore	 a	 comparison	 between	 the	 serum	 and	
faecal	metabolome	of	all	future	animals	and	humans	is	recommended	to	determine	
which	correlates	highly	with	intestinal	inflammation.		
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Immediate	future	work	should	first	of	all	include	repeat	AOM±DSS	studies	in	order	
to	induce	invasive	tumours	arising	from	both	the	sporadic	AOM-induced	adenoma-
carcinoma	 cascade,	 and	 the	 AOM/DSS-induced	 inflammation-dysplasia-carcinoma	
sequence.	In	addition,	we	would	ideally	compare	the	anticipated	early	VOC	changes	
detected	 from	 these	 CRC	 murine	 models	 to	 a	 spontaneous	 intestinal	 adenoma	
mouse	model	(e.g.	Apc(Min/+))	to	look	for	common	VOC	changes	in	both	models.		
	
The	quality	of	an	animal	model	should	be	determined	by	how	well	it	reproduces	a	
human	disease	on	a	molecular	basis	 rather	 than	simply	phenotype;	genomics	and	
metabolomics	are	just	two	of	the	emerging	fields	capable	of	achieving	this.	A	recent	
review	by	Takao	et	al.	evaluated	gene	expression	datasets	from	both	humans	and	
mice	and	 found	significant	 correlations	between	mouse	models	and	humans	with	
conditions	 including	 burn,	 trauma,	 and	 sepsis	 [353].	 Analysis	 also	 revealed	 a	
number	of	commonly	regulated	pathways	by	these	conditions	in	both	humans	and	
mice.	 	The	 linkage	of	human	and	animal	models	of	 IBD	remains	unclear.	Studying	
disease	in	patients	is	much	more	complex	than	studying	model	systems,	therefore	
prior	to	the	performance	of	any	future	studies	involving	murine	models,	it	would	be	
ideal	to	increase	our	understanding	of	how	well	such	murine	models	mimic	human	
inflammatory	 diseases	 in	 patients.	 For	 instance,	 the	 investigation	 of	 the	 faecal	
metabolome	of	a	number	of	different	murine	models	 in	combination,	 rather	 than	
the	use	of	a	single	mechanistic	model	may	be	provide	a	better	reflection	of	human	
disease.		
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Appendix	1	–	Automatic	(Metab)	analysis	vs	conventional	long-hand	analysis	
	
Analysis	of	HS-SPME-GC-MS	analysis	using	Metab	(R	package)	was	assessed	for	 its	
sensitivity,	 precision,	 false	 negative	 rate	 and	 false	 discover	 rate	 compared	 to	 the	
conventional	 long-hand,	 manual	 analysis.	 Metab	 was	 assessed	 using	 12	
chromatograms	 chosen	 at	 random	 (mixture	 of	 time	 points	 and	 gender)	 from	 the	
initial	 experiment	 to	 identify	 the	 healthy	 murine	 metabolome	 (Chapter	 3).	 Each	
chromatogram	was	 thoroughly	manually	 analysed	 in	AMDIS	 twice	and	 compound	
found	were	recorded.	All	chromatograms	included	in	this	comparison	was	used	to	
also	build	the	library	at	the	start	of	the	project,	and	all	were	checked	a	second	time	
prior	to	this	method	analysis.	The	murine	specific	library	used	had	220	compounds	
and	was	built	only	with	murine	faecal	samples.		
	
Samples	were	 then	analysed	using	Metab	based	on	an	AMDIS	batch	 report	using	
the	raw	data	‘.CDF’	files	using	a	time	window	of	0.5	minutes.	Single	reports	for	each	
chromatogram	were	generated	and	‘cleaned	up’	using	the	list	of	compounds	found	
manually.	The	list	of	compounds	found	with	Metab	was	then	compared	to	the	list	
of	compounds	found	manually.	Compounds	found	manually	but	not	by	Metab	were	
labelled	 ‘false	 negatives’,	 compounds	 found	 by	 Metab	 but	 not	 manually	 were	
labelled	‘false	positives’	and	compounds	found	by	both	methods	were	labelled	‘true	
positives’	(Figure	A1.1).		
		
	
Figure	A1.1	False	negative,	false	positive	and	true	positive	definition.		
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Results	 are	 expressed	 using	 the	 sensitivity	 (sum	 true	 positive/sum	 compounds	
found	 manually),	 the	 precision	 (sum	 true	 positive/sum	 compounds	 found	 by	
Metab),	 the	 false	 negative	 rate	 (sum	 false	 negative/sum	 compounds	 found	
manually)	 and	 the	 false	discovery	 rate	 (sum	 false	positive/sum	compounds	 found	
by	Metab)	(Table	A1.1).		
	
Table	A1.1	Sensitivity,	precision,	false	negative	rate	and	false	discover	rate	of	
Metab,	compared	to	manual,	long-hand	analysis.		
Chromatogram	 Sensitivity	(%)	
Precision	
(%)	
False	negative	
rate	(%)	
False	discovery	
rate	(%)	
1	 98.25	 94.92	 1.75	 5.08	
2	 100.00	 94.92	 0.00	 5.08	
3	 97.62	 100.00	 2.38	 0.00	
4	 95.56	 97.73	 2.22	 0.00	
5	 96.08	 98.00	 1.96	 0.00	
6	 96.72	 100.00	 3.28	 0.00	
7	 97.37	 97.37	 2.63	 2.63	
8	 100.00	 100.00	 0.00	 0.00	
9	 100.00	 97.22	 0.00	 2.78	
10	 100.00	 97.06	 0.00	 2.94	
11	 96.97	 98.46	 3.03	 1.54	
12	 98.25	 100.00	 1.75	 0.00	
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Appendix	2	-	T-cell	transfer	chronic	colitis	faecal	VOC	profile	
	
Faecal	 samples	 donated	 from	 Dr	 Jim	 Wilson	 of	 Epistem,	 Manchester	 from	 an	
adoptive	CD4+CD62L+	T	cell	transfer	study	[354].	Using	the	protocol	by	Wirtz	et	al.,	
all	mice	(except	untreated	controls)	were	injected	with	CD4+CD62L+	T	cells	on	day	0	
and	samples	 included	 in	 this	analysis	 (Figure	A2.1)	were	collected	 from	the	colon	
when	mice	were	euthanised	on	day	28;	confidential	 clinical	data	confirm	that	 IgG	
control-treated	T-cell	recipient	mice	developed	colitis.		
	
Figure	A2.1	A	PCA	biplot	for	the	colon	content	samples	from	untreated	control	and	
T-cell	recipient	mice.		
